Combination_ID	CellLine_ID	"In Vivo	Combination Effect Level 1"	Combination Effect Level 2	conclusions	Mechanism_ID
C00179	NEWCL00044	.	Augmenting Drug Sensitivity	"Combination of 5 uM curcumin with 5-FU significantly reduced its cytotoxicity in EJ138 cells, while 15 uM curcumin caused an opposite increase."	MEC00098
C16256	.	"200 uL tumor cell suspensions, containing 2*106 Ehrlich ascites carcinoma cells, were subcutaneously injected into the right thigh of the hind limb of each mouse."	Augmenting Drug Sensitivity	The combination of 5-FU and apigenin had a greater effect than each of 5-FU or apigenin alone against solid Ehrlich carcinoma in mice.	MEC00086
C50333	NEWCL00243; NEWCL00236; NEWCL00242; NEWCL00237	MIA PaCa-2 cells (1*106) in 100 uL PBS were injected into the subcapsular region of the pancreas male athymic nu/nu mice.	Augmenting Drug Sensitivity	"Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products."	MEC00055
C28149	NEWCL00082; NEWCL00077; NEWCL00076	A total of 2*105 HCT 116 cells in 20 uL PBS were injected into the cecum of male athymic nu/nu mice.	Augmenting Drug Sensitivity	Curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway.	MEC00013
C52131	NEWCL00241; NEWCL00236; NEWCL00242; NEWCL00297	"A small left abdominal flank incision was made in male athymic nu/nu mice, and MIA PaCa-2 cells (2*106) in 50 uL PBS were injected into the subcapsular region of the pancreas."	Achieving Therapeutic Synergy	"Resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis."	MEC00069
C96493	NEWCL00358; NEWCL00283; NEWCL00031	Five-week-old BALB/C nude mice received a subcutaneous injection of 1*107 LM3 cells suspended in 100 uL sterile PBS into the right flank.	Achieving Therapeutic Synergy	Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.	MEC00403
C57091	NEWCL00270; NEWCL00271	A total of 2*106 HSC-3 cells were suspended in 100 uL serum-free DMEM and injected subcutaneously into the right flank of BALB/c nude mice to establish OSCC xenograft models.	Achieving Therapeutic Synergy	HNK and 5-FU exert a synergistic therapeutic effect on OSCC by inducing apoptosis.	MEC00091
C28982	.	C57BL/6 micemice were transtracheally instilled with 2*106 of Pc organisms in 50 uL sterile PBS.	Achieving Therapeutic Synergy	All-trans retinoic acid in combination with primaquine clears pneumocystis infection.	MEC00791
C08951	.	"For murine challenge studies, 6 to 8-week-old female C57Bl/6 mice were challenged with 105 plaque forming units (PFU) of WNV via intraperitoneal injection of virus in 0.25 mL total volume."	Achieving Therapeutic Synergy	A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen.	MEC00904
C25861	.	1*107 SW1990 cells in 100 uL phosphate-buffered saline (PBS) were injected into back of BALB/c nude mice.	Achieving Therapeutic Synergy	Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model.	MEC01291
C60653	.	"At the age of 10 weeks, DBA/1 mice were immunized intradermally at the base of the tail with 0.1 ml of emulsion containing 100 ug of type II collagen."	Achieving Therapeutic Synergy	"Doxycycline and hAAT in combination also inhibited IL-6 expression from LPS-stimulated NIH/3T3 mouse fibroblast cells, indicating a contributing mechanism of arthritis inhibition."	MEC01468
C49659	NEWCL10016	SC-M1 cells (5*106 in 100 uL of 0.9% saline) were injected subcutaneously into the hind flank of 6-week-old SCID mice.	Achieving Therapeutic Synergy	Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo.	MEC00863
C85377	NEWCL00162; NEWCL00049	MDA-MB-231 cells (5*106 cells in 100 uL of PBS) were subcutaneously injected to the left flank of femal nude mice.	Achieving Therapeutic Synergy	"Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways."	MEC00937
C01919	NEWCL00027; NEWCL00140	A total of 1*107 SMMC-7721 cells in a volume of 200 uL PBS were injected into the right flank of each mouse (6-week old male Balb/c nude mice weighing 20 g) to form subcutaneous tumors.	Achieving Therapeutic Synergy	The treatment of sorafenib combined with bufalin synergistically suppressed HCC proliferation and induced apoptosis.	MEC00576
C42257	NEWCL00171	Detached H1975 cells were diluted and emulsified with medium to a final concentration of 2*107 cells/ml. The emulsion (200 uL) was inoculated subcutaneously into 4-6-week-old female nude BALB/c mice.	Achieving Therapeutic Synergy	Genistein enhanced the antitumor effects of gefitinib in a NSCLC cell line carrying the T790M mutation. This synergistic activity may be due to increased inhibition of the downstream molecular and pro-apoptotic effects of EGFR.	MEC00586
C87955	NEWCL10345; NEWCL00050; NEWCL00162	HCC1428 cells (1.0*106) were injected subcutaneously into the abdominal mammary fat pads of female BALB/c-nu mice.	Achieving Therapeutic Synergy	Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.	MEC00698
C98479	NEWCL00273; NEWCL00269	Each nude mouse was subcutaneously injected in the flank back skin with 200 uL of serum-free DMEM containing 8 * 106 CAL27 cells.	Achieving Therapeutic Synergy	"C1632 and metformin exerts synergistic anti-tumor effects in OSCC cell lines SCC9 and CAL27, and also inhibits xenograft tumor growth in vivo."	MEC00704
C63570	NEWCL00171	The mice were subcutaneously injected with 1*107 NCI-H1975 cells suspended in 100 uL of Matrigel.	Reversing Drug Resistance	Gefitinib in combination with GA resulted in antitumor growth in the EGFR-T790M secondary mutation NCI-H1975 tumor model due to an enhanced apoptotic effect.	MEC00943
C87707	NEWCL10119; NEWCL00020; NEWCL00059; NEWCL00022	Xenograft tumors were generated by injecting subcutaneously 1*107 MV4-11 cells in 100 uL of PBS on left flank in nude mice.	Achieving Therapeutic Synergy	Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress.	MEC00995
C06930	NEWCL10031; NEWCL00078; NEWCL00079; NEWCL00082	"BALB/c mice were removed hair and injected CT26 cells (1.5*106) suspended in FBS: Matrigel (1:1, 200 uL/mouse) subcutaneously in the flank region of mice."	Achieving Therapeutic Synergy	Hydrogel-mediated delivery of celastrol and doxorubicin induces a synergistic effect on tumor regression via upregulation of ceramides.	MEC01152
C19456	NEWCL00155	About 5*106 cells suspension in 50 uL sterile PBS were mixed with 100 uL Matrigel and administered within both sides of the inguinal mammary fat pad of NU/NU immune-compromised female ovariectomized mice.	Achieving Therapeutic Synergy	These findings demonstrate synergistic growth inhibition of ERalpha positive breast cancer xenografts by combination of tamoxifen with organic selenium compounds.	MEC01164
C79653	NEWCL00170; NEWCL00180; NEWCL00181; NEWCL00171; NEWCL00172; NEWCL00351; NEWCL00175; NEWCL00315	Animal models were constructed by implanting 5*106 PC-9 cells in Matrigel into the flanks of female severe combined immunodeficiency (SCID) mice.	Reversing Drug Resistance	Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.	MEC00021
C36886	NEWCL00345; NEWCL00181; NEWCL00175	H157 and H1299 cells (6*106 cells per mouse) were subcutaneously grafted into the right flanks of six-week-old female athymic nude BALBL/c mice.	Achieving Therapeutic Synergy	"Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells."	MEC00023
C07326	NEWCL00170	"A549 cells were injected subcutaneously (1*106, 100 uL of PBS) into the left flanks of the 7-8-week old BALB/C male nude mice."	Reversing Drug Resistance	EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC.	MEC00025
C95085	NEWCL00145	BGC-823/5-FU cells (5*106) were injected subcutaneously into the left flank of six-week-old BALB/c nude mice.	Augmenting Drug Sensitivity	Cardamonin reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/beta-catenin signal pathway.	MEC00074
C00179	NEWCL00078	.	Reversing Drug Resistance	"Down-regulation of P-gp and HSP-27, two multidrug resistance related factors, may be the mechanism of curcumin reversing the drug resistance of HCT-8/5-FU to 5-FU."	MEC00099
C00179	NEWCL00142	.	Reversing Drug Resistance	Curcumin can reverse 5-FU resistance and inhibits proliferation in GC cells by downregulating the NFkappaB-signaling pathway.	MEC00104
C39248	NEWCL00129	.	Augmenting Drug Sensitivity	"As2O3 in combination with 5-FU treatment caused up-regulation of DR5, caspase 3, caspase 8, and caspase 9, and down-regulation of BCL-2, but had no effect of DR4."	MEC00105
C22519	NEWCL00142; NEWCL00113	Exponentially growing SCG7901/FU cells (5*106) were injected subcutaneously into the dorsum of female BALB/c nude mice.	Reversing Drug Resistance	Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer.	MEC00114
C87491	NEWCL00310; NEWCL00032; NEWCL00065; NEWCL00136	Immunodeficient mice (Rag2-/-/II2rg-/-) were implanted subcutaneously in the dorsal flank region with CEM (5*107 cells).	Decreasing Adverse Drug Reaction	Wogonin potentiates the lethality of ABT-263 in ABT-263-resistant cancer cells and wogonin reduces the effective dose of ABT-263 thereby possibly decreasing the risk of adverse side effects.	MEC00129
C70450	NEWCL00080	.	Reversing Drug Resistance	Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells.	MEC00138
C86878	NEWCL00155; NEWCL00158; NEWCL00160; NEWCL00049; NEWCL00053; NEWCL00329	.	Reversing Drug Resistance	Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression.	MEC00143
C82390	NEWCL00155	.	Achieving Therapeutic Synergy	The combination of curcumin and tamoxifen resulted in a synergistic survival inhibition in MCF-7/LCC2 and MCF-7/LCC9 cells.	MEC00144
C97546	NEWCL00170; NEWCL00180; NEWCL00181; NEWCL00171; NEWCL00172; NEWCL00351; NEWCL00175; NEWCL00315	Tumors were grown by implanting 5*106 cells in Matrigel into female  SCID mice flanks.	Reversing Drug Resistance	Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.	MEC00147
C84861	NEWCL00122; NEWCL00126; NEWCL00123	LN18 cells (5*106/mouse) were subcutaneously injected into the left hind flank of each female BALB/c mouse.	Reversing Drug Resistance	Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression.	MEC00170
C90619	NEWCL00037	.	Augmenting Drug Sensitivity	"GBM-derived cells treated with a combination of SHK and TMZ showed decreases in their proliferation and migration capacities. These decreases were followed by the suppression of GMT through a reduction of beta3 integrin, MMP-2, MMP-9, Slug and vimentin expression via inactivation of PI3K/AKT signaling."	MEC00176
C29048	NEWCL00080	.	Reversing Drug Resistance	Silybin counteracts doxorubicin resistance by inhibiting GLUT1 expression.	MEC00209
C95252	NEWCL00155; NEWCL00049; NEWCL00336	.	Reversing Drug Resistance	Curcumin reversed doxorubicin resistance in human breast cancer MCF 7/DOX and MDA MB231/DOX cells by inhibiting the ATPase activity of ABCB4.	MEC00217
C76104	NEWCL00147	About 5 x106 cells were subcutaneously injected into the right flank of the athymic male nude mice.	Reversing Drug Resistance	EGCG could chemosensitize resistant tumor cells to DOX in vivo through an increase in the accumulation of DOX in the tumors.	MEC00234
C58834	NEWCL00048	.	Reversing Drug Resistance	"Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation."	MEC00280
C23448	NEWCL00077; NEWCL00307	.	Reversing Drug Resistance	"Silibinin restored 1,25D responsiveness in vitamin D-resistant colon cancer cells by downregulation of Snail1 and Snail2 and upregulation of vitamin D receptor."	MEC00285
C14937	NEWCL00170; NEWCL00175; NEWCL00171	A549/DDP-Luc cells (4*106) were subcutaneously injected into the right flank of 4-to-6 week-old female BALB/c nude mice.	Reversing Drug Resistance	Scutellarin increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell Lung cancer via ERK/p53 and c-met/AKT signaling pathways.	MEC00300
C33960	NEWCL00180; NEWCL00170; NEWCL00302; NEWCL00175; NEWCL00172; NEWCL00171	.	Reversing Drug Resistance	Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1alpha mediated XPC transcription.	MEC00305
C14937	NEWCL00134; NEWCL00231	.	Achieving Therapeutic Synergy	Scutellarin synergistically enhances cisplatin effect against ovarian cancer cells through enhancing the ability of cisplatin binding to DNA.	MEC00310
C72340	NEWCL00154; NEWCL00166; NEWCL00268; NEWCL00210; NEWCL00244; NEWCL00153; NEWCL00164; NEWCL00165	AMC-HN4-cisR or HN9-cisR cells (5*106) were injected subcutaneously into the flank of 6-week-old athymic BALB/c male nude mice (nu/nu).	Reversing Drug Resistance	Wogonin significantly sensitized resistant HNC cells to cisplatin both in vitro and in vivo. Wogonin is a promising anticancer candidate that induces ROS accumulation and selective cytotoxicity in HNC cells and can help to overcome cisplatin-resistance in this cancer.	MEC00314
C27185	NEWCL00151; NEWCL00230	.	Decreasing Adverse Drug Reaction	silibinin could restore the sensitivity of cisplatin in drug-resistant human ovarian cancer cells and reduce durg-induced hepatotoxicity in cell level.	MEC00322
C08841	NEWCL00231	.	Reversing Drug Resistance	Rosmarinic acid methyl ester regulates ovarian cancer cell migration and reverses cisplatin resistance by inhibiting the expression of forkhead box M1.	MEC00327
C97380	NEWCL00129	.	Reversing Drug Resistance	Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.	MEC00329
C49649	NEWCL00078	HCT8/DDP cells (1*106) transfected with lenti-KCNQ1OT1 or lenti-NC were suspended in Matrigel matrix and subcutaneously injected into the back of male six-week-old nude mice.	Reversing Drug Resistance	KCNQ1OT1 aggravated cisplatin resistance in CRC cells via the miR-497/Bcl-2 axis.	MEC00333
C49649	NEWCL00170	.	Augmenting Drug Sensitivity	"By suppressing the FA/BRCA pathway DNA repair, curcumin potentiates DDP-induced proliferation inhibitory effect and apoptosis in A549/DDP cell."	MEC00335
C49649	NEWCL00170	.	Reversing Drug Resistance	"Combined curcumin and DDP treatment markedly inhibited A549/DDP cells proliferation, reversed cisplatin resistance and triggered apoptotic death by promoting HIF-1alpha degradation and activating caspase-3, respectively."	MEC00336
C57395	NEWCL00170; NEWCL00180	.	Reversing Drug Resistance	Reversal of cisplatin resistance by epigallocatechin gallate is mediated by downregulation of axl and tyro 3 expression in human lung cancer cells.	MEC00366
C81026	NEWCL00109; NEWCL00110; NEWCL00111; NEWCL00114; NEWCL00107; NEWCL00115	.	Reversing Drug Resistance	Capsaicin induces apoptosis of cisplatin-resistant stomach cancer cells by causing degradation of cisplatin-inducible Aurora-A protein.	MEC00378
C18844	NEWCL00049; NEWCL00155	.	Augmenting Drug Sensitivity	Curcumin reduces mitomycin C resistance in breast cancer stem cells by regulating Bcl-2 family-mediated apoptosis.	MEC00411
C49580	NEWCL00082; NEWCL00076	.	Reversing Drug Resistance	Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.	MEC00417
C75746	NEWCL00082; NEWCL00074	"HCT116/OXA cells were transplanted subcutaneously into the right flank in each BALB/c nude mice (6-8 weeks old, 20+/-2 g weight)."	Reversing Drug Resistance	Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-beta/Smad2/3 signaling pathway.	MEC00423
C01771	NEWCL00016	.	Decreasing Adverse Drug Reaction	Combinations of indole-3-carbinol and silibinin suppress inflammation-driven mouse lung tumorigenesis by modulating critical cell cycle regulators.	MEC00446
C01098	NEWCL00170; NEWCL00181; NEWCL00171; NEWCL00199; NEWCL00180	BALB/c nude mice (5-week-old) were subcutaneously inoculated with A549 cells (1*106).	Reversing Drug Resistance	Curcumol overcomes TRAIL resistance of non-small cell lung cancer by targeting NRH:Quinone Oxidoreductase 2 (NQO2).	MEC00461
C10155	NEWCL00082; NEWCL00073; NEWCL00076	.	Reversing Drug Resistance	Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin.	MEC00465
C67401	NEWCL00077	.	Reversing Drug Resistance	Isoliquiritigenin has the potential to overcome resistance to TRAIL in cancer cells and its chemopreventive effects may depend on TRAIL function.	MEC00466
C62137	.	LNCaP cells (2*106 cells as a 50% suspension in matrigel) in a final volume of 0.1 mL were injected subcutaneously at right flank of Balb c nude mice.	Augmenting Drug Sensitivity	"Curcumin inhibited growth of LNCaP xenografts in nude mice by inducing apoptosis (TUNEL staining) and inhibiting proliferation (PCNA and Ki67 staining), and sensitized these tumors to undergo apoptosis by TRAIL via regulation of death receptors and members of Bcl-2 family and inactivation of NFkappaB."	MEC00505
C20416	NEWCL00124; NEWCL00122	.	Reversing Drug Resistance	"Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2."	MEC00519
C80755	NEWCL00170; NEWCL00185	.	Augmenting Drug Sensitivity	Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-kappaB signaling.	MEC00531
C55665	NEWCL00180; NEWCL00182	Xenografts were obtained by injecting NCI-H460 2*106 cells subcutaneously into the right flank of each female SCID mice (age 5-6 weeks old).	Achieving Therapeutic Synergy	Thymoquinone combined with cisplatin showed synergistic anticancer activity by down-regulating NF-kappaB.	MEC00302
C02830	NEWCL00031; NEWCL00283	Huh7 and Hep3B cells with or without SULF1 expression (1*106) were suspended in PBS and inoculated subcutaneously into the right flanks of 4- to 6-week-old male BALB/c nu/nu nude mice (NCI/NIH).	Achieving Therapeutic Synergy	"The combination of doxorubicin with apicidin significantly increased the anti-tumor effect in the SULF1-expressing Huh7 and Hep3B cells as compared to either apicidin or doxorubicin alone, both in vitro and in vivo."	MEC01189
C00179	NEWCL00082; NEWCL00074	Xenograft tumors were generated by subcutaneous injection of 5*106 HCT116-5FUR cells in male athymic nude mice.	Augmenting Drug Sensitivity	"Combined treatment with curcumin and 5-FU enhanced cellular apoptosis and inhibited proliferation in both parental and 5FUR cells, whereas 5-FU alone was ineffective in 5FUR cells. Curcumin suppressed EMT in 5FUR cells by downregulating BMI1, SUZ12 and EZH2 transcripts, key mediators of cancer stemness-related polycomb repressive complex subunits."	MEC00094
C50333	NEWCL00243; NEWCL00236; NEWCL00242	Xenograft tumors were generated by subcutaneous injection of 1*106 BxPC3-GEMR cells in male athymic nude mice.	Augmenting Drug Sensitivity	"Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression."	MEC00056
C50185	NEWCL00170; NEWCL00298	Xenograft tumors were established by subcutaneous injection of 1*106 LLC cells into 6-week-old male C57BL/6 mice.	Achieving Therapeutic Synergy	Hesperetin can synergize platinum drugs by inhibiting UGT1A3 and increasing levels of reactive oxygen species (ROS).	MEC00195
C12043	NEWCL00242; NEWCL00243	Xenograft tumor models were created by subcutaneously injecting 5*106 BxPC-3 cells into the right flank of the mice.	Achieving Therapeutic Synergy	Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species.	MEC01058
C98820	NEWCL00052; NEWCL00159; NEWCL00160	Xenograft nude mice were inoculated subcutaneously with 0.1 mL of cell suspension (ZR-75-1 and BT-474 cells).	Augmenting Drug Sensitivity	Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway.	MEC00157
C00670	.	Male Wistar rat hearts were isolated using an in vitro Langendorff system.	Achieving Therapeutic Synergy	"Treatment with sildenafil and milrinone in lower concentrations had an equally strong cardioprotective effect regarding infarct size reduction compared with the administration of ""protective"" concentrations."	MEC01430
C55665	NEWCL00134; NEWCL10081; NEWCL10160	Wild-type C57BL/6 mice were injected intra-peritoneally (IP) with 1* 107 ID8-NGL cells suspended in 200 ul sterile PBS.	Achieving Therapeutic Synergy	Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.	MEC01010
C18576	NEWCL10152; NEWCL10013; NEWCL10015; NEWCL10014; NEWCL10191; NEWCL10192; NEWCL10193; NEWCL10194; NEWCL10196; NEWCL10195	VUMC-HGG-14 cells (50*104 cells in 5 uL) were stereotactically injected into the striatum (4-week old female athymic nude mice).	Achieving Therapeutic Synergy	Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin.	MEC01195
C17620	NEWCL00170	"Viable A549 cells (5*106/100 ul PBS per mouse) were mixed with 50% Matrigel, and then subcutaneously injected into the right flank of 7- to 8- week old male Balb/c nude mice."	Achieving Therapeutic Synergy	Suppression of NF-KappaB signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin -induced apoptosis in lung cancer.	MEC01006
C70279	.	A total of one hundred and seventy-four Wistar rats (200-250 g) were used in the entire study.	Achieving Therapeutic Synergy	Fixed low dose of magnesium sulfate enhanced the temperature lowering effect of ketamine on baseline body temperature and morphine-induced hyperthermia.	MEC01529
C99302	NEWCL00039; NEWCL00279	U251 cells (5*107) in 100 uL PBS were injected subcutaneously into the right oxter of male nude mice.	Augmenting Drug Sensitivity	Borneol could enhance anticancer efficiency of doxorubicin against human glioma through triggering ROS-mediated signal.	MEC00226
C42594	NEWCL00039	U251 cell suspension (1*109 cells) was inoculated in the armpit of 6-week-old Balb/c nude mice.	Augmenting Drug Sensitivity	Natural borneol enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage.	MEC00175
C14503	.	"Twenty-four inbred Wuzhishan miniature pigs (12-14 months of age, 30+/-2 kg) were used in this study."	Achieving Therapeutic Synergy	Combination of epinephrine with esmolol attenuates post-resuscitation myocardial dysfunction in a porcine model of cardiac arrest.	MEC00674
C51500	.	Twenty-four C57BL/6 male mice were used in this study	Decreasing Adverse Drug Reaction	Asiatic acid protects against cisplatin-induced AKI via anti-apoptosis and anti-inflammation.	MEC01247
C60643	NEWCL00242; NEWCL00243; NEWCL00241	Tumors were established by subcutaneous injection of 5*106 BxPC-3 cells into the flanks of male nude BALB/c mice.	Achieving Therapeutic Synergy	Shikonin can suppress the growth of human pancreatic tumors and potentiate the antitumor effects of gemcitabine through the suppression of NF-kappaB and NF-kappaB-regulated gene products.	MEC00066
C79794	NEWCL00279; NEWCL00123; NEWCL10271	Tumors were induced in nude mice by subcutaneous injection of 5 * 106 U87 cells or 10 *106 T98 cells in PBS supplemented with 0.1% glucose.	Achieving Therapeutic Synergy	"The combined administration of Delta(9)-Tetrahydrocannabinol and temozolomide exerts a strong antitumoral action in glioma xenografts, an effect that is also observed in tumors that are resistant to TMZ treatment."	MEC01540
C25168	NEWCL00189; NEWCL00160	Tumor inoculation was achieved by subcutaneously injecting 5*104 4T1 cells in the abdominal mammary gland of female BALB/c mice in order to prevent interference with normal bodily functions	Achieving Therapeutic Synergy	Camptothecin-doxorubicin combinations showed synergistic antitumor acitivity.	MEC01141
C24621	NEWCL10082; NEWCL00129	Tumor cells were inoculated into the left flank of 7 week-old female athymic nude mice by subcutaneous injection of 6 * 106 LS174T cells in 0.1 mL Hanks Balanced Salt Solution.	Achieving Therapeutic Synergy	"In vitro and in vivo data support a synergistic antitumor activity of the nanoliposomal C6-ceramide and vinblastine combination, potentially mediated by an autophagy mechanism."	MEC00666
C33091	NEWCL00321	"To establish the xenograft model, the transplanted KPC adenocarcinoma cell lines (5 * 103 cells) in 30 uL PBS were injected in the gastric lobe of the pancreas of C57BL/6 albino mice. "	Achieving Therapeutic Synergy	"The combination of mTOR dual inhibition by Torin 2 and metformin is associated with an altered metabolomic profile and a significant reduction in pancreatic tumor burden compared with single-agent therapy, and it is better tolerated."	MEC00707
C49659	NEWCL10073; NEWCL10123; NEWCL10029; NEWCL10071; NEWCL10143; NEWCL10112	"To produce a subcutaneous xenograft model, RT112 cells (5*106) were injected into the subcutaneous tissue of pathogen-free 6-week-old BALB/cAJcl-nu/nu mice."	Reversing Drug Resistance	Cancer-specific enhancement of CDDP-induced cytotoxicity with triptolide effectively overcome the resistance to a CDDP-based conventional chemotherapy as a treatment for urothelial cancer through an interaction of inactivated glycogen synthase kinase-3beta with p53.	MEC01013
C49659	NEWCL00242; NEWCL00236	"To produce a subcutaneous xenograft model, PANC-1 cells (5*106) were injected into the flanks of 6-week-old nude mice."	Achieving Therapeutic Synergy	The combined therapy of TPL and DDP triggers a synergic apoptosis via inhibiting HSP27 in human gemcitabine-resistant pancreatic carcinoma and has a strong potential to be developed into a new effective regimen for pancreatic cancer treatment.	MEC00866
C34768	NEWCL00026	"To generate a mouse model of araC-resistant ALL, NALM-6/R cells (5 * 105) were subcutaneously injected into the angular veins of sublethally irradiated adult NSI (NOD/SCID IL2rg-/-) mice (20-30 g body weight, 2-3 months of age)."	Reversing Drug Resistance	Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.	MEC01135
C80880	NEWCL00026	"To generate a mouse model of araC-resistant ALL, NALM-6/R cells (5 * 105) were subcutaneously injected into the angular veins of sublethally irradiated adult NSI (NOD/SCID IL2rg-/-) mice (20-30 g body weight, 2-3 months of age)."	Reversing Drug Resistance	Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.	MEC01136
C98305	NEWCL10032	"To establish xenograft model, P388 cells were injected i.p. in DBA/2 mice."	Decreasing Adverse Drug Reaction	"Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity."	MEC00856
C02533	NEWCL00243; NEWCL00236; NEWCL00242	"To establish xenograft model, each mouse was subcutaneously injected with 6x106 Mia PaCa-2 cells in the back."	Achieving Therapeutic Synergy	Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer.	MEC00571
C53571	NEWCL00255	"To establish the rat glioblastoma model,  each rat was anesthetized. Following disinfection and incision of the skin with a scalpel, a hole was drilled through the skull 2-mm lateral and 2-mm anterior to the bregma, on the right side of the skull. "	Achieving Therapeutic Synergy	Combined use of TMZ and VD exerts synergistic antitumor effects on rat models of glioblastoma and may represent an effective therapeutic strategy.	MEC00657
C12590	NEWCL10377	"To establish s.c. bladder cancer models, 1*106 MB49 cells in 100 uL PBS were injected in the right shaved flank of female C57BL/6 mice."	Decreasing Adverse Drug Reaction	Bisdemethoxycurcumin in combination with Alpha-PD-L1 antibody boosts immune response against bladder cancer.	MEC01314
C58370	NEWCL00360; NEWCL10040	"To establish nude mouse transplantation tumor model, HN-CICs cells were subcutaneously injected into BALB/c nude mice (6-8 weeks)."	Achieving Therapeutic Synergy	Combinatorial low dose arsenic trioxide and cisplatin exacerbates autophagy via AMPK/STAT3 signaling on targeting head and neck cancer Initiating cells.	MEC01079
C58370	.	"To establish nude mouse transplantation tumor model, 0.5* 106 ehrlich ascites carcinoma cells were injected in the female BALB/c mice."	Achieving Therapeutic Synergy	Combination of arsenic trioxide and cisplatin synergistically inhibits both hexokinase activity and viability of Ehrlich ascites carcinoma cells.	MEC01202
C77125	NEWCL00129	"To establish nude mouse transplantation tumor model, 0.2 ml of HepG2 cells (1 * 107/ml) were injected subcutaneously in the right axilla of mice."	Achieving Therapeutic Synergy	"Combined canstatin and ATO significantly inhibited cell proliferation, migration and adhesion abilities, and promoted cell apoptosis, and inhibited tumor growth, thus suppressed the progression of HCC."	MEC01100
C95085	NEWCL10053; NEWCL00155; NEWCL10092	"To establish breast cancer xenografts in nude mice, SUM190 cells were mixed with Matrigel and injected under aseptic conditions into mammary fat pads of nude mice (n = 4-8 for each group, 2 * 106 cells per fat pad)."	Achieving Therapeutic Synergy	Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo.	MEC00972
C34271	NEWCL10053; NEWCL00155; NEWCL10092	"To establish breast cancer xenografts in nude mice, SUM190 cells were mixed with Matrigel and injected under aseptic conditions into mammary fat pads of nude mice (n = 4-8 for each group, 2 * 106 cells per fat pad)."	Achieving Therapeutic Synergy	Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo.	MEC00973
C56069	NEWCL10377	"To establish a syngeneic mouse bladder tumor model, 1 * 106 MB49 cells in 100 uL cold PBS were injected subcutaneously into the right flank of the each C57BL/6 mouse strain."	Achieving Therapeutic Synergy	Cucurbitacin B and cisplatin induce the cell death pathways in MB49 mouse bladder cancer model.	MEC01519
C18543	NEWCL00170; NEWCL00180; NEWCL00181	"To determine the in vivo antitumour activity of GA combined with CDDP, viable A549 cells (5 * 106/100ul PBS per mouse) were subcutaneously injected into the right flank of 7- to 8-week-old male SCID mice."	Achieving Therapeutic Synergy	Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling.	MEC01007
C23114	NEWCL00236; NEWCL00242	"To ceate the subcutaneous xenograft model, mice were subcutaneously inoculated with MiaPaCa-2 cells (1*106cells/mouse) in 1 mL of Matrigel."	Achieving Therapeutic Synergy	The combination of guggulsterone to gemcitabine enhanced antitumor efficacy through apoptosis induction by suppressing Akt and nuclear factor KappaB activity and by modulating apoptosis-related protein expression in pancreatic cancer.	MEC00957
C90308	.	"Animals received yohimbine (2 mg/kg) 30 min prior to administration of imipramine(20 mg/kg) (Y + I group) or received vehicle treatment (Ctl group), once a day for seven consecutive days in adult male Wistar rats (250-400 g, 2-3 months of age) and adult male nestin-GFP transgenic mice (25-35 g, 2-3 months of age)."	Achieving Therapeutic Synergy	"Yohimbine and Imipramine combination treatment enhanced the quiescent neural progenitor pool in the hippocampal neurogenic niche similar to ECS, and distinct from chronic imipramine treatment."	MEC00923
C69564	.	Clinical Trial	Achieving Therapeutic Synergy	"While no side effects other than dryness of the lips were noted, a significant reduction of the erythema and edema could be observed in all patients."	MEC01570
C19026	.	"This experiment was carried out on 30 Wistar rats weighing 100-125 g, liver cancer was induced by a carcinogenic dose of 200 mg/kg body weight, I.P. DENA when associated with fasting/refeeding."	Achieving Therapeutic Synergy	Selenium and sulfonamide (sulfamethoxazole) together can possess synergistic chemopreventive action.	MEC00644
C31463	.	Third-stage larvae (L3) were used to infect Sprague-Dawley (SD) rats.	Achieving Therapeutic Synergy	"Albendazole-schisandrin B co-treatment significantly inhibited inflammasome activation, pyroptosis, and apoptosis."	MEC01363
C40913	NEWCL00151; NEWCL00028; NEWCL00129; NEWCL00027; NEWCL00283	The xenograft model was established by subcutaneously injection of 4*106 MHCC97-H cells into the right flank of these female BALB/c nude mice (5 weeks old).	Achieving Therapeutic Synergy	Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL-24 gene in liver cancer cells.	MEC00485
C59135	NEWCL00311; NEWCL00350; NEWCL00209	The xenograft model was established by intraperitoneal injection of 1.5*107 MET-1 cells into SCID/NOD mice.	Achieving Therapeutic Synergy	Combination of the flavopiridol and anti-CD25 monoclonal antibody dramatically enhanced the antitumor effect.	MEC00509
C69281	NEWCL00245; NEWCL00286; NEWCL00291; NEWCL00295; NEWCL00278; NEWCL00318	The two models employed included an orthotopic murine model (NOD/SCID-gamma mice injected intravenously via tail vein with 5*106 PS-R (bortezomib-resistant U266) stably transfected with a construct encoding luciferase) and an immunocompetent model (C57BL/KaLwR1 mice injected intravenously via tail vein with 5*106 murine MM 5TGM1 cells stably expressing luciferase.	Augmenting Drug Sensitivity	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.	MEC00405
C78723	NEWCL00170; NEWCL00181	"The tumor xenografts were established by injecting 2 * 107 A549 cells per mouse in 100 ul DMEM medium and Matrigel (Corning Inc., Corning, NY) in 1:1 ratio on the dorsal flank of athymic male nude mice (6-8-week-old)."	Achieving Therapeutic Synergy	Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.	MEC00986
C41968	NEWCL00022	The tumor xenograft model was established by subcutaneous inoculation of cultured HL-60 cells (1.0 * 107/ml) in 0.1 ml Hank's balanced salt solution (HBSS) into the right axilla back region of female BALB/c-nu/nu nude mice (3-5weeks of age).	Achieving Therapeutic Synergy	Combination of DFO and ATO has Synergistic effects on tumor growth inhibition and apoptosis-inducing in vivo with no significant side effects.	MEC00994
C18210	NEWCL00023; NEWCL10417; NEWCL10418; NEWCL00063; NEWCL00048; NEWCL00022	The triple-regulated CRAd carrying SG611-PDCD5 and nude mouse xenograft models of K562 cells were constructed in this study.	Achieving Therapeutic Synergy	Treatment with SG611-PDCD5 in combination with low-dose daunorubicin elicited more potent anti-proliferative and proapoptotic effects in leukemic cells in a dose-dependent manner.	MEC00733
C02521	NEWCL00103; NEWCL00259	"The topical use of 7, 12-dimethylbenz[a]anthracene (DMBA) in acetone (150 mg/mouse) served as a tumor initiator in swiss albino mice."	Augmenting Drug Sensitivity	Resveratrol synergistically augments anti-tumor effect of 5-FU in vitro and in vivo by increasing S-phase arrest and tumor apoptosis.	MEC00117
C94307	NEWCL00184; NEWCL10072; NEWCL00186	"The SK-MES-1 xenograft model was developed by subcutaneous injection of 1*107 cells with Matrigel into the upper back of 40 nude mice (female, 4-6-week-old, 10-14 g, BALB/cAnN-nu)."	Achieving Therapeutic Synergy	"Combined ATO/PD173074 reduced cell viability along with increased sub-G1 population, phosphatidylserine externalization and mitochondrial membrane depolarization more significantly than single treatments."	MEC01304
C55332	.	A total of twenty-eight female Wistar-Kyoto rats aged 8-10 weeks were used in this study.	Achieving Therapeutic Synergy	"Combined supplementation of Omega-3 PUFAs and proanthocyanidins from grape seed counteracts the effects of the Omega-3 PUFAs on health-promoting lactobacillus and bifidobacterium, and on acetic acid, while maintaining their beneficial effects on cholesterolemia."	MEC00899
C76104	NEWCL00283	The nude mice were subcutaneously inoculated with cell suspension containing 1*107 Hep3B cells per mouse in the right side fossa axillaries.	Achieving Therapeutic Synergy	EGCG emerges as a chemotherapeutic augmenter and synergistically enhances DOX anticancer effects involving autophagy inhibition in HCC.	MEC00232
C49649	NEWCL00155; NEWCL00160; NEWCL00049	"The nude mice were anesthetized through isoflurane inhalation, and 1*107 MCF-7 cells suspending in 0.1 mL PBS was injected subcutaneously into the right axillary of each mouse."	Augmenting Drug Sensitivity	Curcumin sensitizes breast cancer cells to cisplatin through FEN1 down-regulation. Inhibiting ERK phosphorylation stimulated the chemosensitizing effect of curcumin to cisplatin by targeting FEN1.	MEC00334
C57395	.	The mouse strain C57BL/6 of about 8 weeks age with weights of 18-22 g were used in all experiments.	Decreasing Adverse Drug Reaction	"Mitochondrial modulation by Epigallocatechin 3-Gallate ameliorates cisplatin induced renal injury through decreasing oxidative/nitrative stress, inflammation and NF-kB in mice."	MEC00369
C61221	NEWCL00231; NEWCL00252	Six-week-old SCID (severe combined immuno deficiency) mice were inoculated with 100 ul (50% Matrigel/PBS) LNCaP cells suspension (6 * 106) to either dorsal flank with 25-gauge syringe.	Achieving Therapeutic Synergy	Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells.	MEC01103
C61221	NEWCL00231; NEWCL00252	The mice were inoculated with 100 ml (50% Matrigel/PBS) SKOV3 cell suspension (3*106) to both dorsal flanks of the mice .	Achieving Therapeutic Synergy	Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.	MEC00913
C01696	.	"The mice were anesthetized by sevoflurane inhalation, the left common carotid artery was exposed through a small midline incision in the neck and completely ligated near the carotid bifurcation."	Achieving Therapeutic Synergy	Palmitoylethanolamide and Polydatin combination reduces inflammation and oxidative stress in vascular injury.	MEC01210
C55665	.	The mice modle was established by diethylnitrosamine/carbon tetrachloride-induced liver tumorigenesis in adult male Wistar albino rats.	Achieving Therapeutic Synergy	Thymoquinone potentiated the anticancer effect of cisplatin on hepatic tumorigenesis by modulating tissue oxidative stress and endoplasmic GRP78/CHOP signaling.	MEC00924
C62260	.	"The left kidney of the donor rat (Fisher F344) was perfused through the aorta with 4 degree centigrade heparinized Ringer's lactate solution and harvested, after transecting the ureter, the renal artery close to the aorta, and the renal vein near the vena cava. The recipient rat was anesthetized and a left nephrectomy was performed after transecting the renal artery, the renal vein, and the ureter."	Achieving Therapeutic Synergy	"Over a 50-week study, concomitant therapy of MMF and RAPA prevents chronic renal allograft rejection, probably through reduction of ischemic and cytotoxic degenerative changes."	MEC01462
C53641	NEWCL10380	The KIM-1 cell suspension was implanted subcutaneously in BALB/c athymic mice.	Achieving Therapeutic Synergy	The inhibitory effect of the combination of antineoplaston A-10 injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of human hepatocellular carcinoma.	MEC00548
C10758	NEWCL00170	The exponentially growing A549 cells were harvested and a tumorigenic dose of 2.5*106 cells was injected intraperitoneally into the 4-5 week-old mice.	Augmenting Drug Sensitivity	Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growth in vitro and in vivo.	MEC00351
C64244	.	The experiments were carried out on male Balb/c mice (8 - 10 weeks old).	Achieving Therapeutic Synergy	"Schisandrin B, attenuates cisplatin-induced oxidative stress, genotoxicity and neurotoxicity through modulating NF-KappaB pathway in mice."	MEC01366
C15117	.	Lewis lung carcinoma (LLC) cells (1*106) were injected in the rear flak of C57BL/6 mice.	Augmenting Drug Sensitivity	Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells.	MEC00468
C50701	.	The CT-26 mouse colon cancer cells (2*106 cells in 0.1 mL PBS) cultured in DMEM with 10% FBS were subcutaneously injected into the right flanks of the BALB/c male mice.	Decreasing Adverse Drug Reaction	Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma.	MEC00304
C12386	.	The co-treatment of the carcinogen 4-NQO (200 ug/ml) plus arecoline (500 ug/ml) in the drinking water for eight weeks to C57BL-6 mice specifically induced tongue cancer within a further 20 weeks.	Achieving Therapeutic Synergy	Arsenic trioxide plus dithiothreitol showed synergistic cytotoxic effects on mice oral cancer cells.	MEC01331
C02521	NEWCL00207	The B16 murine melanoma cells (2.5*105 cells/0.1 mL) were subcutaneously injected into the left flank of male five-week-old Balb/c nu/nu mice.	Achieving Therapeutic Synergy	Co-treatment using resveratrol and 5-FU inhibited cell proliferation are more efficiently compared with use of either drug alone.	MEC00116
C97947	NEWCL10252	The animal models were established in Sprague Dawley rats by continuous infusion of aconitine into the caudal vein or vena jugularis externa.	Achieving Therapeutic Synergy	The anti-arrhythmic effect of the combination of TTX and LID was greater than that of either TTX or LID alone.	MEC01354
C27241	.	The animal models were established in mice by a mixture of B[a]P plus NNK.	Achieving Therapeutic Synergy	PEITC-NAC plus MI was significantly more effective than the agents alone.	MEC01463
C85983	.	The animal model was established by unilateral ureteral obstruction (UUO) in male CD-1 mice.	Achieving Therapeutic Synergy	Combination therapy of paricalcitol and trandolapril had additive efficacy in retarding renal scar formation during obstructive nephropathy.	MEC00787
C50887	NEWCL00170	The A549/siE-cad cells (2*106) were injected subcutaneously into the underarms of the right forelimbs of 6-week-old BCLB/c mice.	Reversing Drug Resistance	Triptolide inhibits epithelial mesenchymal transition and induces apoptosis in gefitinib resistant lung cancer cells.	MEC01241
C55681	NEWCL10401	The 22 dry cows from 4 dairy farms were 3 to 6 years old suffered from clinical mastitis with S.aureus.	Achieving Therapeutic Synergy	The efficacy of combination therapy with antibiotics and Lf caused antibacterial effect of antibiotics and inhibition of pro-inflammatory cytokine and chemokine production with Lf via the inhibition of NFkappaB activation.	MEC01313
C07892	.	The 1*106 Ehrlich ascitic tumor cells were transplanted subcutaneously in the left thigh of male albino mice for the experiment.	Augmenting Drug Sensitivity	The use of HES as adjuvant therapy with DOX enhanced the therapeutic efficacy and alleviate the resistance to DOX in treatment of solid tumors.	MEC00222
C27661	.	Swiss mice (18-20 g) and Sprague-Dawley rats (120-150 g) were used in this study.	Achieving Therapeutic Synergy	SF and OMT combination had an obvious protective effect on PQ-induced lung injury. The anti-infammatory and antioxidant effect might be involved in the mechanism.	MEC01235
C27661	.	Swiss male mice (18-22 g) were used in this study.	Achieving Therapeutic Synergy	The combination of SF and OMT induced protective effects against CLP-induced lethal sepsis of mice. The possible mechanism of these effects may be associated with the alleviation of systemic inflammation and diminishment of oxidative injury.	MEC01236
C27661	.	The ethanol-induced liver damage mouse model was constructed on Swiss male mice.	Achieving Therapeutic Synergy	The combination of SF and OMT had a protective effect on ethanol-induced liver damage in mice and that antioxidation and anti-inflammatory effects mightbe involved in this protective mechanism.	MEC01237
C37217	.	Healthy adult male albino rats (8-10 weeks old; weighing 120-180 g) of Wistar strain were used in this study.	Decreasing Adverse Drug Reaction	Vanillic acid is a potential antioxidant that reduce cisplatin nephrotoxicity and can be as a combinatorial regimen in cancer chemotherapy.	MEC00633
C27955	NEWCL00074; NEWCL00076; NEWCL00080; NEWCL00353	SW620 cells (1*107) were injected subcutaneously into the right flank area of 6-8-week-old female nude mice.	Achieving Therapeutic Synergy	"Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin."	MEC00420
C87745	NEWCL00074	SW480 cells were subcutaneously injected into the back of the mice (2*106 cells in 200 mL of medium).	Achieving Therapeutic Synergy	Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo.	MEC01232
C77710	NEWCL00233; NEWCL00241	SW1990 cells were injected subcutaneously into the right flank of nude mice using a 23-gauge needle at a 2*106 cells per mouse.	Augmenting Drug Sensitivity	Salinomycin combined with gemcitabine could eliminate the engraftment of human pancreatic cancer more effectively than the individual agents.	MEC00004
C28779	.	"Subcutaneous injections of 2.5*105 viable MH134 cells suspended in 0.1 mL of media were performed in the right flanks of five-week-old male C3H/He mice, creating a bleb."	Achieving Therapeutic Synergy	Combination of doxorubicin and flavopiridol has a synergistic anti-tumor effect in an in vivo HCC model.	MEC00224
C05252	NEWCL10044; NEWCL10351; NEWCL10387; NEWCL10374; NEWCL10203	Subcutaneous injection of 1.0 * 106 UACC 903 or 1205 Lu melanoma cells were injected above both the left and right rib cages of 4-5 week-old female Athymic-Foxn1nu nude mice.	Achieving Therapeutic Synergy	Combination of Celecoxib and Plumbagin decreased melanoma cell proliferation and retarded vascular development of tumors mediated by inhibition of COX-2 and STAT3 leading to decreased levels of key cyclins key on which melanoma cell were dependent for survival.	MEC01161
C03914	.	"Specific-pathogen-free, eight-week-old male DBA/1J mice, and Eight-week-old C57BL/6 mice were used in this study."	Achieving Therapeutic Synergy	Astilbin is a valuable candidate for low-dose MTX combined therapy in RA via increasing A2AAR/adenosine system and decreasing ERK/NFKappaB/STATs signals.	MEC01192
C01817	.	"Specific-pathogen-free, 5-week-old male Mongolian gerbils were orally inoculated with 2 mL of bacterial suspension having a density of 1 * 108 cfu/mL."	Achieving Therapeutic Synergy	Plaunotol and clarithromycin combination exhibited Synergistic effects in the treatment of diseases associated with clarithromycin-resistant H. pylori.	MEC01421
C36011	.	"Specific-pathogen-free, eight-week-old male DBA/1J mice were used in this study."	Decreasing Adverse Drug Reaction	Astragaloside IV combined with ACEi exerted renal protective effects in db/db mice more significantly than their individual used.	MEC00550
C25294	.	"Solid tumors were induced by intramuscular inoculation of 0.2 mL of ascetic fluid, containing approximately 2.5*106 Ehrlich asites carcinoma cells, in the right thigh of the hind limb of each mouse."	Achieving Therapeutic Synergy	Luteolin and 5-flurouracil act synergistically to induce cellular weapons in experimentally induced Solid Ehrlich Carcinoma.	MEC00090
C17620	NEWCL00231	SKOV-3 cells (1*107 cells in 200 ll PBS per mouse) were injected subcutaneously on the right hind flank of mice.	Achieving Therapeutic Synergy	Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis.	MEC01080
C16256	NEWCL00169; NEWCL00141	"SK-Hep-1 cells (5*106 cells per mice) were suspended in 100 L of serum-free RPMI-1640 medium, then subcutaneously injected into the left flank of nude mice (Male, 4-6 weeks old)."	Achieving Therapeutic Synergy	Apigenin may potentiate the cytotoxicity of 5-FU in HCC via inhibition of ROS-mediated drug resistance and concurrent activation of the mitochondrial pathways of apoptosis.	MEC00083
C44803	NEWCL00129	Six-weeks-old BALB/c nude mice were subcutaneously injected with a 200 L cell suspension containing 5*106 HepG2 cells into the axillary region.	Achieving Therapeutic Synergy	The combination of matrine and cisplatin may promote tumor cell apoptosis in liver cancer by activating the caspase apoptosis pathway and suppressing the survivin-associated inhibition of caspase-9.	MEC00301
C99313	.	"To establish the animal model, 1*107 SK-Hep1 cells were suspended in 150 ul mix-ture of serum-free DMEM and matrigel (2: 1) and inoculated subcutaneously in the right legs of nude mice."	Achieving Therapeutic Synergy	Amentoflavone boosts therapeutic efficacy of sorafenib through blockage of anti-apoptotic potential and induction of apoptosis in HCC in vivo.	MEC01081
C31047	NEWCL00079; NEWCL00078; NEWCL00082; NEWCL10370	Six-week-old female nude mice received a subcutaneous injection of HCT-8/FU cells (1 * 106 suspended in 100 uL of PBS) on the right flank.	Achieving Therapeutic Synergy	Cucurbitacin E chemosensitizes colorectal cancer cells via mitigating TFAP4/Wnt/Beta-Catenin signaling.	MEC00917
C80627	.	Six-week old male ApoE KO mice were used in this study.	Achieving Therapeutic Synergy	Tan in conjunction with Ato represents an effective combination therapy to comprehensively combat atherogenesis in ApoE / mice by reducing plaque size and stabilizing vulnerable atheromatous plaques.	MEC01355
C67527	NEWCL00181; NEWCL00199; NEWCL00201	Six week old athymic (nu/nu) male nude mice were subcutaneously injected with three million exponentially growing H1299 cells mixed with equal volume (1:1) of matrigel on the right flank of each mouse.	Augmenting Drug Sensitivity	"Combinations of SAHA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."	MEC00198
C98672	NEWCL00181; NEWCL00199; NEWCL00201	Six week old athymic (nu/nu) male nude mice were subcutaneously injected with about three million exponentially growing H1299 cells mixed with equal volume (1:1) of matrigel on the right flank of each mouse.	Augmenting Drug Sensitivity	"Combinations of TSA with silibinin synergistically augmented the cytotoxic effects of the single agent, which was associated with a dramatic increase in p21 (Cdkn1a)."	MEC00263
C43351	.	Six- to eight-week-old male Syrian golden hamsters were used in this study.	Achieving Therapeutic Synergy	XN administered in combination with PZ could efficiently prevent CCA development and hence provide potential chemopreventive benefits in Ov-induced cholangiocarcinogenesis.	MEC01145
C74854	NEWCL10384	Six- to eight-week-old C57BL/6J female mice were used in this study.	Achieving Therapeutic Synergy	VD3 and SP may constitute an effective treatment regimen to improve wound healing after NM or other skin chemical injury.	MEC00670
C03179	NEWCL10096; NEWCL10117	Six to eight week old immuno-compromised male or female NOD/SCID mice were inoculated with 2 million BC-3 or BCBL-1 cells.	Achieving Therapeutic Synergy	Lenalidomide in combination with arsenic trioxide is an effective therapy for primary effusion lymphoma.	MEC01104
C76104	NEWCL00253; NEWCL00001; NEWCL00002	Single-cell suspensions of PC-3ML cells (1*106 cells) at passage 10 were injected intraperitoneally in 5- to 6-week-old male CB17-SCID mice.	Achieving Therapeutic Synergy	EGCG in combination with low levels of Dox had a synergistic effect in blocking tumor cell growth.	MEC00233
C69357	NEWCL00137; NEWCL00139	SiHa/CDDP cells (1*106) suspended in cold PBS were subcutaneously injected to the right armpit of mice (female BALB/c nude mice).	Achieving Therapeutic Synergy	Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.	MEC00961
C69848	NEWCL10337	Male Kunming mice (8- 10 weeks old; body weight: 22 +/- 2 g) were used to construct a short-term model of cardiomyopathy. 	Reversing Drug Resistance	Calycosin ameliorates doxorubicin-induced cardiotoxicity by suppressing oxidative stress and inflammation via the sirtuin 1-NOD-like receptor protein 3 pathway.	MEC01274
C83756	NEWCL00040	SHG44 cells (5*105 cells per mouse) in 5 uL of Hanks' solution were injected intracranially into the right caudate nucleus of 6- to 8-week-old female nude mice.	Achieving Therapeutic Synergy	Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway.	MEC00180
C49485	.	Seventy-two 35-day-old male albino Lewis rats were used in this study.	Achieving Therapeutic Synergy	The enhanced ameliorative effect of the combination treatment suggested that free radical formation and elevated intracellular calcium levels were two separate mechanisms in light-induced retinal degeneration.	MEC01329
C36772	NEWCL10018; NEWCL10086; NEWCL00142; NEWCL00113; NEWCL10148	"HGC-27 cells were suspended in 100 ul of PBS, and then implanted into the dorsal area, subcutaneously, of male BALB/c nude mice."	Achieving Therapeutic Synergy	"Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC."	MEC00912
C50594	.	"SD rats (250-270 g), C57BL/6 mice (25-30 g), and rabbits (2-3 kg) CS models were used in this study."	Achieving Therapeutic Synergy	Ani/Neo combination could produce therapeutic effects in CS.	MEC01224
C85982	NEWCL00360; NEWCL00361; NEWCL00270	SAS-R or Sa3-R cells (1*106) were injected subcutaneously into the backs of the female athymic nude mice.	Augmenting Drug Sensitivity	Resveratrol targets Urokinase-type plasminogen activator receptor expression to overcome cetuximab-resistance in oral squamous cell carcinoma.	MEC00439
C20591	.	Salmonella Typhimurium in rats were used in this study.	Achieving Therapeutic Synergy	MG has shown to increase the antimicrobial activity of MAR in vitro and ex vivo experiments without affecting the pharmacokinetics of MAR in rats.	MEC01439
C31690	.	"RL-952 cells at logarithmic growth phase were suspended to a density of 5*107/mL and subcutaneously injected into ovariectomized nude mice through the dorsal skin of each side (0.1 mL/mouse, containing 5*106 cells)."	Augmenting Drug Sensitivity	Treatment with either letrozole or curcumin could inhibit the xenografted endometrial tumor growth via inducing apoptosis in tumor cells. Combination of letrozole and curcumin further strengthened the inhibitory effect on tumor growth.	MEC00168
C60150	.	Retrospective clinical study	Achieving Therapeutic Synergy	The addition of mifepristone to medical treatment regimens for first trimester miscarriage significantly decreased the need for repeat medical dosing and surgical curettage.	MEC01433
C39202	NEWCL00129	"Rats received single I.P injection of Diethylnitrosamine (DENA) 200 mg/kg body weight, freshly dissolved in sterile 0.9% saline, as an inducer for hepatocellular carcinoma."	Achieving Therapeutic Synergy	CA4-P showed a potential anti-cancer activity against hepatocellular carcinoma and this effect was greatly enhanced by co-administration with vincristine.	MEC00925
C90689	.	"Male Sprague-Dawley rats, weighing 225 to 250 g were used in this study."	Decreasing Adverse Drug Reaction	"MMF treatment decreases CsA-induced nephrotoxicity, and combined treatment with LSRT has a synergistic effect in preventing chronic CsA nephrotoxicity."	MEC00981
C08827	.	In vivo experiment was carried out with rats.	Achieving Therapeutic Synergy	Combination therapy showed additive effect of the MH which restored lipid peroxidation and improvement of antioxidant parameters.	MEC01452
C48038	.	Forty male Sprague-Dawley rats weighting ranged from 200 to 250 g were used in this study.	Achieving Therapeutic Synergy	"NAR, TMZ, or their combination could attenuate the Nrf-2 expression in the kidney tissue, following the renal IR injury through inhibition of lipid peroxidase, and enhancement of antioxidant activity."	MEC01464
C17335	.	"Female Sprague-Dawley rats, weighing 200-250 g (10-12-week-old), were used in this study. "	Achieving Therapeutic Synergy	The combined administration of loxoprofen and glycine produced a synergistic inhibitory effect on the micturition reflex.	MEC01397
C03873	.	.	Achieving Therapeutic Synergy	Combination of morroniside and diosgenin prevents high glucose-induced cardiomyocytes apoptosis.	MEC01124
C78022	.	"Male Sprague-Dawley rats, weighing between 250 and 350 g were used in this study."	Reversing Drug Resistance	"L-carnitine can protect renal impairment functionally, biochemically and histopathologically with a corresponding reduction of oxidative stress."	MEC01543
C53382	.	Clinical Trial	Decreasing Adverse Drug Reaction	"The present study indicated a significant superiority of combination of ondansetron and aprepitant in management of RINV, in patients undergoing RT, compared to ondansetron as a single agent therapy."	MEC01425
C72836	.	Rabbits quarantine OA was induced by anterior cruciate ligament transection (ACLT) and partial medial meniscectomy on one knee.	Decreasing Adverse Drug Reaction	Glucosamine sulfate and risedronate treatment alone or in combination may be able to stop cartilage swelling. The risedronate treatment could partially stop the fibrillation and the inflammation of synovial membrane as well as modify the orientation of trabeculae in healthy and in osteoarthritic knees.	MEC01395
C47686	NEWCL00155; NEWCL00035	Portions of the suspension (6*106 MCF-7 cells in 0.1 mL) were subcutaneously injected into the right fanks of each female nude mice.	Achieving Therapeutic Synergy	Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo.	MEC00164
C22793	.	PNC-27 was tested in an intraperitoneal mouse model of ovarian cancer.	Achieving Therapeutic Synergy	PNC-27 could target cells surviving paclitaxel and improve its antitumor effect.	MEC00776
C72944	NEWCL00299; NEWCL00253; NEWCL00003	"PC3-luc cells (2*106) per 100L per site were injected subcutaneously in athymic nude mice (BALB/c, 6-week-old)."	Augmenting Drug Sensitivity	"Genistein increases the expression of pro-apoptotic protein Bax, activates apoptotic signals, and enhances the response to cabazitaxel treatment in mCRPC cells."	MEC00030
C18809	NEWCL00253; NEWCL00251	"PC3 cells (shRNA-FOXO3a cells and MOCK cells) were injected subcutaneously into the left inguinal area of nude mice (BALB/c, nu/nu, male, 6-8 weeks old)."	Achieving Therapeutic Synergy	The combination of Platycodin D and sorafenib may exert potent anti-cancer effects specifically via FOXO3a.	MEC00971
C80755	.	PC-3 cells (2*106 cells as a 50% suspension in matrigel) in a final volume of 0.1 mL were injected subcutaneously at right flank of Balb c nude mice.	Achieving Therapeutic Synergy	Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor.	MEC00534
C79568	NEWCL10409	Patient-Derived Xenograft Tumor Models were used in this study.	Achieving Therapeutic Synergy	Combination treatment with All-Trans Retinoic Acid prevents cisplatin-induced enrichment of CD133+ tumor-initiating cells and reveals heterogeneity of cancer stem cell compartment in lung cancer.	MEC00792
C76194	.	Parkinsonian rats were used as animal model in this study.	Achieving Therapeutic Synergy	"L-DOPA + celecoxib combination produces an antiallodynic and antihyperalgesic synergistic interaction at the systemic level, and these effects are mediated, at the central level, through activation of the NO-cGMP-ATP-sensitive K+ channel pathway."	MEC00753
C60643	NEWCL00241; NEWCL00233; NEWCL00242; NEWCL00239	PANC-1 cells suspension (5*107 cells) was injected subcutaneously into the right anterior armpit of female nude mice.	Achieving Therapeutic Synergy	Shikonin induces apoptosis and necroptosis in pancreatic cancer via regulating the expression of RIP1/RIP3 and synergizes the activity of gemcitabine.	MEC00065
C38290	NEWCL00242; NEWCL00241; NEWCL00243	PANC-1 cells (1*106 cells/50 ll) were injected into the pancreatic parenchyma of female BALB/c nude mice.	Achieving Therapeutic Synergy	"Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer."	MEC00962
C34139	.	Orofacial neuropathic pain mouse model was used in this study.	Achieving Therapeutic Synergy	"The DCS/PIO combination not only attenuated orofacial neuropathic pain and anxiety-related behaviors associated with trigeminal nerve injury, but it also improved mitochondrial bioenergetics."	MEC01526
C88236	.	Clinical trial	Achieving Therapeutic Synergy	Combining NX with omega-3 PUFAs increases their effectiveness in reducing serum TG and favorably altering AT gene expression and plasma bile acid profile.	MEC01303
C04478	NEWCL00008	NXS2 tumors were induced in A/J mice by injecting 2*106 cells in 100 mcL PBS subcutaneously on the left flank proximal to the spleen.	Achieving Therapeutic Synergy	RV in combination with IC provided an enhanced anti-tumor treatment in preclinical model as it lowered the tumor burden and increased survival.	MEC00530
C53594	NEWCL00279; NEWCL10059; NEWCL00123	Nude mouse models were established with U373-R GBM cells inoculated subcutaneously into the right flanks of 4-6-week-old female mice.	Reversing Drug Resistance	"SFN effectively inhibited activity of NF-KappaB signaling pathway and then reduced MGMT expression to reverse the chemo-resistance to TMZ in T98G, U87-R and U373-R cell lines."	MEC00627
C64576	NEWCL00129	Nude mice were subcutaneously inoculated with HepG2 cells at a density of 5 * 106 cells/mouse.	Achieving Therapeutic Synergy	"DOX/PEG-Fmoc-GA containing micelles facilitated the efficient cleavage of GA in tumor tissues/cells, leading to a higher level of synergistic antitumor activity with DOX in vitro and in vivo."	MEC01497
C01053	NEWCL00129; NEWCL00140	Nude mice were inoculated subcutaneously with injections of 1*107 SMMC-7721 cells/mouse at the right axilla.	Augmenting Drug Sensitivity	Wogonin enhances 5-FU cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.	MEC00081
C10758	NEWCL00030	Nude mice were injected subcutaneously in axilla area with 0.2 mL HCCLM3 cell suspension with a concentration of 2.5*107 /mL.	Augmenting Drug Sensitivity	"Genistein reinforced the inhibitory effect of cisplatin on HCC cell proliferation and tumour recurrence and metastasis after curative hepatectomy in nude mice, possibly through mitigation of cisplatin-induced MMP-2 upregulation."	MEC00352
C06446	NEWCL10054	NT2/D1 cells (106) mixed with Matrigel were implanted into 6-week-old athymic nude mice bearing the nu/nu gene [NIH(s) (nu/nu)] and housed under pathogen-free conditions.	Achieving Therapeutic Synergy	Addition of fisetin to cisplatin activates both the mitochondrial and the cell death receptor pathway and could be a promising regimen for the elimination of embryonal carcinoma cells.	MEC00985
C29596	NEWCL00329; NEWCL00155; NEWCL10052; NEWCL00049; NEWCL10177	Non-tumor bearing female Sprague Dawley rats (age 6-8 weeks) were examined for the cardiac effects of SFN administration during chronic DOX treatment.	Decreasing Adverse Drug Reaction	Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.	MEC00616
C35718	.	Nitroglycerin induced migraine model were used in this study.	Achieving Therapeutic Synergy	Systemic kynurenine + probenecid treatment significantly diminishes nitroglycerin-induced increase of c-fos immunoreactivity in the brainstem.	MEC01549
C21577	NEWCL10393; NEWCL10360; NEWCL10361; NEWCL00192; NEWCL10198; NEWCL10199	.	Achieving Therapeutic Synergy	Metformin and trametinib combinations are effective in preclinical models and may be a possible option for treatment of NRAS mutant cancers.	MEC00697
C96561	NEWCL00344; NEWCL00082	.	Achieving Therapeutic Synergy	"The synergistic actions of Gamma-T3 and ATST could be attributed to their mediation of 3-hydroxy-3-methyl-glutaryl-CoA reductase, and the subsequent inhibition of protein geranylgeranylation."	MEC01408
C68358	.	NC/Nga mice Induction of AD using Df body ointment was performed.	Achieving Therapeutic Synergy	Combination therapy of glucosamine plus FK-506 was more synergistic efficacy than single-modality treatment with either alone to improve the development of established dermatitis in NC/Nga mice model.	MEC01396
C72207	NEWCL00117; NEWCL00108	N87 cells (3*105 cells) were suspended in 0.1 mL of PBS and inoculated subcutaneously into the right flank of five-week-old male BALB/c nude mice.	Augmenting Drug Sensitivity	"PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis."	MEC00390
C72207	NEWCL00117; NEWCL00108	N87 cells (3 * 105 cells) were suspended in 0.1 mL of PBS and then inoculated subcutaneously into the right flank of five-week-old male BALB/c nude mice.	Achieving Therapeutic Synergy	Pterostilbene enhances sorafenib's anticancer effects on gastric adenocarcinoma.	MEC00835
C00848	NEWCL00117	N87 cells (1*107/per mouse) were inoculated subcutaneously into the right flank of female BALB/c nude mice.	Achieving Therapeutic Synergy	Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway.	MEC00429
C98556	NEWCL00251; NEWCL00252; NEWCL00155; NEWCL00049	Zebrafish and male C57BL/6 mice were used in this study.	Decreasing Adverse Drug Reaction	Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.	MEC01238
C45460	NEWCL10204	Six-week-old female Swiss mice were immunosuppressed with a combination of cyclophosphamide and cortisone acetate.	Achieving Therapeutic Synergy	The PSC and AFG combination therapy was highly effective and should be evaluated in larger-scale experiments.	MEC01424
C64312	NEWCL00048; NEWCL00132	Murine hepatoma H22 cells (10 * 106) suspended in 0.2 ml of serum-free RPMI 1640 were inoculated s.c. in the left armpit of each mouse.	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.	MEC01306
C74792	NEWCL00048; NEWCL00132	Murine hepatoma H22 cells (10 * 106) suspended in 0.2 ml of serum-free RPMI 1640 were inoculated s.c. in the left armpit of each mouse.	Achieving Therapeutic Synergy	The combination of natural product gambogic acid and the proteasome inhibitor MG132 or MG262 results in a synergistic inhibitory effect on growth of malignant cells and tumors in allograft animal models and there was no apparent systemic toxicity observed in the animals treated with the combination.	MEC01307
C45042	NEWCL00129	Murine hepatoma 22 (H22) cells were diluted with icy 0.9% saline and inoculated subcutaneously at right axilla of mice (5*106 viable cells/mL).	Achieving Therapeutic Synergy	The anti-hepatocellular carcinoma effects in vitro and in vivo of 5-FU and oroxylin A combinations were synergistic and oroxylin A increased the sensitivity of HepG2 cells to 5-FU by modulating the metabolic enzymes of 5-FU and apoptotic-related proteins.	MEC00080
C62098	.	Mouse was shaved with electric clippers and an approximately 4 cm2 area was marked and slightly abraded with sterile sandpaper before infection with 20 ul of suspension containing 1*106 C. albicans.	Achieving Therapeutic Synergy	"It is very likely that, by damaging the cell wall, glycyrol helps fluconazole invade C. albicans more readily and attack fluconazole's target in the fungus membrane."	MEC01398
C84395	.	Mouse LLC (Lewis lung cancer) cells (5*106 cells in 0.1 mL) were injected into the right flank of C57BL/6 mice.	Augmenting Drug Sensitivity	Carnosic acid enhances the anti-lung cancer effect of cisplatin by inhibiting myeloid-derived suppressor cells.	MEC00313
C08819	NEWCL00189; NEWCL00146; NEWCL00155	Mouse 4T1 breast cancer cells (1.0*105) were suspended in 0.1 mL of normal saline (NS) and injected subcutaneously in theright axillary fossa of BALB/c mice.	Achieving Therapeutic Synergy	Honokiol inhibited the proliferation of 4T1 cells via apoptosis and significantly enhanced the apoptosis of 4T1 cells induced by adriamycin.	MEC00211
C94552	NEWCL00032; NEWCL00064	MOLT-4 cells were implanted (1*107 cells/ml) into severe combined immunodeficiency (SCID) mice.	Achieving Therapeutic Synergy	The combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.	MEC00840
C47754	.	MOG35-55 in female C57BL/6 mice were used in this study.	Achieving Therapeutic Synergy	Combined atorvastatin and ATRA have immunomodulatory synergistic benefits.	MEC00788
C94033	.	Nineteen late-lactating cows had all 4 mammary quarters individually inoculated (185 cfu) through the teat cistern with the PG-resistant Staph. Aureus SHY97-4320.	Achieving Therapeutic Synergy	"BLF added to PG is an effective combination (i.e., 3- to 5-times higher cure rate) for the treatment of stable Staph. aureu infections highly resistant to beta-lactam antibiotics."	MEC01550
C99451	NEWCL00155; NEWCL00049	"Afer 1 week of NC13 or Vms pre-treatment, 0.5*105 of 4T1 cells were subcutaneously injected into the mammary fat pad of each mouse."	Reversing Drug Resistance	Verminoside sensitizes cisplatin-resistant cancer cells and suppresses metastatic growth of human breast cancer.	MEC01275
C19445	.	Middle cerebral artery occlusion (MCAo) was performed for 2 hours on Sprague-Dawley (SD) rats using intraluminal thread insertion.	Achieving Therapeutic Synergy	By suppressing apoptotic processes citicoline with hypothermia is more effective than either used alone in ameliorating cerebral damage after transient focal ischemia.	MEC01590
C69492	NEWCL10210	Mice with PA pneumonia were used as animal model in this study.	Achieving Therapeutic Synergy	Intranasal L-Met treatment along with antibiotics can cure chronic PA lung infection in mice.	MEC01438
C07139	NEWCL00036; NEWCL10075	Mice were subcutaneously inoculated with 0.1ml of 2.5*106 A375 cells or 5*106 SK-MEL-28 cells (prepared in a 50ul media + 50ul matrigel) in each flank to initiate tumor growth.	Achieving Therapeutic Synergy	Fisetin potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.	MEC00942
C75724	NEWCL00139	Mice were subcutaneously implanted with cell suspension holding 1*106 Caski cells in the right flank.	Achieving Therapeutic Synergy	"Sch B enhanced the anti-tumor effects of DTX in vitro and in vivo via growth, invasion, and apoptosis regulating."	MEC01118
C69906	NEWCL00253; NEWCL00252	Mice were inoculated with PC-3 cells (1*106 per 100 AL medium) into the dorsolateral lobe of the prostatic capsule.	Achieving Therapeutic Synergy	"Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis."	MEC00631
C74541	.	Mice were infected intraperitoneally with parasitized erythro-cytes.	Achieving Therapeutic Synergy	Malaria parasites in the mice given chloroquine plus alkaloids decreased on day 6 and then were not detected by a microscopic examination during observation period.	MEC01380
C10054	NEWCL00279; NEWCL00039	Mice were implanted subcutaneously with GSCs or GSCs stably transfected with pre-miR-590-3p into the right flank regions of mice at 2 * 106 cells density.	Achieving Therapeutic Synergy	"EMAP-II in combination with TMZ suppresse malignant biological behaviors of GSCs via miR-590-3p/MACC1 inhibiting PI3K/AKT/mTOR signaling pathway, and might provide potential therapeutic approaches for human GSCs."	MEC01272
C72298	.	"Equal numbers of male and female Kunming mice, weighting 18-22 g were used in this study."	Decreasing Adverse Drug Reaction	Breviscapine can reduce cisplatin-induced renal toxicity in mice.	MEC01450
C59166	.	"Mice were exposed to X-ray radiation (400 Roentgen), and both mice and rabbits were intraperitoneally injected with cyclophosphamide (100.0 mg/kg) and cytarabine chloride (92.7 mg/kg), respectively, for 3 days to induce myelosuppression."	Decreasing Adverse Drug Reaction	These results substantiate the marked therapeutic effects of CPA to ameliorate myelosuppression induced by radio and chemotherapy.	MEC01481
C54033	.	Mice bearing intramuscularly growing Lewis lung carcinoma were used as animal model in this study.	Achieving Therapeutic Synergy	Small to moderate doses of abrin significantly potentiated the therapeutic effect of cyclophosphamide without increasing the toxicity.	MEC01441
C68816	.	Eight-week-old balb/c albino male mice were used in this study.	Decreasing Adverse Drug Reaction	The gentamicin administration causes nephrotoxicity and the use of alpha-linolenic acid can be helpful against this toxic effect.	MEC00989
C19292	.	"C57BL/6J mice (8-10 weeks old, male), which have been shown to be radiation sensitive, were housed five animals per cage under controlled conditions and received standard laboratory diet through the course of the experiment."	Decreasing Adverse Drug Reaction	AC is able to prevent radiation-initiated genotoxicity by mitigating DNA damage.	MEC01594
C57596	NEWCL00236	MIA PaCa-2 cells (2*106 cells/100 L) were injected subcutaneously into the right flank of female nude mice aged 4-6 weeks.	Augmenting Drug Sensitivity	Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells.	MEC00109
C07781	.	Clinical trial review	Achieving Therapeutic Synergy	The combination was very well tolerated and was not associated with any adverse impact in quality of life compared with paclitaxel alone.	MEC00774
C47222	.	Medical records	Achieving Therapeutic Synergy	The combination of STZ and 5-FU is effective in the treatment of pNETs in terms of survival and radiological response and has an acceptable toxicity profile.	MEC00760
C85377	NEWCL00162; NEWCL00049	MDA-MB-231 cells (5*106 cells in 100L of PBS) were subcutaneously injected to the left flank of each female nude mice.	Augmenting Drug Sensitivity	"beta-Elemene Enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-kappaB signaling pathways."	MEC00073
C85683	NEWCL00155; NEWCL00049; NEWCL00052	MDA-MB-231 cells (2*107) were inoculated subcutaneously into the right flanks of female BALB/c nude mice (6-7 weeks old).	Achieving Therapeutic Synergy	Synergistic effect between celecoxib and luteolin is dependent on estrogen receptor in human breast cancer cells.	MEC00036
C04523	NEWCL00155; NEWCL00049	MCF-7/adr cells (5*105 cells in 0.1mL) suspended in serum-free medium containing 50% Matrigel were inoculated subcutaneously through 25-gauge needles into the right flank of each nude mouse.	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.	MEC00238
C49968	.	MCF-7 cells were inoculated under right mammary gland of female C57 mice.	Achieving Therapeutic Synergy	"Endostar combined with ginsenoside Rg3 has stronger inhibiting effect on breast cancer tumor growth in tumor-bearing mice than single drug, and it can inhibit angiogenesis and cell invasion, and enhance cell autophagy."	MEC00433
C18844	NEWCL00155	MCF-7 cells (1*107/mL) were inoculated into the mammary fat pads of the female nu/nu athymic mice (7 weeks old).	Achieving Therapeutic Synergy	Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells. The combination of MMC and curcumin inhibits MCF-7 cell proliferation and cell cycle progression in vitro and in vivo via the p38 MAPK pathway.	MEC00409
C57493	.	Female (PL/J * SJL/J)mice were immunized with MBP Ac1-11 (100 ug) to establish the animal model.	Decreasing Adverse Drug Reaction	"Monocytes treated with the combination of suboptimal doses of atorvastatin and GA secreted an antiinflammatory type II cytokine pattern and, when used as APCs, promoted Th2 differentiation of naive myelin-specific T cells."	MEC01213
C15069	NEWCL00155	Mammary carcinogenesis was initiated with two intra peritoneal doses (50 mg/kg body weight each) of N-methyl-N-nitrosourea (NMU) dissolved in a physiological NaCl solution.	Achieving Therapeutic Synergy	Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats.	MEC00045
C94054	.	Male Wistar rats weighing 180-210 g were used in this study.	Decreasing Adverse Drug Reaction	Acetovanillone prevents cyclophosphamide-induced acute lung injury by modulating PI3K/Akt/mTOR and Nrf2 signaling in rats.	MEC00758
C96718	.	Male Wistar rats weighing 180-210 g were used in this study.	Achieving Therapeutic Synergy	"AV and ED prevent CP cardiotoxicity by attenuating oxidative stress and tissue injury, and modulating cytoglobin, and PI3K/Akt/mTOR and Keap1/Nrf2 signaling."	MEC00757
C06295	.	Male Wistar rats aged 7-9 weeks (weight range: 180-220 g) were used in this study.	Decreasing Adverse Drug Reaction	The combination of naproxen and citral reduces nociception and gastric damage in rats.	MEC01515
C44236	NEWCL10296	Male Wistar rats (300-400 g) were used in this study.	Achieving Therapeutic Synergy	The combined treatment may have a potential therapeutic value in the initiation of fibrotic process.	MEC00658
C72898	.	"Male Wistar rats (150-200 g, age 6-8 weeks) were used in this study."	Decreasing Adverse Drug Reaction	Aloin alleviates doxorubicin-induced cardiotoxicity in rats by abrogating oxidative stress and pro-inflammatory cytokines.	MEC00810
C03422	.	Male Wistar albino rats weighing 200 +/- 20 g were used in this study.	Decreasing Adverse Drug Reaction	"VA exerts cardioprotective effects against DOX-induced cardiotoxicity by decreasing oxidative stress and biomarkers of cardiotoxicity, suppression of TLR4 signaling and consequently inflammation pathway."	MEC01284
C04501	.	Male Wistar Albino rats were used in this study.	Achieving Therapeutic Synergy	Combined use of theophylline and methylprednisolone had positive effects on the contraction strength and the durations of contraction and semi-relaxation of the diaphragm muscle.	MEC01351
C32613	.	Male Swiss albino mice were given a diet containing high fat.	Achieving Therapeutic Synergy	"Simultaneous treatment with AS, F and their combination protected against HFD induced weight gain and oxidative stress."	MEC01219
C78446	.	Male Swiss albino mice weighing 25 +/- 5 g were used in this study.	Decreasing Adverse Drug Reaction	Adjuvant administration of AcoA with doxorubicin could provide a new treatment strategy for the rescue of jeopardized myocardium from doxorubicin-induced cardiomyopathy.	MEC00807
C79594	.	Male Sprague-Dawley rats weighing 220+ 20 were used in this study.	Decreasing Adverse Drug Reaction	Alpha-Linolenic acid attenuates doxorubicin-induced cardiotoxicity in rats through suppression of oxidative stress and apoptosis.	MEC00968
C50594	.	Male Sprague-Dawley rats were used in this study.	Achieving Therapeutic Synergy	"Current study identified the optimal combination of neostigmine and anisodamine against ischemic stroke, and indicated that the acetylcholine-Alpha7 nicotinic acetylcholine receptor is involved in the protective effects."	MEC00982
C21165	.	Male Sprague-Dawley (SD) rats weighing 200-220 g were used in this study.	Achieving Therapeutic Synergy	Colchicine combined with atorvastatin may have stronger protective effects on improving endothelial function and ameliorating inflammation in rats with hyperlipidemia.	MEC01516
C35852	.	Male rats were used to establish colistin-induced nephrotoxicity animal model in this study.	Achieving Therapeutic Synergy	Combined use of taxifolin and dapagliflozin may confer a therapeutic tool for attenuation of colistin-induced nephrotoxicity.	MEC00635
C82644	NEWCL00141; NEWCL00031	Male nude mice (4-6 weeks) were inoculated subcutaneously with human liver cancer cell lines Huh7.	Achieving Therapeutic Synergy	Celastrol exerts Synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo.	MEC00014
C81026	NEWCL00226; NEWCL00228; NEWCL00355	Male nude mice (4 weeks old) were subcutaneously injected with 200 uL of sterile PBS containing a 143B cell suspension at a density of 106 cells/mL.	Achieving Therapeutic Synergy	Cotreatment with CAP and DDP triggered prosurvival autophagy through reactive oxygen species (ROS)/JNK and p-AKT/mTOR signaling in OS cells.	MEC00377
C31089	.	Male NGS/Sea Mongolian gerbils (17 weeks old) were infected with H. pylori (ATCC43504).	Achieving Therapeutic Synergy	The CFU of Helicobacter pylori was significantly decreased by GTC-scf.	MEC01500
C79321	NEWCL10326; NEWCL10325; NEWCL10324; NEWCL10323; NEWCL00049	Male NCr-nu/nu mice were used in this study.	Achieving Therapeutic Synergy	"Combination of simvastatin and metformin, within pharmacologic dose range (500 nmol/L to 4 umol/L simvastatin and 250 umol/L to 2 mmol/L metformin), significantly and synergistically reduces C4-2B3/B4 CRPC cell viability and metastatic properties, with minimal adverse effects on normal prostate epithelial cells."	MEC00706
C73000	.	Male mice of 6-8 weeks age with weights of 18-22 g were used in all experiments.	Decreasing Adverse Drug Reaction	"Urolithin A attenuated cisplatin-induced kidney injury in mice through the down regulation of inflammatory cytokines/chemokine, immune cells, and oxidative/nitrative stress thus improving cisplatin-induced proximal tubular cell death."	MEC01216
C58456	.	Male K14-VEGF mice (10 weeks old) were used in this study.	Achieving Therapeutic Synergy	The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis.	MEC01423
C98749	NEWCL10339; NEWCL10411; NEWCL00082	Male Institute of Cancer Research (ICR) mice were used in this study.	Decreasing Adverse Drug Reaction	"Bisdemethoxycurcumin attenuates cisplatin-induced renal injury through anti-apoptosis, anti-oxidant and anti-inflammatory."	MEC01259
C06862	.	Male ICR mice (18-22 g) and male Sprague-Dawley rats (300-350 g) were used in this study.	Decreasing Adverse Drug Reaction	Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.	MEC01243
C27359	.	"Male ICR mice, weighing 25-30 g, were used for passive avoidance and water maze tests."	Decreasing Adverse Drug Reaction	Acteoside of Callicarpa dichotoma attenuates scopolamine-induced memory impairments.	MEC01412
C90820	NEWCL00022; NEWCL00033; NEWCL00204	Male CD2F1 mice (24-28 g) were injested with L1210 leukemic cells intravenously into the lateral tail vein.	Achieving Therapeutic Synergy	The combined treatment produced a synergistic loss of clonogenicity in human myeloid (HL-60) and lymphoid (MOLT-3) leukemic cell lines.	MEC00407
C50210	.	Male C57BL/6 mice(18-22g) were exposed to 60Co Gamma-irradiation at a dose of 7.5 Gy or 3 Gy and the dose rate was 1.58 Gy/min	Decreasing Adverse Drug Reaction	AMF is a potential protective agent against radiation injury.	MEC01302
C72398	NEWCL10337	Male C57BL/6 mice were used in this study.	Decreasing Adverse Drug Reaction	Asiatic acid could attenuate DOX-induced myocardial oxidative stress and apoptosis via activation of the AKT signaling pathway.	MEC00969
C06862	.	Male C57BL/6 JAX mice (10-12 weeks) were used to produce subacute Dox injury in mice. 	Decreasing Adverse Drug Reaction	"Schisandrin B prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of MAPK/p53 signaling."	MEC01253
C13933	NEWCL00236; NEWCL00241	Male BALB/c nude mice were subcutaneously inoculated with MiaPaca-2 cells (1*106 cells/mouse) cells in 1 mL of Matrigel.	Augmenting Drug Sensitivity	The combination of gemcitabine and apigenin enhanced anti-tumor efficacy through Akt and NF-kappa B activity suppression and apoptosis induction.	MEC00049
C62662	NEWCL00170; NEWCL00181	Male Balb/c nude mice at 4-6 weeks of age were injected sc in the hind limb with 1 * 107 H1299 cells in 100 ul of phosphate-buffered saline.	Achieving Therapeutic Synergy	Combined treatment with ATO and SAHA resulted in enhanced suppression of non-small-cell lung carcinoma in vitro in H1299 cells and in vivo in a xenograft mouse model.	MEC01255
C43311	NEWCL00172; NEWCL00175	"Male BALB/c nude mice (4-6 weeks old, 18-22 g) were injected subcutaneously in the rear flank with 4 * 106 PC-9OR cells."	Reversing Drug Resistance	Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer.	MEC00573
C97109	.	Male BALB/c mice aged 6 weeks were used in this study.	Achieving Therapeutic Synergy	Acar and low-dose CsA in combination alleviates psoriatic skin lesions by inhibiting inflammation.	MEC01214
C09488	NEWCL00242; NEWCL00243	Male BALB/c immunodeficient nude mice were injected with PANC-1 cells (1*107) with matrigel (100 uL) to the right flank of each mice.	Augmenting Drug Sensitivity	Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-kappaB signaling by 6-shogaol.	MEC00046
C59856	.	Male BABL/c mice aged 6-8 weeks were used in this study.	Achieving Therapeutic Synergy	PKRI alone and combination therapy with PKRI and MPA reduce tumor growth and may alleviate cachexia.	MEC00551
C91592	NEWCL00243	Male athymic nude mice were inoculated with BxPC-3 cells (1*106 cells/mouse) cells.	Augmenting Drug Sensitivity	"Combination of luteolin and gemcitabine promoted apoptotic cell death in pancreatic tumor cells in vivo through inhibition of the K-ras/GSK-3beta/NF-kappaB signaling pathway, leading to a reduction in the Bcl-2/Bax ratio, release of cytochrome c, and activation of caspase 3."	MEC00052
C03662	NEWCL00169; NEWCL00141	Male athymic nude mice (4-6-week) were injected subcutaneously into left flank with 1*107 GFP-SK-Hep-1 cells.	Augmenting Drug Sensitivity	Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway.	MEC00123
C63080	NEWCL00082; NEWCL00077; NEWCL00073	HCT116 cells (1.5*106 cells) in 50 mL of PBS were injected into the cecum of  athymic nu/nu mice (4 weeks old) using a 30-gauge needle.	Augmenting Drug Sensitivity	"Ursolic acid can inhibit the growth and metastasis of CRC and further enhance the therapeutic effects of capecitabine through the suppression of multiple biomarkers linked to inflammation, proliferation, invasion, angiogenesis, and metastasis."	MEC00012
C55696	NEWCL00286; NEWCL00245; NEWCL00295	Male athymic balb/c nude mice were implanted with 2 * 106 cells with Human MM U266 cell lines subcutaneously.	Achieving Therapeutic Synergy	Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma.	MEC01163
C29204	.	Male APP/PS1 transgenic mice and littermate wild type control were used in this study.	Achieving Therapeutic Synergy	This study demonstrated the efficacy of a novel AD therapeutic strategy targeting at multiple disease-causing mechanisms through the Synergistic effects of microdose lithium and pyrroloquinoline quinone.	MEC00542
C84114	NEWCL10288	The MC B6-1 fibrosarcoma was originally induced by s.c.injection of 2 mg of methylcholanthrene in a female C57BL/6 mouse and serially transplanted in syngeneic mice.	Decreasing Adverse Drug Reaction	The addition of selenium decreases the nephrotoxicity of cis-DDP.	MEC00547
C95252	NEWCL00208	M5076 ovarian sarcoma cells (1.0*106 cells/animal) were transplanted i.p. into C57BL/6 mice.	Augmenting Drug Sensitivity	"While DOX alone did not decrease tumor weight, the combination of DOX and curcumin significantly reduced tumor weight. The combined curcumin enhanced apoptosis by DOX, decreased cell viability and suppressed activation of caspase-3, -8, and -9 compared to DOX alone."	MEC00215
C79731	NEWCL00208	M5076 ovarian sarcoma (1 * 106 cells/mouse) were s.c. transplanted onto the backs of BDF1 mice.	Achieving Therapeutic Synergy	Theanine increased not only the antitumor activity on primary tumor but also the metastasis-suppressive efficacy of doxorubicin.	MEC01353
C75746	NEWCL00080	LoVo cells were suspended in serum-free medium and injected subcutaneously into the right flank of the nude mice at 1*106/0.1mL/mouse.	Achieving Therapeutic Synergy	Curcumin combined with oxaliplatin effectively suppress colorectal carcinoma in vivo through inducing apoptosis.	MEC00424
C42410	NEWCL10047; NEWCL10041; NEWCL00330	"Aliquots of cells (0.1 ml, 3 * 106 cells) were mixed with 0.2 ml of phenol red-free Matrigel and injected into the right flank of mice."	Achieving Therapeutic Synergy	"Fisetin not only displays in vitro and in vivo antiangiogenic properties, but also can markedly improve the in vivo antitumour effect of CPA."	MEC01266
C46795	NEWCL00170; NEWCL00181	"LLC cells suspension (200 mL/mouse, 1*107 cells/mL) was implanted carefully subcutaneously into the right side of the back of C57BL/6 mice."	Achieving Therapeutic Synergy	"The combination of curcumin and fenretinide can potentially be effective therapeutic agents for treating NSCLC, at least in part, by regulating endoplasmic reticulum (ER) chaperone protein GRP78."	MEC00158
C66955	.	Lewis lung carcinoma (1*106/0.1 mL) was inoculated subcutaneously in the right flank of each C57/BL6 mouse.	Augmenting Drug Sensitivity	"Continuous low-dose regimen of CTX increases the efficacy of targeting the tumor microvasculature, which produces therapeutic activity with decreased toxicity."	MEC00181
C84475	.	Lewis lung cancer cells (~3*106) were subcutaneously injected into the right anterior leg of each mouse to establish the tumor-bearing mouse model.	Achieving Therapeutic Synergy	"A combinatory treatment strategy of nadroparin with fractionated irradiation had a strong synergistic antitumor effect in vivo, which may be associated with the promotion of apoptosis, inhibited secretion of TGF-Beta1 and IL-6 and down-regulation of CD34 and survivin expression."	MEC01323
C42261	.	Lewis lung cancer cells (1 * 106) was inoculated into the right hind leg of C57BL/6 mice. 	Achieving Therapeutic Synergy	"Combining radiotherapy and cantharidin may have Synergistic effects in driving tumor rejection by increasing T-cell infiltration, proliferation and cytokine production."	MEC00908
C98052	NEWCL00250; NEWCL00263	KTC-1 and TPC-1 cells in logarithmic growth phase were subcutaneously inoculated into the right armpit of Nude BALB/c mice (5*106 cells/mouse).	Achieving Therapeutic Synergy	Resveratrol sensitizes the anti-tumor effects of rapamycin and the PI3K/AKT/mTOR signaling is involved.	MEC00288
C84580	.	Islet Xenotransplantation: Rat islets (400/transplant) were implanted under the renal capsule of recipient mice that were rendered hyperglycemic by single-dose streptozotocin.	Achieving Therapeutic Synergy	Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapy.	MEC01568
C60125	.	Islet Xenotransplantation: Rat islets (400/transplant) were implanted under the renal capsule of recipient mice that were rendered hyperglycemic by single-dose streptozotocin.	Achieving Therapeutic Synergy	Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapy.	MEC01569
C37324	.	"Overnight fasted rats (Adult male Sprague-Dawley rats) were injected intra-peritoneally with strepto zotocin (55 mg/kg) dissolved in citrate buffer (pH 4.5, 0.1 M) to induce diabetes."	Achieving Therapeutic Synergy	Diabetic rats treated with insulin-FA combination demonstrated more pronounced beneficial effects as compared to either agent alone.	MEC01020
C39724	NEWCL00149	"Inbred BALB/c mice with CIN were injected peritoneally with isotonic sodium chloride solution (positive control), CIS, ZER, and a combination of both compounds."	Achieving Therapeutic Synergy	The combination of ZER and CIS has modulated the serum level of interleukin 6 when compared with that in mice treated with isotonic sodium chloride solution.	MEC01401
C50414	NEWCL10187	Amifostine effect on in vivo tumor growth was tested in athymic mice. 	Achieving Therapeutic Synergy	"Amifostine and paclitaxel shown a potential anticancer synergistic effect in vitro and in vivo, whereas amifostine maintained a protective role in peripheral blood profiles."	MEC00770
C24469	NEWCL00074; NEWCL00076	In vivo in a SW620 colon cancer xenograft model in BALB/c nude mice was use in this study.	Achieving Therapeutic Synergy	"MG in combination with silencing of GLOI synergistically inhibited the cancer cells' proliferation, colony formation, migration, and invasion and induced apoptosis in vitro compared with the controls."	MEC01024
C30696	.	"In the Sch B pretreatment group in the hepatotoxicity study, mice (Adult male ICR mice) were treated intragastrically with Sch B at daily doses of 0.125 and 0.5 mmol/kg for 3 days."	Decreasing Adverse Drug Reaction	Sch B may be useful for reducing the potential hepatotoxicity of THA/bis(7)-THA in anti-Alzheimer's therapy.	MEC01581
C74903	.	"In the Sch B pretreatment group in the hepatotoxicity study, mice (Adult male ICR mice) were treated intragastrically with Sch B at daily doses of 0.125 and 0.5 mmol/kg for 3 days."	Decreasing Adverse Drug Reaction	Sch B may be useful for reducing the potential hepatotoxicity of THA/bis(7)-THA in anti-Alzheimer's therapy.	MEC01606
C06962	.	"C57BL/6N female mice, immunosuppressed with cyclophosphamide, were challenged intravenously via the tail vein with 1.0 * 107 C. glabrata."	Achieving Therapeutic Synergy	The combination of liposomal amphotericin B with an echinocandin markedly improved the therapeutic outcome in murine C. glabrata systemic infection.	MEC01546
C85754	NEWCL00302	Human lung cancer xenografts were established by subcutaneously inoculating 5*106 95-D cells into nude mice.	Achieving Therapeutic Synergy	"The synergistic anticancer effects of celastrol and SAHA was demonstrated due to their reciprocal sensitisation, which was simultaneously regulated by NF-kappaB and E-cadherin."	MEC00199
C76936	NEWCL00028; NEWCL00030	Human HCC cell line MHCC97H were used to estabolish xenograft models in the BALB/c mice.	Reversing Drug Resistance	Beta-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.	MEC00939
C05101	NEWCL10125; NEWCL10102	Human GM-CSF-producing trans genic SCID (hGMTgSCID) mice were pretreated with 3 Gy of total body irradiation and then inoculated subcutaneously with UF-1 cells (1 * 107 cells) in their logarithmic growth phase.	Achieving Therapeutic Synergy	A combination of As2O3 and GM-CSF induces differentiation of APL cells both in vitro and in vivo.	MEC01223
C00179	NEWCL00108; NEWCL00352	Human gastric cancer MKN45 tumor xenografts were established in nude mice from cultured MKN45 cells by inoculating subcutaneously 0.2 mL of cell suspension (1.0*108 cells/mL) in the right flank of SPF grade female athymic nude mice.	Augmenting Drug Sensitivity	"Curcumin enhances the anticancer effect of 5-FU against gastric cancer in vitro and in vivo. The possible molecular mechanism may be, at least in part, related to down-regulation of COX-2 and NF-kappaB pathways."	MEC00095
C93360	NEWCL00270; NEWCL00152	HSC3 cells (1*107) were inoculated subcutaneously into the right flank of total eighty 6-8-week-old female BALB/c nude mice.	Achieving Therapeutic Synergy	Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.	MEC00438
C30853	NEWCL10366	High fat diet (HFD)-fed ApoE-/- mice were used in this study.	Achieving Therapeutic Synergy	Combination of metformin and liraglutide has synergistic protective effects on endothelial function.	MEC00702
C11954	NEWCL10318	Heterotopic vascularized heart transplantation was performed into the right cervical portion of the B6 mice.	Achieving Therapeutic Synergy	The combination of MMF and MZ showed mild Synergistic effects in the inhibition of MLR and strong Synergistic effects in a mouse heart transplantation model.	MEC01460
C28568	NEWCL00129; NEWCL00141	"HepG2 cells were collected in 0.2 ml of PBS, and the cell suspensions were then injected subcutaneously into five-week-old BALB/C male nude mice (5*106 cells per mouse)."	Achieving Therapeutic Synergy	MA/ATO combined treatment enhanced antitumor efficacy.	MEC01089
C53650	NEWCL00283; NEWCL00324	Hep3B cells was subcutaneously injected into the left axilla of each five-week-old healthy BALB/c female nude mice.	Achieving Therapeutic Synergy	"Curcumin had a synergistic effect with anti-PD-1 to slow Hep3B cell proliferation, activate lymphocytes, inhibit immune evasion, and down-regulate TGF-beta1 expression."	MEC00493
C76700	.	Healthy adult male Wistar rats (220-250 g) were used throughout the study.	Achieving Therapeutic Synergy	"Crocin and mesalazine produced protective effects on colon tissue via antioxidant and anti-inflammatory actions. In addition, a synergistic effect was observed between crocin and mesalazine in attenuating ulcerative colitis."	MEC01518
C77192	NEWCL00082	A volume of 100 ul HCT116-luc cells suspension (2.5*106 cells/ml) was injected subcutaneously into right dorsal flank of mice (5-week-old female BALB/c nude mice).	Achieving Therapeutic Synergy	Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.	MEC01178
C04317	NEWCL00170; NEWCL00082; NEWCL10120; NEWCL10035; NEWCL10158	HCT116 cells in a solution containing 25 ml of culture medium and 25 ml of mouse sarcoma extracellular matrix (Matrigel) were injected subcutaneously into the dorsal flanks of mice.	Achieving Therapeutic Synergy	Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.	MEC01603
C38026	NEWCL00082; NEWCL00074; NEWCL00076; NEWCL00155; NEWCL00036; NEWCL00113; NEWCL00129; NEWCL00283	HCT116 cells (5*106 cells per mouse) were suspended in PBS and inoculated subcutaneously into the left flank of each female BALB/c nude mice.	Achieving Therapeutic Synergy	Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1.	MEC00453
C18568	NEWCL00082; NEWCL00077; NEWCL00076; NEWCL00338	HCT116 cells (5*106 cells in 100uL of PBS) were harvested and injected subcutaneously into the right flank of five-week-old athymic BALB/cA nu/nu female mice.	Achieving Therapeutic Synergy	Shikonin as a synergistic agent to cisplatin could be a highly efficient way to achieve anticancer synergism by inducing intracellular oxidative stress.	MEC00362
C77192	NEWCL00082	HCT116 cells (2.5*105) were injected subcutaneously into right dorsal flank of 5-week-old female BALB/c nude.	Augmenting Drug Sensitivity	Combinative treatment of beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.	MEC00435
C00179	NEWCL00082; NEWCL00077	HCT116 cells (2*106) in 0.2 mL PBS or saline was injected into the right flank of male BALB/c-nu/nu mice mice to form xenograft tumors.	Achieving Therapeutic Synergy	"Curcumin could significantly augment the cytotoxicity of 5-Fu to the tumorous cells. Pre-treatment with curcumin followed by 5-Fu may mediate autophagy turnover both in vitro and in vivo via AMPK/ULK1-dependent autophagy inhibition and AKT modulation, which may account for the increased susceptibility of the colon cancer cells/xenograft to the cytotoxicity of 5-Fu."	MEC00093
C36915	NEWCL00129; NEWCL00031; NEWCL00140; NEWCL00141; NEWCL00029; NEWCL00028	"To establish the animal model, HCC cells were injected subcutaneously into nude mice."	Achieving Therapeutic Synergy	SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity.	MEC01278
C27255	NEWCL00283; NEWCL00129; NEWCL00027; NEWCL10332	HCC cells (2 * 106 of Huh7 cells or 3 * 106 of Hep3B cells suspended in 200 ul serum free medium) were inoculated into the dorsal flanks of male athymic nude mice (nu/nu) by subcutaneous injection.	Achieving Therapeutic Synergy	 The potent anti-cancer activity of this co-targeting strategy was indeed mediated in parts by inhibition of these key survival/anti-apoptotic proteins.	MEC00668
C55665	NEWCL00142; NEWCL10086; NEWCL00113	"Harvested GC cells were washed in serum-free DMEM, suspended in 100 uL PBS, and implanted subcutaneously into the dorsal area of the nude mice."	Achieving Therapeutic Synergy	"TQ significantly augments cisplatin-induced anti-tumor effects on gastric cancer both in vitro and in vivo, through inhibiting PI3K/AKT signaling pathway, activating the mitochondrial pathway, and down-regulating P-glycoprotein by up-regulating PTEN gene."	MEC00852
C75940	.	Haloperidol-induced tremulous jaw movements (TJMs) in rats were used as a model of parkinsonian-like tremor.	Achieving Therapeutic Synergy	"Memantine and THC supra-additively inhibit haloperidol-induced TJMs, suggesting that co-administration of these drugs might be a new approach to the treatment of tremor."	MEC01607
C02032	NEWCL10078; NEWCL10079	H727 and H720 parental and 3rd generation spheroid cells (3 * 104) were injected into the subcutaneous inguinal fat pad of NOD/SCID mice.	Achieving Therapeutic Synergy	"AZ + SFN combination were effective in inhibiting tumor cell growth, spheroid formation and in reducing tumor formation in immunocompromised mice."	MEC00606
C02032	NEWCL10078; NEWCL10079	H-727 and H-720 cells (2 * 106) were injected into the subcutaneous inguinal fat pad of NOD/SCID mice.	Achieving Therapeutic Synergy	Treatment of H-727 and H-720 subcutaneous xenografts in NOD/SCID mice with the combination of AZ + SFN for two weeks demonstrated highly significant growth inhibition and reduction of 5-HT content and reduced the invasive capacity of H-727 tumor cells.	MEC00604
C48090	NEWCL00178; NEWCL10107	A volume of 100 ul H23 cell suspension (1 * 108 cells/ml in normal saline) was subcutaneously injected into the right flanks of mouse (male BALB/c nude mice of 4-5 weeks old).	Achieving Therapeutic Synergy	Celastrol acts synergistically with afatinib to suppress non-small cell lung cancer cell proliferation by inducing paraptosis.	MEC00879
C67786	NEWCL00132	H22 cells suspension (1 * 107 cell/mL) with sterile normal saline was subcutaneously inoculated into the right oxter of forty-eight healthy mice at a dose of 0.2 mL per mice.	Achieving Therapeutic Synergy	Combination treatment with LEP-2a and CTX processed a significantly synergistic anti-tumor effect in H22 tumor-bearing mice through Fas/FasL mediated caspase-dependent death pathway and mitochondria apoptosis pathway.	MEC00749
C62469	NEWCL00181; NEWCL00171; NEWCL00170	H1975 human lung cancer cells (5 * 107 in 1 ml) or PC9/GR human lung cancer cells (3 * 107 in 1 ml) were injected subcutaneously into the right flank of athymic BALB/c nude mice (3-4 weeks old).	Achieving Therapeutic Synergy	Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase.	MEC01129
C83756	NEWCL00007	GICs (2*105) were subcutaneously injected into the left hind flank of the 6-week-old female NOD/SCID mice.	Augmenting Drug Sensitivity	Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiation.	MEC00179
C57472	.	Four-week-old female CD-1 (ICR) mice weighing 20 +/- 2 g were used in this study.	Achieving Therapeutic Synergy	Melatonin and ghrelin showed synergistic effect on preventing cisplatin-induced ovarian damage via regulation of FOXO3a phosphorylation and binding to the p27 Kip1 promoter in primordial follicles.	MEC00712
C15588	NEWCL00052; NEWCL00160; NEWCL00155; NEWCL00163; NEWCL00329	"Four to six week old female NOD-SCID mice received sub-cutaneous 17Beta-estradiol pellet (0.72 mg/day), 2 weeks prior to injection of 5 * 106 BT-474 cells resuspended in 4% Matrigel."	Achieving Therapeutic Synergy	"Celastrol strongly synergized with ErbB2-targeted therapeutics Trastuzumab, producing higher cytotoxicity with substantially lower doses of Celastrol."	MEC00933
C53856	NEWCL00052; NEWCL00160; NEWCL00155; NEWCL00163; NEWCL00329	"Four to six week old female NOD-SCID mice received sub-cutaneous 17Beta-estradiol pellet (0.72 mg/day), 2 weeks prior to injection of 5 * 106 BT-474 cells resuspended in 4% Matrigel."	Achieving Therapeutic Synergy	"Celastrol strongly synergized with ErbB2-targeted therapeutics Lapatinib, producing higher cytotoxicity with substantially lower doses of Celastrol."	MEC00934
C79238	NEWCL00145	Forty mice were inoculated sub cutaneously with injections of 1 * 106 BGC-823 cells/mouse.	Achieving Therapeutic Synergy	GA attenuated 5-FU-induced apoptosis by modulating metabolic enzymes of 5-FU and the antigastric cancer effect of two drugs combination was much stronger than that of GA or 5-FU alone.	MEC01043
C55665	NEWCL00180; NEWCL00182	 Xenografts were obtained by injecting NCI-H460 2 * 106 cells subcutaneously into the right flank of each mouse.	Reversing Drug Resistance	Combination of TQ and CDDP was well tolerated and significantly reduced tumor volume and tumor weight without additional toxicity to the mice.	MEC01249
C37427	NEWCL10119; NEWCL00021; NEWCL00020; NEWCL00019	"For the leukemic model, 3.0 * 105 spleen cells from MV4-11-engrafted mice were injected intravenously into 75 NSG mice."	Achieving Therapeutic Synergy	The combination of ATRA plus DARA induced Fc-dependent conjugate formation and cytotoxicity among AML blasts in vitro. Combination treatment also led to reduction in tumor volume and resulted in increased overall survival in murine engraftment models of AML.	MEC00790
C07139	NEWCL00149	"For the in vivo experiments, 1*106 HeLa cells (diluted in Matrigel) were established by subcutaneous injec tion into the animal's right flank."	Achieving Therapeutic Synergy	"The combination of fisetin and sorafenib exerted better Synergistic effects in vitro and in vivo than either agent used alone against human cervical cancer, and this synergism was based on apoptotic potential through a mitochondrial- and DR5-dependent caspase-8/caspase-3 signaling pathway."	MEC01003
C58031	NEWCL00082	"For the colorectal peritoneal carcinomatosis (CRPC) experiments, mouse-derived colorectal cancer cells CT26 (5 * 106 cells in 0.5 mL of serum-free medium) were intraperitoneal inoculated into the flanks of Balb/C mice."	Achieving Therapeutic Synergy	Combination treatment of citral potentiates the efficacy of hyperthermic intraperitoneal chemoperfusion with pirarubicin for colorectal cancer.	MEC01318
C67567	.	"For induction of colorectal tumorigenesis, AOM was dissolved in normal saline and injected subcutaneously at a dose of 15 mg/kg, once weekly for 2 weeks."	Achieving Therapeutic Synergy	Thymoquinone subdues tumor growth and potentiates the chemopreventive effect of 5-fluorouracil on the early stages of colorectal carcinogenesis in rats.	MEC01140
C39033	NEWCL10247	"For in vivo experiments, CSCs (5 * 104 cells) were implanted intracranially into 10 week-old female C.B17-lcr SCID mice."	Achieving Therapeutic Synergy	Arsenic trioxide drastically enhanced the anti-proliferative effect of 10058F4 but not apoptotic effects.	MEC00564
C16824	.	"For a xenograft model: Male Sprague Dawley rats (120-140 g) were anaesthetized with isoflurane, and arthritis was induced in the left knee by an intrarticular injection of 2 mg MIA in 25 ul of 0.9% saline."	Achieving Therapeutic Synergy	The combination therapy of tapentadol and pregabalin restored descending noradrenergic inhibitory tone and also inhibited nociceptive transmission at the level of the spinal cord can provide superior analgesia.	MEC00819
C28119	.	"For a xenograft model, mice were rendered diabetic with a single intraperitoneal injection of 210 mg of streptozocin per kg of body weight."	Achieving Therapeutic Synergy	Combination therapy improved survival compared to that of mice given monotherapy and that of untreated controls (P < 0.05) but did not improve organ clearance.	MEC01417
C68176	.	"For a xenograft model, seven-week-old male Dahl salt-sensitive (DS) rats were fed a normal diet (ND; 0.3% NaCl and 4.5% fat) or a high-salt and high-fat diet (HD; 8% NaCl and 29.4% fat)."	Achieving Therapeutic Synergy	Combination therapy with pitavastatin and pemafibrate improved lipid profiles including TG and cholesterol levels and ameliorated endothelial dysfunction.	MEC01185
C04358	NEWCL10245	"For a xenograft model, primagraft cells were injected intrafemorally into NOD SCID Gamma null (NSG) mice."	Achieving Therapeutic Synergy	A selumetinib-dexamethasone combination may be highly effective in RAS pathway-mutated acute lymphoblastic leukemia.	MEC01063
C22259	.	"For a xenograft model, mice were made neutropenic by intraperitoneal (ip) injection of cyclophosphamide at a dose of 100 mg/kg on days 0, 2,4."	Achieving Therapeutic Synergy	Apalcillin when combined with gentamicin is effective in treating serious P. aeruginosa bacteraemia in neutropenic mice.	MEC01414
C22534	NEWCL00082; NEWCL00080; NEWCL10018	"For a xenograft model, HCT-116 cells (1*107 in 150 uL PBS) were subcutaneously injected into the right flank of five-week-old female athymic BALB/c nu/nu mice."	Achieving Therapeutic Synergy	The Synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress.	MEC01022
C95122	NEWCL00149; NEWCL00138; NEWCL00058	"For a xenograft model, cells (2*106 Me180, HeLa, or C33A) were injected subcutaneously into female nude mice aged 10-12weeks (Elevage Janvier)."	Achieving Therapeutic Synergy	Cidofovir and Cetuximab have synergistic antitumor effect in HPV-positive tumors.	MEC01197
C33998	NEWCL10276	"For a xenograft model, CC531 cells were injected into the right liver lobe of seven-week-old male Wag/Rij rats."	Decreasing Adverse Drug Reaction	Dietary glycine protects the heart against FOLFOX-induced injury during treatment for CRLM.	MEC01199
C28922	NEWCL00170	"For a xenograft model, A549/DDP cells were injected into the inguinal mammary fat pad of Balb/c congenic athymic nude mice."	Reversing Drug Resistance	DMC in combination with DDP may be considered as a novel combination regimen for restoring DDP sensitivity in DDP-resistant NSCLC cells.	MEC01031
C14683	NEWCL00074; NEWCL00344	"For a xenograft model, 5 * 106 OR-SW480 cells were subcutaneously injected into the right armpit of 4-week-old female immunodeficient nude BALB/c mice."	Achieving Therapeutic Synergy	Scutellarin resensitizes oxaliplatin-resistant CRC cells to oxaliplatin treatment through inhibition of PKM2.	MEC01087
C32709	NEWCL00155; NEWCL00156; NEWCL00160; NEWCL00049; NEWCL00050; NEWCL00189	"For a xenograft model, 4T1 cells (1 * 106) cells were injected bilaterally into the 4th mammary fat pads of six-week-old female athymic nude (Foxn1nu) mice (strain: Hsd); 3 * 106 MDA-MB-231 cells were injected bilaterally into the 4th mammary fat pads of athymic nude (Foxn1nu) mice."	Achieving Therapeutic Synergy	"When combined with paclitaxel, bazedoxifene may be a potential small molecule for the treatment of both estrogen receptor positive and triple-negative breast cancer."	MEC00783
C52416	NEWCL00049; NEWCL00050	"For a xenograft model, 3*106 MDA-MB-231 cells were inoculated subcutaneously into right flank of mice."	Achieving Therapeutic Synergy	Noscapine potentiated the anticancer activity of Doxorubicin in a synergistic manner against TNBC tumors via inactivation of NF-KB and anti-angiogenic pathways while stimulating apoptosis.	MEC01026
C59329	NEWCL00170; NEWCL00180	"For a xenograft model, 3*106 human H460 cells were injected subcutaneously into the right flanks of the mice."	Achieving Therapeutic Synergy	Nos potentiated the anticancer activity of Gem in an additive to synergistic manner against lung cancer via antiangiogenic and apoptotic pathways.	MEC01025
C74641	NEWCL00170; NEWCL00180	"For a xenograft model, 3*106 H460 cells were injected subcutaneously into right flank area of mice."	Achieving Therapeutic Synergy	Nos enhanced the anticancer activity of Cis in an additive to synergistic manner by activating multiple signaling pathways including apoptosis.	MEC00955
C51197	NEWCL00028; NEWCL00129	"For a xenograft model, 2*106 human HepG2 cells were injected subcutaneously into the right flanks of the mice into the right flanks of the mice."	Achieving Therapeutic Synergy	Cytotoxic autophagy resulting from inhibition of c-Met/mTOR signaling may be achieved in HCC by combined NCTD and crizotinib administration.	MEC01155
C67776	NEWCL00129; NEWCL00151	"For a xenograft model, 2 * 106 HepG2 cells were mixed with 50% Matrigel and injected subcutaneously into the right flank of 6-8 week-old male BALB/c athymic nude mice."	Achieving Therapeutic Synergy	PA may be a promising and excellent sensitizer for improving the anticancer effect of MSeA in hepatoma chemotherapy.	MEC01154
C22495	NEWCL10347; NEWCL00170	"For a xenograft model, 2 * 106 cell suspension was injected subcutaneously into the right flank of female athymic nude mice."	Achieving Therapeutic Synergy	Isothiocyanates (ITCs) enhancing cisplatin efficacy and provides the first in vivo evidence to support ITCs as potential candidates for developing new regimens to overcome platinum resistance.	MEC00715
C56236	NEWCL00048	"For a xenograft model, 1*109 human K562 cells were injected into the inguinal mammary fat pad of Balb/c congenic athymic nude mice."	Achieving Therapeutic Synergy	"An important role for VSTM1 in the pathogenesis of leukemia, and SG611-VSTM1 may be a promising agent for enhancing chemosensitivity in leukemia therapy."	MEC00732
C05284	NEWCL10128; NEWCL10167	"For a xenograft model, 1*106 human MDA-MB-231 HMTL.6 cells were injected into the inguinal mammary fat pad of Balb/c congenic athymic nude mice."	Decreasing Adverse Drug Reaction	[10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models.	MEC01086
C05284	NEWCL10128; NEWCL10167	"For a xenograft model, 1*106 human MDA-MB-231 HMTL.6 cells were injected into the inguinal mammary fat pad of Balb/c congenic athymic nude mice."	Achieving Therapeutic Synergy	[10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models.	MEC01151
C54265	NEWCL00169; NEWCL00140	"For a xenograft model, 1 * 107 SK-hep1 cells were injected subcutaneously into 4-6 weeks old BALB/c nu/nu mice."	Achieving Therapeutic Synergy	Sor and Art combination promotes a dual inhibitory effect on both RAF/MAPK and PI3K/AKT/mTOR pathways which contributes to apoptosis burst.	MEC00953
C76152	NEWCL00109; NEWCL00111; NEWCL10333; NEWCL00107; NEWCL10352; NEWCL00114; NEWCL00115; NEWCL00352	"For a xenograft model, 1 * 107 MKN1 cells were implanted subcutaneously into both flanks of each Balb/c mouse."	Achieving Therapeutic Synergy	"Alpelisib alone or in combination with paclitaxel demonstrated promising anti-tumor activity in in vitro and in vivo models of PIK3CA-mutant GC via inactivating PI3K down-stream molecules, increasing DNA damage response, and apoptosis."	MEC00784
C43918	NEWCL00170	"For a xenograft model, 1.0 * 107/mL A549 cell was injected into the right flanks of the five-week-old female nude mice (nu/nu) with weight of 13-16 g."	Achieving Therapeutic Synergy	ART exhibited significant anti-tumor effect on A549 cells and this efficiency could be enhanced by combination with CIS.	MEC00843
C60387	.	"For a xenograft model, 1 * 106 parasitized red blood cells (pRBCs) were injectedinto C57BL/6 mice via intraperitoneal (i.p.)."	Achieving Therapeutic Synergy	The neuroprotective effects of artesunate + tetramethylpyrazine were mainly related to proteins involved in axon development and transportation between blood and brain.	MEC01057
C88508	.	"For a xenograft model, Ten-week-old LDLR KO mice were fed a high-fat, high cholesterol diet."	Achieving Therapeutic Synergy	Combination therapy with pravastatin and cilostazol exerts beneficial effects by decreasing atherosclerotic lesion progression and improving the proinflammatory state in the vascular endothelium.	MEC01209
C11162	NEWCL00123; NEWCL10001; NEWCL10293	"For a xenograft model, 2.0 * 106 GL261 cells were injected subcutaneously in the hind limof mice."	Achieving Therapeutic Synergy	Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors.	MEC00907
C20718	NEWCL00251; NEWCL00253; NEWCL10357	"For a xenograft model, 2 * 106 VCaP cells per 0.1 ml suspended in a mixture of Matrigel and RPMI 1640 medium (1 : 1) were injected subcutaneously into the back of the mice."	Achieving Therapeutic Synergy	Phenethyl isothiocyanate in combination with dibenzoylmethane inhibits the androgenindependent growth of prostate cancer cells.	MEC00718
C01714	NEWCL00149; NEWCL00137; NEWCL00139	Five-week-old nude BALB/c mice were used for subcutaneous implantation of human cervical tumor cells HeLa (2*106 per site).	Achieving Therapeutic Synergy	The combination of TRAIL with fucoxanthin showed synergistically inhibitory effects on cervical cancer cells.	MEC00462
C49649	NEWCL00269; NEWCL00105	Five-week-old female athymic nude mice (nu/nu) were injected with 2*106 cells in the right flank to form xenograft tumors.	Augmenting Drug Sensitivity	Introduction of curcumin and suboptimal concentrations of cisplatin showed a significant suppressive effect compared with treatment with either agent alone.	MEC00332
C08946	NEWCL00286; NEWCL00245; NEWCL00295; NEWCL00278	Five-week-old athymic nu/nu male Balb/c mice were implanted subcutaneously in the right flank with U266 cells (2 * 106 cells/100 uL of PBS/Matrigel).	Achieving Therapeutic Synergy	Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-KappaB regulated gene products in multiple myeloma xenograft mouse model.	MEC01044
C52710	.	Five groups of 10 female Swiss mice weighing approximately 37 g were used in this study.	Achieving Therapeutic Synergy	"The combination of tagitinin C and Bz exerts potent antiparasitic, immunomodulatory and cardioprotective effects."	MEC01211
C92070	.	Fifty healthy male Sprague-Dawley (SD) rats with eight-week-old and body weight of 200.0 +/- 18.4 g were used in this study.	Achieving Therapeutic Synergy	"Combined semaglutide with RSG exhibited synergistically protective efficacies on retinal cells by decreasing the GFAP expression, inhibiting oxidative stress and PI3K/Akt/MTOR signaling-transduction in DR model rats."	MEC00549
C27185	.	Female Wistar rats with an initial body weight between 170 and 230 g were used.	Decreasing Adverse Drug Reaction	Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.	MEC00323
C49649	.	Female Sprague-Dawley rats at the age of 8 weeks weighing 160-180 g were used in this study.	Decreasing Adverse Drug Reaction	Curcumin ameliorated cisplatin-induced nephrotoxicity and improved its anticancer activity in DMBA induced breast cancer in female Sprague-Dawley rats.	MEC00344
C75746	NEWCL00082	Female nude mice (6-8 weeks old) were exposed to light halothane anesthesia and were inoculated with 1*106 HCT116 human colorectal cancer cells suspended in matrigel.	Augmenting Drug Sensitivity	Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo.	MEC00422
C53437	NEWCL00036; NEWCL00194; NEWCL00193	Female nu/nu athymic nude mice (6-weeks old) were subcutaneously implanted with 0.5*106 Hs-294T melanoma cells with equal volume of matrigel (in 100L) on the left flanks.	Augmenting Drug Sensitivity	EGCG sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma.	MEC00520
C80914	NEWCL10404	Female F344 rats (Harlan) at 9-10 weeks of age were anesthetized with ketamine and xylazine.	Achieving Therapeutic Synergy	The combination regime was more effective than each single agent in inhibiting microvessel formation and stimulating microvessel maturation in the tumor tissues.	MEC00714
C99457	NEWCL00049; NEWCL00155	"Female CD1 athymic nude mice were inoculated into the right flank with MDA-MB-231 cells (2*106/50L matrigel), which were left to form palpable tumours."	Achieving Therapeutic Synergy	Tamoxifen at realistic doses (75 mug kg(-1)) can suppress the growth of ER-negative breast cancer when combined with EGCG. The dominant mechanism for tumour suppression is the concomitant decrease in tumour protein expressions of mTOR and the EGFR.	MEC00145
C01222	NEWCL00252	"Female C57BL/6J mouse homozygous with ""floxed"" allele of Pten gene were used in this study."	Achieving Therapeutic Synergy	"Pterostilbene sensitized tumor cells to SAHA treatment resulting in inhibiting tumor growth and additional decline of tumor progression. These effects were dependent on the reduction of MTA1-associated proangiogenic factors HIF-1Alpha, VEGF, and IL-1Beta leading to decreased angiogenesis."	MEC01201
C80064	NEWCL00063; NEWCL00059; NEWCL00310	Female BALB/c null mice were injected with 107 SUP-B15 cells via tail vein.	Achieving Therapeutic Synergy	Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia.	MEC00278
C01053	NEWCL00113	Female BALB/c nude mice mice were subcutaneously inoculated with injections of 1*106 MGC-803 cells/nude mice.	Augmenting Drug Sensitivity	Wogonin potentiates the antitumor effects of low dose 5-fluorouracil against gastric cancer through induction of apoptosis by down-regulation of NF-kappaB and regulation of its metabolism.	MEC00082
C12369	NEWCL00117; NEWCL00145; NEWCL00111; NEWCL00142; NEWCL00113	Female BALB/c nude mice (4-5 weeks old) were subcutaneously injected with 1*107 NCI-N87 cells (suspended in 100 ul of PBS with 50% Matrigel) to establish tumors.	Achieving Therapeutic Synergy	Cucurbitacin E inhibits cellular proliferation and enhances the chemo-response in gastric cancer by suppressing AKt activation.	MEC01520
C84931	.	Female Balb/c mice weighing 20-22 g were used in this study.	Decreasing Adverse Drug Reaction	In vivo treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis.	MEC00809
C17411	NEWCL00049; NEWCL00189	"4T1 (2.5 * 106 ) tumour cells were subcutaneously injected into the right thigh of female BALB/c mice (5 weeks old, around 20 g)."	Decreasing Adverse Drug Reaction	"NLC-DOX-SC shows to be a superior option over the free combination as it maintains the synergism between DOX and SC in triple negative breast cancer models and is less toxic (less myelossupressive, prevents weight loss and behaviour alterations) than the free combination, showing the benefits of nanomedicine in reducing chemotherapy side effects."	MEC01361
C07139	NEWCL00036; NEWCL00086	Female athymic nude mice of five weeks age were subcutaneously transplanted with A375 or SK-MEL-28 cells (2.5 * 106 A375 cells in 50 ul DMEM + 50 ul matrigel or 5 * 106 SK-MEL-28 cells in 50 ul RPMI + 50 ul matrigel) in each flank.	Achieving Therapeutic Synergy	Fisetin potentiates the anti-invasive and anti-metastatic effects of sorafenib.	MEC01179
C66955	.	Female athymic mice were transplanted with 0.2 mL (1*107 /mL) cell suspension of SKOV-3 cells at the subcutaneous of armpit in right anterior superior limbs.	Achieving Therapeutic Synergy	Ginsenoside Rg3 and CTX combination reinforced the antitumour effect each other and improved the living quality and survival time of mice with tumour.	MEC00182
C45042	NEWCL00077; NEWCL00082	Female athymic BALB/c nude micemice were inoculated subcutaneously with injections of 1*106 HT-29 cells/mouse into the right axilla.	Augmenting Drug Sensitivity	Oroxylin A improves the sensitivity of HT-29 human colon cancer cells to 5-FU through modulation of the COX-2 signaling pathway.	MEC00075
C01771	NEWCL00170; NEWCL00180	"Female A/J mice (5-6 weeks of age) received 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (intraperitoneally, at a dose of 50 mg/Kg, twice a week, for a total of four doses) in 0.1 mL physiological saline solution."	Augmenting Drug Sensitivity	"Exposure of the cells to a mixture of low concentrations of I3C (50 uM) plus silibinin (50 uM) for 72 h caused inhibition of cell growth and extracellular signal-regulated kinase (ERK) and Akt activation and induction of apoptosis, whereas the individual agents did not have any effect."	MEC00445
C40150	.	"To establish experimental autoimmune encephalomyelitis (EAE) mice, female C57BL/6 mice were actively immunized using two subcutaneous injections with an emulsion containing myelin MOG35-55 (250 g) and an equal volume of CFA (250 g) into dierent sites of each hind ank."	Achieving Therapeutic Synergy	They reduced the clinical and pathological defects in EAE mice through modulation of both local (microglia) and systemic (lymphocytes and blood) immunity from inflammatory (Th1/Th17/M1) towards anti-inflammatory (Th2/Treg/M2) phenotypes.	MEC01545
C98710	.	Eighty-eight 29-day-old female Harlan SpragueeDawley rats were used to establish animal model with methylnitrosourea for the induction of mammary gland carcinomas.	Achieving Therapeutic Synergy	The combination of genistin and ipriflavone prevents mammary tumorigenesis and modulates lipid profile.	MEC01393
C91487	.	Eight-week-old male mice were induced of carrageenan paw edema.	Achieving Therapeutic Synergy	Combined choline and aspirin therapy represented a significant synergistic interaction in attenuating acute inflammatory response.	MEC00552
C95500	NEWCL10031	Eight-week old female C57BL/6 mice were used in this study.	Decreasing Adverse Drug Reaction	Crocin synergistically enhances the antiproliferative activity of 5-flurouracil through Wnt/PI3K pathway in a mouse model of colitis-associated colorectal cancer.	MEC01517
C55582	NEWCL00231; NEWCL10371; NEWCL00149; NEWCL10363; NEWCL10364; NEWCL00138	"Effect of Wi-A, CAPE and their combination was examined by female 4-5 weeks old BALB/c nude mice in vivo tumor growth assay using subcutaneous xenografts of SKOV-3."	Achieving Therapeutic Synergy	A combination of Wi-A and CAPE offers selective toxicity and better potency to cancer cells.	MEC01257
C00473	NEWCL00213; NEWCL00215	Each of neuroblastoma SK-N-BE2 and SH-SY5Y cells (6*106) in 100 ul of 1:1 mixture with Matrigel was implanted by subcutaneous (sc) injection on the flank of each mouse (six weeks-old female athymic nu/nu mice) under isoflurane anesthesia condition.	Achieving Therapeutic Synergy	Combination of N-(4-hydroxyphenyl) retinamide and genistein increased apoptosis in neuroblastoma SK-N-BE2 and SH-SY5Y xenografts.	MEC00545
C34583	NEWCL00170; NEWCL00171	Each mouse (five-week-old BALB/c nude mice) was subcutaneously injected with 2 * 106 H1975 lung carcinoma cells in logarithmic growth phase.	Reversing Drug Resistance	Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.	MEC00563
C21822	NEWCL00170; NEWCL00171	Each mouse (five-week-old BALB/c nude mice) was subcutaneously injected with 2 * 106 H1975 lung carcinoma cells in logarithmic growth phase.	Reversing Drug Resistance	Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.	MEC01305
C22519	NEWCL00082; NEWCL00079	DLD1 (1*106) cells were injected subcutaneously into female BALB/c nude mice.	Augmenting Drug Sensitivity	(-)-Epigallocatechin gallate (EGCG) enhances the sensitivity of colorectal cancer cells to 5-FU by inhibiting GRP78/NF-kappaB/miR-155-5p/MDR1 pathway.	MEC00113
C77146	NEWCL10423; NEWCL10424; NEWCL10103	Tumours were induced by injecting 5*106 cells into the right side of each nude mouse.	Achieving Therapeutic Synergy	Vernodalol enhances TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells.	MEC01174
C59959	.	Dietylnitrosamine and 2-acetylami nofluorene were used to induce HCC in male Sprague-Dawley rats.	Achieving Therapeutic Synergy	EA and SOR are effective on the HCC rat model through mitochondria and hepatocytes targeting.	MEC00399
C57198	.	Diet-induced obese (DIO) mouse models were used in this study.	Achieving Therapeutic Synergy	The combination of GSK2041706 with metformin caused greater reductions in cumulative food intake (22.2% at 30 mg/kg and 37.5% at 100 mg/kg) and higher fed plasma glucagon-like peptide 1 and peptide tyrosine tyrosine levels and decreased plasma insulin and glucose-dependent insulinotropic polypeptide levels compared with their monotherapy groups.	MEC00701
C06543	.	Diabetic neuropathy (DN) rat models were used in this study.	Decreasing Adverse Drug Reaction	"DX augmented the DM metabolic disturbance and hepatic dysfunction, however, PH effectively amended these disorders. The low-dose combination of both, had the merits of both medications, with the alleviation of their disadvantages."	MEC01534
C92385	.	Male Sprague-Dawley rats were injected i.v. with streptozotocin (STZ) to induce diabetes.	Achieving Therapeutic Synergy	"Both carnosine and lisinopril exert distinct beneficial effects in a standard model of diabetic nephropathy. Both drugs administered together combine the respective effects of single treatment, albeit without exerting additive nephroprotection."	MEC00748
C36769	.	Diabetes was induced by intraperitoneal injection of streptozotocin (STZ) (60 mg/kg) in rat.	Achieving Therapeutic Synergy	"The combined therapy of losartan and L-carnitine affords additive beneficial effects against diabetes-associated endothelial dysfunction, possibly via normalizing the dysregulated eNOS and reducing the inflammation and oxidative stress in diabetic rats."	MEC01542
C82796	NEWCL00077	CT26.WT (5*106) cells were inoculated subcutaneously in female Balb/c mice.	Achieving Therapeutic Synergy	Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/beta-catenin signaling pathway.	MEC00043
C63184	.	Model rats were induced by i.p. injection of DOX (2 mg/kg) once a week for 4 weeks. 	Reversing Drug Resistance	"Vitexin possesses cardioprotective action against DOX-induced cardiotoxicity by suppressing oxidative stress, inflammation and apoptotic signals."	MEC01083
C71805	NEWCL00073; NEWCL00076	Colorectal tumor TC118 obtained from patients was grafted by subcutaneous implantation of 15 mm3 tumor fragments into the scapular area of nude mice.	Achieving Therapeutic Synergy	Geraniol modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts.	MEC01288
C49909	NEWCL00236	Male Fishcher rats weighing 150-175 g were used in this study.	Achieving Therapeutic Synergy	Combination therapy offers a viable means of improving L-canavanine's intrinsic efficacy while decreasing the concentration of 5-FU required to produce the same cytotoxic effect.	MEC01539
C24324	.	Colon carcinogenesis in five-week-old male was induced by azoxymethane.	Achieving Therapeutic Synergy	EGCG with sulindac synergistically suppresses ACF formation by enhancing apoptosis.	MEC00427
C37519	.	"Male albino Wistar rats were injected i.v. with 1,2-dimethylhydrazine to induce colon cancer."	Achieving Therapeutic Synergy	"The potential role of combined therapeutic effect of Carvacrol and X-radiation against 1,2-dimethylhydrazine-induced colon carcinogenesis."	MEC01598
C86349	.	Colitis was induced in female ICR mice at 7 weeks of age.	Achieving Therapeutic Synergy	"ZER is a novel food factor for mitigating experimental UC and that use of a combination of agents, with different modes of actions, may be an effective anti-inflammatory strategy."	MEC01602
C04513	.	CNE1 < BX1 > cells (7.5*106 cells/mouse) were trypsinized and mixed with growth factor reduced matrigel and injected subcutaneously on the right flank of each mouse.	Achieving Therapeutic Synergy	Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma.	MEC01333
C28146	.	Clinical Trial	Reversing Drug Resistance	The edrophonium-PCHE combination significantly accelerated recovery of mivacurium-induced block compared with that observed with the use of individual antagonists.	MEC00553
C89029	.	Clinical Trial	Achieving Therapeutic Synergy	Levothyroxine and selenium combination results in improved therapeutic effects than the levothyroxine monotherapy in preventing CLT progression.	MEC00642
C87549	.	Clinical trial	Achieving Therapeutic Synergy	"In patients with implanted foreign devices, combination therapy was associated with a better long-term outcome."	MEC00649
C77479	.	Clinical Trial	Achieving Therapeutic Synergy	Amoxicillin/clavulanic acid is a useful therapeutic addition to the existing forms of treatment for amoxicillin-resistant respiratory tract infections.	MEC00794
C77479	.	Clinical Trial	Achieving Therapeutic Synergy	Amoxycillin/clavulanic acid combination was a safe and effective antimicrobial agent for the treatment of respiratory tract infections.	MEC00796
C99130	.	Clinical Trial	Achieving Therapeutic Synergy	This trial showed a significant efficacy for tropisetron over placebo in treatment of obsessive-compulsive disorder symptoms when added to fluvoxamine.	MEC00824
C50091	.	Clinical Trial	Achieving Therapeutic Synergy	"The introduction of MMF combined with the reduction of at least 50% of CNI dose allowed the renal function of liver transplant recipients to significantly improve at 1 year, without any rejection episode and without significant secondary effects."	MEC01567
C37670	.	Clinical trial	Achieving Therapeutic Synergy	Combination therapy of bezafibrate and UDCA improved biliary enzymes in non-cirrhotic Japanese patients with PBC refractory to UDCA.	MEC01345
C33551	.	Clinical trial	Achieving Therapeutic Synergy	Combination of vecuronium plus d-tubocurarine to be significantly more potent than would be expected from a simple additive effect of the individual drugs given alone.	MEC01346
C26291	.	Clinical trial	Achieving Therapeutic Synergy	Combination therapy with trandolapril and candesartan cilexetil has an additive effect on the reduction of microalbuminuria in microalbuminuric normotensive type 2 diabetes patients.	MEC01349
C84783	.	Clinical trial	Achieving Therapeutic Synergy	A fixed-dose combination of trandolapril-verapamil seems to be an effective and safe option for the management of stage 2 hypertension in Mexican patients uncontrolled by monotherapy.	MEC01350
C25386	.	Clinical trial	Decreasing Adverse Drug Reaction	"Patients with COPD may benefit from combination treatment with salmeterol plus theophylline, without a resulting increase in adverse events or other adverse sequelae."	MEC01352
C35498	.	Medical record review	Achieving Therapeutic Synergy	It was observed that the twice-daily application of topical fluorouracil and salicylic acid is a safe and effective treatment for verruca plantaris.	MEC01372
C35498	.	Clinical trial	Achieving Therapeutic Synergy	AK lesions on the hands and/or forearms were effectively treated with low-dose 5-FU/SA under routine conditions in dermatological practice and the treatment was well tolerated.	MEC01371
C28320	.	Clinical Trial	Achieving Therapeutic Synergy	"The fixed combination treatment improves quality of life to a significantly greater extent than calcipotriol, with the once daily regimen most appreciated by patients, in both active disease and recurrency."	MEC01416
C70559	.	Clinical trial	Achieving Therapeutic Synergy	"This profile of moxonidine is highly comparable to a standard first-line antihypertensive drug such as hydrochlorothiazide, without sacrificing tolerance and safety for increased efficacy, in combination with hydrochlorothiazide."	MEC01435
C55168	.	Clinical Trial	Achieving Therapeutic Synergy	Olanzapine/fluoxetine combination demonstrated rapid onset of antidepressant effect (within 7 days) compared to placebo that was sustained over 8 weeks of treatment in a sample of BD patients.	MEC01447
C51793	.	Clinical Trial	Decreasing Adverse Drug Reaction	This regimen was proven to be efficient to prevent and treat nephrotoxicity and neurotoxicity with an acceptable tolerability profile.	MEC01458
C33837	.	Clinical trial	Achieving Therapeutic Synergy	Administration of rebamipide with PPI showed significantly superior healing effect on ulcers with larger dissected size of 20 to 40 mm as compared with PPI mono-therapy.	MEC01560
C18265	.	Clinical trial	Achieving Therapeutic Synergy	Administration of rebamipide with PPI showed significantly superior healing effect on ulcers with larger dissected size of 20 to 40 mm as compared with PPI mono-therapy.	MEC01561
C60253	.	Clinical trial	Achieving Therapeutic Synergy	Administration of rebamipide with PPI showed significantly superior healing effect on ulcers with larger dissected size of 20 to 40 mm as compared with PPI mono-therapy.	MEC01562
C38832	.	Clinical Trial	Achieving Therapeutic Synergy	"The introduction of MMF combined with the reduction of at least 50% of CNI dose allowed the renal function of liver transplant recipients to significantly improve at 1 year, without any rejection episode and without significant secondary effects."	MEC01566
C07208	.	Clinical trial	Decreasing Adverse Drug Reaction	"Intravenous thrombolysis with rt-PA combined with compound anisodine is safe and effective in treating CRAO, which can significantly improve the prognosis of patients."	MEC01588
C61442	.	Clinical Trial	Achieving Therapeutic Synergy	Citicoline in combination to physiotherapy appears to be a promising agent to improve gross motor function in patients with cerebral palsy versus physiotherapy alone.	MEC01593
C27783	NEWCL10216	Clinical Trial	Achieving Therapeutic Synergy	Monodesbutyl-benflumetol and retinol combination showed synergistic interaction in Plasmodium falciparum.	MEC01582
C20892	.	Clinical trial	Achieving Therapeutic Synergy	Use of statin and metformin provides a synergistic improvement in gastrointestinal malignancies outcomes.	MEC00683
C46740	.	Clinical trial	Achieving Therapeutic Synergy	Use of statin and metformin provides a synergistic improvement in gastrointestinal malignancies outcomes.	MEC00684
C83590	.	Clinical trial	Achieving Therapeutic Synergy	Use of statin and metformin provides a synergistic improvement in gastrointestinal malignancies outcomes.	MEC00685
C16588	.	Clinical trial	Achieving Therapeutic Synergy	Use of statin and metformin provides a synergistic improvement in gastrointestinal malignancies outcomes.	MEC00686
C84752	.	Clinical trial	Achieving Therapeutic Synergy	Use of statin and metformin provides a synergistic improvement in gastrointestinal malignancies outcomes.	MEC00687
C88698	.	Clinical trial	Achieving Therapeutic Synergy	The fixed-dose combination of ertugliflozin with metformin is an effective combination that is conveniently administered and may improve medication adherence and persistence.	MEC00689
C27728	.	Clinical trial	Achieving Therapeutic Synergy	Metformin and EGFR-TKI have a synergistic effect in the treatment of DM2 NSCLC patients harboring EGFR-activating mutations.	MEC00700
C88589	.	Clinical Trial	Achieving Therapeutic Synergy	"Combination of glibenclamide-metformin should be considered in patients, without renal or cardiovascular impairment, who are not controlled on monotherapy alone."	MEC00708
C42579	.	Clinical observation	Achieving Therapeutic Synergy	The results from this early experience are promising for a potentially effective topical treatment for vulvodynia.	MEC01446
C52797	.	Arthritis was induced by immunizing with CII in female Srague-Dawley rats.	Achieving Therapeutic Synergy	"SIN and MTX have additive effects, decreasing inflammation and joint damage in CIA rats by modulating osteoclast-related cytokines. These results are indicative of the combined effect of SIN and MTX for anti-arthritic treatment in RA."	MEC01218
C30890	NEWCL00227; NEWCL00225; NEWCL00156	CIA. Female Lewis rats (150 +/- 20 g body weight) were used in this study.	Achieving Therapeutic Synergy	Calcitonin and Prednisolone display antagonistic actions on bone and have Synergistic effects in experimental Arthritis.	MEC01273
C00042	NEWCL00149; NEWCL00137; NEWCL00139	Cervical cancer cell xenograft in vivo in nude mice were used in this study.	Achieving Therapeutic Synergy	Combining metformin and nelfinavir exhibits Synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice.	MEC00696
C67567	NEWCL00145; NEWCL00142; NEWCL00113; NEWCL10086	Cells (5*106) resuspended in 0.2 mL PBS were subcutaneously inoculated into the lower right flank of nude mice.	Achieving Therapeutic Synergy	Thymoquinone can activate caspase-3 and caspase-9 and thus result in the chemosensitisation of gastric cancer cells to 5-FU-induced cell death.	MEC01009
C69357	NEWCL00031; NEWCL00129	CD133 positive Huh7 cells were inoculated subcutaneously into the BALB/c nude mice.	Reversing Drug Resistance	Combination treatment with osthole can resensitize CD133+ HCC cells to cisplatin treatment via the PTEN/AKT pathway.	MEC01107
C49186	NEWCL00256; NEWCL00282	Caki-1 cells (2x106) in 100 ul RPMI-1640 and 100 ul of matrigel were used to inject subcutaneously into each mouse (5-week-old male athymic BALB/c nu/nu mice).	Achieving Therapeutic Synergy	The joint use of GA and SU can provide greater antitumor efficacy compared to either drug alone.	MEC01041
C60870	NEWCL00242; NEWCL00236; NEWCL00243; NEWCL00238; NEWCL00091; NEWCL00232; NEWCL00321	C57BL/6J mice (4-6 weeks) were injected subcutaneously with 0.3*106 KPC cells per tumor suspended in 100L of sterile PBS.	Augmenting Drug Sensitivity	"EGCG synergized with gemcitabine to suppress pancreatic cancer cell growth, migration, and invasion, through modulating epithelial-mesenchymal transition markers and inhibiting Akt pathway."	MEC00067
C06586	.	C57BL/6 mice were inoculated by subcutaneous injection in the right front axilla with 1 * 106 Lewis cells.	Achieving Therapeutic Synergy	Combination of Ginsenoside H dripping pills and cyclophosphamide improve paraneoplastic syndrome and inhibit postoperative recurrence via the reversion of Th1/Th2 shift.	MEC01394
C51354	.	C57BL/6 mice were used in this study.	Achieving Therapeutic Synergy	Treatment with DADS and NAC together effectively protected the liver.	MEC01528
C62867	.	C57BL/6 male mice were fed with a HFD or a normal-fat diet (NFD).	Achieving Therapeutic Synergy	The combination of Mg2+ and SIM shows a synergistic effect on attenuating the HFD-induced bone loss.	MEC01530
C39325	.	EAE was induced in C57/BL6 mice by using 50 Ag of the immunogenic myelin oligodendrocyte glycoprotein (MOG) peptide.	Decreasing Adverse Drug Reaction	"This combination resulted in a significant reduction of disease severity and disease burden with attenuation of the inflammation, axonal loss and demyelination."	MEC01217
C69797	NEWCL00049; NEWCL00050; NEWCL00163	Breast cancer xenografts were created 4-6week female nude mice by subcutaneous injection of the MDA-MB-231 cells (5*106) into the right leg of each mouse.	Augmenting Drug Sensitivity	Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-kappaB signaling pathway.	MEC00360
C42706	NEWCL00155	BALB/c mice model inoculated with 4T1. 1 * 106 4T1 cells were subcutaneously injected into the mammary fat pad region of BALB/c mice to develop solid tumors.	Achieving Therapeutic Synergy	MG could be a potential candidate for combination therapy to reduce the toxicity burden of 5-FU without any toxic impact on host cells.	MEC01138
C06862	NEWCL10365; NEWCL00189	Balb/c mice were inoculated subcutaneously with 2*106 4T1 cells/0.2 ml PBS or S180 cells/0.2 ml PBS.	Decreasing Adverse Drug Reaction	Sch B is capable of protecting Dox-induced chronic cardiotoxicity and enhancing its anticancer activity.	MEC01364
C09488	NEWCL00242; NEWCL00243	BALB/c mice were injected with PANC-1 cells (1 * 107) with matrigel (100 uL) to the right flank of each mice.	Achieving Therapeutic Synergy	6-shogaol can inhibit the growth of human pancreatic tumors and sensitize them to gemcitabine by suppressing of TLR4/NF-KappaB-mediated inflammatory pathways linked to tumorigenesis.	MEC01036
C08624	NEWCL10413	BALB/c mice inoculated with C26 cells were used in this study.	Achieving Therapeutic Synergy	The combination treatment of ME/5FU co-loaded hydrogels exhibited significant synergistic therapeutic efficacy in the BALB/c mouse model with transplanted subcutaneously tumor on the base of C26 cell line by inducing apoptosis and cell cycle arrest.	MEC00691
C28729	.	BALB/c mice were used in this study.	Achieving Therapeutic Synergy	LPV- MFS combination therapy can be effective in the treatment of VL/HIV co-infected patients and provides data that can help to guide a possible therapeutic strategy in VL/HIV co-infection.	MEC01532
C72640	NEWCL00189	BALB/c inbred female mice were used in this study.	Achieving Therapeutic Synergy	"This combination therapy didn't have any noticeable side effects on kidney, liver, and immune system and body weight."	MEC00710
C27687	NEWCL00313; NEWCL00296	Ba/F3-insH cell line xenografts were generated by injecting 5*106 cells in 50% matrigel into six-to eight- week old male nu/nu nude mice.	Achieving Therapeutic Synergy	The combination of ellagic acid with erlotinib has Synergistic effects against EGFR H773_V774 insH mutation.	MEC00148
C34625	NEWCL00224; NEWCL00009	B88 or HSC2 cells (1*106) were suspended in 0.1 mL of serum-free medium and injected into the subcutaneous tissue of 5-week-old nude mice.	Augmenting Drug Sensitivity	Combined therapy of cepharanthine and S-1 exerted antitumor effects on human OSCC xenografts markedly and significantly induced apoptotic cells in tumors treated with cepharanthine plus S-1.	MEC00440
C07341	NEWCL00207	B16TK cells and B16 cells were mixed at a 3:7 ratio and subcutaneously inoculated the right flank of the pathogen-free C57BL/6 J mice (18-22 g).	Achieving Therapeutic Synergy	Resveratrol could synergistically enhance the killing effect of TK/GCV suicide gene system in melanoma B16 cells and transplanted melanoma.	MEC00529
C09339	NEWCL00207; NEWCL00155	B16 tumor-bearing mice. Kunming mice (18-22 g) was inoculated with B16 melanoma cells (3 * 105) by subcutaneously injection at the right axillary space.	Achieving Therapeutic Synergy	"Ceramide could enhance the antitumor activity of Docetaxel in a synergistic manner, which suggest promising application prospects of Ceramide + Docetaxel combination treatment."	MEC00826
C76871	NEWCL00082	Athymic-NCr-nu male mice (8-10 weeks of age) were inoculated subcutaneously in the flank with minced p21-intact HCT116 cells mixed with Matrigel.	Augmenting Drug Sensitivity	"CPT-11 induces cell cycle arrest rather than cell death and that flavopiridol, by activating the caspase cascade, cleaves the inhibitors of apoptosis and sensitizes the cells to undergo cell death."	MEC00140
C82598	NEWCL00031; NEWCL00027	Athymic nude mice were injected with 5*106 HuH-7 cells subcutaneously in the right flank in 100-mL aliquots mixed with Matrigel in 1:1 ratio.	Achieving Therapeutic Synergy	"The combination of triptolide and sorafenib was superior to either drug alone in inducing apoptosis and decreasing viability, whereas triptolide alone was sufficient to decrease nuclear factor kappaB activity."	MEC00002
C74986	NEWCL00140; NEWCL00141; NEWCL00143; NEWCL00129; NEWCL00028; NEWCL00029; NEWCL00030; NEWCL00131; NEWCL00132	Athymic nude mice or male C57BL/6 mice (aged 4-6 weeks and weighing 16-18g) were injected with Bel-7404 cells or Hepa 1-6 cells subcutaneously in the right foreleg (4*106 cells/mouse).	Augmenting Drug Sensitivity	Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.	MEC00395
C53990	.	Sprague-Dawley rats were used in this study.	Achieving Therapeutic Synergy	Pre treatment with FTY720 combined with vitamin E exerts synergistic neuroprotective effects in the simulated cerebral ischemia in vitro.	MEC01203
C50594	.	CIA was induced in DBA/1 mice which were immunized with 100 ug bovine type II collagen and emulsified with an equal volume of complete Freund's adjuvant.	Achieving Therapeutic Synergy	"A combination of anisodamine and neostigmine could decrease arthritic index, reduce joint swelling, and inhibit weight loss."	MEC01443
C74645	NEWCL00022; NEWCL00310; NEWCL00065; NEWCL00032; NEWCL00056	Around 1.5*107 HL-60/H3 cells were subcutaneously injected into the right flank of BALB/C-nude mice.	Augmenting Drug Sensitivity	"Emodin significantly enhanced chemosensitivity of AML cells to Ara-C, inhibited leukemic cell growth, and improved survival in the mouse xenograft model of AML. Dual targeting of Akt and ERK signaling pathways might contribute to the anti-leukemia effects on AML cells in vitro and in vivo."	MEC00156
C37534	NEWCL00145	Approximately 300 cells for the CM-Dil-labeled BGC-823 cells were injected into the yolk sac per zebrafish embryo using a microinjector.	Augmenting Drug Sensitivity	Wogonin exacerbates the cytotoxic effect of oxaliplatin by inducing nitrosative stress and autophagy in human gastric cancer cells.	MEC00414
C48902	NEWCL00098; NEWCL10348	Approximately 1*106 Eca109 cells were suspended in 0.1 ml PBS and subcutaneously injected into the right leg of male BALB/c nude mice (5-week old).	Achieving Therapeutic Synergy	AIF functions as a potent radiosensitizer in human ESCC.	MEC01320
C36243	.	ApoE / mice (8 weeks old) were fed a high fat diet (21% fat and 0.15% cholesterol).	Achieving Therapeutic Synergy	"The combination of simvastatin and pinocembrin synergistically inhibited atherosclerotic lesion development in ApoE-/- mice with hyperlipidemia, which is partially dependent on the protective of vascular endothelium."	MEC01293
C31431	NEWCL10125; NEWCL10049	"APL cells (5 * 104 cells/mouse) were injected intravenously via the tail vein into genetically compatible FVB/N recipients, without conditioning with either radiation or chemotherapy. "	Achieving Therapeutic Synergy	"A synergistic effect on combining ATO and bortezomib in vitro was noted in both ATO-sensitive and ATO-resistant APL cell lines. The mechanism of this synergy involved downregulation of the nuclear factor-KappaB pathway, increase in unfolded protein response (UPR) and an increase in reactive oxygen species generation in the malignant cell."	MEC00560
C04523	NEWCL00155; NEWCL00049	"Animals were maintained at standard condition and exponentially grown 1*106 EAC cells collected from peritoneal cavity from Ascitic mice, and were inoculated into the peritoneal cavity of fresh healthy male Swiss Albino mice."	Achieving Therapeutic Synergy	"Resveratrol chemosensitizes doxorubicin in combination through inhibiting breast cancer cells proliferation and invasion, and inducing apoptosis via suppression of chronic inflammation and autophagy."	MEC00239
C90907	NEWCL00202; NEWCL00043; NEWCL00150; NEWCL00045	Animal models were constructed by subcutaneously injecting MBT-2 cells into both flanks of C3H female mice.	Augmenting Drug Sensitivity	Curcumin potentiates the antitumor effect of BCG through the inhibition of NF-kappaB and induction of TRAIL receptors in bladder cancer cells.	MEC00255
C60407	NEWCL00206; NEWCL00205	Animal models were constructed by inoculating subcutaneously with 106 B16F10 cells in male C57BL/6 mice.	Augmenting Drug Sensitivity	Resveratrol enhances chemosensitivity in mouse melanoma model through connexin 43 upregulation.	MEC00370
C83616	NEWCL00167; NEWCL00128; NEWCL00301; NEWCL00223	Animal models were constructed by injecting Tu212 cells (2*106) into the right flank of nude mice (athymic nu/nu).	Achieving Therapeutic Synergy	"The combined treatment resulted in significantly greater inhibition of tumor growth and delayed tumor progression as a result of increased apoptosis, decreased cell proliferation and reduced pEGFR and pAKT compared to the single agent treatment groups."	MEC00150
C10230	NEWCL00207	Animal models were constructed by injecting intraperitoneally B16-F3m cells (2*106) into Balb/c mice.	Augmenting Drug Sensitivity	"Combination treatment with EGCG and dacarbazine strongly inhibits melanoma growth and metastasis, and the action mechanisms of EGCG are associated with the inhibition of cell spreading, cell-extracellular matrix and cell-cell interactions, MMP-9 and FAK activities."	MEC00426
C72994	NEWCL00073; NEWCL00082; NEWCL00074; NEWCL00077	Animal models were constructed by injecting HCT-116 cells in the right flank of nude mice.	Augmenting Drug Sensitivity	"EST combined with 5-FU could increase the inhibitory effect of 5-FU on HCT-116 cells proliferation, migration and epithelial-mesenchymal transition."	MEC00125
C14119	NEWCL00170; NEWCL00181; NEWCL00171; NEWCL00172	Animal models were constructed by injecting A549 cells (1*107) into nude mice (six-week) in the dorsal area.	Augmenting Drug Sensitivity	Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.	MEC00024
C96493	NEWCL00027; NEWCL00031; NEWCL00129	Animal models were constructed by injecting subcutaneously PLC/PRF/5 cells (1*107) in the right flank of each athymic female mice.	Augmenting Drug Sensitivity	Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.	MEC00404
C45271	.	Animal models of Parkinson's disease (PD) were used in this study.	Achieving Therapeutic Synergy	"MPTP induced death of dopaminergic neurons, microgliosis, increase of gliapses, motor impairment and neuroinflammation in mice, which were inhibited by combined 1-deoxynojirimycin and ibuprofen treatment."	MEC01527
C49659	NEWCL00231	"Animal model was constructed by injecting PBS containing 500,0000 SKOV3 /DDP cells in the BALB/c-nu nude mouse."	Achieving Therapeutic Synergy	Triptolide sensitizes cisplatin-resistant human epithelial ovarian cancer by inhibiting the phosphorylation of AKT.	MEC00001
C13648	.	Animal model of type 2 diabetes were used in this study.	Achieving Therapeutic Synergy	Combination of Trolox C and cytisine are effective for the treatment of type 2 diabetes.	MEC01524
C29048	NEWCL00129; NEWCL00254	"An orthotopic rat model of HCC was used, in which subcutaneously injected Morris hepatoma (MH)-3924A cells (5x106) in syngeneic ACI rats."	Achieving Therapeutic Synergy	"Silibinin strongly synergized with doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis of HEPG2 cells."	MEC00207
C69078	.	Alogliptin (0.03%) and voglibose (0.001%) alone or in combination were administered in the diet to prediabetic db/db mice.	Achieving Therapeutic Synergy	"Chronic treatment with alogliptin in combination with voglibose concurrently increased active GLP-1 circulation, increased insulin secretion, decreased glucagon secretion, prevented the onset of the disease, and preserved pancreatic beta-cells and islet structure in prediabetic db/db mice."	MEC01494
C33862	.	Adult female Wistar Albino mice weighing 10-12g were used in this study.	Decreasing Adverse Drug Reaction	Apigenin and myricetin exhibited a protective and promising preventive strategy against cisplatin-induced nephrotoxicity due to their antioxidant and anti-inflammatory effects.	MEC00318
C63930	.	The in vovo experiment was carried out with male Wistar rats.	Achieving Therapeutic Synergy	"Cotreatment with rapamycin and metformin showed a significant augmented effect compared with individual drug interventions on reversal of these age-dependent biomarkers of oxidative stress, suggesting a synergistic response."	MEC00703
C33935	.	"Bilateral 5-mm-diameter calvarial defects were created in adult Wistar rats and filled with preparations of different doses of simvastatin (0, 0.01, 0.1, 0.25 and 0.5 mg) combined with a-TCP particles or left empty."	Achieving Therapeutic Synergy	"When combined with alpha-TCP particles, 0.1 mg simvastatin is the optimal dose for stimulation of the maximum bone regeneration in rat calvarial defects without inducing inflammation."	MEC01347
C67516	.	Adult male wistar rats (250-275 g) were used in this study.	Achieving Therapeutic Synergy	DEC when combined with HDN blunted EtOH-induced necroinflammation and elevation of liver injury parameters in serum.	MEC00804
C14201	.	Adult male Sprague-Dawley rats weighing 250-270 g were used in this study.	Achieving Therapeutic Synergy	A combination therapy using low-dose MPH and MOR may produce a MOR-sparing effect in chronic pain management.	MEC00825
C05496	.	Focal ischemia was induced in adult male C57/Bl6 mice by occlusion of the left middle cerebral artery (MCA) using an intraluminal filament technique.	Achieving Therapeutic Synergy	Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia.	MEC01286
C93664	NEWCL00155	Adult female athymic nude mice (six-week-old) were injected with MCF7 cells (5*106 cells/mouse) to construct subcutaneous breast cancer xenografts.	Achieving Therapeutic Synergy	Daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer.	MEC00031
C99555	NEWCL00059	"Acute colitis was induced by administration of DSS in drinking water in 35-40 days old female BALB/c mice, weighing 18-22 g,"	Decreasing Adverse Drug Reaction	"Wogonoside may exert its anti-inflammatory effect via dual inhibition of NF-KappaB and NLRP3 inflammasome, suggesting that wogonoside might be a potential effective drug for inflammatory bowel diseases."	MEC01220
C06862	NEWCL00170	About 1.5 * 106 human A549 tumor cells suspended in 200 ul RPMI-1640 were injected into the right forelimb of BALB/c nude mice to establish the tumor-bearing mice model.	Achieving Therapeutic Synergy	"Schisandrin B can not only enhanced the cytotoxicity of doxorubicin, but also inhibited the invasion and metastasis of tumors in an all-round way."	MEC01180
C02521	.	About 0.2 mL H22 cell solution (including 2*107 cells) was taken and injected into the right groin of Balb/c mice.	Achieving Therapeutic Synergy	RES could induce the S phase arrest of H22 cells and enhance the anti-tumor effect of 5-FU on murine hepatoma22 and antagonize its toxicity markedly.	MEC00121
C53703	NEWCL00077	Aberrant crypt foci (ACF) were induced male Wistar rats (6-week old) with DMH.	Achieving Therapeutic Synergy	Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer.	MEC00262
C10359	.	"Aberrant crypt foci (ACF) animal model was induced by subcutaneously injecting 0.2 ml DMH (30 mg/kg b.w.) in male, 6-week-old, F344 rats."	Achieving Therapeutic Synergy	Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model.	MEC00042
C76914	NEWCL00170	"A549/DDP cells were harvested, 5 * 106 cells were in jected subcutaneously into the right oxter of mice."	Achieving Therapeutic Synergy	Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-KappaB and Bcl-2/Bax signaling pathways.	MEC01004
C42547	NEWCL00170	A549 non-small-cell lung cancer cells (2*106) resuspended in 0.1mL of PBS were injected subcutaneously into six weeks old athymic (nu/nu) male nude mice.	Augmenting Drug Sensitivity	Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins.	MEC00469
C97187	NEWCL00170	A549 non-small cell lung cancer cells (2*106) resuspended in 0.1mL of PBS were injected subcutaneously into athymic (nu/nu) male nude mice (5-6 weeks old).	Augmenting Drug Sensitivity	Luteolin enhances TNF-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model.	MEC00483
C73964	NEWCL00181; NEWCL00170	"A549 cells, carrying the luciferase reporter gene (1x107 cells), were subcutaneously injectinto the mice."	Achieving Therapeutic Synergy	Targeting the PDK1- and HOTAIR-mediated downstream molecule EZH2 by the combination of ATL-1 and erlotinib potentially facilitates the development of an additional novel strategy to combat lung cancer.	MEC01194
C49649	NEWCL00170; NEWCL00181; NEWCL00180	A549 cells or shCTR1 A549 cells were resuspended in ice cold serum-free medium (SFM) at 1*107/mL. The cells were mixed with equal volume of Matrigel. The cells (1*106/mouse) were implanted subcutaneously in the right flank near the rear leg of the mice under ketamine-xylazine anesthesia.	Augmenting Drug Sensitivity	"Curcumin treatment enhances the binding of Sp1 to CTR1 and Sp1 promoters, thus induces CTR1 expression and chemosensitization to cisplatin treatment. This process is regulated by the Cu-Sp1-CTR1 regulatory loop and CTR1-dependent."	MEC00331
C57395	NEWCL00170; NEWCL00180; NEWCL00300	A549 cells (5*106) were injected into the dorsal of the female BALB/c nude mice (3-4 week old).	Augmenting Drug Sensitivity	EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells.	MEC00365
C81147	NEWCL00230; NEWCL10084	A2780/CP70 and IGROV1-R10 cells (4 * 106) were injected into nude mice sub cutaneously.	Achieving Therapeutic Synergy	SFN enhances cisplatin sensitivity of ovarian carcinoma cells through up-regulating miR-30a-3p to induce DNA damage and accumulation of intracellular cisplatin.	MEC00607
C88798	NEWCL00077; NEWCL00076; NEWCL00074	A total of 8*106 HT-29 cells were injected subcutaneously into the right flank of female BALB/c nude mice (4 weeks old).	Achieving Therapeutic Synergy	"The addition of luteolin enhanced oncolytic adenovirus-mediated enhanced green fluorescent protein, early region 1A and TRAIL expression, synergistically inhibited tumor growth and promoted CRC cellular apoptosis in vitro and in vivo, and significantly decreased cytotoxicity in lung/bronchial normal epithelial cells, compared with single treatment."	MEC00484
C01919	NEWCL00027; NEWCL00140	A total of 5x106 SMMC-7721 cells in 0.2 ml phosphate-buffered saline (PBS) were injected into the right flank of each mouse (six-week old male Balb/c nude mice) to form subcutaneous tumors.	Achieving Therapeutic Synergy	Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.	MEC00580
C76543	NEWCL00017; NEWCL00018	A total of 5*106 NCI-H295R cells with luciferase reporter were injected into each flank of a Nu/Nu mouse (two xenografts per mouse).	Achieving Therapeutic Synergy	"Treatment with flavopiridol and carfilzomib in all three ACC cell lines resulted in a dose-dependent, anti-proliferative effect, and the combination had synergistic activity as well as in three-dimensional tumor spheroids. The combination treatment increased G2M cell-cycle arrest and apoptosis, and decreased XIAP protein expression in ACC cell lines."	MEC00016
C84557	.	A total of 48 adult (8 weeks old) male Sprague-Dawley rats with mean weight of 250-300 gr were enrolled in this study.	Achieving Therapeutic Synergy	"Both testosterone and its combination with letrozole increased lumbar and femoral BMD of orchiectomized rats, with a higher increase in lumbar BMD in O + T group."	MEC00634
C77184	NEWCL10111; NEWCL00048; NEWCL10162	A total of 3 * 107 of KBM5 or KBM5-T315I cells were inoculated subcutaneously on the flanks of 5-week-old male nude mice.	Reversing Drug Resistance	Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.	MEC00857
C33060	NEWCL00299; NEWCL00170; NEWCL10182; NEWCL10127	A total of 24 athymic nude male mice 6-8 weeks old were injected subcutaneously with 1*106 22Rv1 cells.	Achieving Therapeutic Synergy	Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.	MEC01002
C96810	NEWCL00207	A total of 2*105 B16 cells in a final volume of 100L was injected into the right flanks of each C57BL/6J mouse.	Achieving Therapeutic Synergy	"Curcumin could enhance the killing effect and the bystander effect of HSV-TK/GCV in treating melanoma, which might be mediated by improved gap junction."	MEC00492
C45786	.	"A total of 150 healthy New Zealand white rabbits, weight 1.98 + 0.15 kg, male and female in equal numbers were used in this study."	Achieving Therapeutic Synergy	Schisandrin B had dose-dependent effects in decreasing the magnitude of doxorubicin-induced indicators of cardiomyopathy to a degree that approximated the decrease produced by dexrazoxane treatment.	MEC01365
C24059	NEWCL00241; NEWCL00236; NEWCL00297	"A small incision was made in the left abdominal flank of male athymic nu/nu mice, and luciferase transfected Panc-28 cells (1*106) in 50L PBS were injected into the subcapsular region of the pancreas with a 27-gauge needle."	Augmenting Drug Sensitivity	Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.	MEC00053
C17746	.	"Obsborne-Mendel rats were inoculated once with a heavy suspension of S. mutans 50B4, serotype d, of human origin."	Achieving Therapeutic Synergy	"This study confirms the suggested therapeutic effect of xylitol even when mixed with sucrose, while nonspecific effects were eliminated."	MEC01403
C76931	NEWCL00095; NEWCL00094	A mixture of 1*107 Namalwa cells and PBS was injected subcutaneously in the right oxter of each male non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice (4 weeks old).	Augmenting Drug Sensitivity	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.	MEC00229
C00671	.	A GU mouse model was induced by indomethacin	Achieving Therapeutic Synergy	"DNJ showed protection for gastric functions of GU mice by reducing the levels of MOT and SP, and increasing the levels of SS and VIP."	MEC01245
C00179	NEWCL00098; NEWCL00099	A cell suspension of 200 mL (4*106 EC9706 cells) was inoculated subcutaneously into the right flank of male athymic BALB/c nude mice.	Augmenting Drug Sensitivity	"NF-kappaB signaling pathway was constitutively activated in the ESCC cell lines. Curcumin suppressed the activation of NF-kappaB via the inhibition of IkappaBalpha phosphorylation, and downregulated the expressions of Bcl-2 and CyclinD1 in ESCC cell lines."	MEC00092
C81590	.	A case report	Achieving Therapeutic Synergy	Combination in close sequence resulted in a dramatic improvement in vision and cystoid macular edema.	MEC01348
C35498	.	A case report	Achieving Therapeutic Synergy	A man successfully treated for more than 50 filiform facial warts using a combination of 5-fluorouracil 5% and salicylic acid 20%.	MEC01369
C95691	.	A case report	Achieving Therapeutic Synergy	"Clinical improvement has been achieved with a combination of topical steroids, oral nicotinamide and tetracycline."	MEC01474
C16373	.	A case report	Decreasing Adverse Drug Reaction	levosimendan in combination with a beta-adrenergic antagonist may have beneficial effects in patients with cardiogenic shock who exhibit tachycardia in response to inotropic agents.	MEC01559
C25069	NEWCL10229	8-9-weeks-old BALB/c female mice were used in this study.	Achieving Therapeutic Synergy	"Tafenoquine (10 mg/kg, base), combined or not with artesunate, but not mefloquine, induced rapid clearance of B. microti in vivo by microscopy, but mice remained PCR-positive."	MEC00882
C28471	NEWCL00209; NEWCL00065	"7.5 * 106 HuT-102 tumor cells in 100 ul Media:Matrigel (1:1 ratio) were inoculated subcutaneously in the right flank of NOD/SCID mice (6-8 weeks, ~20 g)."	Achieving Therapeutic Synergy	Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms.	MEC01225
C01496	NEWCL00082; NEWCL00074; NEWCL00077	"Sixty specific pathogen-free mice (Balb/C female mice, 6 week) were used in this study."	Achieving Therapeutic Synergy	Parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-KappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation.	MEC01123
C33351	.	6-8 weeks old Swiss strain albino mice were used in this study.	Achieving Therapeutic Synergy	"SP-metronidazole gave the foremost effect on both mice survival rate and parasite load in the liver, spleen and brain."	MEC01410
C15951	.	6-8 weeks old Male Wistar rats (150-200 g) were use in this study.	Decreasing Adverse Drug Reaction	CGA has perfective effect against MTX-induced liver injury.	MEC00805
C47122	.	6 to 8 weeks old BALB-neuT mice were subcutaneously inoculated in the right flank with 0.2 mL Phosphate-buffered saline (PBS) containing 1*106 SALTO-5 cells.	Augmenting Drug Sensitivity	"Combined rV-neuT+CUR treatment was more effective at reducing tumor growth and increasing mouse survival, anti-Neu humoral response, and IFN-gamma/IL-2 T-cell release in vitro than the individual treatment."	MEC00503
C42090	NEWCL00149; NEWCL10142	5*106 Hela/MMC cells were injected subcutaneously into the right oxter of mice.	Achieving Therapeutic Synergy	Piperine potentiates MMC-induced anti-tumor effect on cervical cancer cells with drug resistance through blocking p-STAT3/p65 and Bcl-2 activation.	MEC01015
C52131	.	"5*106 MiaPaCa2 cells were suspended in DMEM medium and transplanted subcutaneously in each BALB/c nude mice (male, 4 weeks old)."	Augmenting Drug Sensitivity	Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B.	MEC00070
C04593	NEWCL00155; NEWCL00156	5*105 MCF-7 cells were subcutaneously injected into the dorsal flanks of athymic nude mice.	Achieving Therapeutic Synergy	Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo.	MEC00142
C77214	NEWCL00031; NEWCL00027	5*105 HUH7 cells were subcutaneously injected into the dorsal flanks of 30 male 6-week old Athymic nude mice.	Augmenting Drug Sensitivity	Betulinic acid promotes TRAIL function on liver cancer progression inhibition through p53/Caspase-3 signaling activation.	MEC00515
C82649	NEWCL00355; NEWCL00104; NEWCL10376	LM8 and HT1080 cells were suspended (5 * 105 cells/100 ul) in Matrigel and injected subcutaneously into female athymic nude mice.	Achieving Therapeutic Synergy	"Cisplatin combined with caffeine citrate significantly reinforced the anticancer effect compared with cisplatin alone, combination of cisplatin and anhydrous caffeine, and combination of cisplatin and citric acid."	MEC00834
C69733	.	4T1 cells was inoculated subcutaneously into the right mammary glands of female balb/c mice.	Achieving Therapeutic Synergy	Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment.	MEC00252
C73577	.	4T1 cells (1*106) were suspended in 0.1 mL of PBS and injected into the mammary fat pad in the right flank of each BALB/c mice.	Augmenting Drug Sensitivity	"The study demonstrates the feasibility of delivering capecitabine and gensinoside Rg3 in a metronomic chemotherapy regimen, which is proved to be safe, effective, and potentially applicable to clinical treatment."	MEC00011
C40238	NEWCL00155; NEWCL00049; NEWCL00329; NEWCL00189	4T1 (7*105) cells were injected onto the left mammary fat pad of adult female BALB/c mice.	Augmenting Drug Sensitivity	Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis.	MEC00203
C34676	.	Male BALB/c albino mice weighing 30 g were used in this study.	Decreasing Adverse Drug Reaction	"ALA, an n-3 fatty acid, has a protective effect in mice renal tissue."	MEC00988
C50701	.	2*106 CT-26 mouse colon cancer cells in (0.1 ml PBS) cultured in DMEM with 10% FBS were subcutaneously injected into the right flanks of the mice.	Decreasing Adverse Drug Reaction	Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma.	MEC00895
C36464	NEWCL00049; NEWCL00155; NEWCL00227	2*106 human MDA-MB-231 cells were prepared with 200 uL of PBS/matrigel gel (1:1 ratio) and injected subcutaneously into the flanks of athymic nude mice (two-site injections).	Augmenting Drug Sensitivity	Curcumin enhances poly(ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells.	MEC00270
C51704	NEWCL00279; NEWCL00039; NEWCL00122	2*105 cells (U87 and U251) in a volume of 10L were injected into the right frontal lobe of the brain and thereafter the skin incision was sutured with silk thread in athymic mice.	Augmenting Drug Sensitivity	Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models.	MEC00178
C92668	.	Ten mice were challenged with 2 * 109 CFU S. aureus.	Achieving Therapeutic Synergy	The combination of salvianolic acid A with latamoxef completely protects mice against lethal pneumonia caused by methicillin-resistant Staphylococcus aureus.	MEC01368
C96829	NEWCL00348; NEWCL00282; NEWCL10115; NEWCL10173	1*107 ACHN or Caki-1 cells were injected into the backs of each mouse.	Achieving Therapeutic Synergy	Paclitaxel in combination with 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma through VHL-TGFBI signaling.	MEC00767
C74864	NEWCL00050; NEWCL00049; NEWCL00189	1*105 4T1-luc murine cells were inoculated directly into the mouse mammary fat pad.	Achieving Therapeutic Synergy	Piperine enhances TRAIL-based therapeutics for TNBC.	MEC01263
C04523	NEWCL00142; NEWCL00113	1*107 SGC7901/DOX cells were injected subcutaneously into the left inguinal region of each nude mouse when the mice got five weeks old.	Augmenting Drug Sensitivity	RES serves as a novel solution to reverse the DOX-resistance of gastric cancer via preventing EMT by modulating PTEN/Akt signaling pathway.	MEC00240
C77873	NEWCL00134	1*107 OVCAR3 cells in 0.2 ml PBS were inoculated subcutaneously into the dorsal flank of female mice (4 to 6 weeks old and weighing 16 to 20 g).	Achieving Therapeutic Synergy	"The sequential combination of rev-caspase-3 and flavopiridol result in significant synergistic cell killing effects, significant tumor growth suppression and extended survival of mice bearing OVCAR3 cells."	MEC00510
C99532	NEWCL00022	1*106 BNML cells in 0.5 mL of PBS injected into tail vein in male Brown Norway (BN/CrlCmd) rats.	Augmenting Drug Sensitivity	"Curcumin can increase the antileukemic effect of etoposide through reactive oxygen species in sensitive myeloid leukemia cells, and it is harmless to normal human cells."	MEC00132
C33680	.	1*105 of H22 tumor cells were inoculated in axillae of Kunming mice (22-25 g).	Augmenting Drug Sensitivity	Curcumin-enhanced antitumor effects of sorafenib via regulating the metabolism and tumor microenvironment.	MEC00398
C27955	NEWCL00078; NEWCL00074	1*105 HCT8 or SW480 cells were injected subcutaneously into the right flank area of 6-8-week-old female nude mice.	Augmenting Drug Sensitivity	Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance.	MEC00419
C00179	NEWCL00140	0.2 mL SMMC-7721 cell suspension (5*106 cells/mL) was injected subcutaneously into the right forelimb of female BALB/c nude mice.	Achieving Therapeutic Synergy	The molar ratio of 2:1 (CU:5-FU) combination group showed strong synergistic effect in SMMC-7721cells. The mechanism of the synergistic effect may be related to the inhibition of the expression of NF-kappaB (overall) and COX-2 protein.	MEC00096
C18543	NEWCL00226; NEWCL00355	0.2 mL of MG63 cell suspension (1.5*107 cells/ml) was subcutaneously injected into the right flank of mice.	Reversing Drug Resistance	Hypoxia-induced resistance to cisplatin-mediated apoptosis in osteosarcoma cells is reversed by gambogic acid independently of HIF-1Alpha.	MEC01111
C34743	.	0.2 mL Lewis lung carcinoma cell suspensions (1*107/mL) were injected subcutaneously into the armpit of right anterior superior limbs of female C57BL/6 mice.	Augmenting Drug Sensitivity	Ginsenoside Rg3 combined with gemcitabine may significantly inhibit angiogenesis and growth of lung cancer and improve survival and quality of life of tumor-bearing mice.	MEC00051
C26124	NEWCL00349	0.15 mL human bladder cancer cell suspension (with a concentration of 1 * 107 /ml) was injected through the catheter into the urinary bladder cavity.	Achieving Therapeutic Synergy	Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.	MEC01146
C42934	NEWCL00077; NEWCL00070; NEWCL00074; NEWCL00080	.	Augmenting Drug Sensitivity	Ellagic acid synergistically potentiated chemosensitivity to 5-fluorouracil in colorectal cancer cells.	MEC00107
C12224	NEWCL00082	.	Achieving Therapeutic Synergy	Combination of resveratrol and etoposide showed synergistic anti-proliferative effect on hepatocellular carcinoma cells.	MEC00134
C30192	NEWCL00294	.	Achieving Therapeutic Synergy	The combined effects of dexamethasone and genistein on the induction of p21 protein and activation of p21 promoter were synergistic.	MEC00194
C04523	NEWCL00149	.	Achieving Therapeutic Synergy	Resveratrol potentiates cytotoxic properties of doxorubicin used in the study through increasing their intracellular level due to p-glycoprotein inhibition and downregulation of mdr1 gene.	MEC00241
C71802	NEWCL00268	.	Augmenting Drug Sensitivity	Thioridazine plus curcumin induces proteasome activity by up-regulating PSMA5 expression via NOX4-mediated ROS production and that down-regulation of c-FLIP and Mcl-1 expression post-translationally is involved in apoptosis.	MEC00292
C97187	NEWCL00343	.	Augmenting Drug Sensitivity	Luteolin sensitizes TRAIL-induced apoptosis through down-regulation of XIAP.	MEC00487
C99856	NEWCL00178	.	Achieving Therapeutic Synergy	Attenuating Smac mimetic compound 3-induced NF-kappaB activation by luteolin leads to synergistic cytotoxicity in cancer cells.	MEC00488
C02511	NEWCL00275; NEWCL00276	.	Achieving Therapeutic Synergy	Isobolographic analysis demonstrates the additive and Synergistic effects of gemcitabine combined with fucoidan in uterine sarcomas and carcinosarcoma cells.	MEC00048
C69357	NEWCL00096	.	Achieving Therapeutic Synergy	Combination of Osthole and Cisplatin against rhabdomyosarcoma TE671 cells yielded additive pharmacologic interaction by means of isobolographic analysis.	MEC00312
C10758	NEWCL00077; NEWCL00155	.	Achieving Therapeutic Synergy	Genistein modulates the anti-tumor activity of cisplatin in MCF-7 breast and HT-29 colon cancer cells.	MEC00356
C02666	NEWCL00253	.	Achieving Therapeutic Synergy	Luteolin and gefitinib regulate CCP gene expression through a common mechanism involving EGFR-associated tyrosine kinase.	MEC00022
C49580	NEWCL00082	.	Achieving Therapeutic Synergy	Luteolin can induce p53-mediated apoptosis regardless of oxaliplatin treatment and may eliminate oxaliplatin-resistant p53-null colorectal cells.	MEC00416
C01021	NEWCL00286	.	Achieving Therapeutic Synergy	Curcumin significantly ameliorates CFZ cytotoxic effect. Induction of p53/p21 axis and G0/G1 cell cycle arrest were more pronounced for the CFZ-curcumin combination.	MEC00015
C23178	.	.	Decreasing Adverse Drug Reaction	Silymarin possess protective effects against cisplatin hepatotoxic action in animal models.	MEC00345
C98672	NEWCL00243; NEWCL00292; NEWCL00242; NEWCL00239	.	Augmenting Drug Sensitivity	Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells.	MEC00264
C50333	NEWCL00242; NEWCL00234	.	Augmenting Drug Sensitivity	"Curcumin increased the inhibitory effect of gemcitabine on cell viability as well as its pro-apoptotic effect in COX-2 positive, p34 cells, but not in COX-2 negative, Panc-1 cells. In p34 cells, combination of curcumin and gemcitabine downregulated both COX-2 and p-ERK1/2 in a dose-dependent manner."	MEC00058
C59960	NEWCL00252; NEWCL00251	.	Augmenting Drug Sensitivity	Apigenin markedly augmented TRAIL-mediated apoptosis in prostate cancer cells .	MEC00478
C17243	NEWCL00171	.	Augmenting Drug Sensitivity	"Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells."	MEC00020
C76104	NEWCL00129	.	Achieving Therapeutic Synergy	EGCG inhibited DOX-induced overexpression of P-gp through the coordinate inhibitory action on MEK/ERK and PI3K/Akt signaling pathways.	MEC00235
C87732	NEWCL00170; NEWCL00082; NEWCL00075	.	Achieving Therapeutic Synergy	"The cytotoxic synergy by the combination treatment involved the activation of caspase-1, caspase-3, and caspase-8 and generated huge chromosomal degradation. TNF-alpha treatment resulted in nuclear factor (NF)-kappa B activation, while flavopiridol inhibited the NF-kappa B-dependent gene transcription."	MEC00511
C02843	NEWCL00049	.	Augmenting Drug Sensitivity	The combination of EGCG and raloxifene effectively reduced the mitogenic and survival signaling in MDA-MB-231 cells.	MEC00028
C85986	NEWCL00252; NEWCL00253	.	Decreasing Adverse Drug Reaction	Genistein decreases the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells.	MEC00458
C00179	NEWCL00155; NEWCL00049; NEWCL00052; NEWCL00156	.	Decreasing Adverse Drug Reaction	Curcumin was found to sensitize the breast cancer cells to 5-FU through TS-dependent downregulation of nuclear factor-kappaB (NF-kappaB).	MEC00101
C32605	NEWCL00082; NEWCL00077	.	Decreasing Adverse Drug Reaction	"The combinatorial therapy inhibited cellular growth, invasion and colonosphere formation and also reduced CSC population as evidenced by the decreased expression of CSC specific markers: CD133, CD44, CD166 and ALDH."	MEC00196
C69480	NEWCL00129	.	Augmenting Drug Sensitivity	Combined applications of doxorubicin and silymarin caused higher apoptosis and necrosis of cells in 24 h than that of single agent applications.	MEC00220
C44873	NEWCL00253; NEWCL00251; NEWCL00252	.	Augmenting Drug Sensitivity	"There are Synergistic effects of curcumin and bicalutamide. Curcumin inhibits the growth of androgen-independent prostate cancer cells through ERK1/2- and SAPK/JNK-mediated inhibition of p65, followed by reducing expression of MUC1-C protein."	MEC00384
C33862	NEWCL00253	.	Augmenting Drug Sensitivity	Flavonoid apigenin sensitizes human CD44 + prostate cancer stem cells to cisplatin therapy by targeting cancer stem cells (CSCs) subset in prostate cancer.	MEC00317
C57596	NEWCL00077	.	Augmenting Drug Sensitivity	Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways.	MEC00110
C85986	NEWCL00027	.	Augmenting Drug Sensitivity	GE can epigenetically increase ERalpha expression by inhibition of DNMT1 expression which in turn increases apoptotic effect of E2.	MEC00459
C76931	NEWCL00170	.	Augmenting Drug Sensitivity	Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells.	MEC00230
C86152	NEWCL00037; NEWCL00279; NEWCL00039	.	Augmenting Drug Sensitivity	Curcumin potentiates the potent antitumor activity of ACNU against glioblastoma by suppressing the PI3K/AKT and NF-kappaB/COX-2 signaling pathways.	MEC00450
C16256	NEWCL00051	.	Augmenting Drug Sensitivity	5-fluorouracil acts synergistically with apigenin inhibiting cell growth and inducing apoptosis via the down-regulation of ErbB2 expression and Akt signaling.	MEC00085
C95252	NEWCL00215	.	Augmenting Drug Sensitivity	Curcumin suppresses growth and migration of SH-SY5Y cells and enhances the anticancer activity of doxorubicin.	MEC00219
C00179	NEWCL00253; NEWCL00251	.	Augmenting Drug Sensitivity	Curcumin enhances cytotoxicity of 5-FU in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation.	MEC00103
C95252	NEWCL00253; NEWCL00251	.	Augmenting Drug Sensitivity	Curcumin enhances cytotoxicity of doxorubicin in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation.	MEC00218
C23676	NEWCL00171; NEWCL00172; NEWCL00200; NEWCL00174; NEWCL00086	.	Augmenting Drug Sensitivity	"Apigenin upregulated the expression of Noxa in EGFRm tumor cells by targeting the AKT-FoxO3a pathway, thereby synergizing with ABT-263 to suppress tumor cell growth and proliferation in vitro and in vivo."	MEC00130
C22567	NEWCL00352	.	Augmenting Drug Sensitivity	Chrysin potentiated the chemotherapeutic effect of 5-FU in gastric cancer AGS and AGS/FR cells via cell cycle arrest.	MEC00087
C60738	NEWCL00279	.	Augmenting Drug Sensitivity	"Chrysin additively potentiates the antiproliferative, cell cycle arrest and apoptotic activity of cisplatin in human glioma cancer (U87) cells."	MEC00320
C69094	NEWCL00082; NEWCL00149; NEWCL00129	.	Augmenting Drug Sensitivity	"Chrysin can enhance the apoptosis induced by TRAIL, and the apoptosis is caspase-dependent and related to the activation of caspase 8."	MEC00479
C46103	NEWCL00170; NEWCL00180	.	Augmenting Drug Sensitivity	beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.	MEC00294
C46103	NEWCL00180; NEWCL00170	.	Augmenting Drug Sensitivity	Sensitization of lung cancer cells to cisplatin by beta-elemene is mediated through blockade of cell cycle progression.	MEC00296
C06881	NEWCL00022; NEWCL00059; NEWCL00019; NEWCL00199; NEWCL00155; NEWCL00129; NEWCL00339; NEWCL00325; NEWCL00203; NEWCL00020	.	Augmenting Drug Sensitivity	Ara-C combined with CK could achieve the efficacy of higher concentration of ara-C. CK promoted ara-C-induced cell membrane damage and mitochondrial dysfunction and increased ara-C-induced DNA damage.	MEC00155
C88733	NEWCL00074; NEWCL00082; NEWCL00077	.	Augmenting Drug Sensitivity	"Treatment of PIK3CA-mutant cells with fisetin and 5-FU reduced the expression of PI3K, phosphorylation of AKT, mTOR, its target proteins, constituents of mTOR signaling complex and this treatment increased the phosphorylation of AMPKalpha."	MEC00111
C35251	NEWCL00129	.	Augmenting Drug Sensitivity	"Curcumin markedly enhanced the antitumor effects of ABT-737 on HepG2 cells, which was partially dependent on the induction of apoptosis. The sustained activation of the ROS-ASK1-c-Jun N-terminal kinase pathway may be an important mediator of the synergistic effect of curcumin and ABT-737."	MEC00259
C78169	NEWCL00243	.	Augmenting Drug Sensitivity	Geraniol significantly increased the antiproliferative and apoptosis-inducing effects of gemcitabine on BXPC-3 cells.	MEC00064
C31687	NEWCL00231; NEWCL00230	.	Augmenting Drug Sensitivity	Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer by suppressing the expression of anti-apoptotic proteins and activation of mTOR.	MEC00311
C56350	NEWCL00134	.	Augmenting Drug Sensitivity	Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc.	MEC00349
C18543	NEWCL00170	.	Augmenting Drug Sensitivity	Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.	MEC00303
C10758	NEWCL00149	.	Augmenting Drug Sensitivity	"Genistein enhanced the antitumor activity of cisplatin and reduced the expression of NF-kappaB, p-mTOR, p-p70S6K1, p-4E-BP1, and p-Akt."	MEC00354
C95662	NEWCL00226; NEWCL00225; NEWCL00227	.	Augmenting Drug Sensitivity	"The combination of fisetin with etoposide has higher anti-proliferative effects in osteosarcoma associated with cell cycle arrest, allowing the use of lower doses of the chemotherapeutic agent."	MEC00133
C70450	NEWCL00080; NEWCL00077	.	Augmenting Drug Sensitivity	Curcumin enhances the effects of irinotecan on colorectal cancer cells through the generation of reactive oxygen species and activation of the endoplasmic reticulum stress pathway.	MEC00139
C99340	NEWCL00279; NEWCL00123	.	Augmenting Drug Sensitivity	Biochanin A significantly enhanced the anticancer efficacy of temozolomide in GBM cells.	MEC00177
C85406	NEWCL00360	.	Augmenting Drug Sensitivity	Esculetin enhances TRAIL-induced apoptosis primarily through upregulation of DR5.	MEC00538
C10155	NEWCL00282; NEWCL00049; NEWCL00037; NEWCL00317	.	Augmenting Drug Sensitivity	6-Shogaol enhances renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated cytochrome c release and down-regulation of c-FLIP(L) expression.	MEC00464
C26848	NEWCL00142	.	Augmenting Drug Sensitivity	ABT-737 in combination with naringenin showed enhanced anticancer effects on gastric cancer cells.	MEC00258
C90316	NEWCL00314; NEWCL00052	.	Augmenting Drug Sensitivity	Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells via JNK activation.	MEC00265
C56521	NEWCL00082; NEWCL00077	.	Augmenting Drug Sensitivity	Thioridazine plus curcumin induces proteasome activity by up-regulating PSMA5 expression via NOX4-mediated ROS production and that down-regulation of c-FLIP and Mcl-1 expression post-translationally is involved in apoptosis.	MEC00454
C20806	NEWCL00129; NEWCL00283	.	Augmenting Drug Sensitivity	Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases.	MEC00088
C83141	NEWCL00233	.	Augmenting Drug Sensitivity	"Emodin enhances the antitumor effect of gemcitabine in SW1990 pancreatic cancer in vitro and in vivo, which may be via the downregulation of NF-kappaB expression, thus inhibiting the expression of XIAP."	MEC00059
C80534	NEWCL00027; NEWCL00129	.	Augmenting Drug Sensitivity	"Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells."	MEC00162
C50333	NEWCL00242; NEWCL00238; NEWCL00236	.	Augmenting Drug Sensitivity	Curcumin showed synergistic anti-cancer effects with gemcitabineon PC cells.	MEC00057
C18577	NEWCL00242; NEWCL00238; NEWCL00236	.	Augmenting Drug Sensitivity	Curcumin showed synergistic anti-cancer effects with edocetaxel on PC cells by upregulation of TIMP1/TIMP2 with concomitant downregulation of MMP2/MMP9/N-cadherin proteins.	MEC00128
C95252	NEWCL00352	.	Augmenting Drug Sensitivity	Dox-Cur combination therapy exerts more profound apoptotic and anticancer effects on the AGS cell line than curcumin or doxorubicin monotherapy.	MEC00216
C57718	NEWCL00212; NEWCL00340	.	Augmenting Drug Sensitivity	Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.	MEC00436
C14624	NEWCL00230; NEWCL00231; NEWCL00229	.	Augmenting Drug Sensitivity	Combined curcumin and Apo2L/TRAIL treatment results in enhanced induction of apoptotic cell death. Curcumin and Apo2L/TRAIL together can activate both the extrinsic and intrinsic pathways of apoptosis.	MEC00494
C97187	NEWCL00149	.	Augmenting Drug Sensitivity	The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells.	MEC00489
C53657	NEWCL00170; NEWCL00181; NEWCL00180	.	Augmenting Drug Sensitivity	Shikonin increased the anticancer activity of AZD9291 in primary wtEGFR NSCLC cells through ROS-mediated ER stress.	MEC00268
C06799	NEWCL00245	.	Augmenting Drug Sensitivity	"Curcumin enhance the cytotoxicity of PS-341 by interacting with NF-kappaB, at least in part, through JNK mechanism."	MEC00032
C38237	NEWCL00023; NEWCL00022	.	Augmenting Drug Sensitivity	Curcumin could increase the sensitivity of leukemia stem-like KG1a cells to busulfan by downregulating the expression of survivin.	MEC00154
C00179	NEWCL00049	.	Decreasing Adverse Drug Reaction	The addition of curcumin as an adjuvant therapy during 5-FU treatment enhance the chemotherapeutic effectiveness of 5-FU by protecting normal cells from reduced viability and thus permitting higher dosing or longer treatment times.	MEC00102
C48730	NEWCL00155	.	Augmenting Drug Sensitivity	Combination of UA and Dox could reverse the MDR in breast cancer cells by inhibition of P-gp function and disruption of the metabolism of energy and related amino acids.	MEC00212
C29833	NEWCL00149	.	Augmenting Drug Sensitivity	Eugenol enhances the chemotherapeutic potential of gemcitabine and induces anticarcinogenic and anti-inflammatory activity in human cervical cancer cells.	MEC00063
C49649	NEWCL00148	.	Augmenting Drug Sensitivity	Curcumin enhances the effectiveness of cisplatin by suppressing CD133 + cancer stem cells in laryngeal carcinoma treatment.	MEC00341
C49649	NEWCL00148	.	Augmenting Drug Sensitivity	Cisplatin-induced increases in mitochondrial ROS and cell death levels in Hep2 cells were further enhanced through the increase of TRPM2 activation with the effect of curcumin treatment.	MEC00340
C57395	NEWCL00134; NEWCL00231; NEWCL00327	.	Augmenting Drug Sensitivity	EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin Influx transporter CTR1 in ovary cancer.	MEC00368
C57395	NEWCL00149	.	Augmenting Drug Sensitivity	EGCG increases the sensitization of cisplatin to cervical cancer cells by inhibiting cell survival and inducing apoptosis.	MEC00367
C49649	NEWCL00212	.	Augmenting Drug Sensitivity	Curcumin enhances cisplatin sensitivity by suppressing NOX5 expression in human epithelial cancer.	MEC00342
C46103	NEWCL00251; NEWCL00253	.	Augmenting Drug Sensitivity	beta-elemene enhancement of cisplatin-induced apoptosis via mitochondrial activation of the caspase-mediated apoptotic pathway may account for the augmented anti-cancer potency of cisplatin in prostate cancer.	MEC00295
C46103	NEWCL00047; NEWCL00349	.	Augmenting Drug Sensitivity	 beta-elemene augments the antitumor activity of cisplatin in human bladder cancer by enhancing the induction of cellular apoptosis via a caspase-dependent mechanism.	MEC00298
C46103	NEWCL00047; NEWCL00349	.	Augmenting Drug Sensitivity	beta-elemene enhances cisplatin-induced apoptosis in bladder cancer cells through the ROS-AMPK signaling pathway.	MEC00297
C97380	NEWCL00149; NEWCL00137; NEWCL00058; NEWCL00138	.	Augmenting Drug Sensitivity	Synergism of ursolic acid and cisplatin promotes apoptosis and enhances growth inhibition of cervical cancer cells via suppressing NF-kappaB p65.	MEC00328
C57504	NEWCL00170	.	Augmenting Drug Sensitivity	Piceatannol can enhance the cytotoxic effects of gemcitabine by enhancing expression of the proapoptotic protein Bak.	MEC00062
C89761	NEWCL00134	.	Augmenting Drug Sensitivity	Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo.	MEC00350
C32605	NEWCL00082; NEWCL00076; NEWCL00077	.	Augmenting Drug Sensitivity	Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.	MEC00197
C23550	NEWCL00201; NEWCL00180; NEWCL00100; NEWCL00101	.	Augmenting Drug Sensitivity	The depsipeptide plus flavopiridol combination exhibits powerful and selective cytocidal activity against cancer but not normal cells. Apoptosis induced by this combination is mediated by the mitochondria-dependent death pathway.	MEC00256
C23550	NEWCL00179; NEWCL00249; NEWCL00306; NEWCL00248; NEWCL00247	.	Augmenting Drug Sensitivity	"Flavopiridol abrogates depsipeptide-mediated induction of p21 expression, in part, via inhibition of protein kinase C signaling and markedly potentiates the cytotoxic effects of depsipeptide in MPM cells."	MEC00257
C63663	NEWCL00279	.	Augmenting Drug Sensitivity	Cinnamaldehyde is able to enhance the apoptosis induced by DOX on human glioblastoma cells.	MEC00228
C23318	NEWCL00170; NEWCL00171	.	Augmenting Drug Sensitivity	Capsaicin enhances erlotinib-induced cytotoxicity via AKT inactivation and excision repair cross-complementary 1 (ERCC1) down-regulation in human lung cancer cells.	MEC00153
C13131	NEWCL00282; NEWCL00348; NEWCL00257	.	Augmenting Drug Sensitivity	Combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells.	MEC00251
C10758	NEWCL00149; NEWCL00139	.	Augmenting Drug Sensitivity	Genistein enhances the anticancer effect of cisplatin in CaSki cells.	MEC00355
C10758	NEWCL00025; NEWCL00090; NEWCL00195; NEWCL00196; NEWCL00013	.	Augmenting Drug Sensitivity	Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells.	MEC00357
C10758	NEWCL00230; NEWCL00309	.	Augmenting Drug Sensitivity	Genistein enhances the cisplatin-induced inhibition of cell growth and apoptosis in human malignant melanoma cells.	MEC00353
C32534	NEWCL00282	.	Augmenting Drug Sensitivity	"Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells."	MEC00463
C03000	NEWCL00255	.	Augmenting Drug Sensitivity	"Antiproliferative efficacy of EA combined with BEV, probably through inhibition of MGMT expression and time-dependent inhibition of MDR1."	MEC00428
C60738	NEWCL00129	.	Augmenting Drug Sensitivity	Combination of chrysin and cisplatin promoted both extrinsic apoptosis by activating caspase-8 and intrinsic apoptosis by increasing the release of cytochrome c and activating caspase-9 in Hep G2 cells.	MEC00319
C96787	NEWCL00102	.	Augmenting Drug Sensitivity	"Betulinic acid enhances the chemical sensitivity of esophageal cancer cells to cisplatin by inhibiting cell proliferation, reducing cell stemness, and inducing pyroptosis."	MEC00364
C99302	NEWCL00170	.	Augmenting Drug Sensitivity	TRPM8-regulated calcium mobilization plays a critical role in synergistic chemosensitization of Borneol on Doxorubicin.	MEC00227
C47170	NEWCL00048	.	Augmenting Drug Sensitivity	Combination treatment may provide better outcomes in terms of cytotoxicity and thus reduce the dosages of imatinib used.	MEC00277
C39765	NEWCL00170	.	Augmenting Drug Sensitivity	Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway.	MEC00380
C00130	NEWCL00073	.	Augmenting Drug Sensitivity	Procyanidin enhances the impact of 5-Fluorouracil chemotherapy on Caco-2 human colon cancer cells.	MEC00076
C76104	NEWCL00242; NEWCL00236; NEWCL00243; NEWCL00074; NEWCL00075; NEWCL00077; NEWCL00171; NEWCL00199; NEWCL00170	.	Augmenting Drug Sensitivity	EGCG sensitizes chemotherapeutic-induced cytotoxicity by targeting the ERK pathway in multiple cancer cell lines.	MEC00236
C60870	NEWCL00242; NEWCL00236; NEWCL00243; NEWCL00074; NEWCL00075; NEWCL00077; NEWCL00171; NEWCL00199; NEWCL00170	.	Augmenting Drug Sensitivity	EGCG sensitizes chemotherapeutic-induced cytotoxicity by targeting the ERK pathway in multiple cancer cell lines.	MEC00068
C46103	NEWCL00170	.	Augmenting Drug Sensitivity	beta-ELE enhanced the sensitivity of A549/DDP cells to cisplatin and reversed the drug resistance of A549/DDP cells via the mitochondrial apoptosis pathway.	MEC00293
C88839	NEWCL00129; NEWCL00283	.	Augmenting Drug Sensitivity	Chrysin-induced ERK1/2 phosphorylation enhances the sensitivity of human gepatocellular carcinoma cells to sorafenib.	MEC00394
C63502	NEWCL00170	.	Augmenting Drug Sensitivity	Combination treatment of LMB and EGCG augments LMB-induced cytotoxicity through enhanced ROS production and the modulation of drug metabolism and p21/survivin pathways.	MEC00455
C62137	NEWCL00069	.	Augmenting Drug Sensitivity	Curcumin inhibits the cancer cell growth by inducing apoptosis and enhance the therapeutic potential of TRAIL.	MEC00497
C98409	NEWCL00077	.	Augmenting Drug Sensitivity	Combination of nimbolide and TNF-alpha-Increases human colon adenocarcinoma cell death through JNK-mediated DR5 up- regulation.	MEC00467
C44115	NEWCL00170; NEWCL00180	.	Augmenting Drug Sensitivity	Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca 2+-CaMKII-Sp1 pathway.	MEC00481
C62137	NEWCL00252; NEWCL00253	.	Augmenting Drug Sensitivity	Curcumin enhanced the apoptosis-inducing potential of TRAIL in androgen-unresponsive PC-3 cells and sensitized androgen-responsive TRAIL-resistant LNCaP cells.	MEC00500
C62137	NEWCL00155; NEWCL00156; NEWCL00052	.	Augmenting Drug Sensitivity	Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins.	MEC00501
C42547	NEWCL00252; NEWCL00253; NEWCL00251	.	Augmenting Drug Sensitivity	"Wogonin enhances TRAIL-induced cytotoxicity through up-regulation of p53 and Puma, mediated by ROS."	MEC00471
C92271	NEWCL00170	.	Augmenting Drug Sensitivity	Inhibition of the autophagy flux by gingerol enhances TRAIL-induced tumor cell death.	MEC00536
C28720	NEWCL00279; NEWCL00125; NEWCL00039	.	Augmenting Drug Sensitivity	Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.	MEC00528
C28720	NEWCL00036	.	Augmenting Drug Sensitivity	EGCG enhances TRAIL-mediated apoptosis in human melanoma A375 cell line.	MEC00521
C69094	NEWCL00049; NEWCL00077; NEWCL00129; NEWCL00034; NEWCL00240	.	Augmenting Drug Sensitivity	Chrysin overcomed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.	MEC00480
C23676	NEWCL00082; NEWCL00079	.	Augmenting Drug Sensitivity	"Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263 via inhibition of the Mcl-1, AKT, and ERK prosurvival regulators."	MEC00131
C03328	NEWCL00279; NEWCL00312; NEWCL00127; NEWCL00119; NEWCL00039	.	Augmenting Drug Sensitivity	Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation.	MEC00535
C14937	NEWCL00134; NEWCL00231	.	Augmenting Drug Sensitivity	Scutellarin synergistically enhances cisplatin effect against ovarian cancer cells through enhancing the ability of cisplatin binding to DNA.	MEC00309
C67056	NEWCL00036; NEWCL00193; NEWCL00194	.	Augmenting Drug Sensitivity	"The combination treatment resulted in significantly greater inhibition of cell proliferation, increased apoptosis, activation of p21, p27 and caspases (3, 7 and 9) and Bax as well as down-regulation of cdk2, cdk4, cyclin A, NF-kappaB protein p65/RelA and Bcl2 protein and transcript."	MEC00201
C93193	NEWCL00134	.	Augmenting Drug Sensitivity	"The combination therapy of BBR and DDP markedly enhanced more ovarian cancer cell death by inducing apoptosis and necroptosis, which may improve the anticancer effect of chemotherapy drugs. The apoptosis involved the caspase-dependent pathway, while the necroptosis involved the activation of the RIPK3-MLKL pathway."	MEC00379
C16500	NEWCL00077; NEWCL00076; NEWCL00049	.	Augmenting Drug Sensitivity	Combination treatment with morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase.	MEC00456
C67056	NEWCL00054; NEWCL00049; NEWCL00155	.	Augmenting Drug Sensitivity	"SAHA and EGCG promote apoptosis in triple-negative breast cancer cells, possibly through the modulation of cIAP2."	MEC00202
C49649	NEWCL00170; NEWCL00186	.	Augmenting Drug Sensitivity	"Curcumin enhanced the inhibitory effects of cisplatin on the highly migratory CD166+/EpCAM+ subpopulation. combined treatments induced cell cycle arrest, therefore triggering CSC growth inhibition via the intrinsic apoptotic pathway."	MEC00337
C70205	NEWCL00172; NEWCL00171	.	Augmenting Drug Sensitivity	Combining betulinic acid with an EGFR TKI improves drug efficacy in EGFR TKI-resistant lung cancer cells.	MEC00516
C07793	NEWCL00172; NEWCL00171	.	Augmenting Drug Sensitivity	Combining betulinic acid with an EGFR TKI improves drug efficacy in EGFR TKI-resistant lung cancer cells.	MEC00517
C21366	NEWCL00285	.	Augmenting Drug Sensitivity	Epigallocatechin-3-gallate and 6-OH-11-O-hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro.	MEC00522
C68636	NEWCL00012	.	Augmenting Drug Sensitivity	Silibinin improves the cytotoxicity of methotrexate in chemo resistant human rhabdomyosarcoma cell lines.	MEC00071
C49649	NEWCL00266	.	Augmenting Drug Sensitivity	"Curcumin acts against proliferation and sustain the effects of cisplatin by the induction of cell cycle arrest, amplification of DNA damage and contributing to cancer cell destruction by increasing the apoptotic process. Curcumin amplified the expression of P21 in tumor cells and might contribute to increasing the sensitivity to cisplatin."	MEC00343
C33678	NEWCL00354; NEWCL00258; NEWCL00097	.	Augmenting Drug Sensitivity	Combining flavopiridol with 4OH-Tam potently inhibited the growth of RT cells by increasing the ability of either drug alone to induce caspases 2 and 3 thereby causing apoptosis.	MEC00163
C44725	NEWCL00116; NEWCL00082; NEWCL00239; NEWCL00112	.	Augmenting Drug Sensitivity	Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit (RR-M2).	MEC00061
C28784	NEWCL00048; NEWCL00069	.	Augmenting Drug Sensitivity	Galangin caused a decrease in Bcl-2 levels and markedly increased the apoptotic activity of imatinib both in sensitive or imatinib-resistant Bcr-Abl+ cell lines.	MEC00282
C41181	NEWCL00146; NEWCL00155	.	Augmenting Drug Sensitivity	Wogonin increases doxorubicin sensitivity by down-regulation of IGF-1R/AKT signaling pathway in human breast cancer.	MEC00206
C24059	NEWCL00236	.	Augmenting Drug Sensitivity	"UA triggered ER stress, subsequently regulating apoptosis- and autophagy-related pathways and increasing GEM chemosensitivity in pancreatic cancer cells by inhibiting the expression of RAGE."	MEC00054
C97380	NEWCL00231	.	Augmenting Drug Sensitivity	Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1alpha in vitro.	MEC00330
C58165	NEWCL00353; NEWCL00082; NEWCL00077	.	Augmenting Drug Sensitivity	"At low and physiologically achievable concentrations, combinatorial EGCG and NaB are effective in promoting apoptosis, inducing cell cycle arrest and DNA-damage in CRC cells."	MEC00254
C00057	NEWCL00333; NEWCL00334	.	Augmenting Drug Sensitivity	Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells.	MEC00385
C65690	NEWCL00155; NEWCL00049	.	Augmenting Drug Sensitivity	Clofarabine in combination with sulforaphane significantly reactivates DNA methylation-silenced CDKN2A tumour suppressor and inhibits cancer cell growth at a non-invasive breast cancer stage.	MEC00276
C47590	NEWCL00024; NEWCL00019	.	Augmenting Drug Sensitivity	"Curcumin Combined with Thalidomide Reduces Expression of STAT3 and Bcl-xL, Leading to Apoptosis in Acute Myeloid Leukemia Cell Lines."	MEC00382
C13798	NEWCL00213; NEWCL00222	.	Augmenting Drug Sensitivity	Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.	MEC00527
C28720	NEWCL00082	.	Augmenting Drug Sensitivity	Activation of autophagic flux by epigallocatechin gallate mitigates TRAIL-induced tumor cell apoptosis via down-regulation of death receptors.	MEC00524
C58722	NEWCL00170; NEWCL00185; NEWCL00173	.	Augmenting Drug Sensitivity	Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL-induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species.	MEC00506
C05591	NEWCL00255	.	Augmenting Drug Sensitivity	Combining ellagic acid with temozolomide mediates the cadherin switch and angiogenesis in a glioblastoma model.	MEC00172
C23178	.	.	Decreasing Adverse Drug Reaction	Silymarin significantly attenuated the hepatotoxicity as an indirect target of cisplatin in an animal model of cisplatin-induced nephrotoxicity.	MEC00346
C86746	NEWCL00039; NEWCL00122	.	Augmenting Drug Sensitivity	Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma.	MEC00169
C76931	NEWCL00227; NEWCL00226	.	Augmenting Drug Sensitivity	Shikonin promotes adriamycin-induced apoptosis by upregulating caspase 3 and caspase 8 in osteosarcoma.	MEC00231
C19475	NEWCL00283; NEWCL00141; NEWCL00129; NEWCL00140	.	Augmenting Drug Sensitivity	Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition.	MEC00391
C72340	NEWCL00170; NEWCL00149	.	Augmenting Drug Sensitivity	Wogonin potentiates cisplatin-induced cancer cell apoptosis through accumulation of intracellular reactive oxygen species.	MEC00315
C18595	NEWCL00129	.	Augmenting Drug Sensitivity	The combination of apigenin and sorafenib arrested cell cycle and increased apoptotic gene expressions more than single treatment groups.	MEC00392
C36985	NEWCL00061	.	Augmenting Drug Sensitivity	Combined EGCG and bortezomib showed synergistic anticancer effect partly via regulating NF-kappaB pathway.	MEC00035
C93281	NEWCL00116; NEWCL00050	.	Augmenting Drug Sensitivity	Flavopiridol potentiates the cytotoxic effect of the chemotherapeutic agent MMC by promoting drug-induced apoptosis in tumor cells.	MEC00412
C27955	NEWCL00353	.	Augmenting Drug Sensitivity	"Ursolic acid potentiated oxaliplatin to induce apoptosis in colorectal cancer RKO cells and increased the activities of caspase-3, caspase-8, and caspase-9."	MEC00421
C77987	NEWCL00048; NEWCL00019; NEWCL00022; NEWCL00065; NEWCL00068	.	Augmenting Drug Sensitivity	Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.	MEC00279
C90522	NEWCL00155	.	Augmenting Drug Sensitivity	Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line by down-regulating P-glycoprotein.	MEC00223
C80977	NEWCL00022	.	Augmenting Drug Sensitivity	"Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium."	MEC00284
C73328	NEWCL00251	.	Augmenting Drug Sensitivity	"Genistein potentiates the antiproliferative actions of 1,25(OH)2D3 in DU145 cells by two mechanisms: (i) an increase in the half-life of 1,25(OH)2D3 due to the direct inhibition of CYP24 enzyme activity and (ii) an amplification of the homologous up-regulation of VDR."	MEC00287
C44725	NEWCL00155; NEWCL00049	.	Augmenting Drug Sensitivity	A sequence dependent potentiation of the effect of gemcitabine by flavopiridol was demonstrated in breast cancer cell lines and it was independent of ER status. This was accompanied by enhanced apoptosis and the up regulation of p21(WAF-1) protein.	MEC00060
C13933	NEWCL00241; NEWCL00238	.	Augmenting Drug Sensitivity	"Combination treatment with apigenin and gemcitabine inhibited pancreatic cancer cell growth via cell cycle arrest, down-regulation of the prosurvival factor pAkt, and induction of apoptosis."	MEC00050
C59960	NEWCL00170; NEWCL00181	.	Augmenting Drug Sensitivity	"Apigenin enhances TRAIL-induced antitumor activity in NSCLC cells by APG via inhibition of the NF-kappaB, AKT and ERK prosurvival regulators."	MEC00473
C23178	.	.	Decreasing Adverse Drug Reaction	Silymarin selectively protects human renal cells from cisplatin-induced cell death.	MEC00347
C45594	NEWCL00049	.	Augmenting Drug Sensitivity	EGCG and TAP reduced the proliferation of MDA-MB-231 cells by impairing cell-cycle progression.	MEC00434
C19645	NEWCL00256	.	Decreasing Adverse Drug Reaction	Curcumin potentiates the ability of sunitinib to eliminate the VHL-lacking renal cancer cells 786-O.	MEC00271
C02521	NEWCL00076; NEWCL00077	.	Augmenting Drug Sensitivity	"Combined treatment with resveratrol sensitized colon cancer cells to 5-fluorouracil, inducing a further increase in oxidative stress, which was linked to the inhibition of AKT and STAT3 proteins, which are known to have oncogenic potential in colorectal carcinomas."	MEC00119
C80755	NEWCL00253; NEWCL00251	.	Augmenting Drug Sensitivity	"Resveratrol pretreatment altered the expression of IAPs and Bax, and decreased Akt phosphorylation in PC-3 cells, leading to increased caspase activation and apoptosis."	MEC00533
C60407	NEWCL00155	.	Augmenting Drug Sensitivity	Resveratrol decreases Rad51 expression and sensitizes cisplatin resistant MCF-7 breast cancer cells.	MEC00376
C60407	NEWCL00288; NEWCL00140	.	Augmenting Drug Sensitivity	Resveratrol enhances cisplatin-induced apoptosis in human hepatoma cells via glutamine metabolism inhibition.	MEC00372
C60407	NEWCL00183	.	Augmenting Drug Sensitivity	Resveratrol promotes the sensitivity of small-cell lung cancer H446 cells to cisplatin by regulating intrinsic apoptosis.	MEC00374
C60407	NEWCL00251; NEWCL00253; NEWCL00252	.	Augmenting Drug Sensitivity	Resveratrol promotes apoptosis through the induction of dual specificity phosphatase 1 and sensitizes prostate cancer cells to cisplatin.	MEC00373
C04523	NEWCL00049; NEWCL00155; NEWCL00329	.	Augmenting Drug Sensitivity	Resveratrol promotes sensitization to Doxorubicin by inhibiting epithelial-mesenchymal transition and modulating SIRT1/beta-catenin signaling pathway in breast cancer.	MEC00242
C07405	NEWCL00236; NEWCL00242; NEWCL00347	.	Augmenting Drug Sensitivity	Inhibition of autophagy by deguelin sensitizes pancreatic cancer cells to doxorubicin.	MEC00205
C04523	NEWCL00082; NEWCL00077	.	Augmenting Drug Sensitivity	Resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity.	MEC00244
C23576	NEWCL00155; NEWCL00049	.	Augmenting Drug Sensitivity	Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest.	MEC00137
C98052	NEWCL00155; NEWCL00049; NEWCL00162	.	Augmenting Drug Sensitivity	Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.	MEC00290
C23002	NEWCL00155	.	Augmenting Drug Sensitivity	Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.	MEC00072
C50442	NEWCL00155	.	Augmenting Drug Sensitivity	"Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage."	MEC00402
C80755	NEWCL00129	.	Augmenting Drug Sensitivity	Resveratrol could augment TRAIL sensitivity by downregulating survivin.	MEC00532
C28724	NEWCL00077; NEWCL00082; NEWCL00353	.	Augmenting Drug Sensitivity	Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.	MEC00126
C49649	NEWCL00180	.	Augmenting Drug Sensitivity	Co-treatment of the cells with curcumin and cisplatin resulted in increased apoptosis and reversal of Bcl-2-mediated cisplatin resistance. The mechanism by which curcumin down-regulates Bcl-2 and sensitizes cells to cisplatin-induced apoptosis involves proteasomal degradation of Bcl-2.	MEC00339
C00331	NEWCL00086; NEWCL00089; NEWCL00006	.	Augmenting Drug Sensitivity	Qct can sensitize cells to TMZ and that the mechanisms of sensitization involve modulation of p53 family members.	MEC00174
C97187	NEWCL00256; NEWCL00348; NEWCL00257	.	Augmenting Drug Sensitivity	Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis involving Akt and STAT3 inactivation.	MEC00491
C97187	NEWCL00342	.	Augmenting Drug Sensitivity	"The levels of miR-301-3p were down-regulated in PANC-1 cells exposed to luteolin, which inhibits the growth of PANC-1 cells and sensitizes cells to TRAIL."	MEC00490
C78929	NEWCL00279	.	Augmenting Drug Sensitivity	PX can sensitize U87 cells and U87-SLCs to TRAIL treatment through an extrinsic pathway of cell apoptosis.	MEC00007
C76673	NEWCL00155; NEWCL00049; NEWCL00055; NEWCL00065; NEWCL00050; NEWCL00052; NEWCL00160	.	Augmenting Drug Sensitivity	Flavopiridol sensitizes breast cancer cells to TRAIL-induced apoptosis by facilitating early events in the apoptotic pathway.	MEC00513
C76673	NEWCL00057	.	Augmenting Drug Sensitivity	Flavopiridol Strongly Sensitizes Canine Lymphoma Cells to TRAIL-induced Apoptosis by activation of both the extrinsic and the intrinsic branches of the apoptotic machinery.	MEC00512
C22519	NEWCL00242; NEWCL00236; NEWCL00243; NEWCL00074; NEWCL00075; NEWCL00077; NEWCL00171; NEWCL00199; NEWCL00170	.	Augmenting Drug Sensitivity	EGCG sensitizes 5FU-induced cytotoxicity by targeting the ERK pathway in multiple cancer cell lines.	MEC00115
C90715	NEWCL00082	.	Augmenting Drug Sensitivity	Scutellarin sensitizes 5FU-evoked colon cancer cell apoptosis through enhanced caspase-6 activation.	MEC00077
C34810	NEWCL00279	.	Augmenting Drug Sensitivity	Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling.	MEC00171
C59960	NEWCL00129	.	Augmenting Drug Sensitivity	Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5.	MEC00475
C58722	NEWCL00279; NEWCL00039; NEWCL00122	.	Augmenting Drug Sensitivity	Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.	MEC00508
C44115	NEWCL00039; NEWCL00279; NEWCL00125	.	Augmenting Drug Sensitivity	Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin.	MEC00482
C59960	NEWCL00031	.	Augmenting Drug Sensitivity	"Apigenin sensitizes cells to TRAIL-induced apoptosis by activating both intrinsic and extrinsic apoptotic pathway-related caspases. The augmented apoptotic effect by TRAIL/apigenin combination was accompanied by triggering mitochondria-dependent signaling pathway, as indicated by Bax/Bcl-2 ratio up-regulation."	MEC00476
C28720	NEWCL00343; NEWCL00340; NEWCL00211; NEWCL00322	.	Augmenting Drug Sensitivity	EGCG sensitizes human nasopharyngeal carcinoma cells to TRAIL-mediated apoptosis by activation NF-kappaB.	MEC00523
C62137	NEWCL00252; NEWCL00251; NEWCL00253	.	Augmenting Drug Sensitivity	"Curcumin sensitizes prostate cancer cells to TRAIL by inhibiting Akt-regulated NF-kappaB and NF-kappaB-dependent antiapoptotic Bcl-2, Bcl-xL, and XIAP."	MEC00498
C27185	NEWCL00251	.	Augmenting Drug Sensitivity	Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin-induced growth inhibition and apoptotic death.	MEC00321
C62137	NEWCL00348	.	Augmenting Drug Sensitivity	Curcumin Sensitizes Kidney Cancer Cells to TRAIL-Induced Apoptosis via ROS Mediated Activation of JNK-CHOP Pathway and Upregulation of DR4.	MEC00495
C07957	NEWCL00170	.	Augmenting Drug Sensitivity	"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways."	MEC00514
C46690	NEWCL00251; NEWCL00252	.	Augmenting Drug Sensitivity	Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2.	MEC00474
C62137	NEWCL00252; NEWCL00251; NEWCL00253	.	Augmenting Drug Sensitivity	Combined curcumin and TRAIL treatment produced the most loss of viable cells by inducing apoptosis.	MEC00499
C62137	NEWCL00253	.	Augmenting Drug Sensitivity	Curcumin and TRAIL combination regimen is also the most effective treatment for inhibiting the growth of PC3 xenografts compared to curcumin or TRAIL monotherpy. The inhibition of PC3 tumors by combined treatment correlated with significant reduction in expression of p-Akt and NF-kappaB in tumor tissue.	MEC00502
C29997	NEWCL00310	.	Augmenting Drug Sensitivity	"Wogonin attenuates NF-kappaB activity by shifting TNFalpha-induced free radical .O(2)(-) to a more reduced nonradical product, H(2)O(2), and thereby sensitizes TNFalpha-resistant leukemia cells to TNFalpha-induced apoptosis."	MEC00470
C48730	NEWCL00042; NEWCL00275; NEWCL00104	.	Augmenting Drug Sensitivity	Down-regulation of AKT signalling by ursolic acid induces intrinsic apoptosis and sensitization to doxorubicin in soft tissue sarcoma.	MEC00213
C49644	NEWCL00352	.	Augmenting Drug Sensitivity	"A combinational treatment of cisplatin and luteolin induced more effectively cell growth inhibition, compared to cisplatin treatment alone."	MEC00325
C49644	NEWCL00133	.	Augmenting Drug Sensitivity	Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion.	MEC00326
C97336	NEWCL00149	.	Augmenting Drug Sensitivity	Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor- kappa B (NF-kappaB) pathway.	MEC00306
C62137	NEWCL00282; NEWCL00082; NEWCL00077; NEWCL00129; NEWCL00283	.	Augmenting Drug Sensitivity	Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5).	MEC00496
C44873	NEWCL00049; NEWCL00155; NEWCL00156; NEWCL00052; NEWCL00160; NEWCL00163; NEWCL00050; NEWCL00161; NEWCL00290; NEWCL00051; NEWCL00054	.	Augmenting Drug Sensitivity	The combination treatment suppressed the growth of AR triple-negative breast cancer cells more effectively than with the single drug alone.	MEC00383
C74309	NEWCL00098	.	Achieving Therapeutic Synergy	Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/beta-catenin signaling pathway.	MEC00425
C33680	NEWCL00262	.	Achieving Therapeutic Synergy	The combination of curcumin and sorafenib showed synergetic antitumor effect in thyroid cancer cells via PI3K/Akt and ERK pathways.	MEC00397
C59500	NEWCL00048; NEWCL00068; NEWCL00019; NEWCL00022; NEWCL00095; NEWCL00065; NEWCL00064	.	Achieving Therapeutic Synergy	"Bortezomib interacts synergistically with flavopiridol to induce mitochondrial dysfunction and apoptosis, blockade of the IkappaB/NF-kappaB pathway and activation of the SAPK/JNK cascade."	MEC00034
C74471	NEWCL00216; NEWCL00217; NEWCL00305; NEWCL00332; NEWCL00221; NEWCL00214; NEWCL00218; NEWCL00326; NEWCL00219; NEWCL00320	.	Achieving Therapeutic Synergy	"Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. The combination caused reduction in the expression of G(2)/M proteins (cyclin B1, Mad2, MPM2) in 2 cell lines with mt TP53 but not in those with wt TP53."	MEC00200
C93800	NEWCL00082; NEWCL00074; NEWCL00080; NEWCL00073; NEWCL00077	.	Achieving Therapeutic Synergy	"Capsaicin and DIM work synergistically to inhibit cell proliferation and induce apoptosis in colorectal cancer through modulating transcriptional activity of NF-kappaB, p53, and target genes associated with apoptosis."	MEC00443
C48068	NEWCL00093; NEWCL00092	.	Achieving Therapeutic Synergy	Apigenin can synergize with Abivertinib in treating DLBCL visa synergistically inducing apoptosis and inhibiting the p-GS3K-beta and its downstream targets.	MEC00245
C15089	NEWCL00155; NEWCL00049; NEWCL00156	.	Achieving Therapeutic Synergy	The combinative treatment remarkably decreased the mitochondrial membrane potential and activated caspase cascades more than the mono-treatment.	MEC00225
C66872	NEWCL00253; NEWCL00251	.	Achieving Therapeutic Synergy	Phosphodiesterase type 5 inhibitors synergize vincristine in killing castration-resistant prostate cancer through amplifying mitotic arrest signaling.	MEC00127
C07892	NEWCL00155	.	Achieving Therapeutic Synergy	Co-chemotherapy application of doxorubicin and hesperidin on MCF-7/Dox cells showed synergism effect through inhibition of Pgp expression.	MEC00221
C40830	NEWCL00049; NEWCL00155; NEWCL00157; NEWCL00050	.	Achieving Therapeutic Synergy	Selective estrogen receptor modulators and betulinic acid act synergistically to target ERalpha and SP1 transcription factor dependent Pygopus expression in breast cancer.	MEC00165
C35946	NEWCL00155	.	Achieving Therapeutic Synergy	"The combination of Hst and Dox-induced cell cycle arrest, apoptosis, decreased HER2, Rac1, MMP9 expression, and cell migration."	MEC00214
C57357	NEWCL00082	.	Achieving Therapeutic Synergy	Sodium selenite and G-Rh2 combination have a synergistic effect on cell growth inhibition (57%) compared with sodium selenite (25%) and G-Rh2 alone (28%) after 24 hours of treatment.	MEC00448
C21946	NEWCL00155; NEWCL00156	.	Achieving Therapeutic Synergy	Herceptin / resveratrol combinations improved the cytotoxic profile of herceptin in both T47D and MCF-7 breast cancer cell lines.	MEC00432
C10359	NEWCL00077; NEWCL00073; NEWCL00074	.	Achieving Therapeutic Synergy	Curcumin potentiates the growth inhibitory effect of celecoxib. The synergistic growth inhibitory effect was mediated through a mechanism that probably involves inhibition of the COX-2 pathway and may involve other non-COX-2 pathways.	MEC00039
C10359	NEWCL00234; NEWCL00236; NEWCL00242	.	Achieving Therapeutic Synergy	Curcumin synergistically augments the growth inhibition inserted by celecoxib in pancreatic cancer cells expressing COX-2. The synergistic effect was mediated through inhibition of COX-2.	MEC00041
C10359	NEWCL00049	.	Achieving Therapeutic Synergy	Curcumin and celecoxib synergistically inhibited the growth of MDA-MB-231 cells. The synergistic growth inhibitory effect was mediated by a mechanism that possibly involves inhibition of the COX-2 pathways.	MEC00040
C00179	NEWCL00352	.	Achieving Therapeutic Synergy	Combining curcumin with 5-FU significantly increased growth inhibition of AGS cells compared with either curcumin or 5-FU alone.	MEC00097
C00179	NEWCL00077	.	Achieving Therapeutic Synergy	Combination of curcumin and 5-FU showed synergism at higher doses against the human colon cancer cell line HT-29. This synergism was associated with the decreased expression of COX-2 protein.	MEC00100
C45701	NEWCL00015	.	Achieving Therapeutic Synergy	Curcumin down regulates MDR genes. Curcumin can be used as MDR modulator as well as chemosensitizer in combination with cytarabine to reduce the cytotoxicity profile as IC50 value decreases when treated in combination.	MEC00009
C56963	NEWCL00170	.	Achieving Therapeutic Synergy	"Combined treatment with curcumin and carboplatin inhibited tumor cell growth, migration, and invasion compared with either drug alone. The synergistic antitumor activity of curcumin combined with carboplatin is mediated by multiple mechanisms involving suppression of NF-kappaB via inhibition of the Akt/IKKalpha pathway and enhanced ERK1/2 activity."	MEC00408
C49649	NEWCL00170; NEWCL00186	.	Achieving Therapeutic Synergy	"Curcumin significantly suppressed colonies formation and shrank the spheroids in CSC subpopulations when combined with cisplatin.This effect also was manifested by the down-regulation of SOX2, NANOG, and KLF4."	MEC00338
C61515	NEWCL00269; NEWCL00359	.	Achieving Therapeutic Synergy	Co-treatment with cetuximab and curcumin exerts synergistic oral anticancer effects on CAR cells through the suppression of the EGFR signaling by regulation of the MAPK pathway.	MEC00437
C29751	NEWCL00220; NEWCL00215; NEWCL00222	.	Achieving Therapeutic Synergy	Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.	MEC00444
C78868	NEWCL00282; NEWCL00348; NEWCL00257	.	Achieving Therapeutic Synergy	Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells.	MEC00537
C46676	NEWCL00155	.	Achieving Therapeutic Synergy	"Both CK and DDP can inhibit the proliferation, EMT, and induce the apoptosis in MCF-7 cells, which may be related to the PI3K/Akt pathway. In addition, the combination of CK with DDP can produce a better effect."	MEC00307
C92813	NEWCL00140	.	Achieving Therapeutic Synergy	Cells treated with oxaliplatin+ ginsenoside enhanced the anti-tumor effect and may inhibit the proliferation and promoted apoptosis of hepatocellular carcinoma via regulating the expression of PCNA and cyclin D1.	MEC00415
C04523	NEWCL00242	.	Achieving Therapeutic Synergy	The cells' viability was more affected when DOX:RES combinations containing higher contents of RES (1:2-1:5 molar ratios) were used. This can be explained by the ability of RES to reduce the P-glycoprotein (P-gp)-mediated efflux of DOX.	MEC00243
C69797	NEWCL00231; NEWCL00284	.	Achieving Therapeutic Synergy	Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway.	MEC00361
C59754	NEWCL00170; NEWCL00175	.	Achieving Therapeutic Synergy	Combination of cordycepin and apatinib synergistically inhibits NSCLC cells by down-regulating VEGF/PI3K/Akt signaling pathway.	MEC00442
C68221	NEWCL00251; NEWCL00252; NEWCL00253	.	Achieving Therapeutic Synergy	The combination of silibinin and mitoxantrone exhibits a pattern of synergy in reducing cell viability with increased apoptosis.	MEC00273
C29048	NEWCL00251; NEWCL00252	.	Achieving Therapeutic Synergy	"Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis."	MEC00208
C44840	NEWCL00170; NEWCL00199; NEWCL00177	.	Achieving Therapeutic Synergy	Combination therapy with low concentrations of sorafenib and betulinic acid had the capacity to induce high levels of cell death and abolish clonogenic activity in some NSCLC cell lines regardless of KRAS mutations.	MEC00400
C44840	NEWCL00241; NEWCL00243; NEWCL00240	.	Achieving Therapeutic Synergy	Sorafenib in combination with betulinic acid synergistically induces cell cycle arrest and inhibits clonogenic activity in pancreatic ductal adenocarcinoma cells.	MEC00401
C08577	NEWCL00149; NEWCL00058; NEWCL00341	.	Achieving Therapeutic Synergy	EGCG functions synergistically against cancer cell proliferation in combined treatment with enoxacin.	MEC00283
C48767	NEWCL00251	.	Achieving Therapeutic Synergy	"EGCG+ibuprofen treatment has a synergistic effect on apoptosis, and xidative stress, directly or indirectly via ceramide synthesis mediated pro-apoptotic signaling."	MEC00272
C02843	NEWCL00049	.	Achieving Therapeutic Synergy	The synergistic cytotoxicity elicited by the combination of EGCG and raloxifene results from an earlier and greater induction of apoptosis.	MEC00027
C76104	NEWCL00227; NEWCL00225	.	Achieving Therapeutic Synergy	SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition.	MEC00237
C07326	NEWCL00269	.	Achieving Therapeutic Synergy	Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.	MEC00026
C02157	NEWCL00056	.	Achieving Therapeutic Synergy	Epigallocatechin-3-gallate and trichostatin A synergistically inhibit human lymphoma cell proliferation through epigenetic modification of p16INK4a.	MEC00266
C99457	NEWCL00155; NEWCL00156; NEWCL00049; NEWCL00161; NEWCL00331	.	Achieving Therapeutic Synergy	Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells.	MEC00146
C54208	NEWCL00215; NEWCL00213	.	Achieving Therapeutic Synergy	SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.	MEC00018
C14137	NEWCL00129	.	Achieving Therapeutic Synergy	ONO-8711 significantly inhibited PGE2-induced HCC proliferation while increased the inhibitory effect of EGCG on HCC cell viability and migration ability compared with EGCG alone.	MEC00406
C71528	NEWCL00048	.	Achieving Therapeutic Synergy	Synergistic effect of ponatinib and epigallocatechin-3-gallate induces apoptosis in chronic myeloid leukemia cells through altering expressions of cell cycle regulatory genes.	MEC00250
C28720	NEWCL00252	.	Achieving Therapeutic Synergy	EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.	MEC00525
C32924	NEWCL00082; NEWCL00075; NEWCL00083	.	Achieving Therapeutic Synergy	Combination of TAN and 5-FU significantly accelerates apoptosis via JNK mediated pathway.	MEC00079
C62548	NEWCL00049; NEWCL00155; NEWCL00011	.	Achieving Therapeutic Synergy	"25-methoxyl-dammarane-3beta, 12beta, 20-triol and artemisinin synergistically inhibit MDA-MB-231 cell proliferation through downregulation of testes-specific protease 50 (TSP50) expression."	MEC00518
C58717	NEWCL00253	.	Achieving Therapeutic Synergy	"NOB and SOR combination was more effective than SOR and NOB alone and reduced the exposure time for SOR and NOB in PC-3 cells. NOB and SOR combination significantly caused much more apoptotic cell death and cell cycle arrest at G0/G1 phase by up-regulation of Bax, Rb1, and CDKN1A levels in PC-3 cells."	MEC00389
C95159	NEWCL00357; NEWCL00027	.	Achieving Therapeutic Synergy	Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells.	MEC00393
C44388	NEWCL00113	.	Achieving Therapeutic Synergy	The combined treatment of deguelin and cisplatin exhibited a marked inhibition of MGC-803 cell proliferation when compared with that of the single therapies in vitro.	MEC00308
C72385	NEWCL00129; NEWCL00141	.	Achieving Therapeutic Synergy	Celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells by upregulating Noxa.	MEC00260
C01747	NEWCL00283	.	Achieving Therapeutic Synergy	"The combination of Apatinib and Tripterine significantly inhibited the proliferation, migration and invasion ability and promoted the apoptosis of Hep3B cells by downregulating the expression of p-Akt and p-ERK, and upregulating the expression of Caspase-3 and Bax."	MEC00441
C13748	NEWCL00241; NEWCL00243; NEWCL00242	.	Achieving Therapeutic Synergy	Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells.	MEC00047
C02521	NEWCL00082	.	Achieving Therapeutic Synergy	"RSV synergistically promotes 5-FU-mediated apoptosis at its higher concentration irrespective of p53. Conversely, it inhibits 5-FU-triggered apoptosis at lower concentrations in p53+/+ cells."	MEC00120
C02521	NEWCL00074; NEWCL00082	.	Achieving Therapeutic Synergy	"Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer."	MEC00118
C07748	NEWCL00252; NEWCL00253; NEWCL00251	.	Achieving Therapeutic Synergy	The combination of resveratrol with flutamide had a synergistic effect on down-regulation of androgen receptor (AR).	MEC00413
C24569	NEWCL00155; NEWCL00049	.	Achieving Therapeutic Synergy	"Combination of Res and Ral via increased expression of apoptotic genes including Bax, p53 and caspase-3 and caspase-8 is able to promote apoptosis as a mitochondrial dependent pathway in MCF7 and MDA-MB-231."	MEC00029
C15436	NEWCL00048	.	Achieving Therapeutic Synergy	Treatment with resveratrol (concentration-dependent) and imatinib mesylate showed significantly greater inhibition of K562 cell growth and a higher apoptosis rate of K562 cells than imatinib mesylate medication alone and the control group.	MEC00281
C05942	NEWCL00014	.	Achieving Therapeutic Synergy	Resveratrol enhances mitomycin C-mediated suppression of human colorectal cancer cell proliferation by up-regulation of p21WAF1/CIP1.	MEC00010
C72463	NEWCL00337; NEWCL00246	.	Achieving Therapeutic Synergy	The synergistic antiproliferative effect of resveratrol and clofarabine is linked to the inhibition of Akt and Sp1 activities.	MEC00274
C72463	NEWCL00246	.	Achieving Therapeutic Synergy	"Clofarabine and resveratrol cooperatively exerted cytotoxic effects in MSTO-211H cells. The observed synergism was mediated, at least in part, through suppression of the Nrf2 and PI3K/Akt signalings."	MEC00275
C31005	NEWCL00230; NEWCL00281	.	Achieving Therapeutic Synergy	Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation.	MEC00019
C98052	NEWCL00155; NEWCL00049; NEWCL00329	.	Achieving Therapeutic Synergy	The combination of rapamycin and resveratrol is able to block upregulation of autophagy and induce apoptosis in breast cancer cells.	MEC00289
C98052	NEWCL00323; NEWCL00046; NEWCL00274; NEWCL00044	.	Achieving Therapeutic Synergy	"In combination with rapamycin, resveratrol was able to block rapamycin-induced Akt activation, while maintaining mTOR pathway inhibition."	MEC00291
C60407	NEWCL00176; NEWCL00187	.	Achieving Therapeutic Synergy	Resveratrol enhanced anticancer effects of cisplatin on non-small cell lung cancer cell lines by inducing mitochondrial dysfunction and cell apoptosis.	MEC00375
C60407	NEWCL00170	.	Achieving Therapeutic Synergy	Resveratrol combined with cisplatin synergistically induce apoptosis via modulating autophagic cell death in A549 cells.	MEC00371
C16622	NEWCL00032	.	Achieving Therapeutic Synergy	Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells.	MEC00261
C15778	NEWCL00077	.	Achieving Therapeutic Synergy	Low concentration of lycopene and EPA could synergistically inhibit the proliferation of colon cancer cells. The inhibitory mechanism was associated with suppression of phosphatidylinositol 3-kinase/Akt signaling pathway.	MEC00246
C87321	NEWCL00251; NEWCL00253	.	Achieving Therapeutic Synergy	Lycopene and the LXRalpha agonist T0901317 synergistically inhibit the proliferation of androgen-independent prostate cancer cells via the PPARgamma-LXRalpha-ABCA1 pathway.	MEC00167
C75715	NEWCL00041; NEWCL00060; NEWCL00026; NEWCL00293; NEWCL00062	.	Achieving Therapeutic Synergy	Combination of dimethylaminoparthenolide and shikonin alters metabolism and inhibits proliferation of pediatric precursor-B cell acute lymphoblastic leukemia.	MEC00457
C01797	NEWCL00113	.	Achieving Therapeutic Synergy	Curcumin regulates the miR-21/PTEN/Akt pathway and acts in synergy with PD98059 to induce apoptosis of human gastric cancer MGC-803 cells.	MEC00447
C13325	NEWCL00180	.	Achieving Therapeutic Synergy	"Sulfinosine and curcumin overcome MDR in non-small cell lung carcinoma cell line (NSCLC) by regulating the expression of MDR-related genes mdr1, gst-pi and topo Iialpha."	MEC00451
C98114	NEWCL00282; NEWCL00348; NEWCL00257; NEWCL00049; NEWCL00279	.	Achieving Therapeutic Synergy	The combined treatment with NVP-BEZ235 and curcumin induces apoptosis through p53-dependent Bcl-2 mRNA down-regulation at the transcriptional level and Mcl-1 protein down-regulation at the post-transcriptional level.	MEC00386
C06615	NEWCL00067; NEWCL00066; NEWCL00106	.	Achieving Therapeutic Synergy	Capsaicin enhances 5FU sensitivity of cholangiocarcinoma through the inhibition of 5FU-induced autophagy by activating the PI3K/AKT/mTOR pathway.	MEC00122
C85683	NEWCL00155; NEWCL00049	.	Achieving Therapeutic Synergy	The combination of celecoxib and luteolin provided superior inhibition of breast cancer cell growth than either celecoxib or luteolin treatment alone. Decreased levels of Akt phosphorylation (pAkt) were noted after celecoxib and luteolin combination treatment.	MEC00037
C49580	NEWCL00142	.	Achieving Therapeutic Synergy	Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin through the Cyt c/caspase pathway.	MEC00418
C29611	NEWCL00253	.	Achieving Therapeutic Synergy	"Synergistic effects of 5-FU/rutin combination on PC3 cells line enhanced apoptosis, p53 gene expression, and down-regulation of Bcl-2 protein, compared to control separate application."	MEC00106
C80215	NEWCL00078; NEWCL00082	.	Achieving Therapeutic Synergy	Kaempferol has a synergistic effect with 5-FU by inhibiting cell proliferation and inducing apoptosis in colorectal cancer cells via suppression of TS or attenuation of p-Akt activation.	MEC00108
C99902	NEWCL00134	.	Achieving Therapeutic Synergy	Garcinol in combination with DDP promoted cell apoptosis in human ovarian cancer cells.	MEC00324
C30637	NEWCL00082; NEWCL00328	.	Achieving Therapeutic Synergy	The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-kappaB axis.	MEC00387
C87092	NEWCL00049; NEWCL00175; NEWCL00171	.	Achieving Therapeutic Synergy	"The combination of osimertinib and pterostilbene reversed the osimertinib-induced STAT3, YAP1, and CUB domain-containing protein-1 (CDCP1) phosphorylation and slightly suppressed Src phosphorylation in PC9 and H1975 cells."	MEC00267
C94751	NEWCL00149	.	Achieving Therapeutic Synergy	Sequential combination of cisplatin with wedelolactone showed synergistic antitumor effect in cervical cancer cells.	MEC00348
C49889	NEWCL00279; NEWCL00120; NEWCL00038; NEWCL00121; NEWCL00125; NEWCL00123; NEWCL00039	.	Achieving Therapeutic Synergy	"Shikonin not only dose-dependently inhibited EGFR phosphorylation and decreased phosphorylation of EGFR downstream molecules, including AKT, P44/42MAPK and PLCgamma1, but also together with erlotinib synergistically inhibited deltaEGFR phosphorylation in U87MG."	MEC00149
C11166	NEWCL00022; NEWCL00019; NEWCL00048; NEWCL00021	.	Achieving Therapeutic Synergy	"Combination of Azacitidine and curcumin showed a synergy in all leukemic lines and in most leukemic samples, with a decrease in proliferation and an increase in apoptosis compared to the activity of each drug separately. Azacitidine plus curcumin showed low cytotoxicity in healthy samples."	MEC00160
C61153	NEWCL00081; NEWCL00084; NEWCL00072; NEWCL00075; NEWCL00082; NEWCL00074; NEWCL00080; NEWCL00076	.	Achieving Therapeutic Synergy	The combined treatment with regorafenib and silybin induced synergistic anti-proliferative and apoptotic effects by blocking PI3K/AKT/mTOR intracellular pathway.	MEC00161
C10359	NEWCL00129	.	Achieving Therapeutic Synergy	"Curcumin augmented the celecoxib-mediated antitumor effects in HepG2 cells. The addition of curcumin to celecoxib resulted in increased cytotoxicity and caspase-3 activation, ,reduced the levels of Akt, NF-kappaB, PGE2, MDA, CD1, and VEGF, as compared to CXB alone."	MEC00038
C03662	NEWCL00184; NEWCL00079	.	Achieving Therapeutic Synergy	The synergistic antitumor effect of 5-FU combined with allicin was visible against lung and colorectal carcinoma cells. Better results were obtained when a lower concentration of 5-FU was combined with allicin than the single-agent treatment at IC50.	MEC00124
C49133	NEWCL00235	.	Achieving Therapeutic Synergy	EGCG synergistically boosts celecoxib-mediated effects and reduces the levels of celecoxib required to elicit beneficial effects on tumorigenic mediators by a factor of ten.	MEC00044
C30154	NEWCL00087; NEWCL00085; NEWCL00190; NEWCL00191	.	Achieving Therapeutic Synergy	"Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Celastrol treatment increased the levels of ubiquitinated proteins, reduced the levels of tumor necrosis factor-alpha-induced IkappaB phosphorylation, and blocked NF-kappaB translocation to the nucleus."	MEC00173
C91220	NEWCL00135; NEWCL00076; NEWCL00302	.	Achieving Therapeutic Synergy	Synergistic anticancer capabilities achieved by combining TRAIL/APO-2L and celastrol.	MEC00507
C25294	NEWCL00129; NEWCL00141	.	Achieving Therapeutic Synergy	Luteolin synergizes the antitumor effects of 5-fluorouracil against human hepatocellular carcinoma cells through apoptosis induction and metabolism.	MEC00089
C46103	NEWCL00118	.	Achieving Therapeutic Synergy	Synergistic cytotoxicity of beta-elemene and cisplatin in gingival squamous cell carcinoma by inhibition of STAT3 signaling pathwaybeta-elemene promoted the anti-proliferative and apoptotic effect of cisplatin by inhibiting STAT3 and blocking the JAK2-STAT3 signaling pathway in GSCC in vitro and in vivo.	MEC00299
C03344	NEWCL00005	.	Achieving Therapeutic Synergy	The concomitant administration of calcitriol with curcumin synergistically promoted anticancer effects in vitro and in vivo.	MEC00286
C83616	NEWCL00168	.	Achieving Therapeutic Synergy	Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2.	MEC00152
C18844	NEWCL00170; NEWCL00171	.	Achieving Therapeutic Synergy	Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells.	MEC00410
C88883	NEWCL00049	.	Achieving Therapeutic Synergy	The synergistic cytotoxicity elicited by the combination of EGCG and 4-OHT results from an earlier induction of apoptosis but this was not caused by an increase in G1-arrest or 4-OHT-mediated changes in the metabolism of EGCG.	MEC00166
C75169	NEWCL00032	.	Achieving Therapeutic Synergy	DHA in combination with butyric acid acts synergistically at low doses.	MEC00253
C59960	NEWCL00260; NEWCL00261	.	Achieving Therapeutic Synergy	"Apigenin synergizes with TRAIL through regulation of Bcl2 family proteins in inducing cytotoxicity, and suppression of AKT potentiates synergistic cytotoxicity of apigenin with TRAIL in ATC cells."	MEC00472
C51993	NEWCL00283; NEWCL00140	.	Achieving Therapeutic Synergy	Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation.	MEC00396
C58098	NEWCL00170	.	Achieving Therapeutic Synergy	Administration of flavopiridol for 24 h followed 3 days later by exposure to 5-fluorouracil resulted in a highly synergistic interaction.	MEC00359
C70316	NEWCL00134; NEWCL00280; NEWCL00330	.	Achieving Therapeutic Synergy	"Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells. Ovarian carcinoma cells on concurrent or 5-FU followed by BA treatment show increased Sub-G1 cell population, increased rate of cell apoptosis and morphological changes in mitochondrial membrane."	MEC00112
C49723	NEWCL00252; NEWCL00253; NEWCL00251	.	Achieving Therapeutic Synergy	Combining 2-ME(2) with eugenol (i) inhibited growth of prostate cancer cells and induced apoptosis at lower concentrations than either single agent alone.	MEC00135
C57932	NEWCL00130; NEWCL00169	.	Achieving Therapeutic Synergy	"Honokiol combined with rosiglitazone showed more effective growth inhibition in hepatoma cells mediated through the regulation of G0/G1 phase-related proteins p21, cyclin D1, cyclin E1, and Rb and cell cycle progression."	MEC00449
C45375	NEWCL00279	.	Achieving Therapeutic Synergy	Genistein at typical adult dietary plasma levels can significantly enhance the antiproliferative and cytotoxic action of BCNU.	MEC00017
C40238	NEWCL00049; NEWCL00155; NEWCL00050; NEWCL00156; NEWCL00329	.	Achieving Therapeutic Synergy	Genistein synergizes centchroman action in human breast cancer cells.	MEC00204
C10758	NEWCL00289; NEWCL00010; NEWCL00303	.	Achieving Therapeutic Synergy	Genistein can significantly enhance the antiproliferative and cytotoxic action of cisplatin.	MEC00358
C63959	NEWCL00082	.	Achieving Therapeutic Synergy	Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells.	MEC00078
C28144	NEWCL00048; NEWCL00068; NEWCL00313	.	Achieving Therapeutic Synergy	"Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells."	MEC00460
C56247	NEWCL00051; NEWCL00160; NEWCL00052	.	Achieving Therapeutic Synergy	"Synergy between flavopiridol and trastuzumab can result from enhanced apoptosis, and that combination effects on EGFR expression are involved in the interaction."	MEC00430
C83616	NEWCL00167; NEWCL00128; NEWCL00308; NEWCL00301; NEWCL00223; NEWCL00004	.	Achieving Therapeutic Synergy	"Erlotinib treatment activates p53, which plays a critical role in synergistic growth inhibition by erlotinib and EGCG via inhibiting nuclear factor-kappaB signaling pathway."	MEC00151
C28720	NEWCL00236	.	Achieving Therapeutic Synergy	Combination of epigallocatechin-3-gallate and TRAIL synergistically increase the apoptosis and cleavage of procaspase-3 in pancreatic cancer cells.	MEC00526
C06799	NEWCL00286	.	Achieving Therapeutic Synergy	Curcumin potentiates the therapeutic efficacy of bortezomib in multiple myeloma. Combined of curcumin with bortezomib inhibited IL-6/sIL-6R-induced STAT3 and Erk phosphorylation.	MEC00033
C76871	NEWCL00082	.	Achieving Therapeutic Synergy	Flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.	MEC00141
C56247	NEWCL00052; NEWCL00160; NEWCL00158	.	Achieving Therapeutic Synergy	Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells associated with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.	MEC00431
C97187	NEWCL00170; NEWCL00171; NEWCL00335	.	Achieving Therapeutic Synergy	Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission.	MEC00486
C16256	NEWCL00075; NEWCL00077	.	Achieving Therapeutic Synergy	"The dual-drug liposomes demonstrated enhanced inhibition of angiogenesis, better reduction in cell proliferation and increased apoptotic potential. Cell signaling studies indicating a significant upregulation of pAMPK and activity against downstream targets by dual drug liposomes."	MEC00084
C33862	NEWCL00170; NEWCL00180; NEWCL00181	.	Achieving Therapeutic Synergy	Flavonoids potentiated anticancer activity of cisplatin in non-small cell lung cancer cells in vitro by inhibiting histone deacetylases.	MEC00316
C59960	NEWCL00065; NEWCL00316; NEWCL00350	.	Achieving Therapeutic Synergy	"Apigenin breaks TRAIL resistance in HTLV-1-associated ATL by transcriptional down-regulation of c-FLIP, a key inhibitor of death receptor signaling, and by up-regulation of TRAIL receptor 2 (TRAIL-R2)."	MEC00477
C83293	.	.	Achieving Therapeutic Synergy	Ascorbic acid renders cisplatin more effective as an antitumor agent.	MEC00662
C69500	.	.	Achieving Therapeutic Synergy	"The combination of vinblastine and bleomycin achieved a high rate of objective responses in a subgroup of elderly and symptomatic patients, without considerable toxicity."	MEC00667
C95896	.	.	Reversing Drug Resistance	Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation.	MEC00724
C81913	.	.	Achieving Therapeutic Synergy	Glasdegib plus cytarabine/daunorubicin was well tolerated and associated with clinical activity in patients with untreated AML or high-risk MDS.	MEC00730
C03272	.	.	Achieving Therapeutic Synergy	"The combination of IM with a standard ""3+7"" regiment was well tolerated and provided a high response rate."	MEC00739
C28407	.	.	Decreasing Adverse Drug Reaction	MG could prevent the development and progression of mucositis induced by oxaliplatin through multipathway.	MEC00745
C04750	.	.	Achieving Therapeutic Synergy	Combination of khellin and nitroglycerin in the treatment of angina pectoris.	MEC00755
C79568	.	.	Achieving Therapeutic Synergy	Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.	MEC00789
C31244	.	.	Achieving Therapeutic Synergy	HCQ and ivermectin may show a consequential and synergistic action if administered simultaneously both for chemoprophylaxis and treatment of COVID-19.	MEC00818
C98290	.	.	Achieving Therapeutic Synergy	Neferine reduces cisplatin-induced nephrotoxicity by enhancing autophagy via the AMPK/mTOR signaling pathway.	MEC01466
C10101	.	.	Reversing Drug Resistance	Andrographis overcomes 5-fluorouracil-associated chemoresistance through inhibition of DKK1 in colorectal cancer.	MEC00952
C48805	.	.	Achieving Therapeutic Synergy	Combination therapy had additive efficacy in retarding renal scar formation during obstructive nephropathy.	MEC01159
C02284	.	.	Achieving Therapeutic Synergy	"Combination therapy with rasagiline and idebenone produced a synergistic effect that ameliorated RIR injury, restored visual function and provided neuroprotection."	MEC01167
C57775	.	.	Achieving Therapeutic Synergy	Snail overexpression or TGF-Beta1-induced EMT attenuated Neferine-mediated OXA sensitization in HCC.	MEC01181
C57775	.	.	Achieving Therapeutic Synergy	Snail overexpression or TGF-Beta2-induced EMT attenuated Neferine-mediated OXA sensitization in HCC.	MEC01296
C47401	.	.	Decreasing Adverse Drug Reaction	Daphnetin inhibited cisplatin-induced nephrotoxicity by inhibiting NF-KappaB and activating Nrf2 signaling pathways.	MEC01204
C47401	.	.	Decreasing Adverse Drug Reaction	"Nrf2 deficiency aggravated CDDP-induced nephrotoxicity, and Daph treatment significantly ameliorated the renal injury characterized by biochemical markers in WT mice and reduced the CDDP-induced cell damage."	MEC01205
C52865	.	.	Achieving Therapeutic Synergy	Combined use of iloprost and montelukast may reduce ischemic damage in transient spinal cord ischemia and may provide better neurological outcome.	MEC01221
C74677	.	.	Achieving Therapeutic Synergy	"Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells."	MEC01222
C50091	.	.	Achieving Therapeutic Synergy	"When TAC was administered along with MMF and prednisone, all patients showed improvement in response parameters, namely, SLEDAI, serum albumin, and proteinuria."	MEC01459
C27476	.	.	Achieving Therapeutic Synergy	"A non-cytotoxic concentration of cinchonine (10 microM) increased the sensitivity to doxorubicin of multidrug-resistant P388/DOX cells and significantly enhanced the doxorubicin-induced apoptosis and DNA fragmentation in resistant cells, but had no effect in parent cells."	MEC01271
C08339	.	.	Achieving Therapeutic Synergy	Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.	MEC01376
C25969	.	.	Achieving Therapeutic Synergy	"The combination of 1 with each antitubercular drug led to mutual enhancement of the antimycobacterial activity with isoniazid and ethionamide, while no such effect was observed with rifampin or streptomycin."	MEC01381
C07628	.	.	Achieving Therapeutic Synergy	"The combination of 1 with each antitubercular drug led to mutual enhancement of the antimycobacterial activity with isoniazid and ethionamide, while no such effect was observed with rifampin or streptomycin."	MEC01382
C97466	.	.	Achieving Therapeutic Synergy	"The combination of 1 with each antitubercular drug led to mutual enhancement of the antimycobacterial activity with isoniazid and ethionamide, while no such effect was observed with rifampin or streptomycin."	MEC01383
C87030	.	.	Achieving Therapeutic Synergy	"The combination of 1 with each antitubercular drug led to mutual enhancement of the antimycobacterial activity with isoniazid and ethionamide, while no such effect was observed with rifampin or streptomycin."	MEC01384
C43100	.	.	Achieving Therapeutic Synergy	The XYL + CHX combination was efficient and superior to single treatments in controlling biofilm and suppressing S. mutans.	MEC01402
C38304	.	.	Achieving Therapeutic Synergy	A combination of KML001 with doxercalciferol showed a synergistic effect on ALL cell lines.	MEC01418
C53614	.	.	Achieving Therapeutic Synergy	Combined therapy with finasteride and dutasteride can improve hair density in patients already taking finasteride.	MEC01419
C65108	.	.	Achieving Therapeutic Synergy	"Combination therapy with S-1 and PEG-IFN is effective and feasible, and is therefore a promising regimen for advanced HCC."	MEC01420
C13046	.	.	Achieving Therapeutic Synergy	"Triple combination immunosuppressive therapy maintained with additional mycophenolate mofetil successfully controlled recurrent myocarditis, enabled a reduction in the prednisolone dose, and achieved the functional recovery of the left ventricle."	MEC01461
C39034	.	.	Achieving Therapeutic Synergy	Low doses of the diethylpropion + topiramate combination can potentiate the anorectic effect of individual drugs with a better safety profile.	MEC01472
C44944	.	.	Achieving Therapeutic Synergy	Hydroxyurea and acitretin as a novel combination therapy in severe plaque psoriasis.	MEC01484
C96350	.	.	Achieving Therapeutic Synergy	"Tazarotene enhanced the penetration of imiquimod, and could be a therapeutic option in cases where surgical intervention is not possible."	MEC01493
C12957	.	.	Achieving Therapeutic Synergy	"Alitretinoin combined with topical 5-FU seems to be an interesting option in patients with DD, as it can allow a durable clinically complete remission with a good tolerance."	MEC01495
C68965	.	.	Achieving Therapeutic Synergy	"Anidulafungin with amphotericin B results in a synergistic effect against C. albicans and C. glabrata biofilms at serum concentrations of the drugs, but showed no interaction against C. tropicalis and C. parapsilosis complex."	MEC01496
C07427	.	.	Achieving Therapeutic Synergy	Methotrexate and compound glycyrrhizin can be an effective alternative therapy in the treatment of erythrodermic psoriasis with BP.	MEC01498
C58595	.	.	Achieving Therapeutic Synergy	"The combination of domperidone and pseudoephedrine improved self reported snoring and sleepiness, and may have improved apneic episodes and sleep-related nocturnal oxygen desaturation in patients with obstructive sleep apnea provided the proportion of time spent asleep did not diminish."	MEC01503
C61445	.	.	Decreasing Adverse Drug Reaction	Agmatine may improve therapeutic outcomes of doxorubicin since it exerts protective effects against doxorubicin-induced chronic cardiotoxicity in rats.	MEC01505
C10620	.	.	Achieving Therapeutic Synergy	The combination of anisodine and citicoline with standard steroid and mannitol therapy appears to be effective in the treatment of early optic nerve contusion.	MEC01507
C68757	.	.	Achieving Therapeutic Synergy	Co-administration of benfotiamine and citicoline was more effective than either alone in improving memory.	MEC01512
C56474	.	.	Achieving Therapeutic Synergy	"In patients treated with neipilept or with the combination of citicoline with 2-ethyl-6-methyl-3-hydroxypyridine succinate, plasma phosphatidylcholine was significantly increased."	MEC01513
C27121	.	.	Achieving Therapeutic Synergy	Synergistic effects of a low-dose combination of the growth factor bFGF and citicoline after temporary experimental focal cerebral ischemia and furthermore support the effectiveness of a combination treatment regimen for the management of acute stroke.	MEC01514
C50529	.	.	Achieving Therapeutic Synergy	The chemotherapeutic action of tegafur (FT) against adenocarcinoma 755 in mice was markedly potentiated by oral administration of L-cysteine and L-cystine without increasing its toxicity.	MEC01523
C70019	.	.	Achieving Therapeutic Synergy	Danthron has an anticancer effect and can sensitize the chemotherapeutic effect of doxorubicin on pancreatic cancer cells.	MEC01525
C93148	.	.	Achieving Therapeutic Synergy	"Parecoxib in combination with phloroglucinol for acute renal colic has a faster action, also reduces the demand of rescue analgesics."	MEC01535
C88607	.	.	Achieving Therapeutic Synergy	Oxyprogesterone caproate (OPC) administered preoperatively and after surgical and combined therapy from 6 up to 36 months increased the corrected survival rates as compared with that in patients who did not receive hormone treatment.	MEC01541
C75431	.	.	Achieving Therapeutic Synergy	"Based on earlier positive findings in Alzheimer patients with the monoamine oxidase B inhibitor, 1-deprenyl, the authors speculate that a combination of physostigmine, the short-acting cholinesterase inhibitor, and 1-deprenyl might be more beneficial than either agent alone."	MEC01547
C28428	.	.	Achieving Therapeutic Synergy	Lentinan combined with cisplatin in thoracic injection might benefit patients with NSCLC on a certain extent; this systematic review revealed some definite conclusions about the application of Lentinan combined with cisplatin in thoracic injection for NSCLC.	MEC01552
C39765	NEWCL00183	.	Achieving Therapeutic Synergy	Gallic acid induces apoptosis and enhances the anticancer effects of cisplatin in human small cell lung cancer H446 cell line via the ROS-dependent mitochondrial apoptotic pathway.	MEC00975
C39765	NEWCL00170	.	Achieving Therapeutic Synergy	Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway.	MEC01005
C28724	NEWCL00077; NEWCL00082; NEWCL00353	.	Achieving Therapeutic Synergy	Gossypol sensitizes the antitumor activity of 5 FU through down regulation of thymidylate synthase in human colon carcinoma cells.	MEC01085
C65690	NEWCL00049; NEWCL00155	.	Achieving Therapeutic Synergy	The combination of SFN and ClF results in an increase in cell growth arrest and apoptosis at a non-invasive breast cancer stage.	MEC00612
C65690	NEWCL00049; NEWCL00155	.	Achieving Therapeutic Synergy	"clofarabine in combination with sulforaphane, a phytochemical from cruciferous vegetables, significantly reactivates DNA methylation-silenced CDKN2A tumour suppressor and inhibits cancer cell growth at a non-invasive breast cancer stage."	MEC00613
C69357	NEWCL00180	.	Achieving Therapeutic Synergy	The combination of osthole and cisplatin resulted in greater efficacy in growth inhibition and apoptosis induction.	MEC01033
C55665	NEWCL00129; NEWCL00140; NEWCL00283; NEWCL00151	.	Achieving Therapeutic Synergy	"TQ synergistically improves the anti-cancer activity of DDP, and loss of p53 sensitizes HCC cells to TQ-induced apoptosis."	MEC01093
C55665	NEWCL10030; NEWCL10178	.	Achieving Therapeutic Synergy	Equitoxic combination of TQ and CDDP showed additive to synergistic interaction against both UMSCC-14C and OEC cells.	MEC01045
C39248	NEWCL00344	.	Achieving Therapeutic Synergy	Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.	MEC01283
C78929	NEWCL00279	.	Achieving Therapeutic Synergy	Paclitaxel and TRAIL synergize to kill U87 cells and U87-derived stem-like cells in vitro.	MEC00778
C08819	NEWCL10058	.	Reversing Drug Resistance	Honokiol adjuvants to doxorubicin could overcome multidrug resistance P-glycoprotein-mediated in uterine sarcoma.	MEC00873
C07405	NEWCL00236; NEWCL00242; NEWCL00347	.	Achieving Therapeutic Synergy	Inhibition of autophagy by deguelin sensitizes pancreatic cancer cells to doxorubicin.	MEC01109
C49659	NEWCL10186	.	Achieving Therapeutic Synergy	Triptolide synergistically enhanced the antitumor effect of cisplatin in cisplatin resistant human bladder cancer cells.	MEC00864
C49659	NEWCL10114	.	Achieving Therapeutic Synergy	TPL could induce cell apoptosis and synergize with DDP by regulating ROS generation and mitochondrial pathways in HNE1/DDP cells.	MEC01014
C58722	NEWCL00170; NEWCL00185; NEWCL00173	.	Achieving Therapeutic Synergy	Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species.	MEC01090
C58722	NEWCL00279; NEWCL00039; NEWCL00122	.	Achieving Therapeutic Synergy	Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.	MEC01131
C92271	NEWCL00170	.	Achieving Therapeutic Synergy	Inhibition of the autophagy flux by gingerol enhances TRAIL-induced tumor cell death.	MEC01088
C92271	NEWCL00279; NEWCL00312; NEWCL00123	.	Achieving Therapeutic Synergy	Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cells.	MEC00886
C78169	NEWCL00243	.	Achieving Therapeutic Synergy	Geraniol significantly increased the antiproliferative and apoptosis-inducing effects of gemcitabine on BXPC-3 cells.	MEC01335
C67401	NEWCL00344	.	Achieving Therapeutic Synergy	Isoliquiritigenin has the potential to overcome resistance to TRAIL in cancer cells and its chemopreventive effects may depend on TRAIL function.	MEC01076
C31687	NEWCL00231; NEWCL00230	.	Achieving Therapeutic Synergy	The combinatorial effects of cardamonin and cisplatin on anti-proliferation were enhanced by suppressing the expression of anti-apoptotic proteins and activation of mTOR in ovarian cancer cells.	MEC00847
C20806	NEWCL00129; NEWCL00283	.	Achieving Therapeutic Synergy	CGA sensitizes hepatocellular carcinoma cells to 5-FU treatment by the suppression of ERK activation through the overproduction of ROS.	MEC00888
C80534	NEWCL00027; NEWCL00129	.	Achieving Therapeutic Synergy	Chlorogenic acid improves the regorafenib effects in human hepatocellular carcinoma cells.	MEC00812
C90522	NEWCL00155	.	Achieving Therapeutic Synergy	Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line.	MEC01267
C90522	NEWCL00048	.	Achieving Therapeutic Synergy	Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase signaling in multidrug-resistant leukemia K562 cells.	MEC01034
C80215	NEWCL10146; NEWCL00082	.	Achieving Therapeutic Synergy	Kaempferol has a synergistic effect with 5 FU by inhibiting cell proliferation and inducing apoptosis in colorectal cancer cells via suppression of TS or attenuation of p Akt activation.	MEC00946
C56350	NEWCL00230	.	Achieving Therapeutic Synergy	Kaempferol Induces cell death in A2780 ovarian cancer cells and increases their sensitivity to cisplatin by activation of cytotoxic endoplasmic reticulum-mediated autophagy and inhibition of protein kinase B.	MEC00947
C56350	NEWCL00134	.	Achieving Therapeutic Synergy	Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc.	MEC01157
C56350	NEWCL10082	.	Reversing Drug Resistance	Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells.	MEC01116
C22567	NEWCL00352	.	Achieving Therapeutic Synergy	Chrysin potentiated the chemotherapeutic effect of 5-FU in gastric cancer AGS and AGS/FR cells via cell cycle arrest.	MEC01147
C88839	NEWCL00129; NEWCL00283	.	Achieving Therapeutic Synergy	Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib.	MEC01193
C60738	NEWCL00279	.	Achieving Therapeutic Synergy	"Chrysin additively potentiates the antiproliferative, cell cycle arrest and apoptotic activity of cisplatin in human glioma cancer (U87) cells."	MEC00896
C60738	NEWCL00129	.	Achieving Therapeutic Synergy	Combination chrysin and cisplatin significantly enhanced the apoptosis of Hep G2 cancer cells.	MEC00999
C69094	NEWCL00082; NEWCL00149; NEWCL00129	.	Achieving Therapeutic Synergy	Chrysin promotes tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced apoptosis in human cancer cell lines.	MEC01078
C28784	NEWCL00048; NEWCL00069	.	Achieving Therapeutic Synergy	Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells.	MEC01042
C42547	NEWCL00049; NEWCL00077; NEWCL00129; NEWCL00034; NEWCL00240	.	Reversing Drug Resistance	Wogonin overcomes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.	MEC01132
C10155	NEWCL00049; NEWCL00037; NEWCL10134; NEWCL10188	.	Achieving Therapeutic Synergy	6-shogaol enhances TRAIL-mediated apoptosis in renal carcinoma Caki cells via ROS-mediated cytochrome c release and down-regulation of c-FLIP(L) expression.	MEC00853
C10155	NEWCL00031; NEWCL00283; NEWCL00129	.	Achieving Therapeutic Synergy	Attenuation of 6-sho-induced autophagy flux sensitized cells to TRAIL-induced apoptosis via p53 and ROS.	MEC01317
C46103	NEWCL00251; NEWCL00253	.	Achieving Therapeutic Synergy	Beta-Elemene significantly increased cisplatin anticancer effects in the androgen-independent prostate carcinoma cell lines DU145 and PC-3.	MEC00860
C46103	NEWCL10130; NEWCL10055	.	Achieving Therapeutic Synergy	Beta-elemene sensitizes chemoresistant ovarian carcinoma cells to cisplatin-induced apoptosis and that the augmented effect of Beta-elemene on cisplatin cytotoxicity and sensitivity in resistant ovarian tumor cells is mediated through a mitochondria- and caspase-dependent cell death pathway.	MEC01000
C46103	NEWCL00170; NEWCL00180	.	Achieving Therapeutic Synergy	Beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.	MEC00859
C46103	NEWCL00170	.	Achieving Therapeutic Synergy	Beta-elemene reverses the drug resistance of lung cancer A549/DDP cells via the mitochondrial apoptosis pathway.	MEC00861
C46103	NEWCL00180; NEWCL00170	.	Achieving Therapeutic Synergy	Sensitization of lung cancer cells to cisplatin by Beta-elemene is mediated through blockade of cell cycle progression.	MEC01149
C46103	NEWCL00047; NEWCL00349	.	Achieving Therapeutic Synergy	Beta-elemene enhances cisplatin-induced apoptosis in bladder cancer cells through the ROS-AMPK signaling pathway.	MEC00862
C46103	NEWCL00047; NEWCL00349	.	Achieving Therapeutic Synergy	Beta-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas.	MEC01075
C63959	NEWCL00141	.	Reversing Drug Resistance	Bufalin effectively reversed MDR in BEL-7402/5-FU cells through multiple pathways.	MEC00566
C18543	NEWCL00170	.	Achieving Therapeutic Synergy	Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.	MEC01008
C18543	NEWCL00226; NEWCL00355; NEWCL00227	.	Achieving Therapeutic Synergy	GA could increase the chemotherapeutic effect of CDDP in human osteosarcoma treatment through inducing the cell cycle arrest and promoting cell apoptosis.	MEC01133
C87539	NEWCL00022; NEWCL00019; NEWCL10125; NEWCL00059	.	Achieving Therapeutic Synergy	"2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: Involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/ AMPK signaling pathways."	MEC00539
C16297	NEWCL00149; NEWCL00077; NEWCL00076; NEWCL00170	.	Achieving Therapeutic Synergy	The combination of TSN and 2-DG increased the sensitivity of cancer cells to 2-DG.	MEC00541
C35866	NEWCL10077; NEWCL00280	.	Achieving Therapeutic Synergy	Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines.	MEC00543
C33955	NEWCL00077	.	Achieving Therapeutic Synergy	A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.	MEC00544
C22543	NEWCL10020	.	Achieving Therapeutic Synergy	Quercetin enhances the antiproliferative activity of cis-diamminedichloroplatinum (II) in lung cancer cells.	MEC00546
C94489	NEWCL00141; NEWCL00129	.	Achieving Therapeutic Synergy	"CDA-II can strongly potentiate As(2)O(3)-induced apoptosis in hepatoma cells, and two drugs can produce a significant synergic effect."	MEC00554
C90807	NEWCL10295	.	Achieving Therapeutic Synergy	"Treatment with subeffective doses of simvastatin or gamma-tocotrienol alone had no effect, whereas combined treatment of these compounds resulted in a relatively large decrease in intracellular levels of phosphorylated (activated) MAPK, JNK, p38, and Akt."	MEC00555
C90807	NEWCL00248; NEWCL00249; NEWCL10354; NEWCL00246	.	Achieving Therapeutic Synergy	"Statin + Gamma-T3 combinations induced greater cell growth inhibition more than each single treatment via inhibition of mevalonate pathway, a well-known target of both Gamma-T3 and statins."	MEC00903
C22380	NEWCL10295	.	Achieving Therapeutic Synergy	"Treatment with subeffective doses of pravastatin or gamma-tocotrienol alone had no effect, whereas combined treatment of these compounds resulted in a relatively large decrease in intracellular levels of phosphorylated (activated) MAPK, JNK, p38, and Akt."	MEC00556
C07918	NEWCL10295	.	Achieving Therapeutic Synergy	"Treatment with subeffective doses of Lovastatin or gamma-tocotrienol alone had no effect, whereas combined treatment of these compounds resulted in a relatively large decrease in intracellular levels of phosphorylated (activated) MAPK, JNK, p38, and Akt."	MEC00557
C65745	NEWCL10295	.	Achieving Therapeutic Synergy	"Treatment with subeffective doses of mevastatin or gamma-tocotrienol alone had no effect, whereas combined treatment of these compounds resulted in a relatively large decrease in intracellular levels of phosphorylated (activated) MAPK, JNK, p38, and Akt."	MEC00558
C31431	NEWCL00048	.	Achieving Therapeutic Synergy	Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl dependent mechanisms.	MEC00918
C31431	NEWCL00048; NEWCL00019; NEWCL10125; NEWCL10027; NEWCL00022; NEWCL10101; NEWCL00065; NEWCL00095; NEWCL00094; NEWCL10103	.	Achieving Therapeutic Synergy	Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cell.	MEC00920
C31431	NEWCL10069; NEWCL10021; NEWCL10068; NEWCL10066	.	Achieving Therapeutic Synergy	Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.	MEC01039
C31431	NEWCL00278	.	Achieving Therapeutic Synergy	"Bortezomib can enhance ATO actions to induce apoptosis in RPMI 8266 cells, with decrease in expression of bcl-2 and increase of caspase-3, caspase-8 and caspase-9 proteins."	MEC01038
C31431	NEWCL00022	.	Achieving Therapeutic Synergy	Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL61 cell line and primary blasts from patients affected by myeloproliferative disorders.	MEC00887
C71638	NEWCL10125; NEWCL10228	.	Achieving Therapeutic Synergy	Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells.	MEC00900
C71638	NEWCL10125; NEWCL00048	.	Achieving Therapeutic Synergy	Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells.	MEC00561
C81513	NEWCL10125; NEWCL10228	.	Achieving Therapeutic Synergy	Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells.	MEC00901
C81513	NEWCL10125; NEWCL00048	.	Achieving Therapeutic Synergy	Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells.	MEC00562
C56032	NEWCL00039; NEWCL00312	.	Achieving Therapeutic Synergy	"celastrol targets proteostasis by disrupting sulfyhydryl homeostasis, independently of ROS, in human glioblastoma cells. Targeting proteotoxic stress responses by inhibiting HSP90 with 17-N-Allylamino-17-demethoxygeldanamycin sensitizes human glioblastoma to celastrol treatment, thereby serving as a novel synergism to overcome drug resistance."	MEC00565
C91306	NEWCL00171	.	Reversing Drug Resistance	Bufalin reverses hepatocyte growth factor-induced resistance to afatinib in H1975 lung cancer cells.	MEC00567
C52902	NEWCL00142; NEWCL00108; NEWCL00145	.	Reversing Drug Resistance	Bufalin reverses intrinsic and acquired drug resistance to cisplatin through the AKT signaling pathway in gastric cancer cells.	MEC00568
C27831	NEWCL00129; NEWCL10085	.	Achieving Therapeutic Synergy	Combination of cinobufacini and doxorubicin increases apoptosis of hepatocellular carcinoma cells through the Fas- and mitochondria-mediated pathways.	MEC00569
C06214	NEWCL00171	.	Achieving Therapeutic Synergy	"Combination of bufalin and gefitinib potently inhibited the growth of H1975 cells, and induced cell apoptosis. The potential mechanism for anti-tumor might be involved in blocking EGFR-PI3k/Akt pathway."	MEC00570
C78557	NEWCL00245; NEWCL00286; NEWCL10124; NEWCL00278	.	Achieving Therapeutic Synergy	MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.	MEC00572
C17227	NEWCL10125	.	Achieving Therapeutic Synergy	"Bufalin synergized with PD98059 to inhibit the proliferation and induce the apoptosis of NB4 cells, which was associated with the downregulation of survivin expression and the upregulation of caspase-3 activation."	MEC00574
C80165	NEWCL00049; NEWCL00170	.	Achieving Therapeutic Synergy	Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors.	MEC00575
C01919	NEWCL00027; NEWCL00129	.	Achieving Therapeutic Synergy	Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.	MEC00577
C01919	NEWCL00129; NEWCL00031	.	Reversing Drug Resistance	Bufalin reverses resistance to sorafenib by inhibiting Akt activation in hepatocellular carcinoma.	MEC00578
C01919	NEWCL10158	.	Achieving Therapeutic Synergy	Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling.	MEC00579
C66062	NEWCL00155; NEWCL00049	.	Achieving Therapeutic Synergy	Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.	MEC00581
C66062	NEWCL00155; NEWCL00049; NEWCL00329	.	Achieving Therapeutic Synergy	Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway.	MEC00583
C66062	NEWCL00047	.	Achieving Therapeutic Synergy	Bufalin sensitizes human bladder carcinoma cells to TRAIL-mediated apoptosis.	MEC00582
C40034	NEWCL00022	.	Achieving Therapeutic Synergy	"Bufalin in combination with 1,25(OH)(2)D(3) enhanced the expression of VDR target genes, such as CYP24A1 and cathelicidin antimicrobial peptide, and effectively induced differentiation phenotypes."	MEC00584
C38943	NEWCL00160	.	Achieving Therapeutic Synergy	Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.	MEC00590
C38943	NEWCL00314	.	Achieving Therapeutic Synergy	Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells.	MEC00585
C15513	NEWCL10108	.	Achieving Therapeutic Synergy	Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-KappaB pathway.	MEC00587
C31558	NEWCL00213; NEWCL00215	.	Achieving Therapeutic Synergy	Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis.	MEC00588
C70560	NEWCL00253	.	Achieving Therapeutic Synergy	Selenium and genistein act via different molecular mechanisms and exhibit enhanced anticancer effects.	MEC00589
C80432	NEWCL00251	.	Achieving Therapeutic Synergy	"The terazosin/genistein combination was more effective in inhibiting cell growth and VEGF expression as well as inducing apoptosis of the metastatic, androgen-independent prostate cancer cell line, DU-145, than either alone."	MEC00591
C58912	NEWCL00253	.	Achieving Therapeutic Synergy	Thearubigin and genistein combination showed Synergistic effects on human prostate tumor cell (PC-3) growth via cell cycle arrest.	MEC00592
C02627	NEWCL00048	.	Achieving Therapeutic Synergy	Tiazofurin and genistein showed synergistic action on growth inhibition and differentiation of K-562 human leukemic cells.	MEC00593
C93197	NEWCL00252	.	Achieving Therapeutic Synergy	Genistein-topotecan combination was significantly more efficacious in reducing LNCaP cell viability compared with either genistein or topotecan alone.	MEC00594
C55065	NEWCL00160	.	Achieving Therapeutic Synergy	Genistein significantly enhanced the antitumoral effect of trastuzumab on BT-474 breast cancer cells in vitro.	MEC00595
C42640	NEWCL00170	.	Achieving Therapeutic Synergy	Genistein enhances the effect of trichostatin A on inhibition of A549 cell growth by increasing expression of TNF receptor-1.	MEC00596
C42640	NEWCL00148	.	Achieving Therapeutic Synergy	Trichostatin A potentiates genistein-induced apoptosis and reverses EMT in HEp2 cells.	MEC00597
C66334	NEWCL00170	.	Achieving Therapeutic Synergy	Genistein enhances TRAIL-induced cancer cell death via inactivation of autophagic flux.	MEC00599
C66334	NEWCL00283	.	Achieving Therapeutic Synergy	Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells.	MEC00598
C97895	NEWCL00049	.	Achieving Therapeutic Synergy	"Sulforaphane and 5-fluorouracil have been shown to interact synergistically in the breast cancerMDA-MB-231 cell line, resulting in a significant reduction of the number of live cells compared to alone treatments."	MEC00602
C97895	NEWCL00073; NEWCL00077	.	Achieving Therapeutic Synergy	Sulforaphane showed synergistic interaction with 5-fluorouracil involved an intensification of apoptotic cell death.	MEC00600
C97895	NEWCL10038; NEWCL10039	.	Achieving Therapeutic Synergy	"Treatment ACCs cells with SFN and 5-Fu in combination, led to synergistic inhibition on cell growth and a decreased expression in nuclear NF-KappaB p65 protein."	MEC00601
C55540	NEWCL00205	.	Achieving Therapeutic Synergy	combinational treatments with SFN and DAC results in melanoma cell growth inhibition and specific changes in gene expression profiles.	MEC00603
C02032	NEWCL10185; NEWCL10153	.	Achieving Therapeutic Synergy	"Combination AZ + SFN treatment induced dose-dependent suppression of growth, produced a potent anti-proliferative and anti-clonogenic effect, and induced apoptosis through caspase-3 and PARP activation."	MEC00605
C81147	NEWCL00049; NEWCL00050	.	Achieving Therapeutic Synergy	"CIS when supplemented with SFN, inhibits metastasis and stemness potential of TNBC cells by down regulating SIRTs-mediated EMT cascade."	MEC00611
C81147	NEWCL10113; NEWCL10060	.	Achieving Therapeutic Synergy	Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins.	MEC00608
C81147	NEWCL00249; NEWCL00337	.	Achieving Therapeutic Synergy	Pro-oxidant activity of sulforaphane and cisplatin potentiates apoptosis and simultaneously promotes autophagy in malignant mesothelioma cells.	MEC00609
C81147	NEWCL10045; NEWCL10122	.	Achieving Therapeutic Synergy	Combined therapy with sulforaphane and cisplatin is efficient in suppressing tumor formation.	MEC00610
C29596	NEWCL10144	.	Achieving Therapeutic Synergy	Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations.	MEC00614
C29596	NEWCL10144	.	Reversing Drug Resistance	Sulforaphane was able to reverse the resistance to doxorubicin.	MEC00615
C29596	NEWCL00189	.	Achieving Therapeutic Synergy	Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells.	MEC00617
C37122	NEWCL10073; NEWCL10070; NEWCL10071	.	Reversing Drug Resistance	Chronic sulforaphane administration inhibits resistance to the mTOR-inhibitor everolimus in bladder cancer cells.	MEC00618
C92831	NEWCL10121; NEWCL10057	.	Achieving Therapeutic Synergy	The combination of sulforaphane and fernblock XP improves individual beneficial effects in normal and neoplastic human skin cell lines.	MEC00619
C09366	NEWCL00155	.	Decreasing Adverse Drug Reaction	The combination of SFN and gemcitabine potentiates the efficacy of gemcitabine and minimize the toxicity to normal cells.	MEC00620
C09366	NEWCL00175; NEWCL10181	.	Reversing Drug Resistance	SFN inhibits the proliferation of gefitinib-tolerant lung cancer cells via modulation of the SHH signaling pathway.	MEC00621
C76452	NEWCL10110	.	Achieving Therapeutic Synergy	Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/Beta-catenin function.	MEC00622
C85224	NEWCL00073	.	Achieving Therapeutic Synergy	"SFN and Ox alone inhibited cell growth of Caco-2 cells in a dose-dependent manner, an effect, which could be synergistically enhanced, when cells were incubated with the combination of both agents."	MEC00623
C30515	NEWCL00344; NEWCL00076	.	Achieving Therapeutic Synergy	Sulforaphane preconditioning sensitizes human colon cancer cells towards the bioreductive anticancer prodrug PR-104A.	MEC00624
C40575	NEWCL00243; NEWCL00236	.	Achieving Therapeutic Synergy	"SF completely eradicated SO-induced NF-KappaB binding, which was associated with abrogated clonogenicity, spheroid formation, ALDH1 activity, migratory capacity, and induction of apoptosis."	MEC00625
C53594	NEWCL10087; NEWCL00038; NEWCL00122; NEWCL00039	.	Achieving Therapeutic Synergy	SFN enhances TMZ-induced apoptosis in GBM cells by down-regulation of miR-21.	MEC00626
C69906	NEWCL00253; NEWCL00251	.	Achieving Therapeutic Synergy	Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells.	MEC00632
C69906	NEWCL00170	.	Achieving Therapeutic Synergy	Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells.	MEC00630
C69906	NEWCL00225; NEWCL00226	.	Achieving Therapeutic Synergy	Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells.	MEC00629
C69906	NEWCL00283; NEWCL00031; NEWCL00129	.	Achieving Therapeutic Synergy	Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5.	MEC00628
C82816	NEWCL00129	.	Achieving Therapeutic Synergy	Sor-Tau combination led to FOXP3 down-regulation in hepatic cancer cells (HepG2) and improved therapeutic efficacy of sorafenib treated HCC.	MEC00636
C47979	NEWCL00049; NEWCL00155	.	Achieving Therapeutic Synergy	The combination of selenium with docetaxel inhibits cell proliferation through apoptosis and cell arrest in the G2/M phase in MDA-MB-231 breast cancer cells.	MEC00643
C77126	NEWCL00180; NEWCL00181; NEWCL00341	.	Achieving Therapeutic Synergy	Selenium selectively enhanced the radiosensitivity of the tumor cells whereas that of the normal cells was unaffected.	MEC00645
C40967	NEWCL10197	.	Achieving Therapeutic Synergy	The combination of fosfomycin plus meropenem is synergistic for pseudomonas aeruginosa PAO1 in a hollow-fiber infection model.	MEC00650
C40967	NEWCL10300	.	Reversing Drug Resistance	The increase in pharmacodynamic activities resulting from the synergistic action of meropenem with fosfomycin demonstrates the potential relevance of this combination to fight infections caused by MDR and MBL-producing P. aeruginosa strains.	MEC00651
C26102	NEWCL10307	.	Achieving Therapeutic Synergy	"Against CIPR S. flexneri isolates, the CIP/FOS combination induced synergy, and increased bacterial killing in vitro and in a simple invertebrate model of infection."	MEC00652
C49042	NEWCL10312	.	Achieving Therapeutic Synergy	"Linezolid combined with fosfomycin at 4x MIC showed the best synergistic antibacterial effect, and this effect was retained after 24 hours."	MEC00653
C09974	NEWCL10265	.	Achieving Therapeutic Synergy	Fosfomycin and NAC at concentrations achievable in urine displayed a synergistic effect promoting both the formation of biofilms and reduction of sessile cell viability.	MEC00654
C80620	NEWCL10389; NEWCL10388	.	Achieving Therapeutic Synergy	The combination of CDDP and osthole was characterized by the most desirable synergistic interaction.	MEC00655
C83293	NEWCL00352	.	Achieving Therapeutic Synergy	The combined dose of vitamin C and cisplatin could increase the percentage of apoptotic and necrotic cells in comparison with a single dose of cisplatin.	MEC00656
C31798	NEWCL00019; NEWCL10122	.	Achieving Therapeutic Synergy	"Stilbenoid compounds may have the potential to boost the innate immune response by increasing CAMP gene expression, particularly in combination with 1Alpha,25(OH)2 D3."	MEC00659
C86585	NEWCL10227	.	Achieving Therapeutic Synergy	Eravacycline and colistin combination may be a potential therapeutic option for the treatment of CRAB related infections.	MEC00671
C90784	NEWCL10226; NEWCL10286	.	Reversing Drug Resistance	Niclosamide has potentiated the effect of colistin against Col-S and Col-R A.	MEC00672
C86482	NEWCL10226	.	Reversing Drug Resistance	"N-acetylcysteine, at concentrations achievable by topical administration, was shown to revert the colistin-resistant phenotype in A. baumannii, and to exert a relevant activity against biofilms of colistin-susceptible and colistin-resistant A. baumannii strains."	MEC00673
C22495	NEWCL00269	.	Achieving Therapeutic Synergy	Allyl isothiocyanate can inhibit Akt/mTOR proliferation signaling and promote mitochondria dependent apoptotic pathway through AITC-enhanced activities of caspase-3 and caspase-9 in CAR cells.	MEC00716
C96055	NEWCL00129	.	Achieving Therapeutic Synergy	"The combination significantly downregulated MDR1 and LRP1, suggesting the potential to reverse the resistance to 5-FU."	MEC00717
C17908	NEWCL10397; NEWCL10394; NEWCL10395; NEWCL10396; NEWCL10398; NEWCL10399; NEWCL10400; NEWCL10290; NEWCL10289	.	Achieving Therapeutic Synergy	"The combination of cisplatin with the natural compound PEITC induces a strong MPM cell death, while remaining safe for PMC, with limited emergence of cell resistance compared to drugs used alone."	MEC00719
C76480	NEWCL00279	.	Reversing Drug Resistance	Combination of TMZ with micellarized Cyp is a promising strategy for exerting different functions of drugs for tumor treatment.	MEC00720
C76480	NEWCL00279	.	Achieving Therapeutic Synergy	Cyclopamine sensitizes glioblastoma cells to temozolomide treatment through Sonic hedgehog pathway.	MEC00723
C08126	NEWCL00155	.	Achieving Therapeutic Synergy	Combination of cyclopamine and tamoxifen promotes survival and migration of mcf-7 breast cancer cells--interaction of hedgehog-gli and estrogen receptor signaling pathways.	MEC00721
C78281	NEWCL00253	.	Achieving Therapeutic Synergy	The combined cyclopamine and gefitinib were more effective at suppressing the invasiveness of PC3 cells through matrigel in vitro as the drugs alone.	MEC00722
C95896	NEWCL10420; NEWCL00278	.	Achieving Therapeutic Synergy	Combination of cyclopamine and CPT exhibited Synergistic effects on the inhibition of proliferation and induction of apoptosis in myeloma cells.	MEC00725
C21207	NEWCL00233; NEWCL00091	.	Reversing Drug Resistance	"Gemcitabine-resistant pancreatic cancer cells highly express CSCs markers and some of the HH members, and inhibition of HH by cyclopamine is an effective method of reversing gemcitabine resistance in pancreatic cancer."	MEC00727
C79218	NEWCL10248	.	Achieving Therapeutic Synergy	Synergic efficiency for erlotinib-cyclopamine association and provide a suitable in vitro model to explore drug combinations on GBM cells.	MEC00728
C01479	NEWCL00023; NEWCL00129	.	Decreasing Adverse Drug Reaction	"Olaparib interferes with anthracycline metabolism, and suggest that this phenomenon might be utilized for combating anthracycline resistance."	MEC00729
C91820	NEWCL10119; NEWCL00313; NEWCL10331	.	Achieving Therapeutic Synergy	The addition of potent FLT3 inhibitors such as SU11248 to AML chemotherapy regimens could result in improved treatment results.	MEC00731
C96101	NEWCL00065; NEWCL00032; NEWCL10416	.	Achieving Therapeutic Synergy	"The combination of bortezomib and daunorubicin significantly enhanced their apoptosis inducing effect in T ALL cells, which may warrant further investigation in preclinical and clinical investigations."	MEC00735
C40950	NEWCL10119; NEWCL00020; NEWCL00059; NEWCL00022; NEWCL10101; NEWCL10329; NEWCL10330; NEWCL00021	.	Achieving Therapeutic Synergy	NL 101 in combination with daunorubicin could be an alternative novel therapeutic strategy for treating leukemia.	MEC00736
C78830	NEWCL00059; NEWCL00063; NEWCL10069; NEWCL10125	.	Decreasing Adverse Drug Reaction	"PP242 effectively eliminated this deleterious side effect of DNR and synergistically enhanced the anticancer ability of DNR treatment. PP242, especially in combination with DNR, exerts significant antileukemia effects."	MEC00737
C23303	NEWCL00063	.	Decreasing Adverse Drug Reaction	"RAPA effectively eliminated this deleterious side effect of DNR, which might enhance DNR's ability to kill drug-resistant cancer."	MEC00738
C76612	NEWCL10236	.	Achieving Therapeutic Synergy	"Magnolol synergizes with azoles for targeting of C. albicans by inducing a higher intracellular content of antifungals, by tapping into the competitive effect of ABC transporter Cdr1p substrates, and enhancing the effect by targeting of the ergosterol biosynthesis pathway."	MEC00740
C42511	NEWCL10134	.	Achieving Therapeutic Synergy	Magnolol enhanced TRAIL-induced apoptosis via ATF4-dependent DR5 upregulation and downregulation of c-FLIP and Mcl-1 proteins.	MEC00741
C99416	NEWCL00169; NEWCL00283	.	Achieving Therapeutic Synergy	AKT inhibition is associated with magnolol-enhanced the therapeutic effect of sorafenib in HCC.	MEC00744
C63262	NEWCL00298; NEWCL10031	.	Reversing Drug Resistance	Magnolol attenuates cisplatin-induced muscle wasting by M2c macrophage activation.	MEC00746
C55738	NEWCL00231	.	Achieving Therapeutic Synergy	Composite micelles showed reduced systematic toxicity and greater synergistic effect than combination of small molecules of hydrophilic platinum drug Oxa(II) and hydrophobic drug DRB both in vitro and in vivo.	MEC00747
C92687	NEWCL00155	.	Achieving Therapeutic Synergy	Alpha/beta selective retinoids dramatically lowered the effective dose of Taxol needed to induce cytotoxicity of a wide range of tumor cell lines. Examination of pathways common to Taxol and retinoid signaling revealed that this synergy was related in part to effects on Bcl-2 expression/phosphorylation as well as the activity of the c-Jun NH(2)-terminal kinase and activator protein-1.	MEC00761
C08743	NEWCL00155	.	Achieving Therapeutic Synergy	Alpha/beta selective retinoids dramatically lowered the effective dose of Taxol needed to induce cytotoxicity of a wide range of tumor cell lines. Examination of pathways common to Taxol and retinoid signaling revealed that this synergy was related in part to effects on Bcl-2 expression/phosphorylation as well as the activity of the c-Jun NH(2)-terminal kinase and activator protein-1.	MEC00765
C35840	NEWCL10088	.	Achieving Therapeutic Synergy	Paclitaxel combinated with low and nontoxic AZT dose was a novel cancer therapeutic approach to human pharynx faDu cells.	MEC00766
C96829	NEWCL00252; NEWCL00251; NEWCL00253	.	Achieving Therapeutic Synergy	"DAC could significantly increase the susceptibility of PC cells to PTX, and confirmed the synergy of DAC and PTX."	MEC00768
C23445	NEWCL00048	.	Achieving Therapeutic Synergy	BH3 mimetics synergize with paclitaxel in the killing of CML cells.	MEC00769
C48253	NEWCL00242	.	Achieving Therapeutic Synergy	"Paclitaxel combined to birinapant could interrupt cell cycle progression by inducing G2/M arrest, whereas the single-drug treatments would not."	MEC00771
C40727	NEWCL00080	.	Achieving Therapeutic Synergy	Paclitaxel in combination with cisplatin showed the most cytotoxic effect in colorectal cancer cells.	MEC00772
C56476	NEWCL00155; NEWCL00049	.	Achieving Therapeutic Synergy	Paclitaxel in combination with coralyne show a promising therapeutic potential effect in treating breast cancer at lower effective dose.	MEC00773
C36758	NEWCL00181; NEWCL10107	.	Achieving Therapeutic Synergy	E2F inhibition synergizes with paclitaxel in lung cancer cell lines.	MEC00775
C47203	NEWCL00230; NEWCL00231	.	Achieving Therapeutic Synergy	Paclitaxel combined BBI608 results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.	MEC00777
C31120	NEWCL00160	.	Achieving Therapeutic Synergy	Trastuzumab and paclitaxel combination showed synergistic therapy for HER2+ breast cancer.	MEC00779
C56091	NEWCL10328; NEWCL00039	.	Achieving Therapeutic Synergy	"A low dose of taxol in combination with a plasmid vector expressing Bcl-2 siRNA effectively induces apoptosis in glioblastoma cells, markedly decreases tumour cell invasion, completely inhibits in vivo angiogenesis, and remarkably suppresses both intracranial and subcutaneous tumour growth in nude mice."	MEC00780
C72760	NEWCL10040; NEWCL00360	.	Achieving Therapeutic Synergy	The combination of Taxol with DCA showed synergistic inhibitory effects on Taxol resistant cells under hypoxic conditions.	MEC00781
C99275	NEWCL00039; NEWCL00122	.	Achieving Therapeutic Synergy	A combination of TMZ and Taxol exerted synergistic inhibitory effects on Taxol resistant glioma cells.	MEC00782
C77479	NEWCL10308	.	Achieving Therapeutic Synergy	The production of superoxide radicals by human polymorphonuclear leukocytes was impaired only by the presence of high concentrations (100 mg/l) of both clavulanic acid or the combination amoxycillin/clavulanic acid (4/1).	MEC00795
C78370	NEWCL10337	.	Decreasing Adverse Drug Reaction	Curdione ameliorated doxorubicin-induced cardiotoxicity through suppressing oxidative stress and activating Nrf2/HO-1 pathway.	MEC00800
C30347	NEWCL10275; NEWCL10274; NEWCL10277	.	Achieving Therapeutic Synergy	Asiaticoside combined with rapamycin may be effective in the reduction of ISR.	MEC00802
C08897	NEWCL00278; NEWCL00286	.	Achieving Therapeutic Synergy	"Combination of TanI with standard chemotherapeutic drug Len, potentiates cell death in myeloma cells."	MEC00803
C98749	NEWCL00170	.	Reversing Drug Resistance	Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.	MEC00808
C14802	NEWCL00113; NEWCL00142; NEWCL00116	.	Achieving Therapeutic Synergy	The increase of chemotherapy sensitization by Beta-asarone is associated with the inhibition of tumor glycolysis.	MEC00811
C84654	NEWCL00064; NEWCL00032	.	Reversing Drug Resistance	"The combination of 6-TG and PDX, with the inclusion of leucovorin rescue, allows for a safe and effective regimen in MTAP-deficient T-cell ALL."	MEC00813
C24900	NEWCL00251; NEWCL00252	.	Achieving Therapeutic Synergy	Neferine treatment effectively promotes TRAIL-mediated cell death and this effect likely occurs via the autophagic flux and the JNK pathway.	MEC00815
C15497	NEWCL00205	.	Achieving Therapeutic Synergy	Aloin enhances cisplatin antineoplastic activity in B16-F10 melanoma cells by transglutaminase-induced differentiation.	MEC00817
C77812	NEWCL00170; NEWCL10166	.	Achieving Therapeutic Synergy	"Combination of vanadium and carboplatin resulted in synergistic antitumor activity in ex vivo cell cultures, and prompted G0/G1 cell cycle arrest and sensitization of tumor cells to carboplatin-induced apoptosis."	MEC00820
C36880	NEWCL00170	.	Achieving Therapeutic Synergy	Menadione : sodium orthovanadate combination eliminates and inhibits migration of detached cancer cells.	MEC01436
C36880	NEWCL10089; NEWCL10272	.	Achieving Therapeutic Synergy	M:SO combination is an attractive alternative for glioma treatment.	MEC00821
C45595	NEWCL00123; NEWCL00039; NEWCL10059	.	Achieving Therapeutic Synergy	Quercetin and chloroquine synergistically kill glioma cells by inducing organelle stress and disrupting Ca2+ homeostasis.	MEC00822
C58370	NEWCL00230; NEWCL10084; NEWCL00231; NEWCL10183	.	Achieving Therapeutic Synergy	Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells.	MEC00977
C58370	NEWCL00170; NEWCL00180	.	Achieving Therapeutic Synergy	Arsenic trioxide exerts Synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.	MEC00993
C58370	NEWCL00215	.	Achieving Therapeutic Synergy	Co-application of arsenic trioxide (As2O3) and cisplatin (CDDP) on human SY-5Y neuroblastoma cells shows additive effects.	MEC00823
C58370	NEWCL00224; NEWCL00270; NEWCL00271	.	Achieving Therapeutic Synergy	Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells.	MEC01040
C41705	NEWCL00352; NEWCL10373	.	Achieving Therapeutic Synergy	"In combination, the two drugs functioned synergistically to impede the progression and growth of human gastric cancer cells in vitro and gastric cancer cell xenograft nude mice in vivo."	MEC00827
C76914	NEWCL00022; NEWCL00204	.	Achieving Therapeutic Synergy	Combined treatment with QU and cis-Pt showed synergistic effect.	MEC00828
C70728	NEWCL10339	.	Decreasing Adverse Drug Reaction	Sch B appears to protect against CsA-induced nephrotoxicity by decreasing oxidative stress and cell death.	MEC00829
C70728	NEWCL10339	.	Decreasing Adverse Drug Reaction	"SchB has beneficial roles in preventing CsA induced oxidative stress, apoptosis and autophagy by enhancing cell survival via scavenging ROS."	MEC00884
C89866	NEWCL00155; NEWCL10051; NEWCL00242; NEWCL00149; NEWCL00253	.	Achieving Therapeutic Synergy	"The combination of gossypol and BRD4770 increased LC3-II levels and the autophagosome number in PANC-1 cells, and the compound combination appears to act in a BNIP3-dependent manner, suggesting that these compounds act together to induce autophagy-related cell death in pancreatic cancer cells."	MEC00830
C27119	NEWCL00077	.	Reversing Drug Resistance	"GABA-producing L. plantarum is promising as an adjuvant treatment for 5-FU-resistant CRC, and its intervention in neurobiological signaling imply new possibilities for chemoprevention and the treatment of colon cancer-related diseases."	MEC00831
C54915	NEWCL00348; NEWCL00257; NEWCL00282; NEWCL10099; NEWCL00256	.	Achieving Therapeutic Synergy	Triptolide sensitizes RCC cells to TRAIL-induced apoptosis through altered TRAIL death receptor and heat shock protein expression.	MEC01207
C54915	NEWCL00236; NEWCL10017	.	Achieving Therapeutic Synergy	Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.	MEC00832
C54915	NEWCL10169; NEWCL00242	.	Reversing Drug Resistance	Combined therapy with triptolide and TRAIL significantly decreased the cell viability in all the cell lines and increased apoptotic cell death as a result of caspase-3 and caspase-9 activation.	MEC01077
C54915	NEWCL00236; NEWCL00242	.	Achieving Therapeutic Synergy	TPL enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1.	MEC01150
C54915	NEWCL00021; NEWCL00019	.	Reversing Drug Resistance	Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.	MEC01173
C54915	NEWCL10010; NEWCL10046; NEWCL10009; NEWCL10008; NEWCL10007; NEWCL10154	.	Achieving Therapeutic Synergy	The combination of TRAIL and triptolide could enhance susceptibility to TRAIL-induced apoptotic killing in these TRAIL-resistant CCA cells.	MEC00867
C54915	NEWCL00066	.	Achieving Therapeutic Synergy	TRAIL and triptolide in combination decreased cell viability and enhanced apoptosis.	MEC01114
C82826	NEWCL00227	.	Achieving Therapeutic Synergy	Hesperetin combined with etoposide showed additive effects on the inhibition of cell growth.	MEC00837
C43091	NEWCL10285	.	Achieving Therapeutic Synergy	Combination of TA and 5-FU showed synergistic interation in regulating the biological behaviour of keloid fibroblasts in vitro.	MEC00838
C05284	NEWCL00129; NEWCL00031	.	Decreasing Adverse Drug Reaction	Gingerol protected from DOX-induced vascular damage and synergized the cytotoxic effects of DOX against liver cancer cells without influencing the cellular pharmacokinetics.	MEC00839
C10156	NEWCL00289; NEWCL10091	.	Achieving Therapeutic Synergy	Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells.	MEC00841
C15632	NEWCL00129	.	Achieving Therapeutic Synergy	Synergistic Effect of alpha-Solanine and Cisplatin Induces apoptosis and enhances cell cycle arrest in human hepatocellular carcinoma cells.	MEC00842
C53884	NEWCL00069; NEWCL00048; NEWCL10110; NEWCL00059; NEWCL00022; NEWCL00019; NEWCL10083	.	Achieving Therapeutic Synergy	"Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells."	MEC00844
C92614	NEWCL00024; NEWCL00022; NEWCL00026	.	Achieving Therapeutic Synergy	"BI-D1870 induces apoptosis of AML cells alone and in combination with vincristine through blocking mitotic exit, providing a novel approach to overcoming vincristine resistance in AML cells."	MEC00845
C71701	NEWCL00149	.	Achieving Therapeutic Synergy	"Eugenol interacts synergistically with 5-fluorouracil against human cervical cancer, HeLa cell lines, by blocking the cell cycle and inducing apoptosis."	MEC00846
C95098	NEWCL00155; NEWCL10166	.	Achieving Therapeutic Synergy	Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF-KappaB signaling pathway.	MEC00848
C49336	NEWCL00170; NEWCL00180	.	Achieving Therapeutic Synergy	"The combination of Bi(III) with 6-MP endowed the newly developed amorphous [Bi(MP)3(NO3)2]NO3 with excellent anticancer activity against lung cancer cells and the solubility and bioavailability of the obtained [Bi(MP)3(NO3)2]NO3 were dramatically improved, compared with that of 6-MP."	MEC00849
C68939	NEWCL00129	.	Achieving Therapeutic Synergy	Geraniol and simvastatin show a synergistic effect on a human hepatocarcinoma cell line.	MEC00850
C65360	NEWCL10278; NEWCL10279; NEWCL10273	.	Achieving Therapeutic Synergy	Concomitant administration of an antithrombin activator or direct factor Xa inhibitor and direct thrombin inhibitor proved to be a particularly effective combination for controlling the procoagulant effects of hALPCs both in vitro and in vivo.	MEC00851
C44965	NEWCL10125; NEWCL00019; NEWCL00094; NEWCL00065	.	Achieving Therapeutic Synergy	Buthionine Sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors.	MEC01060
C44965	NEWCL00022	.	Achieving Therapeutic Synergy	BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine.	MEC00854
C44965	NEWCL10085; NEWCL00357; NEWCL00129; NEWCL00031	.	Achieving Therapeutic Synergy	Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines.	MEC01099
C88284	NEWCL00022; NEWCL00019; NEWCL10125; NEWCL10074	.	Achieving Therapeutic Synergy	"lonidamine efficaciously cooperates with the anti-leukemic agent arsenic trioxide (ATO) to induce apoptosis in HL-60 and other human leukemia cell lines, with low toxicity in non-tumor peripheral blood lymphocytes."	MEC00855
C98888	NEWCL00155; NEWCL00049	.	Achieving Therapeutic Synergy	Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings.	MEC00858
C90835	NEWCL00082	.	Achieving Therapeutic Synergy	Isoliquiritigenin in combination with docosahexaenoic acid has synergistic anticancer effect on human colorectal cancer cells through ROS-mediated regulation of the JNK and cytochrome c release.	MEC00865
C50739	NEWCL00155; NEWCL10166	.	Achieving Therapeutic Synergy	"The combined treatment with 3-AC and CAI strongly enhanced radiosensitivity, increased cytotoxicity, inhibited cell motility and enhanced DNA damage."	MEC00868
C57517	NEWCL00155; NEWCL10166	.	Achieving Therapeutic Synergy	"The combined treatment with 3-AC and CAI strongly enhanced radiosensitivity, increased cytotoxicity, inhibited cell motility and enhanced DNA damage."	MEC00869
C72890	NEWCL00082; NEWCL00344	.	Achieving Therapeutic Synergy	Since Phloroglucinol and Fucoxanthin alone reduced cancer cell line viability without an effect on normal cells and when in combination enhanced the cytotoxic effect of 5-Fu only in colon cancer cells.	MEC00870
C37903	NEWCL00251	.	Achieving Therapeutic Synergy	GP significantly enhances the anti-tumor activity of ZA in hormone- and drug-resistant prostate cancer cells by targeting many pivotal apoptosis-related proteins.	MEC00983
C37903	NEWCL00134; NEWCL00284	.	Achieving Therapeutic Synergy	"Gossypol, in combination with zoledronic acid, may provide a rational treatment option for ovarian cancer, not only by direct inhibition of cell proliferation, but also inhibition of angiogenesis-related molecules."	MEC00871
C45716	NEWCL00253; NEWCL00251	.	Achieving Therapeutic Synergy	"The combination of TQ and ZA resulted in a significant synergistic cytotoxic activity and DNA fragmentation when compared to any single agent alone, in a dose- and time-dependent manner."	MEC00872
C29558	NEWCL10341	.	Achieving Therapeutic Synergy	Expression of the HCMV UL54 gene was significantly inhibited by combination of GCV with tricin when compared with GCV mono-treatment.	MEC00874
C67961	NEWCL10308	.	Achieving Therapeutic Synergy	HYP-PDI in combination with AC had significant ability to eradicate the pre-formed mature biofilms of S. aureus strains.	MEC00876
C24887	NEWCL00170; NEWCL00181	.	Achieving Therapeutic Synergy	Their combination leads to more retention of doxorubicin in the cells by modulating drug trasporter and thus enhances its therapeutic potential.	MEC00878
C23185	NEWCL00298	.	Achieving Therapeutic Synergy	The radiosensitizing activity of ceramide/DMS on LLC cells most likely reflects the dominance of pro-apoptotic signals related to the mitochondria-dependent pathway.	MEC00880
C23300	NEWCL10002; NEWCL00086	.	Achieving Therapeutic Synergy	Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.	MEC00881
C43718	NEWCL00048	.	Achieving Therapeutic Synergy	Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.	MEC00883
C95068	NEWCL10236	.	Achieving Therapeutic Synergy	"The Synergistic effects between n-butylphthalide and fluconazole potentially relied on the mechanism that n-butylphthalide significantly promoted drug uptake, and suppressed drug efflux via down-regulating the drug transporter encoding genes CDR1 and CDR2."	MEC00885
C28471	NEWCL00022	.	Achieving Therapeutic Synergy	Thymoquinone improved the anti-cancer properties of doxorubicin in a cell line-specific manner.	MEC00889
C28471	NEWCL00129; NEWCL00140; NEWCL00283; NEWCL00151	.	Achieving Therapeutic Synergy	"TQ synergistically improves the anti-cancer activity of DOX, and loss of p53 sensitizes HCC cells to TQ-induced apoptosis."	MEC01092
C17041	NEWCL10080; NEWCL00082; NEWCL00353	.	Achieving Therapeutic Synergy	PG490 strongly enhanced the cytotoxicity of 5-FU. PG490 also simultaneously induced ROS and inhibited NF-KappaB activity and significantly enhanced the cytotoxic effect of 5-FU in three CRC cell lines in vitro.	MEC00890
C05119	NEWCL00243; NEWCL00242	.	Achieving Therapeutic Synergy	"Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential."	MEC01046
C05119	NEWCL10143; NEWCL10070	.	Achieving Therapeutic Synergy	The combination of GEM plus TPL showed significantly enhanced anticancer effects compared to those of GEM or TPL alone.	MEC00891
C98290	NEWCL00170	.	Achieving Therapeutic Synergy	Neferine augments therapeutic efficacy of cisplatin through ROS- mediated non-canonical autophagy in human lung adenocarcinoma (A549 cells).	MEC00892
C28496	NEWCL00155	.	Achieving Therapeutic Synergy	"In combination with the anti-estrogen Tamoxifen, PST had a synergic effect."	MEC00893
C54031	NEWCL10419; NEWCL00231	.	Achieving Therapeutic Synergy	Delphinidin increases the sensitivity of ovarian cancer cell lines to 3-bromopyruvate.	MEC00894
C45395	NEWCL00042	.	Achieving Therapeutic Synergy	Combination therapy with L gossypol and low-concentration doxorubicin inhibited cell proliferation and induced apoptosis in SW982 HSSCs at a significantly greater level compared with either treatment alone.	MEC00897
C73107	NEWCL10100	.	Achieving Therapeutic Synergy	Rituximab synergizes with vincristine in the killing of Ramos Burkitt's lymphoma B cell line.	MEC00898
C40680	NEWCL00248; NEWCL00249; NEWCL10354; NEWCL00246	.	Achieving Therapeutic Synergy	"Statin + Gamma-T3 combinations induced greater cell growth inhibition more than each single treatment via inhibition of mevalonate pathway, a well-known target of both Gamma-T3 and statins."	MEC00902
C97303	NEWCL00065	.	Achieving Therapeutic Synergy	"Enhancement of cell death of radiation-resistant cancer cells by phytosphingosine treatment in combination with gamma-radiation is mediated by nuclear translocation of AIF, which is in turn mediated both by ROS-dependent Bax relocalization and ROS-independent PARP-1 activation."	MEC00905
C54856	NEWCL00049	.	Achieving Therapeutic Synergy	"ALA significantly promoted apoptotic cell death when combined with RT, as reflected by Annexin V staining, expression of apoptosis-related factors, mitochondrial damages as well as cell morphological changes and reduction of cell numbers."	MEC00909
C89396	NEWCL00283; NEWCL10403	.	Achieving Therapeutic Synergy	Combination treatment of ergosterol followed by amphotericin B induces necrotic cell death in human hepatocellular carcinoma cells.	MEC00910
C57399	NEWCL00227; NEWCL10405	.	Reversing Drug Resistance	Voacamine is capable of enhancing the cytotoxic effect of DOX on MDR cells by favouring a lethal autophagic process.	MEC00911
C57399	NEWCL00227; NEWCL10405	.	Reversing Drug Resistance	The plant alkaloid voacamine induces apoptosis-independent autophagic cell death on both sensitive and multidrug resistant human osteosarcoma cells.	MEC01230
C57399	NEWCL00225; NEWCL10410	.	Reversing Drug Resistance	Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts.	MEC01406
C83784	NEWCL00024; NEWCL00019	.	Achieving Therapeutic Synergy	The combination effect of ATO and sorafenib in AML cell lines is apoptotic and autophagy.	MEC00931
C83784	NEWCL00024; NEWCL00019	.	Achieving Therapeutic Synergy	The combination of sorafenib as a VEGF inhibitor with ATO synergistically inhibits cell proliferation and promotes apoptosis.	MEC01289
C83784	NEWCL00129	.	Achieving Therapeutic Synergy	"A synergistic effect is observed between the sorafenib and As2O3 in their inhibition of HepG2 cell proliferation, the mechanisms of which may involve reduction of mitochondrial transmembrane potential and Raf/MEK/ERK pathway inhibition."	MEC01187
C83784	NEWCL00129; NEWCL00031	.	Achieving Therapeutic Synergy	Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.	MEC00914
C83784	NEWCL00031; NEWCL00151; NEWCL10129	.	Achieving Therapeutic Synergy	The combination of As2O3 and sorafenib demonstrated potent anti-tumor activity in Huh7 and freshly-isolated HCC cells via a TRAIL-dependent pathway.	MEC01287
C86383	NEWCL00260; NEWCL00263	.	Achieving Therapeutic Synergy	"The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells."	MEC00915
C31241	NEWCL00082	.	Achieving Therapeutic Synergy	TQ potentiates IM efficacy on HCT116 cells via uptake/efflux genes modulation.	MEC00916
C91158	NEWCL00048	.	Achieving Therapeutic Synergy	As2O3 in combination with imatinib showed favorable cytotoxicity and proapoptotic activity in chronic myelogenous leckemia.	MEC00919
C61395	NEWCL10334	.	Achieving Therapeutic Synergy	"BS21 plays a modulatory role in adipocytes by reducing adipogenesis and lipogenesis, increasing fat oxidation, and inducing browning."	MEC00921
C79203	NEWCL00278; NEWCL00286	.	Achieving Therapeutic Synergy	"ATO and rmhTRAIL had synergistic or additive effects on proliferation inhibition and apoptosis induction in MM cells, and the mechanism underlying the two-drug combination might involve regulation of the expression of several proteins affected by ATO and rmhTRAIL."	MEC00922
C86266	NEWCL10086; NEWCL00113	.	Achieving Therapeutic Synergy	[6]-Gingerol enhances the cisplatin sensitivity of gastric cancer cells through inhibition of proliferation and invasion via PI3K/AKT signaling pathway.	MEC00926
C37715	NEWCL00252; NEWCL00253	.	Achieving Therapeutic Synergy	Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.	MEC00927
C96876	NEWCL00082; NEWCL00344	.	Achieving Therapeutic Synergy	Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002 synergistically inhibite colon carcinoma cell growth.	MEC00928
C89336	NEWCL00050; NEWCL00155; NEWCL00052; NEWCL00156	.	Reversing Drug Resistance	Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer.	MEC00929
C89336	NEWCL00022; NEWCL00019	.	Achieving Therapeutic Synergy	The combination of drugs increased apoptosis in HL-60 cells and increased the percentage of cells in G(0)/G(1) phase in both cell lines.	MEC00930
C52062	NEWCL10109; NEWCL00048; NEWCL00095; NEWCL00253; NEWCL00149; NEWCL00071	.	Achieving Therapeutic Synergy	TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.	MEC00932
C53856	NEWCL00051	.	Achieving Therapeutic Synergy	Downregulation and subcellular distribution of HER2 involved in MDA-MB-453 breast cancer cell apoptosis induced by lapatinib/celastrol combination.	MEC01198
C53856	NEWCL00129	.	Achieving Therapeutic Synergy	Celastrol enhanced the anticancer effect of lapatinib in human hepatocellular carcinoma cells in vitro.	MEC01182
C76781	NEWCL00077	.	Achieving Therapeutic Synergy	Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells.	MEC00935
C76353	NEWCL00271; NEWCL10093	.	Achieving Therapeutic Synergy	Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.	MEC00936
C11292	NEWCL00170; NEWCL00181	.	Achieving Therapeutic Synergy	Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2.	MEC01158
C11292	NEWCL00039; NEWCL00279	.	Achieving Therapeutic Synergy	Beta-Elemene enhances the efficacy of gefitinib on glioblastoma multiforme cells through the inhibition of the EGFR signaling pathway.	MEC00938
C34194	NEWCL00262	.	Achieving Therapeutic Synergy	"The novel combination of mTOR inhibitor with Beta-elemene synergistically attenuates tumor cell growth in follicular thyroid cancer, which requires additional preclinical validation."	MEC00940
C27097	NEWCL00279; NEWCL00123; NEWCL00039; NEWCL00122; NEWCL00255	.	Achieving Therapeutic Synergy	Beta-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway.	MEC00941
C73865	NEWCL00052; NEWCL10166	.	Achieving Therapeutic Synergy	TQ can broadly augment the effect of cyclo in breast cancer cases irrespective of Her-2+ or Her-.	MEC00944
C10732	NEWCL00226; NEWCL00227; NEWCL00225; NEWCL00228; NEWCL10150	.	Achieving Therapeutic Synergy	"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways."	MEC00945
C25024	NEWCL04171	.	Achieving Therapeutic Synergy	Combined low dose treatment of Gamma-tocotrienol and celecoxibthe showed synergistic antiproliferative effects of against +SA mammary tumor cells in culture.	MEC00948
C26107	NEWCL00155	.	Achieving Therapeutic Synergy	"Tan IIA enhanced the chemotherapeutic effect of Dox against breast cancer while reducing its toxic side effects including weight loss, myelosuppression, cardiotoxicity, and nephrotoxicity."	MEC00949
C26107	NEWCL00129	.	Achieving Therapeutic Synergy	"A combination of Tan IIA with ADM could improve life quality by relieving ADM toxicity, decreasing tumor volume, declining serum AST level, and improving liner pathological section in tumor-bearing mice."	MEC01356
C12647	NEWCL00063; NEWCL00026; NEWCL00022; NEWCL10119	.	Achieving Therapeutic Synergy	The combination of Nutlin-3 and Tanshinone IIA exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways.	MEC00950
C74641	NEWCL10232	.	Achieving Therapeutic Synergy	Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1Alpha.	MEC01200
C62668	NEWCL00063	.	Achieving Therapeutic Synergy	Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.	MEC00956
C09338	NEWCL00048	.	Achieving Therapeutic Synergy	Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.	MEC00958
C89612	NEWCL00180; NEWCL00170	.	Achieving Therapeutic Synergy	The putative mechanism behind the metastasis-limiting effects of DHC may involve the suppression of Akt/GSK-3Beta and inhibition of MMP-2 and MMP-9 in lung cancer cells.	MEC00959
C67567	NEWCL00082; NEWCL00344	.	Decreasing Adverse Drug Reaction	Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells.	MEC00960
C50887	NEWCL00171	.	Achieving Therapeutic Synergy	Combined treatment with triptolide and tyrosine kinase inhibitors synergistically enhances apoptosis in non-small cell lung cancer H1975 cells but not H1299 cells through EGFR/Akt pathway.	MEC00963
C96948	NEWCL00171	.	Achieving Therapeutic Synergy	Combined treatment with triptolide and tyrosine kinase inhibitors synergistically enhances apoptosis in non-small cell lung cancer H1975 cells but not H1299 cells through EGFR/Akt pathway.	MEC00964
C15899	NEWCL00171	.	Achieving Therapeutic Synergy	Combined treatment with triptolide and tyrosine kinase inhibitors synergistically enhances apoptosis in non-small cell lung cancer H1975 cells but not H1299 cells through EGFR/Akt pathway.	MEC00965
C97955	NEWCL00024; NEWCL00019	.	Achieving Therapeutic Synergy	Arsenic trioxide and thalidomide combination induces autophagy along with apoptosis in acute myeloid cell lines.	MEC00966
C97955	NEWCL00019; NEWCL00024	.	Achieving Therapeutic Synergy	Arsenic trioxide and thalidomide combination showed inhibitory effects of on angiogenesis and vascular endothelial growth factor expression in leukemia cells.	MEC01290
C51473	NEWCL00149	.	Achieving Therapeutic Synergy	"Reduction in cisplatin concentration, enhanced anti-cancer effects and UHRF1 downregulation due to synergistic interaction between salicylic acid and cisplatin underscores the therapeutic importance of the combination to overcome chemo-resistance and side effects of cisplatin."	MEC00967
C79594	NEWCL00129; NEWCL00155; NEWCL00049	.	Achieving Therapeutic Synergy	The DOX- LNA conjugate showed substantially higher tumor-specific cytotoxicity compared with DOX.	MEC01399
C35218	NEWCL10247	.	Reversing Drug Resistance	"Phosphorylation and thereby activation of the kinases p44/42 and Akt, which are involved in proliferation and survival processes, were inhibited, the mitochondrial membrane potential of the GBM cells was altered, and genes involved in dormancy-associated processes were regulated by the combined treatment strategy."	MEC00970
C74006	NEWCL00148; NEWCL00128	.	Achieving Therapeutic Synergy	"Autophagy might be strongly associated with the antitumor efficacy of ORI/Cet, which may be beneficial to the clinical application of ORI/Cet in LSCC treatment ORI/Cet in LSCC treatment."	MEC00974
C58578	NEWCL10126; NEWCL10024	.	Achieving Therapeutic Synergy	Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma.	MEC01299
C58578	NEWCL00022; NEWCL10125; NEWCL00048	.	Achieving Therapeutic Synergy	Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9.	MEC00976
C36543	NEWCL00063; NEWCL10065	.	Achieving Therapeutic Synergy	"Combining ATO and Dasatinib leads to severe cell apoptosis by activating the UPR apoptotic IRE1/JNK/PUMA axis, while neutralizing the UPR ATF4-dependent anti-apoptotic axis, activated by ATO alone."	MEC00978
C29634	NEWCL00074; NEWCL00076	.	Achieving Therapeutic Synergy	6-Shogaol enhances the anticancer effect of 5-fluorouracil via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions.	MEC00979
C03836	NEWCL10019; NEWCL00075	.	Achieving Therapeutic Synergy	Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation.	MEC01258
C03836	NEWCL00129; NEWCL00140	.	Achieving Therapeutic Synergy	Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma.	MEC00984
C03836	NEWCL00099; NEWCL00098	.	Achieving Therapeutic Synergy	Quercetin enhances the effects of 5-fluorouracil-mediated growth inhibition and apoptosis of esophageal cancer cells by inhibiting NF-KappaB.	MEC01250
C53718	NEWCL00360	.	Achieving Therapeutic Synergy	Inactivation of NF-KappaB and induction of apoptosis through intrinsic caspase-dependent and independent apoptotic pathways are associated with amentoflavone enhanced anti-OSCC efficacy of cisplatin.	MEC00987
C34772	NEWCL00022; NEWCL00048	.	Achieving Therapeutic Synergy	"Low-dose 1,25-dihydroxyvitamin D3 combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis."	MEC00992
C92301	NEWCL00140	.	Achieving Therapeutic Synergy	Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells.	MEC00996
C62720	NEWCL00180; NEWCL00181	.	Achieving Therapeutic Synergy	Combination of arsenic trioxide and valproic acid efficiently inhibits growth of lung cancer cells via G2/M-phase arrest and apoptotic cell death.	MEC01106
C62720	NEWCL00278	.	Achieving Therapeutic Synergy	"VPA can enhance the sensitivity of RPMI 8226 cells to ATO-induced apoptosis, which may be associated with decreasing the BCL-2 expression and increasing the BAX, caspase-8 and caspase-9 gene expression."	MEC00997
C62720	NEWCL00278	.	Achieving Therapeutic Synergy	"VPA and ATO had Synergistic effects on the proliferation of RPMI8226 cells, which may have been associated with the decreased expression of Bcl-2 and the increased expression levels of Bcl-2-associated X protein, Caspase 8 and Caspase 9."	MEC00998
C04341	NEWCL00170	.	Achieving Therapeutic Synergy	Synergistic antitumor effect of Beta-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells.	MEC01001
C17620	NEWCL00155	.	Achieving Therapeutic Synergy	Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.	MEC01067
C41311	NEWCL00019	.	Achieving Therapeutic Synergy	"Thymoquinone, when combined with topotecan in noncytotoxic doses, produced synergistic antiproliferative and proapoptotic effects in AML cells."	MEC01011
C39064	NEWCL00149; NEWCL00137; NEWCL00139	.	Achieving Therapeutic Synergy	Aspirin and triptolide combination treatment has synergistic anti-tumor effects on cervical cancer cells.	MEC01012
C03726	NEWCL00073; NEWCL00082	.	Achieving Therapeutic Synergy	Pterostilbine sensitizes colon cancer cells to 5-fluorouracil cytotoxicity.	MEC01016
C39312	NEWCL00253; NEWCL00252	.	Achieving Therapeutic Synergy	Combination of quercetin and 2-Methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells xenograft tumor growth.	MEC01017
C39312	NEWCL00253; NEWCL00252	.	Achieving Therapeutic Synergy	Combination of quercetin and 2-Methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells xenograft tumor growth.	MEC01292
C39312	NEWCL10034; NEWCL00129	.	Achieving Therapeutic Synergy	Quercetin induces oxidative stress and potentiates the apoptotic action of 2-methoxyestradiol in human hepatoma cells.	MEC01276
C34528	NEWCL00170	.	Achieving Therapeutic Synergy	"Tanshinone IIA combined with adriamycin could synergistically inhibit migration, induce apoptosis and arrest cell cycle at the S and G2 phases in A549 cells."	MEC01018
C14490	NEWCL00142	.	Achieving Therapeutic Synergy	Low-toxicity Sch.B combined with low dosage apatinib has a more potent anti-cancer effect that apatinib alone.	MEC01019
C89957	NEWCL00049; NEWCL00155	.	Achieving Therapeutic Synergy	Germacrone enhanced furanodiene's anti-proliferative effect.	MEC01021
C12909	NEWCL00050	.	Decreasing Adverse Drug Reaction	Parthenolide along with Epirubicin chemotherapy drug could improve cytotoxicity and apoptosis and reduces IC50.	MEC01023
C13955	NEWCL10381; NEWCL00098	.	Achieving Therapeutic Synergy	"Paeonol, in combination with cisplatin, had a significantly synergistic growth-inhibitory effect on oesophageal cell line, which may be related to apoptosis induction."	MEC01027
C96243	NEWCL10031	.	Achieving Therapeutic Synergy	"The combination of CDDP and BR was able to produce a synergistic antitumor effect in CRC cells, thus providing a solid foundation for further development of this combination regimen into an effective therapeutic method for CRC."	MEC01028
C28922	NEWCL00170	.	Achieving Therapeutic Synergy	"Enhancement of the cytotoxicity to CDDP by coadminstration with DMC was mediated by down-regulation of the expression of TP and ERCC1, regulated by PI3K-Akt-Snail pathway inactivation."	MEC01030
C96593	NEWCL00142; NEWCL00108	.	Achieving Therapeutic Synergy	LCA alone or in combination with 5-FU may have significant anticancer effects on gastric cancer cells.	MEC01032
C76367	NEWCL00343; NEWCL00340; NEWCL10033; NEWCL00352; NEWCL00109; NEWCL10025; NEWCL00052; NEWCL00156; NEWCL00155; NEWCL10149	.	Reversing Drug Resistance	Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.	MEC01035
C56461	NEWCL00142; NEWCL00113	.	Achieving Therapeutic Synergy	ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo.	MEC01037
C79238	NEWCL00074; NEWCL00082	.	Achieving Therapeutic Synergy	Gambogic acid potentiates the chemosensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting proliferation and inducing apoptosis.	MEC01066
C89846	NEWCL10145	.	Achieving Therapeutic Synergy	"TPL sensitizes GICs to TMZ by synergistically enhancing apoptosis, which is likely resulting from the augmented repression of NF-KappaB signaling."	MEC01047
C03207	NEWCL00163; NEWCL00155; NEWCL00050; NEWCL00022; NEWCL00231; NEWCL00049; NEWCL00253; NEWCL00251; NEWCL00170; NEWCL00181	.	Achieving Therapeutic Synergy	Pterostilbene enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistance triple negative breast cancer cells.	MEC01048
C76631	NEWCL00048	.	Achieving Therapeutic Synergy	Combination of apicidin and TRAIL may be an effective strategy for treating TRAIL-resistant Bcr-Abl expressing CML cells.	MEC01049
C85456	NEWCL00145	.	Achieving Therapeutic Synergy	The combination of crocin with cisplatin suppresses growth of gastric carcinoma cell line BGC-823 and promotes cell apoptosis.	MEC01050
C22120	NEWCL00260; NEWCL00261	.	Achieving Therapeutic Synergy	Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells.	MEC01051
C01361	NEWCL10134	.	Achieving Therapeutic Synergy	Dicoumarol showed sensitizing effect of on TRAIL-mediated apoptosis.	MEC01052
C01361	NEWCL10073; NEWCL10379; NEWCL10112; NEWCL10070	.	Achieving Therapeutic Synergy	Dicoumarol could enhance cytotoxicity of CDDP in urogenital cancer cells with wild-type p53 through the p53/p21/JNK pathways.	MEC01260
C97853	NEWCL00049	.	Achieving Therapeutic Synergy	"Combination of Zoledronic acid and Plumbagin synergistically suppresses human breast cancer MDA-MB-231SArfp cells in vitro. Plumbagin can inhibit Zoledronic acid-induced activation of the Notch-1 signaling pathway and subsequently reduce the expression of Bcl-2, thus potentiating cancer cell apoptosis."	MEC01053
C29668	NEWCL00245	.	Achieving Therapeutic Synergy	"ATO combined with ITRA can more strongly suppress the growth of multiple myeloma NCI-H929 cells, as compared with a single administration. The synergistic effect of ATO and ITRA significantly down-regulates expression of Gli1 in HH signaling pathway, moreover the inhibition of target gene overexpression may be one of two drug mechanisms."	MEC01054
C30610	NEWCL10327	.	Decreasing Adverse Drug Reaction	"Acteoside is a specific regulator of MDM2 activation in TSLP-stimulated mast cells, which indicates its potential use for the treatment of mast cell-mediated inflammatory diseases."	MEC01055
C12652	NEWCL00048	.	Achieving Therapeutic Synergy	Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.	MEC01056
C07583	NEWCL00279	.	Achieving Therapeutic Synergy	TQ enhanced the anti-cancer activity of TMZ by inhibition of autophagy at the transcriptional level and decreased the colony-forming ability and NO production of U87MG cell line.	MEC01059
C12780	NEWCL10119; NEWCL00020; NEWCL00019; NEWCL00059; NEWCL00023	.	Achieving Therapeutic Synergy	Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.	MEC01061
C61675	NEWCL10103; NEWCL10090; NEWCL10067; NEWCL10062; NEWCL10006	.	Achieving Therapeutic Synergy	Vincristine sensitizes DLBCL cells to the cytotoxic effects of belinostat.	MEC01062
C32745	NEWCL00074	.	Achieving Therapeutic Synergy	Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis.	MEC01170
C32745	NEWCL00032	.	Achieving Therapeutic Synergy	Kaempferol improves TRAIL-mediated apoptosis in leukemia MOLT-4 cells by the inhibition of anti-apoptotic proteins and promotion of death receptors expression.	MEC01153
C32745	NEWCL00039; NEWCL00279	.	Achieving Therapeutic Synergy	kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin.	MEC01064
C92153	NEWCL00049	.	Achieving Therapeutic Synergy	Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells.	MEC01065
C06862	NEWCL00155; NEWCL00230	.	Reversing Drug Resistance	Schisandrin B reverses doxorubicin resistance through inhibiting P-glycoprotein and promoting proteasome-mediated degradation of survivin.	MEC01069
C06862	NEWCL00140; NEWCL00155	.	Decreasing Adverse Drug Reaction	Sch B may bring benefit to clinical chemotherapy by reducing significantly the cumulative doses of DOX and its associated cardiotoxicities.	MEC01137
C51783	NEWCL00279; NEWCL00125; NEWCL00127; NEWCL00039	.	Achieving Therapeutic Synergy	Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.	MEC01070
C29891	NEWCL00129	.	Achieving Therapeutic Synergy	The synergistic inhibitory effect presented by the combination therapy was dependent on the gradient concentration and treatment time.	MEC01071
C25680	NEWCL00098; NEWCL00103; NEWCL10391; NEWCL10348; NEWCL10349; NEWCL10350	.	Achieving Therapeutic Synergy	Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy.	MEC01072
C12588	NEWCL00019; NEWCL00095	.	Achieving Therapeutic Synergy	"Synergism between ATO and MG132 was attained in Raji cells by disruption of the perinuclear mitochondrial cluster, blockage of selective autophagy of mitochondria (mitophagy) by VCR, increased mitochondrial mass, and upregulation of BNIP3 by VPA."	MEC01073
C48781	NEWCL10137	.	Achieving Therapeutic Synergy	ATO and nilotinib treatment alone or in combination greatly suppressed cell proliferation but promoted the differentiation of CML-BC cells towards multiple-lineages.	MEC01074
C48781	NEWCL00048	.	Achieving Therapeutic Synergy	ATO synergistically potentiated the apoptotic efficacy of the TKI AMN107 in imatinib-resistant CML cell.	MEC01098
C99313	NEWCL00169	.	Reversing Drug Resistance	Amentoflavone may be used as a sorafenib sensitizer to enhance sorafenib-induced cytotoxicity and trigger sorafenib-induced apoptosis through extrinsic and intrinsic pathways in SK-Hep1R cells.	MEC01119
C22952	NEWCL10335; NEWCL10372	.	Achieving Therapeutic Synergy	Combination therapy with sorafenib + withaferin showed synergistic efficacy in papillary and anaplastic cancers in vitro with significant induction of apoptosis.	MEC01082
C96992	NEWCL00236	.	Achieving Therapeutic Synergy	Fisetin sensitized human pancreatic cancer cells to gemcitabine-induced cytotoxicity through inhibition of ERK-MYC signaling.	MEC01091
C18218	NEWCL00049; NEWCL00155	.	Achieving Therapeutic Synergy	Triptolide sensitized human breast cancer cells to TNF Alpha induced apoptosis.	MEC01095
C18218	NEWCL10010; NEWCL10046; NEWCL10154	.	Achieving Therapeutic Synergy	Apoptosis of human cholangiocarcinoma cell lines as induced by a combination of TNF-alpha and triptolide is mediated through caspase 3 activation.	MEC01115
C35524	NEWCL00022	.	Achieving Therapeutic Synergy	Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells.	MEC01096
C35524	NEWCL00077; NEWCL00076; NEWCL10082; NEWCL00242; NEWCL00050; NEWCL00052; NEWCL00155; NEWCL00229; NEWCL00231; NEWCL00149; NEWCL00253	.	Achieving Therapeutic Synergy	Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant solid tumor cells.	MEC01332
C52194	NEWCL10048; NEWCL10005; NEWCL00047	.	Achieving Therapeutic Synergy	"2-Methoxyestradiol Induces Mitotic Arrest, Apoptosis, and Synergistic Cytotoxicity with Arsenic Trioxide in Human Urothelial Carcinoma Cells."	MEC01097
C92603	NEWCL10118; NEWCL10064; NEWCL10104; NEWCL10168	.	Achieving Therapeutic Synergy	Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas.	MEC01101
C92603	NEWCL10118; NEWCL10061	.	Achieving Therapeutic Synergy	ES cells showed heterogeneity response to ATO and Eto treatment.	MEC01102
C24748	NEWCL00242; NEWCL00243	.	Achieving Therapeutic Synergy	Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.	MEC01105
C51917	NEWCL10134	.	Achieving Therapeutic Synergy	Osthole enhances TRAIL-mediated apoptosis through downregulation of c-FLIP expression in renal carcinoma Caki cells.	MEC01108
C76205	NEWCL00145; NEWCL00142	.	Achieving Therapeutic Synergy	Beta-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts.	MEC01110
C81435	NEWCL00279; NEWCL10001	.	Achieving Therapeutic Synergy	Honokiol enhanced temozolomide-induced autophagy and apoptosis in drug-sensitive and -tolerant glioma cells.	MEC01112
C81435	NEWCL10022	.	Achieving Therapeutic Synergy	Honokiol eliminates cancer stem-like cells and potentiates temozolomide sensitivity glioblastoma multiforme cells.	MEC01251
C71193	NEWCL00170; NEWCL00181; NEWCL00267; NEWCL00187	.	Achieving Therapeutic Synergy	Cetuximab-Triptolide conjugate suppresses the growth of EGFR-overexpressing lung cancers through targeting RNA polymerase II.	MEC01113
C11915	NEWCL00129; NEWCL10155	.	Achieving Therapeutic Synergy	Sorafenib and ursodeoxycholic combination is efficacious in treating hepatocellular carcinoma by inhibiting cell proliferation and inducing apoptosis through reactive oxygen species dependent activation of ERK and dephosphorylation of STAT3.	MEC01117
C44708	NEWCL00255	.	Achieving Therapeutic Synergy	"Caspase-8, -9, -3 activation which was determined in vitro, trigerred apoptotic mechanism in C6 cells by using low concentrations of combined cis-platin and Epsilon-viniferin."	MEC01121
C04549	NEWCL00155	.	Reversing Drug Resistance	AE could be a potential reversal agent to resensitize ADR resistant in tumor chemotherapy.	MEC01122
C23313	NEWCL00180	.	Achieving Therapeutic Synergy	Arctigenin has a therapeutic potential in combination with chemotherapeutic agents for NSLC.	MEC01165
C23313	NEWCL00074; NEWCL00076	.	Achieving Therapeutic Synergy	Arctigenin enhances the sensitivity of cisplatin resistant colorectal cancer cell by activating autophagy.	MEC01125
C23313	NEWCL00129; NEWCL00149; NEWCL00048	.	Achieving Therapeutic Synergy	Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway.	MEC01281
C96418	NEWCL00278; NEWCL00286; NEWCL10382	.	Achieving Therapeutic Synergy	"Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response."	MEC01126
C10486	NEWCL00048	.	Achieving Therapeutic Synergy	Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway.	MEC01128
C67973	NEWCL00039; NEWCL00123	.	Achieving Therapeutic Synergy	Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.	MEC01130
C64633	NEWCL00279	.	Achieving Therapeutic Synergy	Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway.	MEC01139
C11337	NEWCL00189	.	Decreasing Adverse Drug Reaction	The combined treatment with PV-CXB and PV-HNK showed synergistic effect both in vitro and in vivo.	MEC01142
C76567	NEWCL10125	.	Achieving Therapeutic Synergy	Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line.	MEC01143
C41820	NEWCL00231	.	Achieving Therapeutic Synergy	Combining liposomal honokiol with cisplatin enhances therapeutic effectiveness in ovarian carcinoma.	MEC01336
C41820	NEWCL00170	.	Achieving Therapeutic Synergy	The combination of honokiol with DDP can enhance the antitumor activity.	MEC01144
C12505	NEWCL00076; NEWCL00082	.	Achieving Therapeutic Synergy	"Phloretin and Atorvastatin produce a powerful synergistic interaction in suppressing colon cancer cell growth. This process was accomplished via the synergistic induction of apoptosis and the arrest of the cell cycle at the G2/M checkpoint, which resulted from downregulated cdc2 activation following combined treatment."	MEC01148
C23558	NEWCL00129	.	Achieving Therapeutic Synergy	Sorafenib and vitamin K can function synergistically to inhibit the migration and proliferation of HCC cells.	MEC01156
C62728	NEWCL10202	.	Achieving Therapeutic Synergy	"Anti-inflammatory therapy might be successful with lower aspirin doses when combined with vitamin E, thereby possibly avoiding the side effects of the usually required high dose aspirin treatment."	MEC01160
C84670	NEWCL00069; NEWCL00048; NEWCL10346; NEWCL10120; NEWCL00129; NEWCL10281	.	Achieving Therapeutic Synergy	"A synergistic combination of ponatinib- and forskolin-reduced cell viability was identified in this clinically relevant imatinib-resistant CML cell line, which also proved efficacious in other CML cell lines."	MEC01162
C52995	NEWCL10204	.	Achieving Therapeutic Synergy	The combination demonstrated synergy against the VCZ-R clinical isolate as well.	MEC01166
C14803	NEWCL00170; NEWCL00155; NEWCL00242; NEWCL10044	.	Achieving Therapeutic Synergy	Honokiol inhibits DNA polymerases Beta and Lambda and increases Bleomycin sensitivity of human cancer cells.	MEC01168
C97410	NEWCL00065	.	Achieving Therapeutic Synergy	Thymoquinone and difluoromethylornithine (DFMO) synergistically induce apoptosis of human acute T lymphoblastic leukemia jurkat cells through the modulation of epigenetic pathways.	MEC01169
C69830	NEWCL00065	.	Achieving Therapeutic Synergy	Phytosphingosine sensitizes cancer cells to TRAIL through the synergistic up-regulation of DR4 and DR5 in an NF-kappaB-dependent fashion resulting in caspase-8 activation and subsequent mitochondrial dysfunction.	MEC01171
C50254	NEWCL00039; NEWCL00126	.	Decreasing Adverse Drug Reaction	Morusin induces TRAIL sensitization by regulating EGFR and DR5 in human glioblastoma cells.	MEC01172
C23789	NEWCL00129	.	Achieving Therapeutic Synergy	"In addition to the mitochondrial- and Fas receptor-mediated apoptotic pathways involved, ROS-dependent and p53-regulated DR5 expression was also demonstrated to play a pivotal role in the synergistic enhancement of TRAIL-induced apoptosis instigated by 6-DG in Hep G2 cells."	MEC01175
C14052	NEWCL00252; NEWCL00251	.	Achieving Therapeutic Synergy	"Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage."	MEC01176
C42889	NEWCL00029	.	Achieving Therapeutic Synergy	TSN and RGF combination (TRC) synergistically inhibited the proliferation and migration of MHCC-97L cells. The upregulation of WWOX (WW-domain containing oxidoreductase) played a vital role in the HCC cell growth treated with TRC.	MEC01177
C68125	NEWCL00172	.	Decreasing Adverse Drug Reaction	Cucurbitacin D overcomes gefitinib resistance by blocking EGF binding to EGFR and inducing cell death in NSCLCs.	MEC01183
C82034	NEWCL00279; NEWCL00037	.	Achieving Therapeutic Synergy	PROG enhances the cytotoxic effects of TMZ in GBM cells and reduces its toxic side effects in healthy primary cells.	MEC01184
C41250	NEWCL10235	.	Achieving Therapeutic Synergy	FAR and FAR/FLC affected fitness of C. albicans biofilm and the ERG gene regulation.	MEC01186
C41250	NEWCL10319; NEWCL10321; NEWCL10320; NEWCL10322	.	Achieving Therapeutic Synergy	"Farnesol was not beneficial in combination with fluconazole for fluconazole-susceptible isolates, but partially increased fluconazole activity against one fluconazole-resistant isolate, but not the other one."	MEC01378
C26286	NEWCL10356	.	Achieving Therapeutic Synergy	"A combined treatment with low-dose gefitinib and vitamin E has Synergistic effects that reduce TGF Beta1 induced fibroblast proliferation, cell-cycle arrest and the ERK phosphorylation pathway."	MEC01188
C15248	NEWCL10231	.	Achieving Therapeutic Synergy	These results suggest that neferine might be a potential imatinib sensitizer in CML treatment.	MEC01190
C15248	NEWCL00048	.	Achieving Therapeutic Synergy	Nef is a candidate chemical that can increase STI571 chemosensitivity in STI571-resistant K562 cells by inhibition of P-gp expression and increasing intracellular STI571 accumulation.	MEC01600
C06415	NEWCL00255	.	Reversing Drug Resistance	Acteoside has beneficial effects on TMZ based glioblastoma therapy.	MEC01191
C77855	NEWCL00282; NEWCL10115; NEWCL10174	.	Achieving Therapeutic Synergy	BSO sensitizes RCC cells to As2O3-induced apoptosis through the down-regulation of the intracellular GSH redox system.	MEC01196
C08388	NEWCL00036	.	Achieving Therapeutic Synergy	2-Methoxyestradiol and its combination with ferulic acid induces melanoma cell death via downregulation of Hsp60 and Hsp90.	MEC01206
C78100	NEWCL10133	.	Achieving Therapeutic Synergy	"Beta-elemene combined DC/Dribble vaccine could induce specific immune cells to secrete secretory cells, thus exerting its anti-tumor effect."	MEC01212
C50091	NEWCL00077	.	Achieving Therapeutic Synergy	Mycophenolate mofetil alone and in combination with tacrolimus inhibits the proliferation of HT-29 human colonic adenocarcinoma cell line and might interfere with colonic tumorigenesis.	MEC01226
C21358	NEWCL00212; NEWCL10089; NEWCL00077; NEWCL00180; NEWCL10098; NEWCL00155; NEWCL10190	.	Achieving Therapeutic Synergy	Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors.	MEC01227
C48727	NEWCL10125	.	Achieving Therapeutic Synergy	"CQ exhibits a cytotoxic effect on NB4 cells and has a synergistic effect when combined with ATO, which thereby improves the curative effect of ATO on APL."	MEC01229
C27959	NEWCL00180; NEWCL00170	.	Achieving Therapeutic Synergy	Honokiol exhibits enhanced antitumor effects with chloroquine by inducing cell death and inhibiting autophagy in human non-small cell lung cancer cells.	MEC01231
C57697	NEWCL00175; NEWCL00172	.	Reversing Drug Resistance	"Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol."	MEC01233
C54372	NEWCL00129; NEWCL00283; NEWCL00031	.	Achieving Therapeutic Synergy	Combined treatment with sorafenib and vitamin K2 can work synergistically to inhibit the growth of hepatocellular carcinoma cells.	MEC01234
C98009	NEWCL00039	.	Achieving Therapeutic Synergy	Beta-asarone could promote the entry of TMZ into U252 cells through the membrane.	MEC01239
C98009	NEWCL00039	.	Achieving Therapeutic Synergy	Beta-asarone could promote the entry of TMZ into U251 cells through the membrane.	MEC01269
C02581	NEWCL00149; NEWCL00137	.	Achieving Therapeutic Synergy	"Quercetin and cisplatin had synergistic inhibitory effect on cervical cancer cells. Quercetin might enhance the antitumor effect of cisplatin via inhibiting proliferation, migration and invasion and elevating apoptosis through weakening MMP2, ezrin, METTL3 and P-Gp expression of cancer cells."	MEC01240
C58411	NEWCL00031; NEWCL10056; NEWCL00129; NEWCL10012; NEWCL00169; NEWCL00027; NEWCL10085; NEWCL00357; NEWCL00283	.	Achieving Therapeutic Synergy	"Kaempferol exhibits a synergistic effect with doxorubicin to inhibit proliferation, migration, and invasion of liver cancer."	MEC01242
C31140	NEWCL00031	.	Reversing Drug Resistance	"The combination of glycyrrhizin and lamivudine inhibit the cisplatin efflux from the HCC cells, acting as modulators to reverse cisplatin resistance."	MEC01244
C41273	NEWCL00155	.	Achieving Therapeutic Synergy	"Brucine, either individually or in combination, but not gemcitabine, inhibited NF-kB subunit (p65) expression in MCF-7 cells."	MEC01246
C07068	NEWCL10120	.	Achieving Therapeutic Synergy	The in vitro activity of paromomycin and miltefosine against host cells is TLR4 dependent.	MEC01248
C39948	NEWCL00171; NEWCL00200	.	Reversing Drug Resistance	"The combination of erlotinib and ampelopsin induces cell death via the Nox2-ROS-Bim pathway, and ampelopsin could be used as a novel anti-cancer agent combined with EGFR-TKI to overcome resistance to erlotinib in EGFR-mutant NSCLC."	MEC01252
C89196	NEWCL10046; NEWCL10402; NEWCL10007	.	Achieving Therapeutic Synergy	NQO1 may be important in sensitizing cells to anticancer drugs and inhibition of NQO1 may be a strategy for the treatment of CCA.	MEC01254
C24892	NEWCL10073	.	Reversing Drug Resistance	Concomitant use of dicoumarol could enhance the cytotoxicity of doxorubicin in urothelial cancer cells with wt-p53 through the p53/p21/p38 MAPK pathways.	MEC01256
C47697	NEWCL00292; NEWCL00242	.	Achieving Therapeutic Synergy	Arsenic trioxide inhibits Skp2 expression to increase chemosensitivity to gemcitabine in pancreatic cancer cells.	MEC01261
C13108	NEWCL00155	.	Reversing Drug Resistance	"Sch A specifically reverses P-gp-mediated DOX resistance in MCF-7/DOX cells by blocking P-gp, NF-KappaB, and Stat3 signaling. Inhibition of P65 and Stat3 shows potent anti-MDR effect on MCF-7/DOX cells."	MEC01262
C48418	NEWCL10421; NEWCL10422	.	Reversing Drug Resistance	Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells.	MEC01264
C46171	NEWCL00256; NEWCL00348	.	Achieving Therapeutic Synergy	"Honokiol can effectively overcome the limitation of Rapamycin treatment alone, and the combination treatment can markedly restrict the growth of RCC, with particular importance to post-transplantation renal cancer."	MEC01265
C54867	NEWCL00129; NEWCL10170	.	Achieving Therapeutic Synergy	Kaempferol-mediated sensitization enhances chemotherapeutic efficacy of sorafenib against hepatocellular carcinoma.	MEC01268
C58550	NEWCL10032	.	Achieving Therapeutic Synergy	"The combination cyclophosphamide and roxithromycin, but not the individual compounds, is toxic to endothelial cells by inducing apoptosis."	MEC01270
C73681	NEWCL00360; NEWCL10140	.	Reversing Drug Resistance	Celastrol effectively inhibit SPC25 expression and reverse CR phenotype.	MEC01277
C23876	NEWCL00031; NEWCL00129	.	Achieving Therapeutic Synergy	Tan-IIA combined with sorafenib or SC-1 exerted synergistic cytotoxicity in HCC cells.	MEC01280
C57420	NEWCL00049	.	Decreasing Adverse Drug Reaction	ATG might alleviate the side effects and improve the therapeutic efficacy of DOX.	MEC01282
C64576	NEWCL00155	.	Achieving Therapeutic Synergy	Combination of Glycyrrhetinic acid as an angiogenesis inhibitor and Doxorubicin obtain the synergistic anticancer efficacy and reduce cardiotoxicity.	MEC01295
C82677	NEWCL00049; NEWCL00162	.	Achieving Therapeutic Synergy	The anti-tumor efficiency of pterostilbene is promoted with a combined treatment of Fas signaling or autophagy inhibitors in triple negative breast cancer cells.	MEC01297
C74319	NEWCL00082; NEWCL00353	.	Achieving Therapeutic Synergy	Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C.	MEC01300
C76221	NEWCL00227	.	Achieving Therapeutic Synergy	"A dramatic inhibition of cellular proliferation, invasion, and migration in cells treated with Ssd alone or in combination with SP600125 was observed."	MEC01301
C03351	NEWCL00155; NEWCL10166; NEWCL10294	.	Achieving Therapeutic Synergy	"Combined Gamma -tocotrienol and PPAR Gamma antagonists treatment in PPAR Gamma negative/silenced breast cancer cells are mediated through PPAR Gamma -independent mechanisms that are associated with a downregulation in COX-2, PGDS, and PGD2 synthesis."	MEC01308
C45627	NEWCL10312	.	Achieving Therapeutic Synergy	Antimicrobial effect of BDMC combined with antibiotics was superior to treatment with that of a single agent alone.	MEC01309
C19308	NEWCL10312	.	Achieving Therapeutic Synergy	Antimicrobial effect of BDMC combined with antibiotics was superior to treatment with that of a single agent alone.	MEC01310
C78359	NEWCL00286; NEWCL00278; NEWCL10028	.	Achieving Therapeutic Synergy	Cladribine exhibited inhibitory effects on MM cells in vitro. MM1.S is the only cell line showing significant response to the clinically achievable concentrations of cladribine-induced apoptosis and inactivation of STAT3.	MEC01311
C68656	NEWCL00022	.	Achieving Therapeutic Synergy	"Delphinidin-induced sensitization of HL-60 cells to As(III) may lead to dose reduction of As(III) in clinical application, and ultimately contribute to minimizing its side effects."	MEC01312
C68656	NEWCL10125	.	Achieving Therapeutic Synergy	"Delphinidin selectively sensitized NB4 cells to As(III), resulting in the enhancement of As(III) cytotoxicity by strengthening intrinsic/extrinsic pathway-mediated apoptosis induction, rather than affecting the As[i] levels."	MEC01315
C13054	NEWCL00279; NEWCL00039	.	Achieving Therapeutic Synergy	"G2/M arrest, necrosis and autophagy appeared to cooperatively contribute to the synergistic cytotoxicity of AsIII and gamabufotalin."	MEC01316
C07401	NEWCL10034	.	Achieving Therapeutic Synergy	Costunolide causes mitotic arrest and enhances radiosensitivity in human hepatocellular carcinoma cells.	MEC01319
C83635	NEWCL00251; NEWCL00253	.	Achieving Therapeutic Synergy	Dihydroisotanshinone I combined with radiation inhibits the migration ability of prostate cancer cells through DNA damage and CCL2 pathway.	MEC01321
C84475	NEWCL00170	.	Achieving Therapeutic Synergy	"Combination of nadroparin and irradiation had a strong synergistic antitumor effect in a dose- and time-related manner in vitro, which was reflected in the inhibition of cell viability, invasion and metastasis, promotion of apoptosis, inhibited secretion level of TGF-Beta1 and downregulation of CD147, MMP-2 and survivin expression."	MEC01322
C23838	NEWCL00178	.	Achieving Therapeutic Synergy	VCN 2 sensitizes NCI H23 cells to radiation.	MEC01324
C23838	NEWCL00178	.	Achieving Therapeutic Synergy	VCN-2 can be a potential chemotherapeutic and radiosensitizing agent in NSCLC.	MEC01325
C46840	NEWCL10280	.	Achieving Therapeutic Synergy	Arctigenin protects against ultraviolet-A-induced damage to stemness through inhibition of the NF-KappaB/MAPK pathway.	MEC01326
C72558	NEWCL00032	.	Achieving Therapeutic Synergy	"BDMC stimulates the dephosphorylation and p53-binding activity of Bcl-2 and suggest that BDMC may induce a neutralization of Bcl-2's anti-apoptotic function, thereby enhancing X-ray-induced apoptosis."	MEC01328
C10976	NEWCL10119	.	Achieving Therapeutic Synergy	Effect of decitabine in combination with arsenic trioxide on prolife-ration and apoptosis of human acute myeloid leukemia MV4-11 cells.	MEC01330
C91293	NEWCL00049; NEWCL10163	.	Achieving Therapeutic Synergy	Chrysin synergistically enhanced the effect of epirubicin.	MEC01334
C36454	NEWCL10125; NEWCL00048	.	Achieving Therapeutic Synergy	Honokiol induces paraptosis and apoptosis and exhibits schedule-dependent synergy in combination with imatinib in human leukemia cells.	MEC01337
C55280	NEWCL00155; NEWCL00049	.	Achieving Therapeutic Synergy	"The synergistic effect of TQ and TAM on human breast cancer cell lines showed cell viability reduction as well as apoptosis induction, independent to estrogen."	MEC01338
C68723	NEWCL10076; NEWCL10091; NEWCL00289; NEWCL10011; NEWCL10172; NEWCL10184	.	Achieving Therapeutic Synergy	The therapeutic effect of combining topotecan with vincristine was greater than additive in most tumor models of childhood solid tumors tested.	MEC01339
C65878	NEWCL00097; NEWCL10077; NEWCL10076; NEWCL00280; NEWCL10063; NEWCL10004; NEWCL10023	.	Achieving Therapeutic Synergy	Volasertib exhibits antitumor activity and synergy with vincristine in alveolar rhabdomyosarcoma.	MEC01340
C92656	NEWCL00033; NEWCL10109; NEWCL10132	.	Achieving Therapeutic Synergy	Dipyridamole and vincristine combination showed synergistic inhibitory effects on the growth of human leukaemia and lymphoma cell lines.	MEC01341
C52845	NEWCL00155; NEWCL00159	.	Achieving Therapeutic Synergy	"Pterostilbene shows an additive inhibitory effect on breast cancer cells when combined with tamoxifen, most likely from augmented cancer cell apoptosis."	MEC01342
C50052	NEWCL00314	.	Achieving Therapeutic Synergy	Quercetin and carboxyamidotriazole showed synergistic anticancer effects in breast carcinoma cells.	MEC01343
C63875	NEWCL10308; NEWCL10255	.	Achieving Therapeutic Synergy	The co-administration of verbascoside and gentamicin was more effective and synergistic activities (FICI<1) against clinical isolates.	MEC01357
C69618	NEWCL10206; NEWCL10255; NEWCL10298	.	Achieving Therapeutic Synergy	Silybin showed a remarkable synergistic activity in combination with some antibiotic agents against drug-resistant bacteria.	MEC01358
C17411	NEWCL00155; NEWCL00189	.	Achieving Therapeutic Synergy	"The SLN-DOX-SC demonstrated to be more effective than the free DOX against 4T1 cells. So, the developed SLN efficiently encapsulate DOX and SC and show good potential as an alternative for cancer treatment."	MEC01360
C71184	NEWCL00129	.	Reversing Drug Resistance	SCH acts by affecting the normal formation and functioning of the Pgp-substrate complexes.	MEC01362
C44375	NEWCL00077	.	Decreasing Adverse Drug Reaction	Sch A decreased the DON-induced cyclooxygenase-2 expression and prostaglandin E2 production and pro-inflammatory cytokine interleukin 8 expression and secretion.	MEC01367
C36721	NEWCL00049	.	Achieving Therapeutic Synergy	Cancer cell killing efficiency of MB increases in the combination with SA due to reduction prevention and stabilization of monomeric form of MB.	MEC01370
C71760	NEWCL10012	.	Achieving Therapeutic Synergy	Combination of saikosaponin c and telbivudine synergistically enhances the anti-HBV activity.	MEC01373
C33194	NEWCL10390; NEWCL10221	.	Reversing Drug Resistance	"Saikosaponin B2 inhibited daclatasvir-resistant mutant strains of HCV, especially in combination with daclatasvir."	MEC01374
C48757	NEWCL00048	.	Achieving Therapeutic Synergy	Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.	MEC01375
C67017	NEWCL10246; NEWCL10270	.	Achieving Therapeutic Synergy	Additive improvement in G551D CFTR-mediated Cl-secretion suggests that resveratrol could enhance ivacaftor therapy in these patients and improve CF-related rhinosinusitis.	MEC01409
C97927	NEWCL10222; NEWCL10223; NEWCL10225; NEWCL10224	.	Achieving Therapeutic Synergy	The disruption of the citric acid cycle and inhibition of nucleotide biogenesis are the key metabolic features associated with synergistic bacterial killing by the combination against polymyxin-susceptible and -resistant A. baumannii.	MEC01411
C20591	NEWCL10305	.	Achieving Therapeutic Synergy	"MG alone or in combination with a sub-MIC of MRB effectively inhibited the adhesion, invasion, and intracellular survival of Salmonella Typhimurium in vitro by downregulating quorum sensing and virulence genes."	MEC01440
C74648	NEWCL10412	.	Achieving Therapeutic Synergy	"Apigenin-7-O-glucoside alone, and apigenin-7-O-glucoside in combination with pyrimethamine, were found to be potent anti-T. gondii agents."	MEC01444
C59759	NEWCL10251	.	Achieving Therapeutic Synergy	The combined effect of CDV and IUdR on VV replication in monolayer CEF cultures was characterized as a markedly synergistic one.	MEC01445
C34640	NEWCL00215	.	Achieving Therapeutic Synergy	Combination treatment with Everolimus and Paroxetine showed synergistic post-ischemic neuroprotective efficacy.	MEC01449
C79000	NEWCL00140	.	Achieving Therapeutic Synergy	Mixtures of beta-aescin and 5-FU showed a synergistic effect on the 50% inhibitory effect when their ratio was 4:1 when compared with either agent alone.	MEC01453
C73132	NEWCL00180; NEWCL10353	.	Achieving Therapeutic Synergy	"Co-treatment with NAC attenuated the two drug combination-induced autophagy, apoptosis, DNA damage and decrease of cell migration and invasion ability."	MEC01455
C92406	NEWCL00049; NEWCL00156	.	Achieving Therapeutic Synergy	Acacetin and Pinostrobin inhibit malignant breast epithelial cell adhesion and focal adhesion formation to attenuate cell migration.	MEC01456
C10466	NEWCL00240	.	Reversing Drug Resistance	Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression.	MEC01457
C35334	NEWCL10337	.	Achieving Therapeutic Synergy	Naringin protects myocardial cells from doxorubicin induced apoptosis partially by inhibiting the p38MAPK pathway.	MEC01465
C45714	NEWCL00170	.	Achieving Therapeutic Synergy	Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation.	MEC01467
C16480	NEWCL10305	.	Achieving Therapeutic Synergy	Cefixime-ofloxacin combination could be effective against moderately susceptible fluoroquinolone S. Typhi but not fluoroquinolone-resistant isolates.	MEC01469
C54961	NEWCL00346	.	Achieving Therapeutic Synergy	"Strong and moderate synergistic antiviral effects were observed for betulin and ACV against HSV-1 when the concentrations of ACV and betulin were higher than 0.068 and 0.4 microg/ml, respectively."	MEC01475
C23725	NEWCL00157; NEWCL00155	.	Achieving Therapeutic Synergy	17-beta-oestradiol partially reversed the anti-proliferative effects of MTX in the MDA-MB-436 line and potentiated growth inhibition in the E2 responsive cells.	MEC01476
C36127	NEWCL00253; NEWCL00252	.	Achieving Therapeutic Synergy	These results provide novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells.	MEC01485
C81544	NEWCL00031	.	Achieving Therapeutic Synergy	These results suggest that combinations of 3TC and PCV may act synergistically against HBV in vivo.	MEC01488
C95100	NEWCL10298; NEWCL10308	.	Achieving Therapeutic Synergy	Green tea extract and catechins potentiated the antimicrobial action of gentamicin against some clinical isolates of S. aureus and standard P. aeruginosa strains.	MEC01499
C07164	NEWCL20324; NEWCL20323	.	Reversing Drug Resistance	Sanguinarine reversed cisplatin resistance in A2780/R cells through intracellular GSH depletion.	MEC01501
C02110	NEWCL00071	.	Achieving Therapeutic Synergy	Cucurbitacin I inhibits cell migration and invasion and enhances chemosensitivity in colon cancer.	MEC01521
C02976	NEWCL00082; NEWCL00077	.	Achieving Therapeutic Synergy	CuB plus Gef treatment caused a significant growth and cell cycle inhibition and induced apoptosis in both cell lines.	MEC01522
C85964	NEWCL00155	.	Achieving Therapeutic Synergy	Combination of toremifene plus atamestane was as effective as toremifene or tamoxifen alone but may not provide any additional benefit over toremifene alone or tamoxifen alone.	MEC01531
C59366	NEWCL00149; NEWCL00139; NEWCL00137; NEWCL00058	.	Achieving Therapeutic Synergy	Cisplatin and Caffeic acid in combination synergistically inhibited the growth of cells and induced apoptosis in HeLa and CaSki cells. The mechanism that is most likely to be behind the efficacy of this treatment is the modulation of apoptosis-regulated expression.	MEC01536
C69776	NEWCL10308; NEWCL20309; NEWCL10255; NEWCL20310; NEWCL20311; NEWCL20312; NEWCL20313; NEWCL10226; NEWCL20315; NEWCL20316; NEWCL20317; NEWCL10230; NEWCL20318; NEWCL20319; NEWCL20320; NEWCL20321; NEWCL20322	.	Achieving Therapeutic Synergy	"When Camellia sinensis was combined with nalidixic acid, it was able to inhibit S. Typhi at sub-MIC levels."	MEC01537
C48863	NEWCL10308; NEWCL20309; NEWCL10255; NEWCL20310; NEWCL20311; NEWCL20312; NEWCL20313; NEWCL10226; NEWCL20315; NEWCL20316; NEWCL20317; NEWCL10230; NEWCL20318; NEWCL20319; NEWCL20320; NEWCL20321; NEWCL20322	.	Achieving Therapeutic Synergy	Ten times reduction in MICs was observed against Staphylococcus aureus when used in combination with oxacillin.	MEC01538
C24753	NEWCL00099	.	Achieving Therapeutic Synergy	These two agents in combination synergistically inhibited cell growth and induced apoptosis.	MEC01544
C71898	NEWCL10286	.	Achieving Therapeutic Synergy	Herbal compound plumbagin was identified to stimulate gentamicin uptake by CRKp via enhancing TCA efflux and PMF to achieve a synergistic antibacterial effect. Plumbagin may be used in combination with aminoglycosides for severe CRKp infection by potentiating their therapeutic efficacy and lowering dosage.	MEC01548
C31323	NEWCL00049; NEWCL00156; NEWCL00052; NEWCL00155	.	Achieving Therapeutic Synergy	Some UFAs can be used as modulators of tumor cell chemosensitivity.	MEC01553
C97202	NEWCL00236; NEWCL00242	.	Achieving Therapeutic Synergy	GLA has a synergistic effect with gemcitabine at concentrations that correspond to in vivo therapeutic doses. GLA with 5-FU is synergistic only at a tight range of high concentrations of 5-FU. GLA lacks toxic side effects and may be useful in combination with gemcitabine.	MEC01554
C72772	NEWCL00049; NEWCL00155; NEWCL00227	.	Achieving Therapeutic Synergy	Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy.	MEC01555
C17427	NEWCL10254; NEWCL10310; NEWCL10316; NEWCL10257; NEWCL10256; NEWCL10299	.	Achieving Therapeutic Synergy	Amentoflavone had a considerable antibacterial effect and synergistic interaction with antibiotics against various bacterial strains. The formation of hydroxyl radical would be a cause of the synergistic effect and that this oxidative stress originated from a transient NADH depletion. .	MEC01556
C62233	NEWCL10254; NEWCL10310; NEWCL10316; NEWCL10257; NEWCL10256; NEWCL10299	.	Achieving Therapeutic Synergy	Amentoflavone had a considerable antibacterial effect and synergistic interaction with antibiotics against various bacterial strains. The formation of hydroxyl radical would be a cause of the synergistic effect and that this oxidative stress originated from a transient NADH depletion. .	MEC01557
C84763	NEWCL10254; NEWCL10310; NEWCL10316; NEWCL10257; NEWCL10256; NEWCL10299	.	Achieving Therapeutic Synergy	Amentoflavone had a considerable antibacterial effect and synergistic interaction with antibiotics against various bacterial strains. The formation of hydroxyl radical would be a cause of the synergistic effect and that this oxidative stress originated from a transient NADH depletion. .	MEC01558
C96554	NEWCL10340	.	Achieving Therapeutic Synergy	MGO has potent inhibitory activity against influenza viruses and also enhanced the effect of NA inhibitors.	MEC01563
C09829	NEWCL10340	.	Achieving Therapeutic Synergy	MGO has potent inhibitory activity against influenza viruses and also enhanced the effect of NA inhibitors.	MEC01564
C30370	NEWCL10340	.	Achieving Therapeutic Synergy	MGO has potent inhibitory activity against influenza viruses and also enhanced the effect of NA inhibitors.	MEC01565
C95441	NEWCL00033	.	Achieving Therapeutic Synergy	Simultaneous exposure of VCR and MTX produced subadditive or mutually protective interactions.	MEC01571
C72648	NEWCL10286	.	Achieving Therapeutic Synergy	Tea polyphenols used in combination with commonly used antibiotics showed synergistic bactericidal effect against multidrug-resistant Klebsiella pneumoniae.	MEC01572
C94917	NEWCL10286	.	Achieving Therapeutic Synergy	Tea polyphenols used in combination with commonly used antibiotics showed synergistic bactericidal effect against multidrug-resistant Klebsiella pneumoniae.	MEC01573
C21794	NEWCL10286	.	Achieving Therapeutic Synergy	Tea polyphenols used in combination with commonly used antibiotics showed synergistic bactericidal effect against multidrug-resistant Klebsiella pneumoniae.	MEC01574
C31990	NEWCL10215	.	Achieving Therapeutic Synergy	A combination of spectinomycin with erythromycin was found to be more effective against Chlamydia trachomatis.	MEC01576
C28090	NEWCL10215	.	Achieving Therapeutic Synergy	A combination of spectinomycin with doxycycline was found to be more effective against Chlamydia trachomatis.	MEC01577
C87608	NEWCL10263; NEWCL10260; NEWCL10261; NEWCL10262; NEWCL10259; NEWCL10258	.	Reversing Drug Resistance	Propolis could enhance the efficiency of antibiotics used in UTIs and could represent an alternative solution.	MEC01578
C78668	NEWCL10263; NEWCL10260; NEWCL10261; NEWCL10262; NEWCL10259; NEWCL10258	.	Reversing Drug Resistance	Propolis could enhance the efficiency of antibiotics used in UTIs and could represent an alternative solution.	MEC01579
C77481	NEWCL10263; NEWCL10260; NEWCL10261; NEWCL10262; NEWCL10259; NEWCL10258	.	Reversing Drug Resistance	Propolis could enhance the efficiency of antibiotics used in UTIs and could represent an alternative solution.	MEC01580
C62269	NEWCL10304; NEWCL10303	.	Reversing Drug Resistance	ApuL showed synergistic action in combination with antibiotics.	MEC01589
C27192	NEWCL10250	.	Achieving Therapeutic Synergy	"Rofecoxib inhibited endothelial cell proliferation, migration, and tube formation (differentiation) at clinically relevant doses. In combination with radiation, inhibition of endothelial cell function further increased twofold."	MEC01595
C12361	NEWCL00052; NEWCL00049; NEWCL00155	.	Achieving Therapeutic Synergy	Cucurbitacin B causes increased radiation sensitivity of human breast cancer cells via G2/M cell cycle arrest.	MEC01596
C77973	NEWCL10249	.	Achieving Therapeutic Synergy	Targeting STAT3 signaling in CD133-positive NSCLC cells with cucurbitacin I suppressed CSC-like properties and enhanced chemoradiotherapy response.	MEC01597
C44970	NEWCL00170; NEWCL00181	.	Achieving Therapeutic Synergy	Honokiol demonstrated low cytotoxicity to NSCLC cells and a pronounced radiosensitizing effect on NSCLC cells exposed to carbon ions than X-rays.	MEC01599
C46656	NEWCL10312	.	Achieving Therapeutic Synergy	Antimicrobial effect of BDMC combined with antibiotics was superior to treatment with that of a single agent alone.	MEC01601
C50854	NEWCL10286	.	Achieving Therapeutic Synergy	Tea polyphenols used in combination with commonly used antibiotics showed synergistic bactericidal effect against multidrug-resistant Klebsiella pneumoniae.	MEC01604
C88535	NEWCL10286	.	Achieving Therapeutic Synergy	Tea polyphenols used in combination with commonly used antibiotics showed synergistic bactericidal effect against multidrug-resistant Klebsiella pneumoniae.	MEC01605
C53075	NEWCL00236; NEWCL00242	.	Achieving Therapeutic Synergy	Sulforaphane potentiates the efficacy of 17-AAG against pancreatic cancer through enhanced abrogation of Hsp90 function.	MEC01608
C30252	.	.	Achieving Therapeutic Synergy	"Initial combinations of empagliflozin + metformin for 24 weeks significantly reduced HbA1c versus empagliflozin once daily and metformin twice daily, without increased hypoglycemia, reduced weight versus metformin twice daily, and were well tolerated."	MEC00677
C57523	NEWCL10406; NEWCL10407; NEWCL10408	.	Achieving Therapeutic Synergy	2-DG significantly inhibited glycolysis in all LGSOC lines and combination with metformin showed synergistic inhibitory effect.	MEC00540
C21577	NEWCL10406; NEWCL10407; NEWCL10408	.	Achieving Therapeutic Synergy	"Metformin and trametinib combination showed synergistic inhibition of RAS mutated VOA1312 and VOA1056 cells, but not for non-Ras mutated VOA5646 cells."	MEC00559
C74164	NEWCL10385; NEWCL10386; NEWCL00231; NEWCL00134; NEWCL00230	.	Achieving Therapeutic Synergy	Combining PARP inhibitors with metformin enhances its anti-proliferative activity in BRCA mutant ovarian cancer cells.	MEC00676
C79321	NEWCL10342; NEWCL10338	.	Achieving Therapeutic Synergy	Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth.	MEC00678
C20036	NEWCL10375	.	Achieving Therapeutic Synergy	Sorafenib and metformin synergistically decreased the proliferation of ATC cell lines and the outgrowth of their derived cancer stem cells.	MEC00694
C20036	NEWCL00129	.	Achieving Therapeutic Synergy	This study demonstrated cytotoxic effects of metformin and synergistic antitumor effects of sorafenib.	MEC00679
C30853	NEWCL00236	.	Achieving Therapeutic Synergy	"liraglutide in combination with metformin has a synergistic anti-tumor effect on the pancreatic cancer cells, which may be at least partly due to activation of AMPK signaling."	MEC00680
C87955	NEWCL10368; NEWCL10078	.	Achieving Therapeutic Synergy	"Metformin and everolimus in combination are more effective than monotherapy in inhibiting pancreatic NET (PAN-NET) cell proliferation, whereas no additive effects were observed on pulmonary neuroendocrine tumor (PNT) cell proliferation."	MEC00681
C87786	NEWCL00278; NEWCL00291	.	Achieving Therapeutic Synergy	The synergistic effect of PFK15 with metformin exerts anti-myeloma activity via PFKFB3.	MEC00682
C92213	NEWCL00170; NEWCL00171; NEWCL00172	.	Achieving Therapeutic Synergy	Metformin synergistic pemetrexed suppresses non-small-cell lung cancer cell proliferation and invasion in vitro.	MEC00688
C08624	NEWCL00082; NEWCL10355	.	Achieving Therapeutic Synergy	Metformin combined with 5-FU treatment significantly inhibited tumor cell proliferation and tumor metastasis.	MEC00690
C80401	NEWCL00252; NEWCL00253	.	Achieving Therapeutic Synergy	MET + VPA induced a significant decrease in proliferation and an increase in apoptosis in tumor cells.	MEC00692
C16072	NEWCL10119; NEWCL10331; NEWCL00021; NEWCL10329; NEWCL00059; NEWCL00022	.	Achieving Therapeutic Synergy	The combination of 6-BT with metformin resulted in significant cytotoxicity (60-70%) in monocytic AML cell lines and was associated with inhibition of FLT3-ITD activated STAT5 and reduced c-Myc and GLUT-1 expression.	MEC00693
C59319	NEWCL00095; NEWCL10100	.	Achieving Therapeutic Synergy	"Metformin showed synergistic cytotoxic effects in combination with dacarbazine, reduced cell viability, and increased apoptosis in Raji and Ramos lymphoma cells in comparison with the use of each drug alone."	MEC00695
C42712	NEWCL00173; NEWCL10415; NEWCL00171; NEWCL00180; NEWCL00181; NEWCL00170	.	Achieving Therapeutic Synergy	Metformin and gefitinib are synergistic in LKB1 wild-type NSCLC cells.	MEC00699
C26342	NEWCL00263; NEWCL10372	.	Achieving Therapeutic Synergy	"Gemigliptin induces cytotoxic activity, and has a synergistic activity with metformin in inducing cytotoxicity via regulation of Akt and AMPK in thyroid carcinoma cells."	MEC00705
C28255	NEWCL00048	.	Achieving Therapeutic Synergy	"Ionizing radiation enhances PMA-induced megakaryocytic differentiation at a relatively late phase, and that the late-phase accelerated differentiation depends on the persistence of the intracellular ROS level."	MEC00906
C79146	NEWCL00149	.	Achieving Therapeutic Synergy	"Potentiation of DDP with C3G improves cancer cell susceptibility, specifically cervical cancer cells, to DDP."	MEC01029
C59741	NEWCL00031	.	Achieving Therapeutic Synergy	UTI enhanced the 5-FU sensitivity of HCC cells by attenuating their stemness via inhibiting Wnt/Beta-catenin signaling.	MEC01298
C99442	NEWCL10297	.	Achieving Therapeutic Synergy	"MTR, like SAHA, induced the apoptosis of SS cells, while the two drugs in combination showed clear synergy or potentiation."	MEC01434
C27865	NEWCL10233	.	Achieving Therapeutic Synergy	Beta-lapachone reverted antifungal resistance of S. cerevisiae and C. albicans strains overexpressing CaCdr2p and CaMdr1p transporters by inhibiting these proteins activities. CaCdr2p ATPase activity was not impaired by the compound.	MEC01551
C53795	NEWCL00251	.	Achieving Therapeutic Synergy	"The synergistic interaction between beta-lap and radiation in killing cells is the result of two distinct mechanisms: First, radiation sensitizes cells to beta-lap by up-regulating NQO1, and second, beta-lap sensitizes cells to radiation by inhibiting SLD repair."	MEC01591
C53795	NEWCL00353	.	Achieving Therapeutic Synergy	"beta-Lap is cytotoxic against RKO cells, both in vitro and in vivo, and also sensitized cells to ionizing radiation by inhibiting sublethal radiation damage repair. beta-lap is potentially useful as a potent anti-cancer chemotherapy drug and potent radiosensitizer against cancer cells."	MEC01592
C10234	NEWCL00180; NEWCL00201	.	Achieving Therapeutic Synergy	Gossypol profoundly sensitizes thoracic cancer cells to the cytotoxic effect of Apo2L/TRAIL via activation of the mitochondria-dependent death signaling pathway.	MEC01610
C10234	NEWCL10043; NEWCL00100	.	Achieving Therapeutic Synergy	Gossypol profoundly sensitizes thoracic cancer cells to the cytotoxic effect of Apo2L/TRAIL via activation of the mitochondria-dependent death signaling pathway.	MEC01084
C64007	NEWCL00344	.	Achieving Therapeutic Synergy	Mangiferin in combination with oxaliplatin favours apoptotic cell death and thereby improves the efficacy of oxaliplatin in vitro.	MEC01120
C64007	NEWCL00149	.	Achieving Therapeutic Synergy	Mangiferin in combination with oxaliplatin favours apoptotic cell death and thereby improves the efficacy of oxaliplatin in vitro.	MEC01611
C23832	.	Ascites OT (5*106) cells were intraperitoneally transplanted in female Wistar rats.	Achieving Therapeutic Synergy	"Triptorelin and exemestane increase antitumor activity of cisplatin in respect to the transplantable malignant ascites OT and significantly increase survival of animals, especially when triptorelin and cisplatin are used in combination."	MEC01294
C71617	.	Clinical Trial	Achieving Therapeutic Synergy	Garlic extracts or compounds have a good potential as antitubercular(s) drug if given as a supplement to ATT.	MEC01478
C27680	.	SD rats (200 g +/- 20 g) were used in this study.	Decreasing Adverse Drug Reaction	Gentiopicroside (GPS) could exert hepatoprotective effects on leflunomide (LEF)- and/or methotrexate (MTX)-treated arthritic rats.	MEC01215
C87415	.	"Male Wistar rats, weighing 175 +/- 25 g were used in this study."	Decreasing Adverse Drug Reaction	Ceftriaxone and/or vitamin C administration are able to minimize the toxic effects of DZN by its free radical-scavenging and potent antioxidant activity.	MEC00660
C80540	.	Male New Zealand white rabbits (3 to 3.5kg) were used in this study.	Achieving Therapeutic Synergy	The study demonstrated a synergistic interaction between the alpha-adrenergic blockade and the potentiation of the nitric oxide/cyclic guanosine monophosphate pathway to increase neurogenic relaxation of trabecular smooth muscle relaxation.	MEC00877
C91732	.	Adult male Albino Swiss mice weighing 22-26 g were used in this study.	Achieving Therapeutic Synergy	XANT in combination with levetiracetam exerts beneficial anticonvulsant pharmacodynamic interactions in the 6 Hz mouse psychomotor seizure model.	MEC01404
C17530	NEWCL00077	Human colorectal HT29 cell xenografts (1*106 cells) were transplanted s.c. into the hind limb of each animal (Female BALB/c nude mice (nu+/nu+) aged 6 weeks).	Achieving Therapeutic Synergy	Combined treatment (UFT/FA+oxaliplatin) reduced tumor weight by 39% compared to oxaliplatin alone (p<0.05) or UFT/FA (p<0.05).	MEC01388
C74039	NEWCL10358; NEWCL00205	"For a xenograft model, Female C57BL/6 mice, 6-8 weeks of age, 18-20 g, were subcutaneously (s.c.) immunized in the abdominal region with 2x105, 5x105 or 1x106 B16F10 cells. "	Decreasing Adverse Drug Reaction	The B16F10 tumor cell vaccine treated with MIP in combination with RP and VP was safe and efficient.	MEC00816
C06709	NEWCL10369	"For a xenograft model, 4*106 U87MG cells were inoculated subcutaneously into one flank of 5-6 weeks old, female nude mice."	Achieving Therapeutic Synergy	"NOS synergistically potentiated the efficacy of FDA-approved anti-cancer drugs against human glioblastoma cells, thereby allowing them to be used at lower doses and hence minimizing their toxic side effects."	MEC01094
C30671	.	Adult female Wistar albino rats were used in this study.	Decreasing Adverse Drug Reaction	Zafirlukast and vincamine may be regarded as potential therapeutic strategies with antioxidant and anti-inflammatory activities against tamoxifen-induced oxidative damage in rat liver.	MEC00663
C22796	NEWCL00099; NEWCL10348	"EC9706 cells (5*106), which were labeled with firefly luciferase, were subcutaneously inoculated into the armpit of the right forelimb of 6-week-old female BALB/c nude mice."	Achieving Therapeutic Synergy	Alpha-solanine enhances the chemosensitivity of esophageal cancer cells by inducing microRNA 138 expression.	MEC01068
C52446	.	Clinical trial	Decreasing Adverse Drug Reaction	The use of FAS before liver resection is associated with improved OS compared with surgery alone among patients with advanced synchronous pancreatic neuroendocrine liver metastases.	MEC00759
C29576	.	Clinical trial	Achieving Therapeutic Synergy	"Combination therapy with hydroquinone, tretinoin, and fluocinolone is the most cost-effective treatment when compared with any of its dyads or with hydroquinone alone."	MEC00785
C26930	.	Clinical Trial	Achieving Therapeutic Synergy	The triple DMARD combination therapy provided a new treatment option for those patients for whom treatment with biologics is difficult.	MEC01415
C54941	.	Clinical trial	Achieving Therapeutic Synergy	"Combination chemotherapy with oxaliplatin, 5-FU, and FA is an active and well-tolerated regimen as first-line treatment in patients with metastatic or recurrent gastric cancer."	MEC01390
C54941	NEWCL10031	"Cecum was exteriorized, and 2 * 106 cells were administrated to cecum wall using an insulin-gauge syringe."	Achieving Therapeutic Synergy	When compared to FOLFOX the significantly stronger chemo-immunotherapeutic responses were achieved by the combination of Nano-Folox and 5-Fu without showing toxicity.	MEC01385
C21874	.	A case report	Achieving Therapeutic Synergy	"Combination of imiquimod, 5-fluorouracil, and tretinoin is an effective viable treatment modality for treating melanoma in situ during a pandemic with telemedicine."	MEC00786
C29934	.	A 5/6 nephrectomy mouse model of CDK was used in this study.	Achieving Therapeutic Synergy	Apocynin in conjunction with a coadjuvant for modulating blood pressure may be useful for controlling the progression of CRF.	MEC00756
C73606	.	.	Achieving Therapeutic Synergy	"Low-dose chemotherapy with methotrexate and vinblastine for 1 year was effective and well tolerated by adult patients with aggressive, recurrent fibromatosis."	MEC00665
C21617	.	.	Achieving Therapeutic Synergy	The results of the ECHELON-1 study showed a significantly longer modified progression-free survival (mPFS) following BV+AVD than with ABVD in primary HL.	MEC00669
C84024	.	.	Achieving Therapeutic Synergy	Increasing the dose of aclarubicin in CAG regimen seemed to be useful and relatively safe in relapsed and refractory AML.	MEC00713
C34393	.	.	Achieving Therapeutic Synergy	"The treatment of advanced and recurrent Hodgkin's disease with chlorambucil, vinblastine, procarbazine and prednisone in combination."	MEC00750
C63861	.	.	Achieving Therapeutic Synergy	Weekly administration of 5-FU/FA/cisplatin is an active and well-tolerated regimen. Toxicity is manageable and allows chemotherapy on an outpatient basis without hydration program as required when cisplatin is used at the dose of 50 mg/m2.	MEC01392
C31212	NEWCL10243; NEWCL10241	.	Achieving Therapeutic Synergy	Caspofungin and micafungin in combination with farnesol showed synergistcant interaction against Candida parapsilosis biofilms.	MEC00646
C81199	NEWCL10287	.	Achieving Therapeutic Synergy	"The combinations of ceftazidime-avibactam with ertapenem, and ceftazidime-avibactam with tigecycline were able to reduce the MIC to less than the susceptibility breakpoint in all KPC- and OXA-48-producing K. pneumoniae."	MEC00648
C81199	NEWCL10301; NEWCL10302	.	Achieving Therapeutic Synergy	Ceftazidime-avibactam-fosfomycin has the potential to offer infected patients with high bacterial burdens a therapeutic hope against infection with MDR P. aeruginosa that lack metallo-Beta-lactamases.	MEC00647
C04404	NEWCL00181; NEWCL00049	.	Achieving Therapeutic Synergy	Combination therapy of breast and lung cancer cell lines using docetaxel or vinblastine with tamoxifen synergistically increases the anti-proliferative affect of single agents.	MEC00664
C85215	NEWCL00252; NEWCL00251; NEWCL00253	.	Achieving Therapeutic Synergy	Combined use of inhibitors of EGF-EGFR and hedgehog signaling with docetaxel could represent a more promising strategy for treatment in patients with metastatic and androgen-independent prostate cancer.	MEC00726
C62681	NEWCL10255; NEWCL10286	.	Achieving Therapeutic Synergy	"Three-drug combination of sanguinarine + EDTA + streptomycin showed synergistic activity against almost all the strains, as well as a strong reduction in the effective doses of sanguinarine, EDTA and streptomycin."	MEC00801
C79198	NEWCL00344; NEWCL00082	.	Achieving Therapeutic Synergy	Atorvastatin with gamma-tocotrienol and celecoxib exhibited a strong synergy against human colon cancer cells in causing cell cycle arrest and apoptosis.	MEC00833
C09745	NEWCL00276; NEWCL10058	.	Reversing Drug Resistance	Hydrocinchonine exerted MDR reversal activity and synergistic apoptotic effect with TAX in MES-SA/DX5 cells almost comparable with quinidine and cinchonine as a potent MDR-reversal and combined therapy agent with TAX.	MEC01127
C79823	NEWCL10205	.	Achieving Therapeutic Synergy	Green tea catechins potentiate the effect of antibiotics and modulate adherence and gene expression in Porphyromonas gingivalis.	MEC01208
C85554	NEWCL00049; NEWCL00155	.	Achieving Therapeutic Synergy	Combination treatment with doxorubicin or cisplatin hindered mammosphere forming efficiency and inclusively eliminated both cancer stem as well as non-stem cancer cells.	MEC01228
C37984	NEWCL00129	.	Achieving Therapeutic Synergy	"The inhibition of viral gene replication was enhanced by the combination of triple combination of amantadine, ursodeoxycholic acidbip, and henyl dimethyl dicarboxylate."	MEC01279
C83484	NEWCL10312; NEWCL10311; NEWCL10310	.	Achieving Therapeutic Synergy	Rhein in combination with AM or OX could lead to the development of new combinations of antibiotics against MRSA infection.	MEC01377
C82062	NEWCL00252; NEWCL00253	.	Achieving Therapeutic Synergy	Ibandronate effectively inhibits growth of prostate cancer cell lines via inhibition of the farnesyl-IPP-synthase and exhibits Synergistic effects with docetaxel.	MEC01379
C54941	NEWCL10362	.	Achieving Therapeutic Synergy	Combination of Oxa-FUFA showed supra-additive cytotoxic effects in colon carcinoma.	MEC01389
C80324	NEWCL00080; NEWCL00077	.	Achieving Therapeutic Synergy	Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation.	MEC01387
C80324	NEWCL00152; NEWCL00269	.	Achieving Therapeutic Synergy	A 1.5- up to 17-fold reduction in the IC50 of both raltitrexed and 5-fluorouracil plus folinic acid was observed in the combination setting compared with the concentrations of the each drug used alone.	MEC01386
C98936	NEWCL00064	.	Achieving Therapeutic Synergy	Methioninase in combination with 5-fluorouracil and folinic acid showed cytotoxic synergism in CCRF-CEM.	MEC01391
C66993	NEWCL10209	.	Achieving Therapeutic Synergy	ZnO-NPs potentiate the antimicrobial action of ciprofloxacin and ceftazidime.	MEC01400
C62408	NEWCL10234; NEWCL10238; NEWCL10239; NEWCL10240; NEWCL10242; NEWCL10244	.	Achieving Therapeutic Synergy	1/2 MIC dose of xanthorrhizol in combination with 1/2 MIC dose of ketoconazole or 1/2 MIC dose of amphotericin B exhibited growth inhibition of all Candida species tested and reduced viable cells by several logs within 4 h.	MEC01405
C34635	NEWCL10237; NEWCL10240	.	Achieving Therapeutic Synergy	Synergistic anticandidal activity of menthol in combination with itraconazole and nystatin against clinical Candida glabrata and Candida krusei isolates.	MEC01437
C45186	NEWCL10211	.	Achieving Therapeutic Synergy	The combined effects of asarones and drugs principally recorded substantial synergistic activity (fractional inhibitory concentration index (FICI) <0.5).	MEC01454
C62804	NEWCL10359; NEWCL00019	.	Achieving Therapeutic Synergy	The Clad+Gem+Bu+SAHA combination provides synergistic cytotoxicity in lymphoma cell lines.	MEC01473
C94002	NEWCL10212; NEWCL10213; NEWCL10292; NEWCL10291; NEWCL10255; NEWCL10286; NEWCL10298; NEWCL10214	.	Achieving Therapeutic Synergy	"1,4-naphthoquinone combined with ascorbate have significant antitumor effects against MCF-7 cells in vitro and Ehrlich-ascites carcinoma in mice."	MEC01477
C69668	NEWCL00346	.	Achieving Therapeutic Synergy	Oleanolic acid and combination displayed either a synergistic interaction or did not show any interaction against two drug-sensitive strains.	MEC01480
C87662	NEWCL10308	.	Achieving Therapeutic Synergy	Combinatorial therapy with a low concentration of oxacillin controlled different laboratory and highly diversified clinical MRSA strains.	MEC01482
C69464	NEWCL10308	.	Achieving Therapeutic Synergy	The natural compound pannarin might be a good candidate for the individualization of novel templates for the development of new antimicrobial agents or combinations of drugs for chemotherapy.	MEC01483
C98638	NEWCL10308; NEWCL10298	.	Achieving Therapeutic Synergy	"ApuL-oxacillin combination showed synergistic effect on the oxacillin-resistant isolates UFPEDA-670 and 671, which were not sensitive to lectin alone."	MEC01506
C12423	NEWCL10286	.	Achieving Therapeutic Synergy	Tea polyphenols used in combination with commonly used antibiotics showed synergistic bactericidal effect against multidrug-resistant Klebsiella pneumoniae.	MEC01575
C05210	.	.	Achieving Therapeutic Synergy	"Metformin/pioglitazone/exenatide in patients with newly diagnosed T2DM is more effective and results in fewer hypoglycaemic events than sequential add-on therapy with metformin, sulfonylurea and then basal insulin."	MEC00709
C95038	.	The study was carried out on 40 male Wistar rats (230-250 g).	Achieving Therapeutic Synergy	A mixture of mitochondrial substrates of succinic and malic acids more effectively than antihypoxant trimetazidine prevented functional and metabolic disorders in rat myocardium during acute ischemia.	MEC01451
C11135	.	"The mice were administered with AMO, PGS and AP respectively for 11 days, and intraperitoneally injected with 5-FU for 6 days since the 3rd day of the experiment."	Achieving Therapeutic Synergy	"Combination of AMO and PGS, not AMO or PGS alone, significantly ameliorated diarrhea, inhibited intestinal pathology, and modulated gut microbial structure in 5-FU induced mice."	MEC01508
C74113	.	"Male C57BL/6 mice between 8-10 weeks were injected with DMSO, 15 mg/kg doxorubicin, or doxorubicin plus 25 mg/kg visnagin or 10 mg/kg diphenylurea intraperitoneally (n=4-5 each)."	Decreasing Adverse Drug Reaction	"There are synergistic antioxidative effects among the antioxidants, SAMe and vitamins C and E, that protect the liver from TAA-induced HDIR, suggesting that antioxidant treatment may best be done using a balanced ""cocktail.""."	MEC00661
C88574	.	Retrospective observational survey study 	Achieving Therapeutic Synergy	"Combination therapy with cyclic rifaximin-Alpha and continuous arabinogalactan combined with lactoferrin are effective in SUDD treatment in terms of symptom resolution, bowel movement normalization, prevention of recurrences with very good patient's compliance."	MEC01586
C43330	.	"Male adult Sprague-Dawley rats, weighing 201 to 251 g were used in this study."	Achieving Therapeutic Synergy	Serotonin and dopamine produce dose-related cutaneous analgesic effects as an infiltrative anesthetic.	MEC01359
C15417	.	Male albino rats (150-200g) were used in this study.	Achieving Therapeutic Synergy	Addition of JAT as a supportive regimen to interferon and ribavirin effectively potentiates their anti-fibrotic effects.	MEC01609
C64666	.	"Forty-two female New Zealand white rabbits (5-6 weeks old), weighing between 1.2 and 1.8 kg were used in this study."	Achieving Therapeutic Synergy	"The combination of the AMC with gentamicin did not induce a synergistic effect, whereas the combination of the two antibiotics with 1,8-cineole did."	MEC01510
C51443	.	Clinical trial	Achieving Therapeutic Synergy	Triple immunosuppressive therapy significantly reduced proteinuria and preserved renal function in refractory NS patients.	MEC01587
C90798	.	.	Achieving Therapeutic Synergy	The combination of a purine analog with rituximab was safe and effective for patients with recurrent HCL.	MEC00675
C48702	.	.	Achieving Therapeutic Synergy	Trimetazidine and plasmin combined with alprostadil can effectively treat lower extremity arteriosclerosis obliterans.	MEC01504
C77475	NEWCL00231; NEWCL00134; NEWCL10283; NEWCL10284	.	Achieving Therapeutic Synergy	A synergistic effect of EPD and cisplatin in an ovarian drug resistant cell line as well as a synergistic effect of EPD and paclitaxel in two other ovarian cell lines.	MEC00762
C33437	NEWCL10343; NEWCL00073; NEWCL00129; NEWCL10383; NEWCL00155; NEWCL00052; NEWCL00146; NEWCL00252; NEWCL00253; NEWCL10200	.	Achieving Therapeutic Synergy	Supplementation of Selenium enhanced chemotherapeutic effect of Taxol and Doxorubicin in these cells beyond that seen with the chemotherapeutic drugs used alone.	MEC00763
C97676	NEWCL00022	.	Achieving Therapeutic Synergy	"Yomogin may be useful in combination with 1,25-(OH)(2) D(3) or all- trans-RA in the differentiation therapy for myeloid leukemias."	MEC00793
C25772	NEWCL10308	.	Achieving Therapeutic Synergy	Mupirocin and amoxicillin-clavulanate were synergistic against 9 of 49 (18%) strains of methicillin-resistant and methicillin-susceptible Staphylococcus aureus and coagulase-negative staphylococci (CNS).	MEC00797
C97041	NEWCL00049; NEWCL00155	.	Achieving Therapeutic Synergy	Germacrone enhanced furanodiene's anti-proliferative effect.	MEC00799
C90372	NEWCL00281; NEWCL00134	.	Achieving Therapeutic Synergy	Combination treatment showed a synergistic pro-apoptotic effect and synergistically induced G1/S phase cell cycle arrest.	MEC00836
C57631	NEWCL04171	.	Achieving Therapeutic Synergy	"Combination therapy with these agents may provide enhanced therapeutic response in breast cancer patients, while avoiding the toxicity associated with high-dose COX-2 inhibitor monotherapy."	MEC00951
C76406	NEWCL10282	.	Decreasing Adverse Drug Reaction	"Acteoside could protect the cells from X ray induced damage through enhancing the scavenging activity of ROS, decreasing the Bax/Bcl 2 ratio and downregulating the activity of procaspase 3, as well as modulating the mitogen activated protein kinase signaling pathways."	MEC01327
C70557	NEWCL10308; NEWCL10298; NEWCL10255; NEWCL10233	.	Achieving Therapeutic Synergy	"CHG may be combined with either crude EO or its major component 1,8-cineole for enhanced, synergistic antimicrobial activity against a wide range of microorganisms in planktonic and biofilm modes of growth."	MEC01511
C15478	NEWCL10217; NEWCL10218; NEWCL10219; NEWCL10220	.	Achieving Therapeutic Synergy	"Among chitosan-conjugated derivatives, Chitosan-caffeic acid showed the highest antibacterial activity and also exhibited the synergistic antibacterial effect in combination with tetracycline, erythromycin, and lincomycin against acne-related bacteria."	MEC01583
C26757	NEWCL10217; NEWCL10218; NEWCL10219; NEWCL10220	.	Achieving Therapeutic Synergy	"Among chitosan-conjugated derivatives, Chitosan-caffeic acid showed the highest antibacterial activity and also exhibited the synergistic antibacterial effect in combination with tetracycline, erythromycin, and lincomycin against acne-related bacteria."	MEC01584
C11345	NEWCL10217; NEWCL10218; NEWCL10219; NEWCL10220	.	Achieving Therapeutic Synergy	"Among chitosan-conjugated derivatives, Chitosan-caffeic acid showed the highest antibacterial activity and also exhibited the synergistic antibacterial effect in combination with tetracycline, erythromycin, and lincomycin against acne-related bacteria."	MEC01585
C69596	NEWCL10308; NEWCL10317	Forty-two female New Zealand white rabbits were used as animal model in this study.	Achieving Therapeutic Synergy	"1,8-cineole showed a synergistic effect in combination with both AMC and gentamicin, which offer possibilities for reducing antibiotic usage."	MEC00798
C47047	NEWCL10378; NEWCL10088	.	Achieving Therapeutic Synergy	TPF regimen combining cinobufotalin suppressed proliferation and promoted apoptosis synergistically in hypopharyngeal squamous cell carcinoma and laryngeal squamous cell carcinoma cells.	MEC00764
C00006	.	.	.	.	MEC01612
C00010	NEWCL00023	.	Achieving Therapeutic Synergy	"Study concluded that the mRNA expression level of PTEN had a remarkable reduction in AML patients. 
In our research, PTEN was overexpressed by SAL/HESP compared to the other two treatment groups. PTEN stimulates PIP3 dephosphorylation, resulting in the inactivation of the PI3K-AKT signaling."	MEC01613
C00028	NEWCL20325;NEWCL20344;NEWCL00189;NEWCL00344	.	Decreasing Adverse Drug Reaction	"Rh2 markedly improved the anti-cancer effect of anti-PD-L1 antibody by increasing the CXCL10 expression in the TME, and subsequently promoting the CD8+ T cells infiltration and activation."	MEC01614
C00032	NEWCL20345;NEWCL00252	.	Achieving Therapeutic Synergy	"KDM4A is overexpressed in PCa tumors, particularly in metastatic tumors."	MEC01615
C00036	NEWCL00348;NEWCL20346;NEWCL20347;NEWCL00089;NEWCL00086;NEWCL20348;NEWCL10412	.	Achieving Therapeutic Synergy	The BET inhibitory activity and selective cFLIP reduction in cancer cells.	MEC01616
C00039	NEWCL10181;NEWCL00172	.	Reversing Drug Resistance	Apoptosis likely through Bim elevation and Mcl-1 reduction	MEC01617
C00059	NEWCL00344;NEWCL10146;NEWCL00353;NEWCL20328;NEWCL00074;NEWCL00082	.	Augmenting Drug Sensitivity	pEGFR was nearly completely suppressed in both HCT116 and LoVo cells	MEC01618
C00068	NEWCL00157;NEWCL00240	.	Reversing Drug Resistance	PARP1 inhibition and antiproliferative activity of the representative analogues.	MEC01619
C00074	NEWCL10249;NEWCL00170;NEWCL20329;NEWCL20330	.	Reversing Drug Resistance	"Nobiletin promotes apoptosis of human bladder cancer cells by activating the proapoptotic proteins caspase-3, caspase-9, BAD and BAX"	MEC01620
C00113	NEWCL00225	.	Achieving Therapeutic Synergy	Higher doses would inhibit the activation of Mcl-1 leading to apoptosis.	MEC01621
C00119	NEWCL10127	.	Reversing Drug Resistance	Revealed the high PPP1CA expression in tumour tissues of PCa patients 	MEC01622
C00125	NEWCL00082	.	Augmenting Drug Sensitivity	Prunus sp. plus NAC complex is able to sensitize CRC to 5-FU by significantly reducing chemotherapy-induced survival autophagy	MEC01623
C00210	.	 albino mice	Reversing Drug Resistance	Mild expression of TLR4	MEC01624
C00234	.	.	Augmenting Drug Sensitivity	.	MEC01625
C00256	.	.	Augmenting Drug Sensitivity	Blt displaying 4500-fold increase	MEC01626
C00267	NEWCL00178;NEWCL00199	.	Achieving Therapeutic Synergy	"The protein expression of c-FLIP was higher in 344SQ, H23, and H358."	MEC01627
C04523	NEWCL00349;NEWCL00047	.	Achieving Therapeutic Synergy	.	MEC01628
C00289	NEWCL00077;NEWCL00353;NEWCL00074;NEWCL10080;NEWCL00082	MC38	Augmenting Drug Sensitivity	.	MEC01629
C00290	NEWCL10086;NEWCL00352	.	Achieving Therapeutic Synergy	"HGC-27 cells result in G2/M phase arrest, which is mainly in the G2 phase rather than the mitotic phase."	MEC01630
C00295	NEWCL20340;NEWCL20341;NEWCL20342	.	Reversing Drug Resistance	KEGG pathway analysis was performed to identify pathways enriched in DEGs.	MEC01631
C00299	NEWCL00170;NEWCL20343	.	Achieving Therapeutic Synergy	Bax mRNA expression was significantly higher.	MEC01632
C00310	NEWCL00129	.	Achieving Therapeutic Synergy	Reducing the expression of p62.	MEC01633
C00321	.	.	Achieving Therapeutic Synergy	Inhibits the COX-2 and COX-3	MEC01634
C00328	NEWCL00047	.	Achieving Therapeutic Synergy	Increasing expression of nuclear FLNA (90 kda) proteins and enhanced tumor-suppressive effect after curcumin administration	MEC01635
C00345	.	Rodent C6 Intracranial Tumor Transplantation Model	Achieving Therapeutic Synergy	 The Combination of Borneol and Radiotherapy Inhibited Glioma Growth by Inducing Autophagy.Borneol Sensitized Glioma Cells to Radiation by Targeting the mTORC1/eIF4E/HIF-1a Pathway	MEC01636
C00367	NEWCL00129	.	Achieving Therapeutic Synergy	"The combination of PGG and 5-FU had Synergistic effects on reversal the aggressive phenotypes of HepG2 cells, increasing the proportion of Bax/Bcl-2, promoting the activation of caspase-9 and caspase-3, and inducing apoptosis."	MEC01637
C00388	.	.	Achieving Therapeutic Synergy	"GA possessed antibacterial activity against enterococci, including VRE strains, and restored the activity of vancomycin against VRE in vitro and in vivo."	MEC01638
C00397	NEWCL00203	.	Achieving Therapeutic Synergy	"The silibinin and capsaicin combination could effectively inhibit LPS- induced over the production of NO, TNF-alpha, IL-6, and COX-2. Their effective anti-inflammatory effect was related with the inhibiton of NF-kappaB and MAPK activities."	MEC01639
C00400	NEWCL00129;NEWCL00031	.	Achieving Therapeutic Synergy	"DG signifcantly enhances DOX and Vola cytotoxicity, potentiates downregulation of PLK1 mRNA 
expression, potentiates downregulation of PCNA 
and upregulation of p53, caspase 3, and PARP1 
mRNA expression induced by DOX and Vola, increases active caspase 3 concentration caused 
by DOX and Vola in HepG2 and Huh 7 cells.Downregulation of PLK1 induced by DG alone 
or in combination with DOX and Vola correlates 
with apoptosis induction and consequent cell death"	MEC01640
C00456	NEWCL20349;NEWCL00231	.	Achieving Therapeutic Synergy	The results showed that 0.1 mg/ml or 0.5 mg/ml (data not shown) of ASP combined with paclitaxel (0.1-5 nM) caused a synergistic cytotoxic effect (CI<1) in both cell lines	MEC01641
C00457	NEWCL00149	.	Achieving Therapeutic Synergy	"magnolol can induce autophagy/mitophagy and apoptosis, whereas blockage of autophagy/mitophagy remarkably enhances the anticancer efficacy of magnolol, suggesting that targeting mitophagy may be a promising strategy to overcome chemoresistance and improve anticancer therapy."	MEC01642
C00466	.	.	Achieving Therapeutic Synergy	The combination of sub-MIC levels of CEL and vancomycin showed a synergistic effect in a time-kill assay and exhibited significant protective efficacy in Galleria mellonella larval infection model compared with either drug used alone.CEL exhibits a significant antibacterial and synergic activity against VRE in vitro and in vivo and has the potential to be a new antibacterial agent or adjuvant to vancomycin as a therapeutic option in com- bating VRE.	MEC01643
C00489	NEWCL10112	.	Achieving Therapeutic Synergy	"When combined with the DNMT inhibitor decitabine, TSC exhibits a synergistic anti-cancer effect. Additionally, protein analysis elucidates a significant reduction in the expression of the tyrosine kinase receptor Axl. Notably, elevated concentrations of TSC correlate with the up-regulation of the transcription factor forkhead box class O1 (FoxO1) and increased levels of the proapoptotic proteins Bim and p21."	MEC01644
C00499	NEWCL00155;NEWCL00049	.	Achieving Therapeutic Synergy	"The qRT-PCR results showed significant (p < 0.05) downregulation in the expression of VEGF and Bcl2 genes, and upregulation in the expression of Bax"	MEC01645
C00523	.	.	Achieving Therapeutic Synergy	"cedrol focuses on inhibiting 5alpha-reductase and activating Shh/Gli pathway, and minoxidil, which up-regulated VEGF, down-regulated TGF-beta, and activated ERK/AKT pathway. This drug combination provides a new therapeutic strategy for androgenetic alopecia"	MEC01646
C00566	NEWCL00129	.	Achieving Therapeutic Synergy	"co-treatment with RES and FGF1 significantly inhibited DOX-induced hepatic inflammation and apoptosis, but also that co-treatment with RES and FGF1 markedly suppressed DOX-induced hepatic oxidative stress, via targeting the AMPK/ NRF2 pathway and subsequently ameliorating hepatic dysfunction."	MEC01647
C00578	.	Wistar rats	Achieving Therapeutic Synergy	.	MEC01648
C00587	NEWCL00226;NEWCL00228	.	Achieving Therapeutic Synergy	"PL sensitized the MG-63, 143B and KHOS/NP cells and improved the efficacy of DOX."	MEC01649
C00590	NEWCL00059;NEWCL10125	.	Achieving Therapeutic Synergy	"The combination of Rapamycin and Niacin synergistically decreased cell viability of AML cell lines. The combination treatment induced the apoptotic cell population of THP-1 and NB4 by 4.9-fold and 7.3-fold, respectively. In THP-1 cells, the cell cycle was arrested at the G2/M phase by 10% whereas the NB4 cells were accumulated at the G0/G1 phase. The combination treat_x0002_ment decreased Akt and p-Akt expression. Besides, the ATG7 expression was reduced by combination treatment on THP-1 cells. Similarly, the ATG5 level was downregulated in NB4 cells. The level of LC3B-II/LC3B-I, which is an indicator of autophagy flux, was upregulated in THP-1 and NB4 cells."	MEC01650
C00610	NEWCL20325	humanized PD-1 knock-in mice and genetically modified C57BL/6J mice express- ing the human full-length PD-1 protein	Achieving Therapeutic Synergy	"RCE plus oxaliplatin apparently activates hPD-1 tumor-infiltrating CD8+ T cells, resulting in elevations of released interleukin-2 (IL-2) and granzyme B (GrB), and kills hPD-L1 MC38 CRC cells. RCE plus oxaliplatin considerably reduced tumor growth in humanized PD-1/PD-L1-expressing mouse MC38 CRC allograft. Moreover, RCE plus oxaliplatin remarkably increased the infiltration of CD8+ T cells in tumor tissues, as well as increasingly produced GrB of tumor-infiltrating CD8+ T cells in the tumor microenvironment."	MEC01651
C00623	NEWCL00200;NEWCL00171	.	Achieving Therapeutic Synergy	"Experi- mental validation demonstrated that combining PR with erlotinib and gefitinib enhanced drug responsiveness by inhibiting Aurora kinase activity and inducing apoptosis in LUAD cells. Additionally, gene expression changes confirmed these combined effects, with the suppression of the Aurora B pathway and upregulation of the apoptotic pathway, which was accompanied by increased expression of multiple pro-apoptotic genes."	MEC01652
C00626	NEWCL00200;NEWCL00171	.	Achieving Therapeutic Synergy	"Experi- mental validation demonstrated that combining PR with erlotinib and gefitinib enhanced drug responsiveness by inhibiting Aurora kinase activity and inducing apoptosis in LUAD cells. Additionally, gene expression changes confirmed these combined effects, with the suppression of the Aurora B pathway and upregulation of the apoptotic pathway, which was accompanied by increased expression of multiple pro-apoptotic genes."	MEC01653
C00644	NEWCL00030;NEWCL00169	HCC-LM3 xenograft model	Achieving Therapeutic Synergy	Osthole inhibits GSK-3beta/AMPK/mTOR pathway-controlled glycolysis and increases radiosensitivity of subcutaneous transplanted hepatocellular carcinoma in nude mice	MEC01654
C00658	.	"LLC, B16F10 cells xenograft model"	Reversing Drug Resistance	RocA promoted the infiltration and differentiation of CD4+ TILs and coordinated with anti-PD-1 antibody to overcome checkpoint resistance in multiple tumor models.	MEC01655
C00689	.	mcr-1-negative strains	Reversing Drug Resistance	"Apigenin effectively enhanced the antimicrobial activity of colistin against multidrug-resistant Enterobacteriaceae, including mcr-1-positive strains, in vitro and in vivo."	MEC01656
C00800	.	.	Achieving Therapeutic Synergy	Bevacizumab and SHP-60 combination has a significant synergistic effect in inhibiting tumor angiogenesis compared to Bevacizumab alone. 	MEC01657
C00900	.	.	Achieving Therapeutic Synergy	Combination of 6-gingerol and colistin exhibits Synergistic effects against colistin-resistant MDR-KP isolates	MEC01658
C00921	NEWCL00131;NEWCL00031;NEWCL00129	H22 xenograft model	Achieving Therapeutic Synergy	"Sal exerted a dual blockade on the M phase and the G1/S transition in HCC cells, thereby inducing a permanent cell cycle arrest. This mechanism may have been instrumental in significantly amplifying the anticancer sensitivity of 5-FU in HCC."	MEC01659
C00926	.	.	Achieving Therapeutic Synergy	"Herein, a metal-coordinated carrier-free nanodrug (named as USFe3+ LA NPs) was developed for ferroptosis-mediated multimodal synergistic anti-HCC. Natural product ursolic acid (UA) was incorporated to enhance the sensitivity of tumor cells to sorafenib (SRF)"	MEC01660
C00928	NEWCL00245;NEWCL10124;NEWCL00278	NCI-H929/H929-BR cells xenograft model	Achieving Therapeutic Synergy	"In vivo, JA also demonstrated a strong anti-tumor effect with no observable toxicity. In addition, JA showed synergetic effects in combination with bortezomib, and enhanced the anti-tumor effect of bortezomib in bortezomib-resistant cells."	MEC01661
C00929	NEWCL00074;NEWCL00077	"SW480/NC, SW480/NNMT xenograft model"	Achieving Therapeutic Synergy	vanillin targets NNMT and attenuates NNMT-related resistance to 5-Fu	MEC01662
C00945	NEWCL20336;NEWCL00129	"HepG2, Hep3B  xenograft model"	Achieving Therapeutic Synergy	"PD suppressed the activity of acid sphingomyelinase, PD-enhanced lysosomal membrane permeabilization to release sorafenib, augmenting the anticancer effect of sorafenib both in vivo and in vitro. "	MEC01663
C00948	NEWCL00170	B16F10 implantation	Achieving Therapeutic Synergy	"Compared with single drugs, the co - delivery system of curcumin combined with SN38 prodrug exhibited better anti - proliferative and cell - cycle arrest effects in A549 cells."	MEC01664
C00949	NEWCL00078;NEWCL00074	.	Achieving Therapeutic Synergy	Corilagin enhanced the efficacy of 5-FU targeting human CRC by promoting the regulatory effects of 5-FU on GRP 78 protein expression.	MEC01665
C01000	.	.	Achieving Therapeutic Synergy	Gigantol is a potential colistin adjuvant that can be used in combination with colistin to combat infections caused by multi - drug - resistant Gram - negative pathogens.	MEC01666
C01009	NEWCL00230;NEWCL00080	.	Reversing Drug Resistance	treatment with VOA plus PTX inhibits growth and induces apoptosis in ovarian resistant cancer cells through inhibition of NF-kB nuclear translocation. 	MEC01667
C01005	NEWCL10387;NEWCL00149;NEWCL00129;NEWCL00031	"RMA-S (MHC-I-deficient tumor cell), B16F10, and CT26 (MHC-I-sufficient) tumor models"	Achieving Therapeutic Synergy	"PL induces misfolded proteins, impedes autophagy, increases ROS and tumor conjugation with NK cells. Furthermore, PL enhances the expression of NK cell-activating receptors on NK cells and its ligands on tumor cells, possibly leading to increased susceptibility to NK cell killing. "	MEC01668
C01003	NEWCL10127	.	Achieving Therapeutic Synergy	Silencing PPP1CA increased cell sensitivity to abiraterone while promoting apoptosis and inhibiting clone formation. Overexpressing PPP1CA exerted the opposite effects.	MEC01669
C01011	NEWCL20339	.	Achieving Therapeutic Synergy	"Vitexin can enhance the radiosensitivity of glioma by reducing the expression of miR-17-5p and miR-130b-3p, increasing the expression of PTEN, and thereby inhibiting the expression of HIF-1alpha."	MEC01670
C01012	NEWCL00170	.	Achieving Therapeutic Synergy	"Fascaplysin induced both ferroptosis and apoptosis in lung cancer cells for the first time. Furthermore, it promoted the expression of PD-L1 in NSCLC cells and enhanced the anticancer effect of PD-1 immune checkpoint inhibitors."	MEC01671
C01014	NEWCL00242	.	Achieving Therapeutic Synergy	the effects of fraxetin on the sensitivity of PCCs to the chemotherapy drug gemcitabine were activated	MEC01672
C48730	NEWCL00082;NEWCL00077	.	Achieving Therapeutic Synergy	"significantly decreased PARP, and significantly increased cleaved caspase-9/caspase-9 and cleaved-PARP/PARP protein expression levels following treatment with the combination of 15 uM UA + 1.5 uM DOX compared with the single treatments in HCT116 and HT-29 cells"	MEC01673
C01016	"NEWCL10369,NEWCL20338"	.	Augmenting Drug Sensitivity	Erianin erianin inhibits the malignant phenotype of GSCs and increases the sensitivity of TMZ in TMZ-resistant GSCs by inducing ferroptosis.	MEC01674
C01019	NEWCL00170;NEWCL00180;NEWCL00181	.	Achieving Therapeutic Synergy	"TIIA could increase the susceptibility of NSCLC cells to NK cell-mediated lysis by up-regulating ULBP1 and DR5,"	MEC01675
C02522	NEWCL00327	.	Reversing Drug Resistance	"Dauricine reverses drug resistance by activating the STK11/AMPK signaling pathway, upregulating the expression of STK11, inhibiting the growth and metabolism of tumor cells, and downregulating the expression of Nrf2 and Pgp."	MEC01676
C02525	NEWCL00215;NEWCL20337	AD model mice	Augmenting Drug Sensitivity	"Mat synergistically enhanced the ability of HS72, an catalytic anti-oligomeric Abeta42 scFv antibody, to degrade Abeta42 aggregates and protect neural cells by increasing HS72's turnover number (or molecular activity). The combination of scFv HS72 with Mat reduced or removed Abeta42 aggregates or plaques more effectively than HS72 alone, which will increase scFv HS72's potency in AD immunotherapy."	MEC01677
C02526	NEWCL00049	JC cells xenograft	Reversing Drug Resistance	"Glabratephrin (Glab), a prenylated flavonoid from Tephrosia purpurea with a unique chemical structure, increased doxorubicin accumulation and cytotoxicity in triple negative breast cancer cells with high levels of Pgp, characterized by both acquired or intrinsic resistance to doxorubicin. Glab also reduced the growth of Pgp-expressing tumors, without adding significant extra-toxicities to doxorubicin treatment. Interestingly, Glab did not change the expression of Pgp, but it reduced the affinity for Pgp and the efflux of doxorubicin, as suggested by the increased Km and the reduced Vmax. In silico molecular docking predicted that Glab binds two residues (phenylalanine 322, glutamine 721) localized in the transmembrane domains of Pgp, facing the extracellular environment. Moreover, site-directed mutagenesis identified glycine 185 as a critical residue mediating the reduced catalytic efficacy of Pgp elicited by Glab. We propose Glab as an effective and safe compound able to reverse doxorubicin resistance mediated by Pgp in triple negative breast cancers, opening the way to a new combinatorial approach that may improve chemotherapy efficacy in the most refractory and aggressive breast cancer."	MEC01678
C02528	NEWCL10162	KBM5 or KBM5-T315I cells xenograft	Reversing Drug Resistance	PL effectively reduces viability and triggers apoptosis in IM-sensitive- and -resistant CML cells. We have shown that PL is a novel proteasome inhibitor through inhibition of 20S proteasome and 19S proteasomal deubiquitinase in CML cells. 	MEC01679
C25294	NEWCL00353;NEWCL00074	RKO or SW480 cells xenograft model	Augmenting Drug Sensitivity	"(1) Luteolin inhibits the proliferation and invasion of RKO and SW480 cells, thereby promoting G2/M phase arrest and COAD cell apoptosis. (2) The pharmacological mechanism of luteolin in the treatment of COAD involves targeting GPSM2 and mediating the FOXO signaling pathway. (3) In vivo experiments once again validated our findings in vitro and also demonstrated the synergistic effect of traditional medicine with chemotherapy drugs."	MEC01680
C95252	NEWCL00076	.	Reversing Drug Resistance	"Cur reversed P-gp-mediated MDR inSW620/Ad300 cells by regulating metabolic change. Cur reduced intracellular GSH and ATP levels by inhibiting polyamine biosynthesis and D-glutamine metabolism, thereby inhibiting the anti-oxidative stress ability of SW620/Ad300 cells and P-gp-mediated drug efflux (Fig. 5). This study provides a rational for the clinical application of Cur and Dox to reverse P-gp-mediated MDR in cancer. "	MEC01681
C95253	NEWCL10352;NEWCL00116	SNU668 cells xenograft	Achieving Therapeutic Synergy	"CAFs enhanced resistance to chemotherapy in GC through the activation of the JAK2/STAT3 signaling pathway. Curcumin, a natural product derived from turmeric, effectively reduced CAF-induced STAT3 activation in GC cells and subsequently enhanced the effects of chemotherapy in GC models. The combination of curcumin and conventional chemotherapy may thus be a promising strategy with which to overcome resistance to chemotherapy in GC with profuse fibroblasts."	MEC01682
C02530	NEWCL00037;NEWCL00039;NEWCL00279	U118MG cells xenograft	Achieving Therapeutic Synergy	MCL can selectively bind to the noncatalytic C247 residue of GAPDH. MCL can facilitate GBM cell death by initiating non-glycolysis-related functions of GAPDH. GAPDH is overexpressed in GBM and represents an attractive target for GBM therapy. The combination of DMAMCL with TMZ significantly increases antitumour efficacy by promoting DNA damage.	MEC01683
C02532	NEWCL00031	Huh7R cells xenograft	Reversing Drug Resistance	"Quercetin significantly impeded proliferation and stimulated apoptosis in Huh7R cells, while also suppressing the growth of transplanted tumors. The impact of QUE enhanced the efficacy of SOR treatment for Huh7R. Additionally, bioinformatic and western blot analyses indicated that the underlying mechanisms may be associated with EGFR tyrosine kinase inhibitor resistance, the PI3K-AKT signaling pathway, and HCC. Furthermore, molecular docking and dynamics simulation assays revealed that QUE exhibited strong affinity and stability towards its hub targets, EGFR and AKT1. It is noteworthy that the activation of EGFR by its ligand, EGF, mitigated the effects of co-treatment with QUE and SOR."	MEC01684
C02630	NEWCL00129;NEWCL00181;NEWCL00155;NEWCL00170;NEWCL00149;NEWCL00252;NEWCL20336	.	Achieving Therapeutic Synergy	"Curcumin induced a significant G1 arrest in PC-3, which may be mediated by the induction of p21(WAF1/CIP1) and C/EBPbeta. Curcumin was able to inhibit both the constitutional and TNF-alpha-induced NF-kappaB activation in a time-dependent manner."	MEC01685
C02632	NEWCL00170;NEWCL00345;NEWCL00172;NEWCL10181	.	Augmenting Drug Sensitivity	"Combination treatment with MA and osimertinib improved the sensitivity of lung cancer cells to EGFR-TKIs through ROS suppression of the KRAS-ERK signaling pathway, as well as NRF2-SLC7A11 axis inhibition- and mitochondrial Ca2+ overload-triggered ferroptosis. "	MEC01686
C02634	NEWCL20331;NEWCL00173;NEWCL00181;NEWCL00176;NEWCL00200;NEWCL00200;NEWCL00171;NEWCL00180;NEWCL20334	SNU-C5RR cells xenograft	Augmenting Drug Sensitivity	"Cisplatin-resistant PDOs together with lung cancer cell lines to confirm the anti-cancer biology behavior of Solamargine, such as growth inhibition, G1/G0 phase arrest and apoptosis induction. Moreover, we unveiled Solamargine exhibited lung cancer suppression by targeting SMO in the hedgehog signaling pathway. Although further investigations should be done to verify whether SMO is the key target in lung cancer, our data is of great value forpromising combination therapy and would provide a possible solution for the improvement of individualized therapeutic and prognosis of lung cancer in the coming days."	MEC01687
C02635	NEWCL00230;NEWCL00231	OC cells xenograft	Achieving Therapeutic Synergy	ASII enhanced the sensitivity of DDP-resistant OC cells to DDP by suppressing growth and inducing apoptosis. It suggests that ASII may be a promising drug for the treatment of DDP resistance in OC.	MEC01688
C02638	NEWCL00251	.	Augmenting Drug Sensitivity	"Specifically, drug treatment significantly reduced the expression levels of GPX4 and SLC7A11 in cells while increased the expression of ACSL4"	MEC01689
C03001	NEWCL20457	.	Achieving Therapeutic Synergy	"Protocatechuic acid,?epicatechin, and?rutin?were identified in both extracts. They exhibited fungistatic activity with a median minimum inhibitory concentration (MIC50) of 15.62??g/mL for the?ethanolic extract?(EEB) and 62.50??g/mL for the aqueous extract (AEB) against?C. albicans. In growth kinetics, both extracts reduced the?viable cell count?of?C. albicans?by 2 logs after 24?h compared to the positive control. The extracts reduced germ tube formation by 81.6?% for EEB and 86.3?% for AEB. The synergistic combination with?fluconazole?and?nystatin?resulted in a 50?% reduction in the concentration required to inhibit?C. albicans?growth. No?hemolytic activity?was detected in human erythrocytes at the tested concentrations."	MEC01690
C03002	NEWCL20457	.	Achieving Therapeutic Synergy	"Protocatechuic acid,?epicatechin, and?rutin?were identified in both extracts. They exhibited fungistatic activity with a median minimum inhibitory concentration (MIC50) of 15.62??g/mL for the?ethanolic extract?(EEB) and 62.50??g/mL for the aqueous extract (AEB) against?C. albicans. In growth kinetics, both extracts reduced the?viable cell count?of?C. albicans?by 2 logs after 24?h compared to the positive control. The extracts reduced germ tube formation by 81.6?% for EEB and 86.3?% for AEB. The synergistic combination with?fluconazole?and?nystatin?resulted in a 50?% reduction in the concentration required to inhibit?C. albicans?growth. No?hemolytic activity?was detected in human erythrocytes at the tested concentrations."	MEC01691
C03003	NEWCL20457	.	Achieving Therapeutic Synergy	"Protocatechuic acid,?epicatechin, and?rutin?were identified in both extracts. They exhibited fungistatic activity with a median minimum inhibitory concentration (MIC50) of 15.62??g/mL for the?ethanolic extract?(EEB) and 62.50??g/mL for the aqueous extract (AEB) against?C. albicans. In growth kinetics, both extracts reduced the?viable cell count?of?C. albicans?by 2 logs after 24?h compared to the positive control. The extracts reduced germ tube formation by 81.6?% for EEB and 86.3?% for AEB. The synergistic combination with?fluconazole?and?nystatin?resulted in a 50?% reduction in the concentration required to inhibit?C. albicans?growth. No?hemolytic activity?was detected in human erythrocytes at the tested concentrations."	MEC01692
C03004	NEWCL20457	.	Achieving Therapeutic Synergy	"Protocatechuic acid,?epicatechin, and?rutin?were identified in both extracts. They exhibited fungistatic activity with a median minimum inhibitory concentration (MIC50) of 15.62??g/mL for the?ethanolic extract?(EEB) and 62.50??g/mL for the aqueous extract (AEB) against?C. albicans. In growth kinetics, both extracts reduced the?viable cell count?of?C. albicans?by 2 logs after 24?h compared to the positive control. The extracts reduced germ tube formation by 81.6?% for EEB and 86.3?% for AEB. The synergistic combination with?fluconazole?and?nystatin?resulted in a 50?% reduction in the concentration required to inhibit?C. albicans?growth. No?hemolytic activity?was detected in human erythrocytes at the tested concentrations."	MEC01693
C03005	.	.	Achieving Therapeutic Synergy	"the combination may serve as potential preservatives when used at concentrations that do not cause side effects in humans, contributing to a reduction in food losses."	MEC01694
C03006	NEWCL20413;NEWCL10120	.	Achieving Therapeutic Synergy	"Our findings report the presence of six bioactive compounds derived from the methanol extract of?C. hirsutus. In addition, the plant was found to play an important antioxidant role, exhibiting a rich phytochemical content and significant antioxidant enzyme activity. Further,?in silico?experiments revealed that the molecules 4-methyl-2-pentadecyl-1,3-dioxolane and laminitol demonstrated strong binding affinity to the retinoblastoma (Rb) tumor suppressor, indicating promising beneficial potential biological activity and strengthening the need for further research to explore the direct applications of these chemicals in medicinal chemistry.?"	MEC01695
C03007	.	.	Achieving Therapeutic Synergy	"PTP1B has been highlighted to be a promising indicator for evaluating therapeutic agents against IR and T2DM. The extracts used were effective in inhibiting PTP1B, increasing glucose uptake, as well as possessing antioxidant characteristics. In this study, it was observed that the antidiabetic and antioxidative efficacy increased in a dose-dependent manner. On comparing the phytochemicals obtained in GC-MS results with previous literature, it was observed that the presence of antidiabetic and antioxidative phytochemicals might be responsible for imparting the beneficiary properties."	MEC01696
C03008	.	antibiotic-resistant?S. aureus?strains	Achieving Therapeutic Synergy	The results of the present study suggest that some acetylenic spiroketal enol ethers of?A. rupestris?may be candidates for natural resistance-modifying agents and this is the first time that these two acetylenic spiroketal enol ethers were tested and reported to show synergistic activity against MRSA.	MEC01697
C03009	.	70 patients with autoimmune thyroiditis	Achieving Therapeutic Synergy	"In conclusion, Bailing capsule combined with the levothyroxine sodium are effective and safe in the treatment of autoimmune thyroiditis, with good control of disease progression, improvement of thyroid function, reduction of thyroid function-related antibody levels, and inhibition of inflammation even though large controlled randomized clinical trials are necessary to confirm the outcomes."	MEC01698
C03010	.	rats	Decreasing Adverse Drug Reaction	"In conclusion, the above data indicated that the combined extract dose had beneficial renoprotective effects against CIS-induced nephrotoxicity. Its action may involve by suppressing TNF-alpha, KIM-1, and caspase-3 levels."	MEC01699
C03011	.	swiss mice	Achieving Therapeutic Synergy	"Based on this study, it can be concluded that the CCL19 levels of Swiss mice with PbA infection in the effective treatment group increased with the AM-ACT combination. Although it still requires further research, this study shows that the water extract of Annona muricata leaves increases chemokines which have the function of helping naive T cell migration to improve the immune system. While Annona muricata leaf water extract shows promise as a potential source of new antimalarial drugs, more research is needed to understand its mechanisms of action and potential side effects. Additionally, any new antimalarial drugs derived from Annona muricata leaf water extract would need to be rigorously tested in clinical trials to ensure their safety and efficacy."	MEC01700
C03030	.	.	Achieving Therapeutic Synergy	"In conclusion, the treatment of CHF combined with atrial fibrillation with neuvosin + sacubitril valsartan can more effectively improve cardiac function and reduce the condition of atrial fibrillation, which is worthy of clinical promotion and application."	MEC01701
C03031	NEWCL00149	.	Achieving Therapeutic Synergy	"This study showed that a combination of turmeric and black rice bran exhibits greater cytotoxic activity than the individual extracts, promising an alternative anticancer treatment, particularly for cervical cancer."	MEC01702
C03032	NEWCL10012	.	Achieving Therapeutic Synergy	"The results showed that compared with control group, the concentrations of HBeAg and HBsAg in Chinese Yam polysaccharide group, entecavir group and combination group decreased(P&lt;0.01 or P&lt;0.001), and both of them inhibited HBV-DNA in HepG2.2.15 cells(P&lt;0.01), and the HBV-DNA inhibition of HepG2.2.15 cells in the combination group was more obvious(P&lt;0.001), and the protein expression levels of p-p38 MAPK and NTCP were significantly decreased(P&lt;0.05 or P&lt;0.01), the mRNA expression level of p38 MAPK increased, and the mRNA expression level of NTCP decreased(P&lt;0.05 or P&lt;0.01). To sum up, Chinese Yam polysaccharide can reduce the expression of NTCP protein and mRNA through p38 MAPK signaling pathway and cooperate with entecavir in anti-HBV."	MEC01703
C03033	.	male albino rats	Achieving Therapeutic Synergy	Our results suggested that combination of two medicinal plants showed synergistic anti ulcer activity and decreased the formation of ulcer lesions in rats.	MEC01704
C03034	NEWCL20458	.	Achieving Therapeutic Synergy	The combination significantly enhanced the efflux pump inhibition effect compared to the extract or tetracycline alone (p<0.05 for both). These findings support the potential use of polyphenol-rich?P. emblica?extracts as adjuncts to conventional antibiotics in treating drug-resistant bacterial infections.	MEC01705
C03035	NEWCL00155	.	Achieving Therapeutic Synergy	"In conclusion, the ethanolic extract of WS demonstrated a synergistic effect as an adjuvant with DOX, showing promise as a combination therapy for breast cancer."	MEC01706
C03036	.	.	Achieving Therapeutic Synergy	"The combination of?Solanum torvum?ethanol extract with doxycycline displayed Synergistic effects against biofilm formation inhibition and eradication in all tested?Bacillus?strains. Taken together,?Solanum torvum?ethanol extract shows promise for developing new combination antibacterial therapies."	MEC01707
C03037	NEWCL00082;NEWCL00080	.	Achieving Therapeutic Synergy	HMB is shown to enhance the sensitivity of CRC cells to anti-PD-1 immunotherapy in vivo. Mechanistic studies reveal that the HMB combination exerts its synergistic anticancer effects and enhances anti-PD-1 immunotherapy by inducing GSDME-dependent pyroptosis.	MEC01708
C03050	NEWCL00129	.	Achieving Therapeutic Synergy	"In this study, a nano self-assembled polysaccharide isolated from VBRB was shown to synergistically enhance the anti-HCC effects of low-dose MTX both in vitro?and?in vivo. The mechanism underlying this enhancement involved the downregulation of BCRP and MRP2, leading to increased MTX accumulation in the tumour. Comprehensive analysis of the structure and combined effects of VRP3-4 indicates its great potential for targeted?drug therapy?in HCC chemotherapy."	MEC01709
C03051	.	male Sprague-Dawley rats	Achieving Therapeutic Synergy	"Mechanistically, metabolomics revealed that the medium-dose combination group exerts anti-hyperuricemia activity by positively regulating?selenium compound?metabolic pathways, which are closely related to the recovery of renal damage. Transcriptomics showed that ISO-induced myocardial infarction is closely associated with the overexpression of the myocardial contraction pathway. While TG alone has no regulatory effect on myocardial contraction, and SAL alone only has a minor adjustment effect on this pathway, the combination of both drugs significantly inhibited the myocardial contraction pathway. This highlights the synergistic advantage of the combined therapy."	MEC01710
C03052	NEWCL20459	.	Achieving Therapeutic Synergy	"GUT E and OBL B displayed a potent antibacterial action, while SRPE and BRF were not efficient. GUT E demonstrated a synergistic action with antimicrobials against MRSA. BRP28, BRP29 and GUT E inhibited biofilm formation and enhanced the bactericidal activity of suppressed macrophages. Molecular docking suggested that GUT E has a versatile interaction with PBP2a, exhibiting a highly favorable estimated free energy of binding both to the active and allosteric sites."	MEC01711
C03053	NEWCL20459	.	Achieving Therapeutic Synergy	"GUT E and OBL B displayed a potent antibacterial action, while SRPE and BRF were not efficient. GUT E demonstrated a synergistic action with antimicrobials against MRSA. BRP28, BRP29 and GUT E inhibited biofilm formation and enhanced the bactericidal activity of suppressed macrophages. Molecular docking suggested that GUT E has a versatile interaction with PBP2a, exhibiting a highly favorable estimated free energy of binding both to the active and allosteric sites."	MEC01712
C03054	NEWCL00037;NEWCL00039;NEWCL00279	.	Achieving Therapeutic Synergy	"In conclusion, our work is the first to demonstrate that MCL can selectively bind to the noncatalytic C247 residue of GAPDH. MCL can facilitate GBM cell death by initiating non-glycolysis-related functions of GAPDH. GAPDH is overexpressed in GBM and represents an attractive target for GBM therapy. The combination of DMAMCL with TMZ significantly increases antitumour efficacy by promoting DNA damage. As DMAMCL is currently in clinical trials, this study provides additional evidence for its clinical application and further study of DMAMCL-based combination treatments."	MEC01713
C03055	NEWCL00082;NEWCL00076	.	Achieving Therapeutic Synergy	"CPT-11 inhibited the growth of colorectal cancer cells in a dose-dependent manner, and OXY combined treatment had additive effects. Mice in the CPT-11 group experienced significant weight loss and severe diarrhea, while the co-administration of OXY alleviated these adverse effects. Bioinformatics analysis revealed that the targets of OXY and CPT-11 were enriched in pathways such as PI3K/Akt and cell cycle, suggesting that the combination therapy might exert a synergistic effect by modulating these pathways."	MEC01714
C03056	NEWCL20460	.	Achieving Therapeutic Synergy	"These findings suggest that the combined use of black elderberry extract and quinine might serve as an effective antiviral strategy against IAV and SARS-CoV-2, particularly since the synergistic effect allows for lower doses of each product while retaining therapeutic efficacy. In summary, this combinational in vitro approach, when expanded to other respiratory RNA viruses and confirmed in clinical studies, has the potential to open a promising avenue for pandemic preparedness."	MEC01715
C03057	NEWCL00155;NEWCL00170;NEWCL00149	.	Achieving Therapeutic Synergy	Our study illustrates that combining CV extract with a chemical inhibitor of the PI3K signalling pathway induces an additive cytotoxic effect on cancer cells.?	MEC01716
C03058	NEWCL20461	.	Achieving Therapeutic Synergy	"It was possible to show that the peptide, extract, and the combination exert antifungal activity against?C. albicans, regardless of the resistance phenotype. However, we found that resistance to FLC due to mutations in the ergosterol biosynthesis pathway increases the susceptibility to oxidative stress damage.?"	MEC01717
C03059	.	.	Achieving Therapeutic Synergy	"This study reveals a synergistic mechanism by which C3G, in combination with alpha-tocopherol, protects neuronal cells from oxidative damage."	MEC01718
C03060	.	mice	Achieving Therapeutic Synergy	"The 75% Sishen Pill + 60 mg/kg sodium propionate can improve the symptoms of kidney-yang deficiency syndrome, promote the growth and development of mice, inhibit excessive bacterial proliferation, support the growth of beneficial bacteria, and enhance intestinal enzyme activity. Its effects are superior to the use of sodium propionate or Sishen Pill alone.?"	MEC01719
C03061	.	.	Achieving Therapeutic Synergy	"In our in vitro MBC studies and clinical treatment simulation, it was demonstrated that?C. sativa?chestnut burr extract, integrated within a circular bioeconomy framework, holds great promise as a sustainable addition to current anti-H. pylori?therapy by enhancing antibiotic efficacy."	MEC01720
C03080	.	.	Achieving Therapeutic Synergy	"In our in vitro MBC studies and clinical treatment simulation, it was demonstrated that?C. sativa?chestnut burr extract, integrated within a circular bioeconomy framework, holds great promise as a sustainable addition to current anti-H. pylori?therapy by enhancing antibiotic efficacy."	MEC01721
C03081	.	.	Achieving Therapeutic Synergy	"In summary, the combined treatment of EE and CA can effectively inactivate?C. sakazakii, and its antibacterial mechanism is related to several mechanisms. (1) The combined action can lead to cell membrane hyperpolarization, destruction of cell membrane integrity, and enhancement of cell membrane permeability. (2) The combined action can reduce the bacterial protein and DNA levels and make the intracellular ROS levels first increase and then decrease. (3) The combined action can seriously damage the cell morphology. In addition, the combined treatment of EE and CA has also been proven to have good application prospects in the disinfection of?C. sakazakii?on production equipment, packaging materials, containers, and tableware. Together, these findings provide a new strategy for developing a safe, efficient, and low-cost natural disinfectant and could help reduce the contamination of PIF by?C. sakazakii."	MEC01722
C03082	NEWCL10127	.	Achieving Therapeutic Synergy	"In conclusion, we reveals a novel regulator PPP1CA driving abiraterone resistance. The natural product nodularin-R ameliorates abiraterone resistance by inhibiting PPP1CA. The combination of nodularin-R and abiraterone exerts synergistic anti-CRPC effects."	MEC01723
C03083	.	.	Achieving Therapeutic Synergy	"Compared to the single drug, chidamide combined with matrine showed a more significant effect on proliferation inhibition and apoptosis induction on CTCL cells both?in vitro?and?in vivo. The results from the?in vitro?and?in vivo?studies suggested that matrine could enhance the anti-tumor effect of chidamide by increasing the protein expression of cleaved caspase- 3 and decreasing the expression of E-cadherin, NF-kappaB, p-Bad, and Bcl-2 to activate apoptosis."	MEC01724
C03084	NEWCL00227;NEWCL00355;NEWCL20462;NEWCL00228	.	Achieving Therapeutic Synergy	"Our study demonstrates that daidzin inhibits the viability, induces cell apoptosis, and suppresses the lung metastasis of OS cells by binding to the beta-catenin protein, thus reducing its protein stability and further inhibiting the Wnt signaling pathway. Furthermore, daidzin can enhance the cisplatin sensitivity of OS cells, suggesting that daidzin has translational value to be a potential adjuvant to improve treatment outcomes for OS."	MEC01725
C03085	.	.	Achieving Therapeutic Synergy	"The combination of phytochemical nanoparticles?F. carica?and silver nanoparticles showed better results than each of them separately, and this showed decay destruction in DNA so, it might be able to antagonize PZQ side effects that appeared in the best protected-treated mice group. Also, prophylactic Ag-NPCs recorded a reduction in DNA damage by schistosomal cercariae."	MEC01726
C03086	NEWCL20459	.	Achieving Therapeutic Synergy	"In conclusion, ginsenoside Rg3 and nonnatural compound K, derived from major ginsenosides in?Panax ginseng, are potential new antibiotic adjuvants that are associated with conventional antibiotics for MRSA."	MEC01727
C03087	NEWCL20459	.	Achieving Therapeutic Synergy	"In conclusion, ginsenoside Rg3 and nonnatural compound K, derived from major ginsenosides in?Panax ginseng, are potential new antibiotic adjuvants that are associated with conventional antibiotics for MRSA."	MEC01728
C03088	.	zebrafish model	Achieving Therapeutic Synergy	"The combination of ZER and CIS exhibited superior anti-angiogenic effects compared to either treatment alone, suggesting a promising therapeutic strategy for cancer treatment."	MEC01729
C03089	NEWCL00230	.	Achieving Therapeutic Synergy	"This study demonstrates that the combination of propolis and cisplatin exerts stronger antitumor effects compared to individual treatments, highlighting propolis as a promising natural agent capable of enhancing the efficacy of standard chemotherapeutic agents."	MEC01730
C03090	.	vancomycin-resistant Enterococcus faecium	Achieving Therapeutic Synergy	"These findings underscore the potential of CBD-enriched cannabis oil and omega-3 as a novel therapeutic approach for neuropathic pain management, offering promising implications for future research and clinical practice."	MEC01731
C03091	NEWCL00049;NEWCL00155	.	Achieving Therapeutic Synergy	"GAL could reverse the activity of VAN against VREfm by damaging bacterial cell envelope, inhibiting biofilm formation, and reducing biomolecule contents, emphasizing its potential as a valuable adjunct to VAN in treating VREfm infections."	MEC01732
C03092	NEWCL10088;NEWCL00165	.	Achieving Therapeutic Synergy	"L-NAME and GTP showed a synergistic effect on MDA-MB-231 and CSC-LCs. Such an effect was not observed on MCF-7. Sildenafil and GTP, on the other hand, showed synergistic cytotoxicity in all the cells mentioned above. Flow cytometric tests resulted in more than 70% apoptosis in MDA-MB-231 and MCF-7. Also, sub-G1 arrest among MCF-7 cells and a considerable decrease in ROS production by MDA-MB-231 cells following treatment with Sildenafil and GTP were observed."	MEC01733
C03093	NEWCL00113	.	Achieving Therapeutic Synergy	"ES extract demonstrated significant cytotoxic potential in HNSCC cells without affecting normal cells. It enhanced the radiosensitivity of HNSCC cells by upregulating BAX and p-MLKL expression, leading to increased cell death. These results suggest ES extract exhibits a potential radiosensitizing capacity in HNSCC."	MEC01734
C03094	NEWCL00059;NEWCL10125	.	Achieving Therapeutic Synergy	"In conclusion, our study suggests, for the first time to our knowledge, that the combination of Rapamycin and Niacin synergistically reduced the cell proliferation of AML cells. Our results demonstrated that Rapamycin and Niacin combination induced apoptotic cell death and arrest the cell cycle on AML cells. The combination treatment induced autophagy in AML cells."	MEC01735
C03095	NEWCL20463;NEWCL00172	.	Achieving Therapeutic Synergy	"This study confirmed that the combination of osimertinib, a third-generation anticancer drug, and HAD-B1, a natural anticancer drug, had a potentially synergistic effect on non-small cell lung cancer resistant to EGFR-targeted anticancer drugs."	MEC01736
C03096	.	Sprague-Dawley (SD) male rats	Achieving Therapeutic Synergy	"To sum up, BXD has a protective effect against CPT-11-induced intestinal dysfunction by inhibiting inflammation through inactivation TLR4/NF-kappaB signaling pathway. In particular, the combined use of BXD and 5-ASA holds great promise for treating CPT-11-induced delayed diarrhea."	MEC01737
C03209	.	rats	Achieving Therapeutic Synergy	The lepidine has potent anti-diabetic effects and may add more to the therapeutic value of metformin when the two agents are used in combination.	MEC01738
C03210	.	.	Achieving Therapeutic Synergy	"The combination of TTO and terpinen-4-ol produced an additive effect (FICI: 0.508). To the best of our knowledge, this study is the first to demonstrate the combined effectiveness of TTO and kojic acid against S. Typhimurium.?"	MEC01739
C03211	.	Pseudomonas aeruginosa	Achieving Therapeutic Synergy	"The findings confirmed synergism between CiT and TcN and revealed their quorum quenching (QQ) potential. At sub-inhibitory levels, CiT-TcN combination significantly impeded pyocyanin, total bacterial protease, hemolysin, and pyochelin production alongside inhibiting biofilm formation in P. aeruginosa.?"	MEC01740
C03212	NEWCL10088;NEWCL00165	.	Achieving Therapeutic Synergy	"In conclusion, the combination of quercetin and sulforaphane demonstrates significantly enhanced efficacy in suppressing the progression of breast cancer cells. This is achieved through mechanisms including cytotoxicity, ROS generation, apoptosis induction, and cell cycle arrest at the G2/M phase in MDA-MB-231 cells. The combination of QT with SFN also effectively inhibits the phosphorylation of ERK, JNK, and p38, thereby modulating the activity of CDKs and cyclins to promote cell cycle arrest. These findings suggest that the synergistic interaction between quercetin and sulforaphane may provide a promising therapeutic approach for breast cancer treatment. Further investigations using in vivo model systems are necessary to validate these results and assess the clinical potential of this combination therapy."	MEC01741
C03213	.	.	Achieving Therapeutic Synergy	"The checkerboard method evaluated 48 combinations, with 23 indicating synergistic action. Among these, carvacrol 10 mg/kg plus polymyxin B 2 mg/kg exhibited?in vivo?antimicrobial activity in a mouse model of infection, resulting in increased survival and a significant decrease in bacterial load in the blood."	MEC01742
C03214	.	Methicillin-resistant Staphylococcus aureus	Achieving Therapeutic Synergy	"Our study reveals the synergistic activity of baicalin combined with oxacillin sodium against USA300?in?vitro. This combination therapy maintains antimicrobial activity while reducing the dosage of conventional antibiotics, helping to delay the emergence of resistance. Bacterial cell membrane and cell wall are the main targets of baicalin. Baicalin can lead to increased cell membrane permeability and loss of barrier function, allowing traditional antibiotics to penetrate cells easily and effectively exert antibacterial activity. Therefore, our research indicates that the combined use of baicalin with oxacillin sodium antibiotic helps to reduce MRSA's antibiotic resistance. Future research plans will delve into the mechanism of action of baicalin and oxacillin sodium in combination against MRSA biofilms based on the quorum sensing system."	MEC01743
C03215	.	Trichophyton violaceum	Achieving Therapeutic Synergy	Hence Synergy of TTO with KTZ is most proficient because it reduces the MFC of azole maximally while potentiating the fungicidal activity of KTZ.	MEC01744
C03216	.	drug-resistant?Pseudomonas aeruginosa	Achieving Therapeutic Synergy	"A series of experiments demonstrated that the combined application of cuminaldehyde and tetracycline could lead to a significant enhancement of their antibiofilm potential. This enhanced antibiofilm potential was attributed to the accumulation of reactive oxygen species and increased cell membrane permeability. Besides, this combinatorial application reduced the secretion of various virulence factors from?P. aeruginosa. Therefore, this combined approach holds promise for effectively treating?P. aeruginosa?biofilms."	MEC01745
C03217	.	.	Achieving Therapeutic Synergy	"The combined treatment exhibited significant antitumor efficacy with low toxic side effects in a xenograft model. In conclusion, our study provides new insights into combination therapies to enhance anti-NPC efficacy."	MEC01746
C03218	NEWCL00028	DEN-induced Piezo1-knockout mouse model	Achieving Therapeutic Synergy	"This study uncovers a novel mechanism by which JPHY enhances DOX sensitivity in HCC, acting through modulation of Piezo1-mediated autophagy via the PI3K/AKT/mTOR pathway."	MEC01747
C03219	NEWCL00039	BALB/c mice were inoculated with C6 cells to establish a mouse xenograft glioma model	Achieving Therapeutic Synergy	"CEO can regulate the expression of these proteins through the HIF-1 signaling pathway, alleviating the TMZ resistance caused by the tumor microenvironment and thereby enhancing the sensitivity of glioma cells to TMZ. In vivo, LIG synergized with TMZ to inhibit tumor growth and enhance the sensitivity of TMZ-resistant GBM.?The combination of CEO and TMZ is a promising therapeutic strategy for GBM, particularly in overcoming TMZ resistance."	MEC01748
C03220	NEWCL10334;NEWCL00203	obesity (DIO) mouse model	Achieving Therapeutic Synergy	"Mechanistically, co-treatment with BBR and ISL upregulated the protein expression of the IRS1-PI3K-Akt insulin signaling pathway, enhanced glucose uptake in adipocyte, and suppressed the interaction between macrophage and adipocyte. The synergistic combination of BBR with ISL can be a promising and effective strategy for improving obesity-induced adipose inflammation and insulin resistance."	MEC01749
C03221	NEWCL10348;NEWCL00103	KYSE-30 cells were subcutaneously injected into the right flank of the nude mice	Achieving Therapeutic Synergy	The combination of oridonin and cisplatin can synergistically inhibit the development of ESCC through the activation of the NOXA-BCL2 axis signaling pathway.?	MEC01750
C03222	.	A rat model of CBP was induced in rats by prostate bilateral injections of Escherichia coli	Achieving Therapeutic Synergy	Pc combined with CIP can mitigate CBP by targeting Pik3cb to inhibit the NF-kappaB/IL-6/JAK2/STAT3 signaling pathway	MEC01751
C03223	.	A mouse model of depression in comorbid with sexual dysfunction was created	Achieving Therapeutic Synergy	The amelioration effects of CTE and its combination with FLX on depression in comorbid with sexual dysfunction were confirmed for the first time.	MEC01752
C03224	NEWCL10031	The CT-26 xenograft tumor-bearing mouse model	Achieving Therapeutic Synergy	"The combination of GQD extract and CPT-11 significantly increased tumor growth suppression and decreased intestinal toxicity in the mouse model. The anti-cancer synergy was reduced Treg cell immunosuppression and increased CD4+?and CD8+?T cell populations. GQD extract regulated glucose uptake and cell viability in CT-26 cells under anaerobic glycolysis, potentially disrupting cancer cell glycolysis. GQD also alleviated intestinal toxicity by modulating cytokine levels and promoting macrophage polarization from M1 to M2 in colon tissues."	MEC01753
C03225	NEWCL10340	H1N1-infected BABL/c mouse model	Achieving Therapeutic Synergy	Combining LH with Osel or Bal could enhance the antiviral efficiency for influenza viruses compared to the monotherapy using any of these three drugs.	MEC01754
C03226	.	in a mouse model of orthotopic HCC	Achieving Therapeutic Synergy	BBD increases the antitumor effect of CLM by modulating the tumor immune microenvironment and attenuating its the toxic side effects of CLM.	MEC01755
C03227	.	a high-calorie intake mouse model of chronic obesity	Achieving Therapeutic Synergy	Intake of EGCG and beta-cryptoxanthin reduces obesity in both subcutaneous and visceral fat. These findings suggest that simultaneous intake of EGCG and beta-cryptoxanthin not only reduces obesity but also has a systemic beneficial effect on the body's normal physiological function.	MEC01756
C03228	.	liver?fibrosis?was induced by?intraperitoneal injection?of CCl4	Achieving Therapeutic Synergy	"The combined use of PAE and MET exhibits a significant synergistic effect in the prevention and treatment of liver fibrosis, with the TGF-beta/Smad signaling pathway playing a crucial role in this process.?"	MEC01757
C03229	.	Applying zebrafish AD/OP comorbidity model	Achieving Therapeutic Synergy	"The combined treatment of OST and NOT exhibited Synergistic effects in combating AD and OP. Moreover, the anti-inflammatory effects of the combined treatment were superior to those observed with individual treatments."	MEC01758
C03230	.	Mouse brain hemorrhagic stroke model	Achieving Therapeutic Synergy	WFA combination with LEP promote neurogenesis mediated by posthemorrhagic leptin by activating STAT3/SOCS3 signaling.	MEC01759
C03231	NEWCL00231;NEWCL00134	SKOV3 cells was injected subcutaneously into nude mice for xenograft formation	Achieving Therapeutic Synergy	A synergistic effect of SB-HD and DDP against OC through modulating oxidative stress via NRF2-FTH1 autophagic degradation pathway	MEC01760
C03232	NEWCL10103;NEWCL20464;NEWCL20465;NEWCL00092	" for the establishment of DLBCL xenograft model, SUDHL-4 cells were subcutaneously injected in the right flank of the mice."	Achieving Therapeutic Synergy	Wogonin treatment eliminates DLBCL cells by inducing mitochondria-dependent apoptotic cell death?in vitro?and suppresses the growth of the DLBCL tumor in an animal model?in vivo	MEC01761
C03233	NEWCL00052	SKOV3 cells was injected subcutaneously into nude mice for xenograft formation	Achieving Therapeutic Synergy	"The potential anticancer effects of pistachio hull extract in combination with CFZ. The findings indicate that this combination can modulate the expression of genes associated with drug resistance (MDR1?and?MRP1), as well as?NF-kappaB p65?and?Caspase3.?"	MEC01762
C03260	.	C. albicans?was isolated from patients diagnosed with VVC	Achieving Therapeutic Synergy	"PACs enhance probiotic antifungal activity, leading to superior inhibition of?C. albicans?colonization and biofilm formation."	MEC01763
C03261	NEWCL00082;NEWCL00074	.	Achieving Therapeutic Synergy	"The synergistic anticancer effects of ABE and OPCs in CRC cells, partially mediated through the regulation of apoptosis and the oncogene LMNB1 within the AKT signaling pathway."	MEC01764
C03262	.	S.?aureus	Achieving Therapeutic Synergy	"PLU is not only a potent anti-S.?aureus?compound, but it can also enhance the growth-inhibitory effects of NIT, CPR, MEC, and CHL against?S.?aureus."	MEC01765
C03263	NEWCL00082	HCT116 cells was injected subcutaneously into nude mice for xenograft formation	Achieving Therapeutic Synergy	"Both?in vivo?and?in vitro?results established the effectiveness of HQEZ in enhancing the efficacy of 5-FU in colorectal cancer treatment. The downregulation of MDR1, POLH, RRM1 and TS contributes to the synergistic effect of HQEZ on 5-FU."	MEC01766
C03264	.	Letrozole combined with high-fat diet (HFD) was used to establish an overweight PCOS rat model	Achieving Therapeutic Synergy	"Berberine combined with JPYSHZF can improve the sex hormone levels, ovarian function, glucose and lipid metabolism levels, and gastrointestinal hormone levels in obese PCOS rats by activating the PI3K/AKT signaling pathway, thereby playing a role in treating obese PCOS."	MEC01767
C03265	.	The work was carried out in vitro on eggs and infective larvae (L3) of H. contortus.	Achieving Therapeutic Synergy	Artemisia cina?and?Tagetes lucida?extracts can act synergistically against the nematode?Haemonchus contortus?due to their high anthelmintic activity and similar active compounds.	MEC01768
C03266	.	A mouse model of food stagnation	Achieving Therapeutic Synergy	"Combination of Simo Decoction and Golden Bifid increases the abundance of Bacteroides and Bifidobacterium and promotes the production of SCFAs, which is instrumental for alleviation of FD."	MEC01769
C03267	.	Methicillin-resistant?Staphylococcus aureus	Achieving Therapeutic Synergy	"Nano TTO exhibited bactericidal activity against MRSA by interfering with membrane functions, representing a promising beta-lactam antibiotic adjuvant capable of combating MRSA infections and inspiring us to search for more effective candidates as potential antibiotic adjuvants."	MEC01770
C03268	.	A PPH rat model was established using mifepristone and misoprostol	Achieving Therapeutic Synergy	"The combined regimen of motherwort injection and oxytocin exhibits superior efficacy in preventing PPH compared to oxytocin monotherapy. A key mechanistic insight is the activation of the MAPK signaling pathway, which underpins the synergistic action of motherwort injection with oxytocin in enhancing uterine contraction."	MEC01771
C03269	.	Streptozocin -induced diabetic ApoE-/-?mice	Achieving Therapeutic Synergy	"The PE demonstrated efficacy against diabetic AS and cooperated with atorvastatin for some additional benefits, especially in liver protection, indicating that PE has the potential to be developed as a supplement for the management of diabetes-related AS."	MEC01772
C03270	NEWCL00129;NEWCL00031	Huh7 cells were injected into the backs of male nude mice	Achieving Therapeutic Synergy	"Sora/WA co-treatment significantly increased HCC cell death.This effect was primarily achieved through the induction of ROS generation and the inhibition of TrxR1 activity, resulting in increased DNA damage and activation of the ER stress pathway."	MEC01773
C03329	.	cockroaches were cultured at 27C and 60 % relative humidity. Insects were bred in glass jars and fed with autoclaved mice-food croquettes.	Achieving Therapeutic Synergy	Trans-anisaldehyde and thymol have the best insecticidal activity against?B. germanica. gamma-Terpinene and linalool have excellent synergistic activity with beta-cypermethrin at a concentration of 0.5%.	MEC01774
C03330	.	the lipopolysaccharide (LPS)-induced depression model	Achieving Therapeutic Synergy	"The antidepressant-like effects elicited by chronic fluoxetine or by synergistic doses of GS were involved in the upregulation of hippocampal PACAP levels, in association with ameliorated neuroinflammation and neuroplasticity signaling in LPS-injected mice. GS synergism may play a key part in the antidepressant-like effects of the prescriptional dose of Yueju."	MEC01775
C03331	NEWCL00049;NEWCL00189	in vivo experiments were carried out using MDA-MB-231 xenograft mice.?	Achieving Therapeutic Synergy	This study provides evidence that the combination therapy of DOX and DBT has the potential to treat TNBC by promoting ferroptosis through the Nrf2/HO-1/GPX4 axis.	MEC01776
C03332	.	?Both A375 cells and B16F10 tumor-bearing mice were used for in vitro and in vivo experiments	Achieving Therapeutic Synergy	A synergistic anti-melanoma effect of SLE/TMZ both?in vitro?and?in vivo. The inhibition of the STAT3 pathway is identified as one of the mechanisms through which SLE augments the efficacy and diminishes the toxicity of TMZ in anti-melanoma treatment.	MEC01777
C03333	NEWCL10348;NEWCL20466	KYSE 30 cell suspension was injected into the right upper limb of nude mice. 	Achieving Therapeutic Synergy	SBLM enhanced the anti-cancer effect of CP through inhibiting the PI3K/Akt/Bcl-2 signaling pathway to induce the cells apoptosis.	MEC01778
C03334	.	"A mouse model of Lewis lung cancer,Each nude mouse was inoculated to the scapular region with MGC-803 cells"	Achieving Therapeutic Synergy	"SLC enhanced the effect of cisplatin in inhibiting NSCLC by inducing cell apoptosis, augmenting immune responses, balancing the gut microbiota, and regulating key metabolic pathways.?"	MEC01779
C03335	.	"19 previously identified?C. auris?isolates along with the wild-type strains?C. albicans,?C. glabrata,?C. tropicalis, and?Cryptococcus neoformans."	Achieving Therapeutic Synergy	"Cb-EE, alone or in combination with fluconazole, effectively treated C. auris infections in vitro and in vivo, suggesting its prospective role as an antifungal agent against this emerging pathogen."	MEC01780
C03336	.	An ischemic stroke rat model was established	Achieving Therapeutic Synergy	"Yaomu fermentation exerts Synergistic effects by modulating pathways such as PI3K-Akt signaling, calcium signaling, cAMP signaling, and neuroactive ligand-receptor interactions. Metabolomics research identified tryptophan metabolism as the primary pathway through which Yaomu fermentation achieves its Synergistic effects.?The study also examined the therapeutic effects of HFD on IS, which primarily operates through pathways associated with arginine biosynthesis, riboflavin metabolism, arginine and proline metabolism, taurine and hypotaurine metabolism, and tryptophan metabolism. "	MEC01781
C03337	.	.	Achieving Therapeutic Synergy	The three key components of HYQ that enter the bloodstream exert synergistic anti-inflammatory effects by targeting different molecular entities and engaging in various mechanisms.	MEC01782
C03338	.	hyperlipidemia and hepatosteatosis induced by a high-cholesterol diet (HCD) in an animal model	Achieving Therapeutic Synergy	"Concurrent supplementation with both LC and GB exhibited enhanced efficacy in alleviating liver damage induced by an HCD, surpassing the effects of individual supplements. These valuable effects could occur through ROS scavenging, inhibition of free radical production, antioxidant reactivation, and upregulation of hepatic beta-catenin and GLP-1R expression."	MEC01783
C03339	NEWCL00113;NEWCL00142	each nude mouse was inoculated to the scapular region with MGC-803 cells	Achieving Therapeutic Synergy	"SOD3 played a critical tumor-suppressive role in gastric cancer by modulating the SOD3/EGFR/PKP3/DSC2 axis.MCP, a natural compound that selectively boosted SOD3 levels, enhanced chemotherapy efficacy while reducing peripheral neurotoxicity."	MEC01784
C03340	NEWCL00129	a xenograft mouse model was established by subcutaneously injecting HepG2 cells	Achieving Therapeutic Synergy	"ACT enhanced efficacy and reduced the toxicity of OXA in the treatment of HCC, potentially via the regulation of INPP4B to inhibit the PI3K/AKT signaling pathway."	MEC01785
C03341	.	the homeostasis model assessment of insulin resistance (HOMA-IR) in leptin receptor-deficient (db/db) mice	Achieving Therapeutic Synergy	"The 4:1 combination of total alkaloids from Coptis chinensis and total ginsenosides from Panax ginseng significantly improves insulin resistance and glucose and lipid metabolism disorders in db/db mice, surpassing the efficacy of individual treatments. The synergistic mechanism correlates with enhanced AMPK/ACC signaling pathway activity."	MEC01786
C03342	.	Intracellular oxidative stress was evaluated in NIH/3T3 cells (mouse embryonic fibroblasts) by measuring reactive oxygen species (ROS) using dichlorodihydrofluorescein diacetate	Achieving Therapeutic Synergy	"Equimolar mixtures of model polyphenols: EGCG, quercetin, and rosmarinic acid demonstrated enhanced effects, with the strongest synergy in ternary mixtures (CI = 0.67-0.86), potentially achievable in GT:PM combinations.?"	MEC01787
C04480	NEWCL20467;NEWCL10374	.	Achieving Therapeutic Synergy	The use of the extract together with dacarbazine (both in non-toxic concentrations) resulted in the enhancement of their anticancer activity. The pretreatment of melanoma cells with?M. longifolia?extract potentiated the activity of a low dose of dacarbazine to an even higher extent.	MEC01788
C04481	NEWCL00231;NEWCL20468	.	Achieving Therapeutic Synergy	"OXY's ability to reduce cancer cell viability, induce apoptosis, arrest cell cycle progression, and enhance cancer cells' sensitivity to chemotherapy.?The potential molecular mechanisms behind its effects may involve the inhibition of the PI3K/AKT/mTOR pathway, leading to a reduced production of anti-apoptotic proteins. "	MEC01789
C04482	.	activated strains and fungal suspensions of C. albicans	Achieving Therapeutic Synergy	"The combined application of KBN and MN somewhat impacts the structural integrity of?Candida albicans?biofilms and affects the expression of several key genes involved in biofilm formation, including?ALS1,?ALS3,?HWP1,?HSP90, and?CSH1."	MEC01790
C04483	.	a subcutaneous grafted tumor model of mouse lung cancer by injecting Lewis cells	Achieving Therapeutic Synergy	"The combination of NGA and Almonertinib inhibited the expression of CYP3A4, P-gp, and BCRP via PXR modulation. Meanwhile, it inhibited the EGFR/PI3K/AKT pathway and enhanced the sensitivity of NSCLC to Almonertinib, exerting synergistic anti-tumor effects.?"	MEC01791
C04484	.	"S. aureus?(ATCC25923, ATCC29213, ATCC13565 and CMCC26074)"	Achieving Therapeutic Synergy	The combination of Nisin and CSE could serve as an effective natural preservative to control S. aureus in dairy products.	MEC01792
C04485	.	a high-fat diet (HFD) in inducing type 2 diabetes in Sprague-Dawley (SD) rats	Achieving Therapeutic Synergy	The combination therapy exhibited superior safety compared to single-drug treatments. Hematoxylin and eosin (H&E) staining revealed that HFD-induced diabetes caused inflammatory changes in the duodenum and colon. The combination therapy markedly alleviated inflammatory symptoms.	MEC01793
C04486	.	129 patients with HER-2 negative GC	Achieving Therapeutic Synergy	"FJQR and fluoropyrimidine have Synergistic effects as maintenance treatment in HER-2 negative GC, with good efficacy and safety."	MEC01794
C04487	.	"Gram-positive strains of?Streptococcus pneumoniae?(S. pneumonia?ATCC 49136),?Streptococcus mutans?(S. mutans?ATCC 25175),?Staphylococcus aureus?(S. aureus?ATCC 25923); gram-negative strains of?Klebsiella pneumonia (K. pneumonia?ATCC 700603),?Escherichia coli?(E. coli?ATCC 35218),?Pseudomonas aeruginosa (P. aeruginosa?ATCC 27853); and fungal strains of?Candida albicans?(C. albicans?ATCC 14053) and?Candida krusei?(C. krusei?ATCC 14243)"	Achieving Therapeutic Synergy	"Across all studied strains, the prepared mixture of 10%?S. persica?and 0.5% ChNPs (SChNPs) demonstrated a large zone of inhibition with a distinct decrease in MIC, indicating its synergistic effect. The use of SChNPs mixture as a mouthwash can act synergistically to control oropharyngeal microbes that are implicated in secondary micorbial infections associated with primary viral infections."	MEC01795
C04488	NEWCL20469	.	Achieving Therapeutic Synergy	"Both XN and HOP EX significantly decrease cell viability and stemness in HNSCC cells and enhance the cytotoxic effects of Cisplatin, suggesting a synergistic interaction. The induction of ER stress and subsequent activation of the unfolded protein response (UPR) promote autophagy, leading to increased apoptosis."	MEC01796
C04489	.	Clinical isolates of?S. aureus	Achieving Therapeutic Synergy	"Citral-azithromycin synergy as a promising strategy to enhance antibiotic efficacy against MRSA while minimizing cytotoxicity, supporting the potential of phytochemical-adjuvant combinations in combating antimicrobial resistance."	MEC01797
C04490	.	"fluconazole-resistant?Candida albicans, one strain of Gram-positive bacteria: oxacillin and mecillinam-resistant Coagulase Negative (CON)?Staphylococcus saprophyticus, and 3 Gram-negative MDR bacteria included extended-spectrum beta-lactamases (ESBL)?Klebsiella pneumoniae, as well as MDR?E. coli?and?Pseudomonas aeruginosa, which resisted to ceftazidime, cefepime, aztreonam, ciprofloxacin, piperacillin, imipenem, and gentamicin."	Achieving Therapeutic Synergy	The promising antimicrobial synergy of the EEP-Honey mixture against MDR urinary pathogens	MEC01798
C04491	NEWCL20470	the animal model of COP	Achieving Therapeutic Synergy	The neuroprotection effects of NBP and ZLD against COP-induced brain injury are closely linked to the activation of the PI3K/AKT/GSK-3beta signaling pathway.	MEC01799
C04492	.	"five bacterial strains, viz., B. subtilis (MTCC441), S. aureus (ATCC25922), E. coli (ATCC29213), K. pneumoniae (MTCC39), P. aeruginosa (MTCC424) "	Achieving Therapeutic Synergy	"The fruit extracts of P. emblica and its phenolic compounds could be utilized to augment the effectiveness of conventional antibiotics, which have acquired resistance to bacterial infections."	MEC01800
C04493	NEWCL00149	.	Achieving Therapeutic Synergy	"Curcumin and tanshinone IIA, either alone or in combination, could potentially modulate the development and progression of cancer."	MEC01801
C04494	.	E. coli-JME and P. aeruginosa-JMP	Achieving Therapeutic Synergy	"CVEF, in combination with antibiotics, effectively targets resistance phenotypes of P. aeruginosa, impairing growth, virulence, and biofilms. This supports further research into natural compounds alongside antibiotics to treat drug-resistant infections."	MEC01802
C04495	NEWCL00203	.	Achieving Therapeutic Synergy	"The binding of IAA enhanced the immunomodulatory activity of LbGp and coordinated the immune response, and did not trigger an inflammatory response, which was potentially attributed to the alteration of spatial structure of LbGp through the binding of IAA."	MEC01803
C04496	NEWCL20471	The mice were induced with CL by subcutaneously injecting 0.1 ml of promastigotes at stationary phase (106 parasites/mL) into their tails	Achieving Therapeutic Synergy	"In vitro and in vivo antileishmanial efficacy of REE and its main compounds MC, CP, and LN mainly in combination with GC; which indicated the high synergic effects of these compounds."	MEC01804
C04497	.	Induction of diabetes in experimental animals	Achieving Therapeutic Synergy	The combination of garlic and?C. colocynthis improves DM-induced reproductive injury than when used separately.	MEC01805
C04498	NEWCL20472	.	Achieving Therapeutic Synergy	"A combination of the extract of the aerial part of?R. dentatus?L and cisplatin significantly suppressed the viability and invasion potential of tongue cancer cells while promoting apoptosis and autophagy in vitro. Moreover, the synergistic inhibitory impact on the viability of cancer cells was notably observed with the combined use of?R. dentatus?L. extract and cisplatin."	MEC01806
C04499	NEWCL10334;NEWCL00129;	.	Achieving Therapeutic Synergy	"A potential complementary role of polyphenols in enhancing the efficacy of metformin, possibly allowing for reduced metformin dosage and mitigating its side effects.?"	MEC01807
C04751	NEWCL00129;NEWCL00031	.	Achieving Therapeutic Synergy	"Combination of DG with DOX or Vola enhances their antitumor effects in HCC cell lines, by decreasing PLK1 and PCNA expressions and increasing p53 expression."	MEC01808
C04752	NEWCL00129;NEWCL00031	.	Achieving Therapeutic Synergy	"Combination of DG with DOX or Vola enhances their antitumor effects in HCC cell lines, by decreasing PLK1 and PCNA expressions and increasing p53 expression."	MEC01809
C04753	.	P. aeruginosa	Achieving Therapeutic Synergy	Cuminaldehyde can be combined with aminoglycoside antibiotic gentamicin for the control of biofilm-associated infections caused by the opportunistic pathogen?P. aeruginosa.	MEC01810
C04754	NEWCL00155;NEWCL00049	.	Achieving Therapeutic Synergy	The combined use of noni with CYL potentially enhances the antitumor activity of CYL and suppresses myelotoxicity and hepatotoxicity induced by CYL in tumor-bearing mice.	MEC01811
C04755	NEWCL00050	sequential passages in mice via weekly intraperitoneal transplantations of 2?*?106 EAC cells.	Achieving Therapeutic Synergy	The combination of CYL with noni has a better antitumor effect than that of either noni or CYL alone in both in vitro and in vivo studies.?	MEC01812
C04756	.	 a mouse myocardial chronic heart failure model 	Achieving Therapeutic Synergy	GS enhanced the anti-heart failure effect of metoprolol. Its mechanism of action might be related to the inhibition of autophagy mediated by the activation of the PI3K/Akt/mTOR pathway.	MEC01813
C04757	.	.	Achieving Therapeutic Synergy	"The combined extracts of RN and PM at a 4:1 ratio considerably improve hDPC proliferation and viability, even under testosterone-induced cytotoxicity, positioning them as prospective agents for promoting hair development."	MEC01814
C04758	.	"S. aureus?were used: ATCC 25923 (methicillin sensitive); ATCC 700698 (methicillin resistant-MRSA), and JKD6008 (MRSA and intermediate vancomycin resistance-VISA).?"	Achieving Therapeutic Synergy	"L. grata EO in combination with ampicillin could be a viable treatment option against S. aureus infections, including MRSA strain."	MEC01815
C04759	.	"Enterobacter aerogenes (EA3 and EA27), Staphylococcus aureus (MRSA4and MRSA6), Klebsiella pneumoniae (ATCC11296 and KP63), Pseudomonas aeruginosa (PA01 and PA124), and Escherichia coli (ATCC10536 and AG100)."	Achieving Therapeutic Synergy	"the extracts of?N.?lappaceum?and?H.?thebaica?plants have both antibacterial and antibiotic-resistance modulatory potential. The leaf extract of?N.?lappaceum?has shown significant inhibition of bacterial H+-ATPase-mediated proton pumping and changes in the cell membrane integrity, suggesting possible modes of action."	MEC01816
C04760	.	four?Candida?spp. strains	Achieving Therapeutic Synergy	A synergistic action of the Eugenia uniflora extract extract with Fluconazole and Micafungin was observed.?	MEC01817
C04761	NEWCL10122	30 subjects with both sensitive skin and acne	Achieving Therapeutic Synergy	"The efficacy of the GO and RT extracts in synergistically suppressing inflammation, improving acne vulgaris, and reducing redness.?"	MEC01818
C04762	NEWCL20473	.	Achieving Therapeutic Synergy	The combined treatment of BJIGT and RZ might reduce inflammation and regulate autophagy dysfunction in TDP-43-induced ALS.	MEC01819
C04763	.	E. faecalis?(ATCC 29212)	Achieving Therapeutic Synergy	The synergistic antibacterial activities of Rh2 and Ca(OH)2?against E. faecalis.?	MEC01820
C04764	.	Stock cultures of Gram-positive (S. aureus?ATCC 29213 and?S. aureus?ATCC 43300 (MRSA)) and Gram-negative (E. coli?ATCC 25922) bacteria	Achieving Therapeutic Synergy	The combination of C. vulgaris methanol extract and O. elongatum essential oil at very low doses may be promising anti-MRSA candidates.	MEC01821
C04765	.	C. albicans 103	Achieving Therapeutic Synergy	"The combination of 3ja and FLC significantly induced reactive oxygen species accumulation, disrupted membrane integrity, altered membrane sterols, and promoted apoptosis in C. albicans."	MEC01822
C04766	.	"E. coli?(PTCC 1860),?S. Typhimurium (PTCC 1735), S. flexneri?(PTCC 1234), and?E. faecalis?(PTCC 1858)"	Achieving Therapeutic Synergy	"The combination of T. ammi oil and ampicillin demonstrated a synergistic effect, and biofilm formation was inhibited. E. faecalis exhibited the greatest sensitivity, while S. flexneri exhibited the lowest sensitivity."	MEC01823
C04767	.	.	Achieving Therapeutic Synergy	"Has a high value in evaluating the efficacy of Xueshuantong combined with edaravone in the treatment of ACI. It can clarify changes in the coagulation function of patients, thereby guiding clinical follow-up treatment."	MEC01824
C04768	.	.	Achieving Therapeutic Synergy	.	MEC01825
C04769	NEWCL00049	.	Achieving Therapeutic Synergy	"Jadomycin B, a natural product isolated from Streptomyces venezuelae, exerts an anti-cancer effect on human triple negative breast cancer cells in vitro and has anti-tumoral effects in vivo in animal models of breast cancer. "	MEC01826
C04770	.	adult male rabbits	Achieving Therapeutic Synergy	"The combination of A. Vera and vitamin E acts synergistically to promote collagen production, which is crucial for wound contraction and strength."	MEC01827
C04771	.	.	Reversing Drug Resistance	.	MEC01828
C04772	.	BLT humanized mouse model	Achieving Therapeutic Synergy	"By harnessing the tumor-killing efficacy of monoclonal antibodies and the T cell-mediated immunity elicited by vaccines, this approach represents a promising advancement in achieving significantly improved cancer treatment outcomes."	MEC01829
C04773	NEWCL00031;NEWCL00131	c57 mice	Achieving Therapeutic Synergy	"A novel cancer nanovaccine for in situ HCC therapy, which was shown to induce the apoptosis of cancer cells under hypoxic environment. The nanovaccine exhibited strong local and systemic antitumor immunity."	MEC01830
C04774	.	C57BL/6J mice	Achieving Therapeutic Synergy	"The combination therapy significantly inhibited tumor growth by reprogramming T cells toward an immune-activated state, enhancing their cytotoxicity, preventing their exhaustion, and increasing the recruitment of them into the tumor microenvironment. "	MEC01831
C04775	NEWCL00199;NEWCL20474;NEWCL00298	.	Achieving Therapeutic Synergy	TET effectively activates the STING/TBK1/IRF3 pathway in NSCLC	MEC01832
C04776	NEWCL00170;NEWCL00180;NEWCL00171;NEWCL00199	male BALB/c nude mice	Achieving Therapeutic Synergy	Narciclasine sensitized cisplatin-resistant NSCLC tumor spheroids to cisplatin by inducing apoptosis	MEC01833
C04777	.	.	Achieving Therapeutic Synergy	Bufalin significantly reduced EGFR protein levels via CMA and enhanced TMZ efficacy in GBM by modulating the EGFR signaling pathway. 	MEC01834
C04778	NEWCL00170;NEWCL00181;NEWCL00171;NEWCL00298	.	Achieving Therapeutic Synergy	"Berberine synergistically inhibited NSCLC in combination with multiple ferroptosis inducers, and this combination synergistically down-regulated the mRNA and protein expression of SLC7A11, GPX4, and NRF2, resulting in ferroptosis accompanied by significant depletion of GSH, and aberrant accumulation of reactive oxygen species and malondialdehyde."	MEC01835
C04779	.	"Male db/db homozygous mice, littermate db/m mice"	Achieving Therapeutic Synergy	"ATG and puerarin, two agents isolated from herbal medicines have additive renal protective effects in diabetic mice with DKD."	MEC01836
C04780	NEWCL00203	Adult C57BL/6 N male mice	Achieving Therapeutic Synergy	"The synergistic anti-inflammatory effects of SBR-Pel, which include the reduction of NO, ROS, and pro-inflammatory cytokine levels."	MEC01837
C04781	.	.	Achieving Therapeutic Synergy	.	MEC01838
C04782	.	.	Achieving Therapeutic Synergy	.	MEC01839
C04783	NEWCL00155	.	Achieving Therapeutic Synergy	Represents a significant step forward in understanding the combined potential of TCM compounds for BC treatment.	MEC01840
C04784	.	SPF Male Sprague-Dawley rats	Achieving Therapeutic Synergy	"Both PAE and GLY have individually demonstrated favourable analgesic , neuroprotective, anti-inflammatory, and antioxidant effects. "	MEC01841
C04785	NEWCL00052	.	Reversing Drug Resistance	"The present study provides evidence that digested Chaga extract is effective against aggressive BC subtypes, targeting key molecules associated with the malignant phenotype, and demonstrates that Inonotus obliquus can represent a good source of alternative antitumor drugs or a remedy that, in combination with conventional drugs, may increase their effectiveness or reduce their dosage."	MEC01842
C04786	NEWCL00052	.	Reversing Drug Resistance	"The present study provides evidence that digested Chaga extract is effective against aggressive BC subtypes, targeting key molecules associated with the malignant phenotype, and demonstrates that Inonotus obliquus can represent a good source of alternative antitumor drugs or a remedy that, in combination with conventional drugs, may increase their effectiveness or reduce their dosage."	MEC01843
C04787	NEWCL00149;NEWCL00139	.	Reversing Drug Resistance	Combining V. pseudo-Negundo with Cisplatin resulted in higher levels of reactive oxygen species (ROS) and more pronounced apoptotic responses via a mitochondrial-dependent pathway. 	MEC01844
C04788	.	"C57BL/6 mice, Galleria mellonella larvae"	Achieving Therapeutic Synergy	"Light on AmpB's mechanism of action and characterize gladiolin as an AmpB potentiator, showing an antifungal mechanism distinct from its proposed antibiotic activity."	MEC01845
C04789	.	chickens	Reversing Drug Resistance	"Matrine and berberine hydrochloride could synergically treat the infection of this strain by regulating the organ indices, improving the pathological situation, decreasing the bacterial load, and regulating the inflammatory factors. "	MEC01846
C04790	.	mites	Achieving Therapeutic Synergy	"The Synergistic effects of scoparone and spirodiclofen on mites occurs through the inhibition of P450 activity, thus reducing spirodiclofen metabolism. "	MEC01847
C04791	.	Wistar albino rats	Achieving Therapeutic Synergy	"Such microemulsions, particularly those incorporating cardamom oil, may offer an effective alternative for diabetes management, warranting further exploration and development in clinical applications."	MEC01848
C04792	NEWCL00253	.	Achieving Therapeutic Synergy	"Our results demonstrate low toxicity-immunogenic cell death inducers have the potential to convert an immunologically ""cold"" tumor microenvironment to a ""hot"" tumor microenvironment, permissive to immune checkpoint blockade. Clinical trials are warranted testing the combination of immunogenic cell death inducers with immune checkpoint inhibitors in the treatment of patients with advanced prostate cancers."	MEC01849
C04793	NEWCL00080	.	Achieving Therapeutic Synergy	"In both cell lines, the drug combination showed synergistic effect at low doses. However, as the doses and exposure rates increased, the efficacy of the combination therapy decreased and became additive or antagonistic. These results show that the synergistic effect of the combination therapy is especially evident at low and medium doses."	MEC01850
C04794	NEWCL00181	.	Achieving Therapeutic Synergy	"The combination of PPVII and DDP significantly enhanced antitumor activity in H1299 cells through the modulation of DNA damage and ferroptosis, suggesting its potential as an effective therapeutic approach against DDP-resistant NSCLC."	MEC01851
C04795	NEWCL10086	.	Achieving Therapeutic Synergy	The combination usage of SIL?+?SFN has been viewed as a chemotherapeutic drug since it prevents the synthesis of PI3K/AKT and ERK 1/2 MAPK mediated control of cell growth and cell cycle-regulating proteins.	MEC01852
C04796	NEWCL00252	.	Achieving Therapeutic Synergy	.	MEC01853
C04797	NEWCL00203	ApoE-/- mice	Achieving Therapeutic Synergy	"NS influences autophagy through the PI3K/Akt/mTOR pathway, significantly regulating the interplay between lipid accumulation, apoptosis, and inflammatory responses [73,74]. Our study elucidates a previously unrecognized synergy between NGR1 and SSB2 in combating atherosclerosis through PI3K/Akt/mTOR pathway inhibition and autophagy restoration."	MEC01854
C04798	.	male Wistar rats	Achieving Therapeutic Synergy	"ASV combined with QUE could alleviate silica-induced pulmonary inflammation and fibrosis in rats, with the protective mechanism potentially mediated through enhanced autophagy activation and suppressed pyroptosis pathway."	MEC01855
C04799	NEWCL00344;NEWCL00076	.	Achieving Therapeutic Synergy	.	MEC01856
C04800	.	Male Golden Syrian hamsters	Achieving Therapeutic Synergy	"The importance of modifying post-surgical environment, via co-administration of adjuvant chemoradiation, in generating robust anti-tumor immunologic activity. Chemoradiation and dendritic cell vaccines are available for clinical use/trial which endows this approach the merit of potential clinical application."	MEC01857
C04801	NEWCL00352	"pathogen-free-grade 615 mice, MFC"	Achieving Therapeutic Synergy	"AEPS can effectively inhibit PD-1/PD-L1 expression, diminish macrophage M2 polarization, modulate the immune infiltration microenvironment, and suppress invasion and metastasis in gastric cancer. Moreover, AEPS-PD-1 antibody combination therapy may strengthen AEPS's anticancer effects."	MEC01858
C04802	NEWCL00355	.	Achieving Therapeutic Synergy	"The combined treatment of SHK and VPA induced apoptosis through the ROS-EGR1-Bax axis, contributing to the anti-tumour effect. "	MEC01859
C04803	NEWCL00352	AGS tumor-bearing mice	Achieving Therapeutic Synergy	"These polymeric prodrug NPs effectively disrupted intracellular redox balance and induced cell ferroptosis, offering a novel approach for developing biocompatible and effective therapies for gastric cancer."	MEC01860
C04804	NEWCL00199;NEWCL20475;NEWCL00298	.	Achieving Therapeutic Synergy	"In vivo, combined treatment with tricin and an anti-PD-1 antibody markedly suppressed the growth of tumors. The combination treatment had nearly no toxicity to the organs of the mice. In terms of immune regulation, tricin increased the numbers of CD8+ T lymphocytes and the levels of the functional cytokines TNFalpha, IFNgamma, and Granzyme B."	MEC01861
C04805	NEWCL20476	SPF C57BL/6J male mice	Achieving Therapeutic Synergy	Longya Lilium combined with fluoxetine has a more significant antidepressant effect and fewer adverse reactions	MEC01862
C04806	NEWCL00189	female Balb/c mice	Achieving Therapeutic Synergy	"PTX and SHP have a synergistic anti-tumor effect, likely through their combined action on immune pathways within the TME. This includes inhibiting angiogenesis, reducing inflammatory cell infiltration, and promoting T cell viability. "	MEC01863
C04807	NEWCL00049	.	Achieving Therapeutic Synergy	"The synergistic interaction between Sv extracts and melatonin enhances apoptotic cell death through activation of caspase-dependent pathways through caspase-3 and caspase-8, accompanied by changes in cell morphology, DNA fragmentation, and alterations in gene expression profiles."	MEC01864
C04808	.	.	Achieving Therapeutic Synergy	"After RJ and PAX treatment, a decrease in proliferation and cell migration was observed in oral squamous cells. RJ reduced the toxic effect of PAX. The glycolytic capacity of cells was minimized with the combination of RJ and PAX, thus reducing the demand for glucose. After transcriptome analysis, genes actively involved in signaling pathways such as DNA replication, cell cycle and nucleotide repair mechanism were suppressed. "	MEC01865
C04809	.	NMRI mice	Achieving Therapeutic Synergy	"In vitro effects of CP alone, particularly its synergistic interactions with MNZ against G. lamblia. "	MEC01866
C04810	.	The cold and wet KO patients	Achieving Therapeutic Synergy	"The combination of modified San Bi Tang and GSC treatment has a better effect on improving pain, joint function, and exacerbation of cold in patients than simple glucosamine sulfate treatment. "	MEC01867
C04811	.	.	Achieving Therapeutic Synergy	.	MEC01868
C04812	.	"Pasteur 1173P2, Msmeg mc2155 ATCC 700084, H37Rv ATCC 27294"	Reversing Drug Resistance	"The synergistic interaction of Y-13 with the TrpE allosteric inhibitor, indole propionic acid, suggests that prospective IND analogues could shut down tryptophan biosynthesis and protein biosynthesis in pathogens, leading to a new class of antibiotics. Finally, we discuss a strategy to expand the genome mining of antibiotic-producing microbes specifically for antimycobacterial development."	MEC01869
C04813	NEWCL10127;NEWCL10323	ICR mice	Reversing Drug Resistance	"By targeting importin-beta1, DD1-Br significantly blocked the nuclear transport of multiple CRPC drivers, particularly AR-V7, a main contributor to enzalutamide resistance, leading to the integral suppression of downstream oncogenic signaling."	MEC01870
C04814	NEWCL20477	Balb/c mice	.	Narirutin inhibited the growth of lung cancer cells by targeting TMEM16A. The multi-target combinatorial administration of narirutin and DDP significantly improve the treatment effect on lung cancer and eliminate side effects.	MEC01871
C04815	NEWCL00095	NPG mice	Achieving Therapeutic Synergy	"Taken together, this work afforded evidence that the combination with GA or other herbal derivatives could augment the treatment efficacy of CAR-T immunotherapy."	MEC01872
C04816	.	male BKS-Leprem2cd479/Gpt (db/db) mice	Reversing Drug Resistance	"The hotspot of PPARgamma is druggable for the discovery of new allosteric synergists, and the combination therapy of allosteric synergists and TZD drugs may provide a potential alternative approach to the treatment of type 2 diabetes mellitus."	MEC01873
C04817	.	"ATCC 19606, ATCC 25922, ATCC 13048, C6, ATCC 27883, ATCC 35659, ATCC 27853, ATCC 13311, ATCC 13880, ATCC 6633, ATCC 19433, ATCC 7644, ATCC 9144, ATCC 12386"	Achieving Therapeutic Synergy	"THY proved active against 10 of them. THY also showed Synergistic effects when combined with GTM, STM, and CHL, and the reaction of some of these against bacteria, were considered as critical (A. baumannii) and of high priority (S. aureus) by the WHO, reducing the MIC of these ABXs by 75% to 87.5%. "	MEC01874
C04818	NEWCL00049;NEWCL00065	.	Achieving Therapeutic Synergy	Cys227 modification can exert both negative and positive impacts on MKK3 kinase activity. Comprehensive elucidation of the underlying molecular events requires cocrystal X-ray structures of the MKK3-MEKK3 complex with and without bound arvenin I.	MEC01875
C04819	NEWCL00047;NEWCL10070	BALB/c nu/nu male mice	Reversing Drug Resistance	"JB showed similar efficacies in a series of sensitive and chemo-resistance cancer cells. The unique structural features of JB render a new action mechanism in raising the ROS levels to overcome tumor chemoresistance, and thus, providing a potential opportunity for JB in future anti-cancer drug development."	MEC01876
C04820	NEWCL00215;NEWCL00123	.	Achieving Therapeutic Synergy	"The effect of Shh stimulation on cell growth, cell cycle, and CSLCs properties in neuroblastoma and glioblastoma in the presence of Oct4. We also evaluated the effects of DAU in neuroblastoma and glioblastoma stem-like cell growth and indicated that DAU attenuated Oct4/Shh co-activated stemness and induced apoptosis via blocking AKT/beta-catenin signaling in neuroblastoma and glioblastoma."	MEC01877
C04821	.	male C57BL/6 mice	Achieving Therapeutic Synergy	"Eupho-A enhanced IFNgamma production in NK cells and, when used in combination with IFNgamma, synergistically promoted GSDME expression. This led to the activation of pyroptosis in tumor cells by increasing GZMB-mediated GSDME cleavage, ultimately enhancing NK cell-mediated cell killing. "	MEC01878
C04822	.	.	Achieving Therapeutic Synergy	.	MEC01879
C04823	NEWCL00170	.	Achieving Therapeutic Synergy	"Quercetin is a natural compound that can be easily extracted from fruits and vegetables, thus having low cytotoxicity. For this, quercetin is a promising alternative candidate for traditional chemo-agents in cancer treatment."	MEC01880
C04824	NEWCL20325;NEWCL10031	.	Achieving Therapeutic Synergy	"CAG promoted the antigen-presenting expression of tumors to enhance the antitumor effect of CD8 T cells, and the combination of CAG and PD-1 antibody had a superior antitumor effect."	MEC01881
C04825	NEWCL10339	C57BL/6 mice	Decreasing Adverse Drug Reaction	"A relative stable state of kaempferide with only a small amount of conversion into kaempferol by a pharmacokinetic study. Then, both in vitro and in vivo studies indicated kaempferide had a therapeutic role on either cisplatin or ischemia-reperfusion induced acute kidney injury. And the protective role of kaempferide might be through inhibiting oxidative stress and inducing autophagy."	MEC01882
C04826	.	G. mellonella infection	Reversing Drug Resistance	PP3 restores the susceptibility to several antifungal drugs for Candida albicans strains with gain-of-function mutations in the transcription factor Mrr1. 	MEC01883
C04827	.	C. glabrata cells	Achieving Therapeutic Synergy	.	MEC01884
C04828	NEWCL00031;NEWCL00283	.	Reversing Drug Resistance	"In summary, our findings demonstrate that oceanapiside targets the sphingolipid pathway in the pathogenic yeast Candida glabrata. Supporting evidence from treatment of C. glabrata cell cultures with OPS includes inhibition of polarized growth and budding, disorganization of actin assembly, reversal of antifungal activity by phytosphingosine, and accumulation of phytosphingosine. To date, OPS is the first bifunctional sphingolipid antifungal marine natural product described to inhibit sphingolipid synthesis, specifically at the step converting phytosphingosine to phytoceramide. Future study involving cytotoxicity testing could be undertaken to validate the safety of OPS as an antifungal candidate, but, in all likelihood, synthetic analogues should be pursued for more ""drugable"" therapeutics."	MEC01885
C04829	NEWCL00348	.	Reversing Drug Resistance	"Lob could enhance the sensitivity of Len in HCC/Len cells. In Len-resistant CDX and PDX models, Lob could reverse the resistance of HCC to Len with reductions in tumor volume of 68% and 60% respectively. "	MEC01886
C04830	.	nude mice(NCI-H226)	Reversing Drug Resistance	"Curcumin targeted ACHN cell cycle and cellular metabolism by promoting the differential expression of let-7C. To the best of our knowledge, this is the first study to mechanistically report the cancer chemosensitisation potential of curcumin in kidney cancer cells via induction of let-7C."	MEC01887
C04831	NEWCL20360	.	Reversing Drug Resistance	"Erianin has the potential to induce cell apoptosis, inhibit cell proliferation and migration, altered cell cycle in DDP-resistance LUAD cells, which may be accomplished through the Wnt3/beta-Catenin/Survivin/Caspase3/Bcl-2/Cyclin D1 axis."	MEC01888
C04832	NEWCL20333;NEWCL00187	.	Achieving Therapeutic Synergy	"SREBP-1 was found to induce the resistance of LUSC to anti-tumor drug treatment, and downregulating the activity of SREBP-1 can upregulate the sensitivity of LUSC cells to anti-tumor drugs."	MEC01889
C04833	NEWCL20333;NEWCL00187	.	Achieving Therapeutic Synergy	"SREBP-1 was found to induce the resistance of LUSC to anti-tumor drug treatment, and downregulating the activity of SREBP-1 can upregulate the sensitivity of LUSC cells to anti-tumor drugs."	MEC01890
C04834	NEWCL20333;NEWCL00187	.	Achieving Therapeutic Synergy	"SREBP-1 was found to induce the resistance of LUSC to anti-tumor drug treatment, and downregulating the activity of SREBP-1 can upregulate the sensitivity of LUSC cells to anti-tumor drugs."	MEC01891
C04835	NEWCL20333;NEWCL00187	.	Achieving Therapeutic Synergy	"SREBP-1 was found to induce the resistance of LUSC to anti-tumor drug treatment, and downregulating the activity of SREBP-1 can upregulate the sensitivity of LUSC cells to anti-tumor drugs."	MEC01892
C04836	NEWCL20333;NEWCL00187	.	Achieving Therapeutic Synergy	"SREBP-1 was found to induce the resistance of LUSC to anti-tumor drug treatment, and downregulating the activity of SREBP-1 can upregulate the sensitivity of LUSC cells to anti-tumor drugs."	MEC01893
C04837	NEWCL20333;NEWCL00187	.	Achieving Therapeutic Synergy	"SREBP-1 was found to induce the resistance of LUSC to anti-tumor drug treatment, and downregulating the activity of SREBP-1 can upregulate the sensitivity of LUSC cells to anti-tumor drugs."	MEC01894
C04838	NEWCL20333;NEWCL00187	.	Achieving Therapeutic Synergy	"SREBP-1 was found to induce the resistance of LUSC to anti-tumor drug treatment, and downregulating the activity of SREBP-1 can upregulate the sensitivity of LUSC cells to anti-tumor drugs."	MEC01895
C04839	NEWCL20333;NEWCL00187	.	Achieving Therapeutic Synergy	"SREBP-1 was found to induce the resistance of LUSC to anti-tumor drug treatment, and downregulating the activity of SREBP-1 can upregulate the sensitivity of LUSC cells to anti-tumor drugs."	MEC01896
C04840	NEWCL00036;NEWCL00086;NEWCL10122	BALB/c null mice	Reversing Drug Resistance	KuH inhibits the growth of melanoma cells both in vitro and in vivo. Two mechanisms contribute to the antimelanoma effects of KuH: it induces cytotoxic ER stress and triggers dysregulated autophagy activity. 	MEC01897
C04841	NEWCL00036;NEWCL00086;NEWCL10122	BALB/c null mice	Reversing Drug Resistance	KuH inhibits the growth of melanoma cells both in vitro and in vivo. Two mechanisms contribute to the antimelanoma effects of KuH: it induces cytotoxic ER stress and triggers dysregulated autophagy activity. 	MEC01898
C04842	NEWCL00036;NEWCL00086;NEWCL10122	BALB/c null mice	Reversing Drug Resistance	KuH inhibits the growth of melanoma cells both in vitro and in vivo. Two mechanisms contribute to the antimelanoma effects of KuH: it induces cytotoxic ER stress and triggers dysregulated autophagy activity. 	MEC01899
C04843	.	.	Reversing Drug Resistance	"The benzoate esters BO-1, BO-2, BO-4, ellipeiopsol B, and zeylenol were identified as IRMs due to their synergistic antibacterial activities against fluoroquinolone-resistant strain SA1199B, achieved by suppressing the bacterial resistance."	MEC01900
C04844	NEWCL20433;NEWCL00340	.	Reversing Drug Resistance	"The natural compound Butein inhibits NPC cells by downregulation of survivin in an Akt-Weel-CDK1 signaling-dependent manner. We demonstrated that Butein inhibits survivin phosphorylation, which induced Fbxl7-induced survivin ubiquitination and degradation."	MEC01901
C04845	NEWCL00172	female athymic nude mice	Reversing Drug Resistance	The natural product Lico A inhibited c-Met signaling and disrupted c-Met ubiquitination in a c-Cbl-dependent manner. Targeting c-Met degradation is a promising strategy to abrogate gefitinib resistance in NSCLC cells. The current study provided new insights on the role of Lico A in NSCLC treatment and suggested that this compound may be a promising therapeutic agent for gefitinib-resistant NSCLC.	MEC01902
C04846	NEWCL00172;NEWCL00170;NEWCL00180	female athymic nude mice	Reversing Drug Resistance	"Gastrodin can suppress the phosphorylation of survivin by attenuating Akt/WEE1/CDK1 signal transduction. Moreover, gastrodin can inhibit the interaction between USP19 and survivin to stimulate the destruction and ubiquitination of survivin. "	MEC01903
C04847	NEWCL00241;NEWCL00236;NEWCL10047	.	Reversing Drug Resistance	"GR PaCa cells have stronger invasive and angiogenic ability compared with GS cells, and they may achieve resistance to Gem via enhanced NF-kappaB signaling. A low concentration of parthenolide inhibited the invasive and angiogenic potential in GS and GR PaCa cell lines and also increased the Gem sensitivity of GR cells. "	MEC01904
C04848	NEWCL10120;NEWCL20478;NEWCL00240	.	Reversing Drug Resistance	Marein is a competitive inhibitor of ABCG2 trsnporter and a novel and effective modulator of MDR in cancer and may be exploited as a chemo-sensitizer for treatment of drug resistant cancer.	MEC01905
C04849	NEWCL00189;NEWCL10031	CT26-Luc colorectal tumor model(mice)	Achieving Therapeutic Synergy	"GA, a naturally occurring flavonoid, serves as a potent chemosensitizer, addressing the challenge of delayed prodrug activation and insufficient therapeutic response. By co-assembling GA with an SN38 prodrug (FSSN), we successfully achieved a stable carrier-free nanomedicine, significantly widening the therapeutic window of SN38."	MEC01906
C04850	NEWCL00233;NEWCL00242;NEWCL00240;NEWCL00239;NEWCL00236;NEWCL20479;NEWCL20480	.	Achieving Therapeutic Synergy	THM not only has significant anticancer activity but also enhances the effect of alphaPD-1 immunotherapy. 	MEC01907
C04851	NEWCL00031;NEWCL00131	.	Achieving Therapeutic Synergy	"Targeting ANXA2 in liver cancer and elucidated the mechanisms by releasing HSP90, which promoted tumor antigens presentation and increased the killing of tumor cells. "	MEC01908
C04852	NEWCL10339	Male C57BL/6J mice	Achieving Therapeutic Synergy	"C5 demonstrated robust activation of the Keap1-Nrf2 signaling, along with favorable metabolic stability, high renal exposure, and well-tolerated safety profiles, making it a promising candidate for mitigating drug-induced kidney injury. Both cellular and animal studies showed that C5 effectively mitigated CIMD and CIKI via robustly activating the Nrf2-ARE signaling. "	MEC01909
C04853	NEWCL00170;NEWCL00178;NEWCL00180	.	Reversing Drug Resistance	"HO-1 intervention with NDGA/SB 202190 modulated intracellular iron homeostasis and restored ferroptosis by suppressing the Nrf2/HO-1 pathway, effectively reversing cisplatin resistance. "	MEC01910
C04854	NEWCL00231;NEWCL20468;NEWCL00230;NEWCL00327	.	Achieving Therapeutic Synergy	HF inhibits COL1A1 production via the mTOR-eIF2alpha-ATF4 axis in CAFs.	MEC01911
C04855	NEWCL10001;NEWCL20481	GL261R-Luci mice	Reversing Drug Resistance	"The therapeutic efficacy of RT associated with pyroptosis-mediated TIME activation by GOLPH3L inhibitor VB5 can be further improved when combined with anti-PD-1 therapy, which can reactivate exhausted T cells in the tumor microenvironment."	MEC01912
C04856	NEWCL00189;NEWCL00203	.	Achieving Therapeutic Synergy	"BHS, a natural compound, significantly synergized with paclitaxel to inhibit breast tumour growth and lung metastasis. "	MEC01913
C04857	NEWCL10339;NEWCL00348;NEWCL00256	.	Reversing Drug Resistance	"ATL-I promoted the autophagic degradation of EPAS1 by upregulating ATP6V0D2 to increase lysosomal activity and promote the fusion of autophagosomes and lysosomes. Additionally, we found that hyperactivation of EPAS1 was a possible mechanism of sunitinib resistance in ccRCC, and ATL-I partially reversed this resistance."	MEC01914
C04858	NEWCL20336;NEWCL00129	.	Reversing Drug Resistance	"The natural compound C1 was screened as a broad ""green"" GST inhibitor, which effectively down-regulated GST levels and enabled the selective elimination of HCC cells (HepG2 and HepG2/DDP) while showing adequate safety to HL-7702. More importantly, C1 showed a sensitizing anti-HCC effect of Cisplatin in HepG2/DDP cells and in vivo. The natural PM exhibited broad GST inhibitory effect, the low toxicity to normal cells, and sensitization to the anti-HCC effect of Cisplatin. "	MEC01915
C04859	NEWCL00065;NEWCL00353	mouse MC38 xenograft tumors	Achieving Therapeutic Synergy	.	MEC01916
C04860	NEWCL00338;NEWCL10031	Establishment of a CPT11-induced gut mucositis model in colorectal cancer xenograft mice	Decreasing Adverse Drug Reaction	Insights into the molecular and microbial mechanisms involved in CPT11-induced gut mucositis and underscores the potential therapeutic application of DDIE in mitigating CPT11 chemotoxicity through its impact on the Gus-expressing bacterium E. faecalis.	MEC01917